

02-07-00

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 8907-087-999 Total Pages 192

First Named Inventor or Application Identifier

Thomas et al.

Express Mail Label No. EL 236 252 908 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form [Total Pages 4]
Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages 99]
(preferred arrangement set forth below)

-Descriptive title of the Invention
-Cross Reference to Related Applications
-Statement Regarding Fed sponsored R&D
-Reference to Microfiche Appendix
-Background of the Invention
-Brief Summary of the Invention
-Brief Description of the Drawings (if filed)
-Detailed Description of the Invention (including drawings, if filed)
-Claim(s)
-Abstract of the Disclosure

3. ☒ Drawing(s) (35 USC 113) [Total Sheets 13]
4. ☒ Oath or Declaration [Total Sheets 6]

- a. ☐ Newly executed (original or copy)
- b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
- i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
- ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☐ Computer Readable Copy
- b. ☒ Paper Copy (identical to computer copy) from prior application
[Total Pages 59]
- c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment Papers (cover sheet & document(s)
Copy from prior application [Total pages 8]
9. ☒ 37 CFR 3.73(b) Statement ☒ Power of Attorney
(when there is an assignee) [Total Pages 3]
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity Statement filed in prior application,
Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: 08/834,497 filed April 4, 1997.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 20583
(Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below

NAME					
ADDRESS					
CITY			STATE	ZIP CODE	
COUNTRY			TELEPHONE	FAX	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEPrior application: Examiner M. TungArt Unit 1644

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR § 1.53(b), of pending prior application no. 08/834,497 filed on April 4, 1997.

of Thomas J. Winston, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Zsuchihashi, and Roger K. Wolff

(inventor(s) currently of record in prior application)

for HEREDITARY CHROMATOSIS GENE

(title of invention)

1. ☒ The filing fee is calculated below:

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	1	-20	0	\$18.00 each	\$ 0.00
Independent	1	-3	0	\$78.00 each	\$ 0.00
Basic Fee					\$ 690.00
Multiple Dependency Fee If Applicable (\$260.00)					\$ 0.00
Total					\$ 690.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern					- \$ 0.00
Total Filing Fee					\$ 690.00

2. ☒ Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.
3. ☒ Amend the specification by inserting before the first line the following sentence: This is a continuation of prior application no. 08/834,497, filed April 4, 1997, which is a continuation-in-part of application no. 08/630,912 filed April 4, 1996, application no. 08/632,673 filed April 16, 1996 and application no. 08/652,265 filed May 23, 1996.

- 4a. ☐ Transfer the drawings from the prior application to this application and abandon the prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file.
- 4b. ☐ New formal drawings are enclosed.
- 4c. ☒ Informal drawings are enclosed.
- 5a. ☐ Priority of application no. filed on in is claimed under 35 U.S.C. §119.
- 5b. ☐ The certified copy has been filed in prior application no. , filed .
6. ☒ The prior application is assigned of record to Bio-Rad Laboratories, Inc..
- 7a. ☐ The Power of Attorney appears in the original papers in the prior application no. , filed .
- 7b. ☒ Since the Power of Attorney does not appear in the original papers, a copy of the Power in prior application no. 08/834,497, filed April 4, 1997 is enclosed.
8. ☒ This application contains nucleic acid and/or amino acid sequences required to be disclosed in a Sequence Listing under 37 CFR §§1.821-1.825. It is requested that the Sequence Listing in computer readable form from prior application no. 08/834,497, filed on April 4, 1997 be made a part of the present application as provided for by 37 C.F.R. §1.821(e). The sequences disclosed therein are the same as the sequences disclosed in this application. A copy of the paper Sequence Listing from application no. 08/834,497 filed on April 4, 1997 is enclosed.
9. ☒ The undersigned states, under 37 C.F.R. §1.821(f), that the content of the enclosed paper Sequence Listing from application no. 08/834,479 filed April 4, 1997 is the same as the content of the computer readable form submitted in application no.08/834,479,filed on April 4, 1997 .
10. ☒ Additional enclosures or instructions. Please cancel Claims 2-91 before calculating the filing fee.

Date

2/4/00

Respectfully submitted,

Brian M. Poissant

Brian M. Poissant
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090

28,462
(Reg. No.)

42067

HEREDITARY HEMOCHROMATOSIS GENE

5

This application is a continuation-in-part of Serial No. 08/630,912, filed April 4, 1996, Serial No. 08/632,673, filed April 16, 1996 and Serial No. 08/652,265, filed May 23, 1996.

10

BACKGROUND OF THE INVENTION

Hereditary hemochromatosis (HH) is an inherited disorder of iron metabolism wherein the body accumulates excess iron. In symptomatic individuals, this excess iron leads to deleterious effects by being deposited in a variety of organs leading to their failure, and resulting in cirrhosis, diabetes, sterility, and other serious illnesses.

15 Neither the precise physiological mechanism of iron overaccumulation nor the gene which is defective in this disease has been described.

HH is typically inherited as a recessive trait; in the current state of knowledge, homozygotes carrying two defective copies of the gene are most frequently affected by the disease. In addition, heterozygotes for the HH gene are more susceptible to sporadic porphyria cutanea tarda and potential other disorders (Roberts et al., Lancet 20 349:321-323 (1997). It is estimated that approximately 10-15% of individuals of Western European descent carry one copy of the HH gene mutation and that there are about one million homozygotes in the United States. HH, thus, represents one of the most common genetic disease mutations in individuals of Western European descent. Although 25 ultimately HH produces debilitating symptoms, the majority of homozygotes and heterozygotes have not been diagnosed.

The symptoms of HH are often similar to those of other conditions, and the severe effects of the disease often do not appear immediately. Accordingly, it would be desirable to provide a method to identify persons who may be destined to become 30 symptomatic in order to intervene in time to prevent excessive tissue damage associated with iron overload. One reason for the lack of early diagnosis is the inadequacy of

presently available diagnostic methods to ascertain which individuals are at risk, especially while such individuals are presymptomatic.

Although blood iron parameters can be used as a screening tool, a confirmed diagnosis often employs liver biopsy which is undesirably invasive, costly, and carries a risk of mortality. Thus, there is a clear need for the development of an inexpensive and noninvasive diagnostic test for detection of homozygotes and heterozygotes in order to facilitate diagnosis in symptomatic individuals, provide presymptomatic detection to guide intervention in order to prevent organ damage, and for identification of heterozygote carriers.

The need for such diagnostics is documented, for example, in Barton, J.C. et al. Nature Medicine 2:394-395 (1996); Finch, C.A. West J Med 153:323-325 (1990); McCusick, V. Mendelian Inheritance in Man pp. 1882-1887, 11th ed., (Johns Hopkins University Press, Baltimore (1994)); Report of a Joint World Health Organization/Hemochromatosis Foundation/French Hemochromatosis Association Meeting on the Prevention and Control of Hemochromatosis (1993); Edwards, C.Q. et al. New Engl J Med 328:1616-1620 (1993); Bacon, B.R. New Engl J Med 326:126-127 (1992); Balan, V. et al. Gastroenterology 107:453-459 (1994); Phatak, P.D. et al. Arch Int Med 154:769-776 (1994).

Although the gene carrying the mutation or mutations that cause HH has previously been unknown, genetic linkage studies in HH families have shown that the gene that causes the disease in Caucasians appears to reside on chromosome 6 near the HLA region at 6p21.3 (Cartwright, Trans Assoc Am Phys 91:273-281 (1978); Lipinski, M. et al. Tissue Antigens 11:471-474 (1978)). It is believed that within this locus, a single mutation gave rise to the majority of disease-causing chromosomes present in the population today. See Simon, M. et al. Gut 17:332-334 (1976); McCusick, V. *supra*. This is referred to herein as the "common" or "ancestral" or "common ancestral" mutation. These terms are used interchangeably. It appears that about 80% to 90% of all HH patients carry at least one copy of the common ancestral mutation which is closely linked to specific alleles of certain genetic markers close to this ancestral HH gene defect. These markers are, as a first approximation, in the allelic form in which they were present at the time the ancestral HH mutation occurred. See, for example, Simon, M. et al. Am J Hum Genet 41:89-105 (1987); Jazwinska, E.C. et al. Am J Hum Genet

53:242-257 (1993); Jazwinska, E.C. et al. Am J Hum Genet 56:428-433 (1995);
 Worwood, M. et al. Brit J Hematol 86:863-866 (1994); Summers, K.M. et al. Am J
Hum Genet 45:41-48 (1989).

Several polymorphic markers in the putative HH region have been
 5 described and shown to have alleles that are associated with HH disease. These markers
 include the published microsatellite markers D6S258, D6S306 (Gyapay, G. et al. Nature
Genetics 7:246-339 (1994)), D6S265 (Worwood, M. et al. Brit J Hematol 86:833-846
 (1994)), D6S105 (Jazwinska, E.C. et al. Am J Hum Genet 53:242-257 (1993); Jazwinska,
 E.C. et al. Am J Hum Genet 56:428-433 (1995)), D6S1001 (Stone, C. et al. Hum Molec
 10 Genet 3:2043-2046 (1994)), D6S1260 (Raha-Chowdhury et al. Hum Molec Genet 4:1869-
 1874 (1995)) as well as additional microsatellite and single-nucleotide-polymorphism
 markers disclosed in co-pending PCT application WO 96/35802 published November 14,
 1996, the disclosure of which is hereby incorporated by reference in its entirety.

Although each of such markers may be of use in identifying individuals
 15 carrying the defective HH gene, crossing-over events have, over time, separated some of
 the ancestral alleles from the mutation that is responsible for HH, thereby limiting the
 utility of such surrogate markers. The limited diagnostic power of surrogate markers is
 obvious considering the fact that the frequency of the ancestral allele in the population is
 generally higher than the estimated frequency of the disease-causing mutation. The
 20 desirability of identifying the gene responsible for HH has long been recognized due to
 the health benefits that would be available via gene-based diagnostics, which has an
 intrinsically higher predictive power than surrogate markers and may eventually lead to
 the identification and diagnosis of disease-causing mutations other than the ancestral
 mutation. In addition, identification of the HH gene would further our understanding of
 25 the molecular mechanisms involved in HH disease thereby opening new approaches for
 therapy. This goal has motivated numerous, but previously unsuccessful attempts to
 identify the HH gene.

These attempts have been made by a variety of methods. For example,
 genes known to be involved in iron transport or metabolism have been examined as
 30 candidates. An example of one unsuccessful attempt is the assignment of the ferritin
 heavy chain gene to Chromosome 6p, and subsequent exclusion of this gene on the basis
 of its precise localization outside of the HH region, and failure to find mutations in HH

patients. See Dugast, I.J. et al. Genomics 6:204-211 (1990); Summers et al. Hum Genet 88:175-178 (1991).

Another strategy has been to employ the genomic DNA surrounding the postulated HH locus to select expressed genes from this region. These genes have been evaluated in HH patients for mutations in an attempt to identify them as the causative gene. Examples of searches that have not resulted in the identification of the HH gene are illustrated in El Kahloun et al. Hum Molec Genet 2:55-60 (1992), Goei et al. Am J Hum Genet 54:244-251 (1994), and Beutler et al. Blood Cells, Molecules, and Diseases 21:206-216 (1995).

Finally, although the strategy of using positional information obtained from genetic studies has long been a widely used approach, estimates of the position of the HH gene remained imprecise. Examples of this uncertainty are demonstrated in Gruen et al. Genomics 14:232-240 (1992) and in Gasparini et al. Hematology 19:1050-1056 (1994). Indeed, a number of contradictory conclusions have been reported, some placing the HH gene proximal of HLA-A (Edwards et al. Cytogenet Cell Genet 40:620 (1985); Gasparini, P. et al. Hum Molec Genet 2:571-576 (1993)) while others placed the gene distal of HLA-A (Calandro et al. Hum Genet 96:339-342 (1995)).

Until very recently, in spite of the linkage studies placing the HH disease gene in the HLA region of Chromosome 6, the biological relevance of alterations in HLA Class I components has not been particularly well explored. Work by de Sousa et al. Immun Lett 39:105-111 (1994), and more recent work by Rothenberg, B.E. and Volland, J.R. Proc Natl Acad Sci USA 93:1529-1534 (1996) indicated that β -2-microglobulin knock-out mice develop symptoms of iron overload. β -2-microglobulin is presented on cell surfaces as a complex with HLA Class I MHC's. de Sousa et al. *supra*. (1994) and Barton, J.C. and Bertoli, L.F. Nature Medicine 2:394-395 (1996) speculated that β -2-microglobulin associated proteins or a unique Class I gene could be involved in the control of intestinal iron absorption and possibly HH disease.

In spite of the extensive efforts in the art to find the gene responsible for HH, the gene has remained elusive. Nevertheless, as will be appreciated it would be highly desirable to identify, isolate, clone, and sequence the gene responsible for HH and to have improved diagnostic methods for detection of affected individuals, whether homozygotes or heterozygotes.

SUMMARY OF THE INVENTION

One aspect of the invention is an isolated nucleic acid comprising a nucleic acid sequence selected from the group consisting of:

nucleic acid sequences corresponding to the nucleic acid sequence of SEQ ID NO:1 (which corresponds to the genomic sequence of the HH gene including introns and exons as shown in Figure 3);

nucleic acid sequences corresponding to the nucleic acid sequences selected from the group consisting of SEQ ID NO:3 (which corresponds to the genomic sequence of the HH gene containing the 24d1 mutation as shown in Figure 3), SEQ ID NO:5 (which corresponds to the genomic sequence of the HH gene containing the 24d2 mutation as shown in Figure 3), SEQ ID NO: 7 (which corresponds to the genomic sequence of the HH gene containing the 24d1 and the 24d2 mutations as shown in Figure 3);

nucleic acid sequences corresponding to the nucleic acid sequence of SEQ ID NO:9 (which corresponds to the cDNA sequence including the coding sequence of the HH gene as shown in 4);

nucleic acid sequences corresponding to the nucleic acid sequences selected from the group consisting of SEQ ID NO:10 (which corresponds to the cDNA sequence including the coding sequence of the HH gene containing the 24d1 mutation as shown in Figure 4), SEQ ID NO:11 (which corresponds to the cDNA sequence including the coding sequence of the HH gene containing the 24d2 mutation as shown in Figure 4), and SEQ ID NO:12 (which corresponds to the cDNA sequence including the coding sequence of the HH gene containing the 24d1 and the 24d2 mutations as shown in Figure 4);

In one embodiment, the nucleic acid is DNA. In another embodiment, the DNA is cDNA. In another embodiment, the nucleic acid is RNA. In another embodiment, the nucleic acid is a nucleic acid sequence corresponding to the nucleic acid sequence of SEQ ID NO:1. In another embodiment, the nucleic acid is a nucleic acid sequence corresponding to the nucleic acid sequence of SEQ ID NO:9. In another embodiment, the nucleic acid is a nucleic acid sequence corresponding to a nucleic acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7. In another embodiment, the nucleic acid is a nucleic acid sequence

corresponding to a nucleic acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

5 A further aspect of the invention is a cloning vector comprising a coding sequence of a nucleic acid as set forth above and a replicon operative in a host cell for the vector.

A further aspect of the invention is an expression vector comprising a coding sequence of a nucleic acid set forth above operably linked with a promoter sequence capable of directing expression of the coding sequence in host cells for the vector.

10 A further aspect of the invention is host cells transformed with a vector as set forth above.

A further aspect of the invention is a method of producing a mutant HH polypeptide comprising: transforming host cells with a vector capable of expressing a polypeptide from a nucleic acid sequence as set forth above; culturing the cells under
15 conditions suitable for production of the polypeptide; and recovering the polypeptide.

A further aspect of the invention is a peptide product selected from the group consisting of: a polypeptide having the amino acid sequence corresponding to the sequence of SEQ ID NO:2; a polypeptide having the amino acid sequence corresponding to the sequence of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8; a peptide
20 comprising at least 6 amino acid residues corresponding to the sequence of SEQ ID NO:2; a peptide comprising at least 6 amino acid residues corresponding to the sequence of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. In one embodiment, the peptide is labeled. In another embodiment, the peptide is a fusion protein.

A further aspect of the invention is a use of a peptide as set forth above as
25 an immunogen for the production of antibodies. In one embodiment, there is provided an antibody produced in such application. In one embodiment, the antibody is labeled. In another embodiment, the antibody is bound to a solid support. In a further embodiment, the antibody is monoclonal.

A further aspect of the invention is a method to determine the presence or
30 absence of the common hereditary hemochromatosis (HH) gene mutation in an individual, comprising: providing DNA or RNA from the individual; and assessing the DNA or RNA for the presence or absence of the HH-associated allele A of a base-pair mutation

24d1, wherein, as a result, the absence of the allele indicates the absence of the HH gene mutation in the genome of the individual and the presence of the allele the presence of the HH gene mutation in the genome of the individual. In a further embodiment, the method further comprises assessing the DNA or RNA for the presence of the base-pair mutation designated 24d2.

In a further embodiment the assessment can be made in combination with one or more microsatellite repeats or other polymorphisms. Thus, in a further aspect of the invention, the assessing step further comprises assessing the DNA or RNA for the presence or absence of any one of the following HH-associated alleles of base pair polymorphisms HHP-1, HHP-19, or HHP-29, wherein, as a result, the presence of the 24d1 and/or 24d2 allele in combination with the presence of at least one of the base pair polymorphisms HHP-1, HHP-19, or HHP-29 indicates the likely presence of the HH gene mutation in the genome of the individual and the absence of 24d1 and/or 24d2 allele in combination with the absence of at least one of the base pair polymorphisms HHP-1, HHP-19, or HHP-29 indicates a likely absence of the HH gene mutation in the genome of the individual. In another embodiment, the assessing step further comprises assessing the DNA or RNA for the presence or absence of any one of the following alleles defined by markers having microsatellite repeats: 19D9:205; 18B4:235; 1A2:239; 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122, D6S105:124; D6S306:238; D6S464:206; and D6S1001:180, wherein, as a result, the presence of the 24d1A and/or 24d2 allele in combination with the presence of at least one microsatellite repeat allele indicates the likely presence of the HH gene mutation in the genome of the individual and the absence of the 24d1 and/or 24d2 allele in combination with the absence of any one or all of the microsatellite repeat alleles indicates the likely absence of the HH gene mutation in the genome of the individual. In another embodiment, the assessing step is performed by a process which comprises subjecting the DNA or RNA to amplification using oligonucleotide primers flanking the base-pair polymorphism 24d1 and/or 24d2 and oligonucleotide primers flanking at least one of the base-pair polymorphisms HHP-1, HHP-19, and HHP-29. In another embodiment, the assessing

step is performed by a process which comprises subjecting the DNA or RNA to amplification using oligonucleotide primers flanking the base-pair polymorphism 24d1 and/or 24d2 and oligonucleotide primers flanking at least one of the microsatellite repeat alleles. In another embodiment, the assessing step is performed by a process which

5 comprises subjecting the DNA or RNA to amplification using oligonucleotide primers flanking the base-pair polymorphism 24d1 and/or 24d2, oligonucleotide primers flanking at least one of the base-pair polymorphisms HHP-1, HHP-19, and HHP-29, and oligonucleotide primers flanking at least one of the microsatellite repeat alleles.

A further aspect of the invention is a set of oligonucleotides for use in an

10 oligonucleotide ligation assay determination of the presence or absence of an HH-associated allele of a base-pair polymorphism, wherein the base pair polymorphisms comprises 24d1 and the oligonucleotides comprise the sequences of SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

A further aspect of the invention is a kit for the detection of the presence

15 or absence or an HH-associated allele of a base-pair polymorphism, the base-pair polymorphism comprising 24d1, as designated herein, the kit comprising the above oligonucleotide primer set. In another embodiment, the kit further comprises oligonucleotide primers for amplifying the DNA containing the base-pair polymorphism.

Another aspect of the invention is a kit for detection of a polymorphism in

20 the HH gene in a patient, the sample kit comprising at least one oligonucleotide of at least 8 nucleotides in length selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, or 12, wherein the oligonucleotide is used to amplify a region of HH DNA or RNA in a patient sample. In another aspect of the invention the kit further comprises at least a second oligonucleotide selected from the group consisting of SEQ ID NOS: 1, 3,

25 5, 7, 9, 10, 11, or 12, wherein the first and second oligonucleotides comprise a primer pair.

A further aspect of the invention is a method to evaluate potential responsiveness of an individual infected with hepatitis C to interferon treatment, comprising determining the presence or absence of the common hereditary

30 hemochromatosis gene in the individual according to any of the above methods.

A further aspect of the invention is an oligonucleotide primer useful for amplification of DNA, the oligonucleotide primer designed on the basis of the DNA

sequence of any one of SEQ ID NO: 18, SEQ ID NO:19, SEQ ID NO:29, and SEQ ID NO:30.

A further aspect of the invention is a method for diagnosing whether a patient is afflicted with hereditary hemochromatosis (HH) disease, comprising: contacting
5 cells of the patient with antibodies directed against an epitope on an HH protein product corresponding substantially to SEQ ID NO:2; and observing whether the antibodies localize on the cells, wherein, in the observing step, if antibodies do not localize to the cell there is a probability that the patient is afflicted with HH. In one embodiment, the method is conducted *in vitro*. In another embodiment, the method is conducted *in vivo*.

10 A further aspect of the invention is a method for treating a patient diagnosed as having hereditary hemochromatosis (HH) disease, comprising delivering a polypeptide corresponding to the amino acid sequence of SEQ ID NO:2 to tissues of the patient. The patient can be homozygous or heterozygous for 24d1, and may be a compound 24d1/24d2 heterozygote. In an embodiment, the polypeptide is delivered
15 directly to the tissues. In another embodiment, the polypeptide is delivered intravenously. In another embodiment, the polypeptide is delivered to the tissues through gene therapy.

A further aspect of the invention is an animal model for hereditary hemochromatosis (HH) disease, comprising a mammal possessing a mutant or knocked-out HH gene.

20 A further aspect of the invention is metal chelation agents derived from nucleic acid sequences described above or from a peptide product as described above in a physiologically acceptable carrier. In one embodiment, the metal is selected from the group consisting of iron, mercury, cadmium, lead, and zinc.

A further aspect of the invention is a method to screen mammals for
25 susceptibility to metal toxicities, comprising, screening such mammals for a mutation in the HH gene and wherein those mammals identified as having a mutation are more susceptible to metal toxicities than mammals not identified as having a mutation. In one embodiment, the metal is selected from the group consisting of iron, mercury, cadmium, lead, and zinc.

30 A further aspect of the invention is a method for selecting patients infected with hepatitis virus for α -interferon treatment, comprising screening such patients for a mutation in the HH gene and wherein those patients not identified as having a mutation

are selected to proceed with α -interferon treatment and those identified as having a mutation are selected to undergo phlebotomy prior to α -interferon treatment.

A further aspect of the invention is a T-cell differentiation factor comprising a moiety selected from the group consisting of molecules derived from nucleic acid sequences described above and from peptide products described above.

A further aspect of the invention is a method for screening potential therapeutic agents for activity in connection with HH disease, comprising: providing a screening tool selected from the group consisting of a cell line, a cell free, and a mammal containing or expressing a defective HH gene or gene product; contacting the screening tool with the potential therapeutic agent; and assaying the screening tool for an activity selected from the group consisting of HH protein folding, iron uptake, iron transport, iron metabolism, receptor-like activities, upstream processes, downstream processes, gene transcription, and signaling events.

A further aspect of the invention is a therapeutic agent for the mitigation of injury due to oxidative processes *in vivo*, comprising a moiety selected from the group consisting of molecules derived from nucleic acid sequences described above and from peptide products described above.

A further aspect of the invention is a method for diagnosing a patient as having an increased risk of developing HH disease, comprising: providing DNA or RNA from the individual; and assessing the DNA or RNA for the presence or absence of the HH-associated allele A of a base mutation designated herein 24d1 in combination with assessing the DNA or RNA for the HH-associated allele G of a base mutation designated herein 24d2, wherein, as a result, the absence of the alleles indicates the absence of the HH gene mutation in the genome of the individual and the presence of the alleles indicates the presence of the HH gene mutation in the genome of the individual and an increased risk of developing HH disease. In an embodiment, this assessment is done in combination with one or more microsatellite repeats or other polymorphisms. Thus, in a further aspect of the invention, the assessing step further comprises assessing the DNA or RNA for the presence or absence of any one of the following HH-associated alleles of base pair polymorphisms HHP-1, HHP-19, or HHP-29, wherein, as a result, the presence of the 24d1 and/or 24d2 allele in combination with the presence of at least one of the base pair polymorphisms HHP-1, HHP-19, or HHP-29 indicates the likely presence of the HH

gene mutation in the genome of the individual and the absence of 24d1 and/or 24d2 allele in combination with the absence of at least one of the base pair polymorphisms HHP-1, HHP-19, or HHP-29 indicates a likely absence of the HH gene mutation in the genome of the individual. In another embodiment, the assessing step further comprises assessing the

5 DNA or RNA for the presence of absence of any one of the following alleles defined by markers having microsatellite repeats: 19D9:205; 18B4:235; 1A2:239; 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-1:167; 241-5:108; 241-10 29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122, D6S105:124;

D6S306:238; D6S464:206; and D6S1001:180, wherein, as a result, the presence of the 24d1A and/or 24d2 allele in combination with the presence of at least one microsatellite repeat allele indicates the likely presence of the HH gene mutation in the genome of the individual and the absence of the 24d1 and/or 24d2 allele in combination with the absence of any one or all of the microsatellite repeat alleles indicates the likely absence of the HH gene mutation in the genome of the individual.

15 A further aspect of the invention is a therapeutic agent for the mitigation of iron overload, comprising a moiety selected from the group consisting of molecules derived from nucleic acid sequences described above and from peptide products described above.

20 A further aspect of the invention is a method for treating hereditary hemochromatosis (HH) disease, comprising: providing an antibody directed against an HH protein sequence or peptide product; and delivering the antibody to affected tissues or cells in a patient having HH.

25 A further aspect of the invention is an antisense oligonucleotide directed against a transcriptional product of a nucleic acid sequence selected from the group consisting of therapeutic agent for the mitigation of iron overload, comprising a moiety selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

30 A further aspect of the invention is an oligonucleotide of at least 8 nucleotides in length selected from nucleotides 1-46, 48-123; 120-369; 365-394; 390-540; 538-646; 643-1004; 1001-1080; 1083-1109; 1106-1304; 1301-1366; 1363-1386; 1389-

1514; 1516-1778; 1773-1917; 1921-2010; 2051-2146; 2154-2209; 2234-2368; 2367-2422;
 2420-2464; 2465-2491; 2488-2568; 2872-2901; 2902-2934; 2936-2954; 2449-3001; 3000-
 3042; 3420-3435; 3451-3708; 3703-3754; 3750-3770; 3774-3840; 3840-3962; 3964-3978;
 3974-3992; 3990-4157; 4153-4251; 4257-4282; 4284-4321; 4316-4333; 4337-4391; 4386-
 5 4400; 4398-4436; 4444-4547; 4572-4714; 4709-4777; 5165-5397; 5394-6582; 5578-5696;
 5691-5709; 5708-5773; 5773-5816; 5818-5849; 5889-6045; 6042-6075; 6073-6108; 6113-
 6133; 6150-6296; 6292-6354; 6356-6555; 6555-6575; 6575-6616; 6620-6792; 6788-6917;
 6913-7027; 7023-7061; 7056-7124; 7319-7507; 7882-8000; 7998-8072; 8073-8098; 9000-
 9037; 9486-9502; 9743-9811; 9808-9831; 9829-9866; 9862-9986; 9983-10075; 10072-
 10 10091; 10091-10195; 10247-10263; 10262-10300; 10299-10448; 10448-10539; 10547-
 10564; 10580-10612; 10608-10708; 10703-10721; 10716-10750; 10749-10774; 10774-
 10800; and 10796-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 9
 nucleotides in length selected from nucleotides 1-47; 47-124; 119-370; 364-395; 389-541;
 15 537-647; 642-1005; 1000-1081; 1082-1110; 1105-1305; 1300-1367; 1362-1387; 1388-
 1515; 1515-1918; 1920-2011; 2050-2147; 2153-2210; 2233-2369; 2366-2423; 2419-2465;
 2464-2492; 2487-2569; 2871-2935; 2935-3002; 2999-3043; 3419-3436; 3450-3755; 3749-
 3771; 3773-3841; 3839-3963; 3963-3979; 3973-3993; 3989-4158; 4152-4252; 4256-4283;
 4283-4334; 4336-4401; 4397-4437; 4443-4548; 4571-4778; 5164-5398; 5393-5583; 5577-
 20 5710; 5707-5774; 5772-5817; 5817-5850; 5888-6046; 6041-6076; 6072-6109; 6112-6134;
 6149-6355; 6355-6556; 6554-6576; 6574-6793; 6787-7125; 7318-7508; 7881-8001; 7997-
 8073; 8072-8099; 8999-9038; 9485-9503; 9742-9812; 9807-9832; 9828-9867; 9861-9987;
 9982-10076; 10071-10092; 10090-10196; 10246-10264; 10261-10301; 10298-10449;
 10447-10540; 10546-10565; 10579-10751; 10748-10775; 10773-10801; and 10795-10825
 25 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 10
 nucleotides in length selected from nucleotides 1-48; 46-125; 118-1006; 999-1082; 1081-
 1111; 1104-1306; 1299-1368; 1361-1388; 1387-1516; 1514-1919; 1919-2012; 2049-2148;
 2152-2211; 2232-2370 2365-2424; 2418-2466; 2463-2493; 2486-2570; 2870-2936; 2934-
 30 3003; 2998-3044; 3418-3437; 3449-3772; 3772-3842; 3838-3964; 3962-3994; 3988-4284;
 4282-4335; 4335-4402; 4396-4438; 4442-4549; 4570-4779; 5163-5711; 5706-5775; 5771-
 5818; 5816-5851; 5867-6047; 6040-6077; 6071-6110; 6111-6135; 6148-6356; 6354-6577;

6573-7126; 7317-7509; 7880-8074; 8071-8100; 8998-9039; 9484-9504; 9741-9813; 9806-9833; 9827-9988; 9981-10093; 10089-10197; 10245-10265; 10260-10302; 10297-10450; 10446-10541; 10545-10566; 10578-10752; 10747-10776; and 10772-10825 of SEQ ID NO:1, 3, 5, or 7.

5 A further aspect of the invention is an oligonucleotide of at least 11 nucleotides in length selected from nucleotides 1-49; 45-1389; 1386-1517, 1513-1920; 1918-2013; 2048-2149; 2151-2212; 2231-2371; 2364-2425; 2417-2467; 2462-2571; 2869-2937; 2933-3004; 2997-3045; 3417-3438; 3448-3773; 3771-3843; 3837-3965; 3961-3995; 3987-4285; 4281-4336; 4334-4403; 4395-4439; 4441-4550; 4569-4780; 5162-5712; 5705-10 5776; 5770-5819; 5815-5852; 5886-6111; 6100-6136; 6147-6357; 6353-6578; 6572-7127; 7316-7510; 7879-8075; 8070-8101; 8997-9040; 9483-9505; 9740-10198; 10244-10266; 10257-10303; 10296-10451; 10445-10542; 10544-10567; 10577-10753; 10746-10777; and 10771-10825 of SEQ ID NO:1, 3, 5, or 7.

15 A further aspect of the invention is an oligonucleotide of at least 12 nucleotides in length selected from nucleotides 1-50, 44-1390; 1385-1518; 1512-1921; 1917-2014; 2047-2150; 2150-2213; 2230-2372; 2363-2468; 2461-2572; 2868-2938; 2932-3005; 2996-3046; 3416-3439; 3447-3774; 3770-3844; 3836-3966; 3960-4286; 4280-4337; 4333-4440; 4440-4551; 4568-4781; 5161-5713; 5704-5777; 5669-5820; 5814-5853; 5885-6112; 6109-6137; 6146-6358; 6352-6579; 6571-7128; 7315-7511; 7878-8076; 8069-8102; 20 8996-9041; 9482-9506; 9739-10199; 10243-10267; 10256-10304; 10295-10452; 10444-10543; 10543-10566; 10576-10754; 10745-10778; and 10770-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 13 nucleotides in length selected from nucleotides 1-51; 43-1391; 1384-1519; 1511-1922; 25 1916-2015; 2046-2151; 2149-2214; 2229-2469; 2460-2573; 2867-2939; 2931-3047; 3415-3440; 3446-3775; 3769-3845; 3835-3967; 3959-4287; 4279-4338; 4332-4441; 4439-4552; 4567-4782; 5160-5778; 5668-5821; 5813-5854; 5884-6113; 6108-6138; 6145-6359; 6351-6580; 6570-7129; 7314-7512; 7877-8077; 8068-8103; 8995-9042; 9481-9507; 9738-10200; 10242-10453; 10443-10544; 10542-10567; 10575-10779; and 10769-10825 of 30 SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 14 nucleotides in length selected from nucleotides 1-52; 42-1392; 1383-1520; 1510-1923;

1915-2016; 2045-2152; 2148-2215; 2228-2574; 2866-2940; 2930-3048; 3414-3441; 3445-3776; 3768-3968; 3959-4288; 4278-4339; 4331-4442; 4438-4553; 4566-4783; 5159-5822; 5812-5855; 5883-6114; 6107-6139; 6144-6360; 6350-6581; 6569-7130; 7313-7513; 7876-8078; 8067-8104; 8994-9043; 9480-9508; 9737-10201; 10241-10454; 10442-10545;

5 10541-10568; and 10574-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 15 nucleotides in length selected from nucleotides 1-53; 41-1393; 1382-1521; 1509-1924; 1914-2017; 2044-2153; 2147-2216; 2227-2575; 2865-2942; 2929-3049; 3413-3442; 3444-3777; 3767-3969; 3958-4289; 4277-4340; 4330-4443; 4437-4554; 4565-4784; 5158-5823; 10 5811-5856; 5882-6115; 6106-6140; 6143-6361; 6349-7131; 7312-7514; 7875-8105; 8993-9044; 9479-9509; 9736-10202; 10240-10546; 10540-10569; and 10573-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 16 nucleotides in length selected from nucleotides 1-1394; 1381-1925; 1913-2018; 2043-15 2154; 2146-2217; 2226-2576; 2864-3050; 3412-3443; 3443-3778; 3766-4341; 4329-4444; 4436-4555; 4564-4785; 5157-5857; 5881-6116; 6105-6141; 6142-7132; 7311-7515; 7874-8106; 8992-9045; 9478-9510; 9735-10203; 10239-10547; 10539-10570; and 10572-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 17 nucleotides in length selected from nucleotides 1-1926; 1912-2019; 2042-2155; 2145-2218; 2225-2577; 2863-3051; 3411-3779; 3765-4342; 4329-4445; 4435-4556; 4563-4786; 15 5156-5858; 5880-6117; 6104-6142; 6141-7133; 7310-7516; 7873-8107; 8991-9046; 9477-9511; 9734-10204; 10238-10548; 10538-10571; and 10571-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 18 nucleotides in length selected from nucleotides 1-2020; 2041-2156; 2144-2219; 2224-2578; 2862-3052; 3410-3780; 3764-4446; 4434-4557; 4562-4787; 5155-5859; 5879-6118; 15 6103-6143; 6140-7134; 7309-7517; 7872-8108; 8990-9047; 9476-9512; 9733-10205; 10237-10549; 10537-10572; and 10570-10825 of SEQ ID NO:1, 3, 5, or 7.

A further aspect of the invention is an oligonucleotide of at least 8 nucleotides in length selected from nucleotides 1-55; 55-251; 250-306; 310-376; 380-498; 15 500-528; 516-543; 541-578; 573-592; 590-609; 611-648; 642-660; 664-717; 712-727;

725-763; 772-828; 813-874; 872-928; 913-942; 940-998; 997-1046; 1054-1071; 1076-1116; 1115-1182; 1186-1207; 1440-1483; 1482-1620; 2003-2055; 2057-2107; 2116-2200; and 2453-2469 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 9
5 nucleotides in length selected from nucleotides 1-56; 54-252; 249-307; 309-377; 379-499; 499-529; 515-544; 540-579; 572-593; 589-610; 610-649; 641-661; 663-718; 711-728; 724-764; 771-829; 812-875; 871-929; 912-943; 939-999; 996-1047; 1053-1072; 1075-1117; 1114-1183; 1185-1208; 1439-1484; 1481-1629; 2002-2056; 2056-2108; 2115-2201; and 2452-2470 of SEQ ID NO:9, 10, 11 or 12.

10 A further aspect of the invention is an oligonucleotide of at least 10
nucleotides in length selected from nucleotides 1-57; 53-253; 248-308; 308-378; 378-500; 498-530; 514-545; 539-580; 571-594; 588-611; 609-662; 662-729; 723-765; 770-876; 870-944; 938-1000; 995-1048; 1052-1073; 1074-1118; 1113-1184; 1184-1209; 1438-1485; 1480-1630; 2001-2057; 2055-2109; 2114-2202; and 2451-2471 of SEQ ID NO:9,
15 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 11
nucleotides in length selected from nucleotides 1-58; 52-254; 247-309; 307-379; 377-501; 497-531; 513-546; 538-595; 587-612; 608-663; 661-730; 722-766; 769-877; 869-1049; 1051-1074; 1073-1119; 1112-1185; 1183-1210; 1437-1486; 1479-1631; 2000-2058; 2054-
20 2110; 2113-2203; and 2450-2472 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 12
nucleotides in length selected from nucleotides 1-255; 246-310; 306-380; 376-502; 496-596; 586-613; 607-664; 660-767; 768-1050; 1050-1075; 072-1120; 1111-1186; 1182-1211; 1436-1487; 1478-1632; 1999-2059; 2053-2121; 2112-2204; and 2449-2473 of SEQ
25 ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 13
nucleotides in length selected from nucleotides 1-311; 305-381; 375-503; 495-614; 606-665; 659-768; 767-1051; 1049-1076; 1071-1121; 1110-1187; 1181-1212; 1435-1633; 1998-2060; 2052-2205 and 2448-2474 of SEQ ID NO:9, 10, 11 or 12.

30 A further aspect of the invention is an oligonucleotide of at least 14
nucleotides in length selected from nucleotides 1-312; 304-382; 374-504; 494-615; 605-

666; 658-769; 766-1052; 1048-1077; 1070-1188; 1180-1213; 1434-1634; 1997-2061; 2051-2206; and 2447-2475 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 15 nucleotides in length selected from nucleotides 1-313; 303-383; 373-505; 493-616; 604-667; 657-770; 765-1053; 1047-1078; 1069-1189; 1179-1214; 1433-1635; 1996-2062; 2050-2207; and 2446-2476 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 16 nucleotides in length selected from nucleotides 1-314; 302-384; 372-668; 656-771; 764-1054; 1046-1079; 1068-1190; 1178-1215; 1432-1636; 1995-2208; and 2445-2477 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 17 nucleotides in length selected from nucleotides 1-315; 301-385; 371-669; 655-772; 763-1055; 1045-1080; 1067-1191; 1177-1216; 1431-1637; 1994-2209; and 2444-2478 of SEQ ID NO:9, 10, 11 or 12.

A further aspect of the invention is an oligonucleotide of at least 18 nucleotides in length selected from nucleotides 1-773; 762-1056; 1044-1081; 1066-1192; 1176-1217; 1430-1638; 1993-2210; and 2443-2479 of SEQ ID NO:9, 10, 11 or 12.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

Figure 1 is a physical map showing the positions of markers on Chromosome 6 telomeric of the HLA region and the set of genomic clones used in our gene discovery efforts. In the Figure, "y" designates a YAC (yeast artificial chromosome) clone, "p" designates a p1 clone, "b" designates a BAC (bacterial artificial chromosome) clone, and "pc" designates a PAC (p1 artificial chromosome).

Figure 2 is a subset of chromosomes showing the overlap of ancestral DNA between HH affected chromosomes from patients at markers in a narrow region of Chromosome 6, approximately 4.8 Mbp telomeric of the HLA region. These overlapping regions were used to define the minimal HH region. Shaded regions are "ancestral regions" maintained "identical by descent." The region that is ancestral and in common between all of these chromosomes is between markers 241-29 and 63-3. This is where the HH gene should reside.

Figure 3 is a nucleotide sequence of the genomic DNA containing the HH gene (SEQ ID NO:1). The sequence comprises approximately 11,000 nucleotides. The sequence corresponding to the HH gene coding regions have been capitalized and underlined. The positions of the 24d1 and the 24d2 mutations and the 24d7 sequence variants are shown where base 5474 corresponds to the position of the 24d1 mutation, base 3512 corresponds to the position of the 24d2 mutation, and base 3518 corresponds to the position of the 24d7 sequence variation. Sequences corresponding to the genomic DNA including the 24d1 mutation are referred to herein as SEQ ID NO:3, sequences corresponding to the genomic DNA including the 24d2 mutation are referred to herein as SEQ ID NO:5, and sequences corresponding to the genomic DNA including the 24d1 and the 24d2 mutations are referred to herein as SEQ ID NO:7.

Figure 4 is the nucleotide sequence of the translated portion of the cDNA (SEQ ID NO:9) corresponding to coding regions in the HH gene. The nucleotide sequence of the cDNA is arbitrarily numbered beginning at 1 with the A in the start codon (ATG). The predicted amino acid sequence of the protein product is provided (SEQ ID NO:2); and sequence variants in the gene, as well as the associated changes in the amino acid sequence caused by such variants are indicated on the Figure at base 187 (residue 63), base 193 (residue 65), and base 845 (residue 282). Sequences corresponding to cDNA including the 24d1 mutation are referred to herein as SEQ ID NO:10, sequences corresponding to the cDNA including the 24d2 mutation are referred to herein as SEQ ID NO:11, and sequences corresponding to the cDNA including the 24d1 and the 24d2 mutations are referred to herein as SEQ ID NO:12. Sequences of the predicted protein product including the amino acid change caused by the 24d1 mutation is referred to herein as SEQ ID NO:4, sequences of the predicted protein product including the amino acid change caused by the 24d2 mutation is referred to herein as SEQ ID NO:6, and sequences of the predicted HH protein product including the amino acid change caused by the 24d1 and 24d2 mutations is referred to herein as SEQ ID NO:8.

Figure 5 shows the oligonucleotide sequences used for amplification (SEQ ID NOS:13 and 14) and OLA determination (SEQ ID NOS: 15, 16 AND 17) of the 24d1 gene mutation of the present invention.

Figure 6 shows a 517 base sequence representing the genomic DNA surrounding the 24d1 gene mutation of the present invention. Figure 6a shows the

position of 24d1 in the normal G allele and the portions of the sequence used for the design of the primers illustrated in Figure 5 (SEQ ID NO:20), and Figure 6b shows the position of 24d1 in the mutated A allele and the portions of the sequence used for the design of the primers illustrated in Figure 5 (SEQ ID NO:21).

Figure 7 shows the sequence alignment between the predicted amino acid sequence of the HH gene protein product (SEQ ID NO:2) in comparison to RLA (rabbit leukocyte antigen) (SEQ ID NO:22) and an MHC Class I protein (SEQ ID NO:23). The dots above certain amino acids correspond to conservative amino acid residue differences, i.e., glycine for alanine, valine for isoleucine for leucine, aspartic acid for glutamic acid, asparagine for glutamine, serine for threonine, lysine for arginine, and phenylalanine for tyrosine, or the reverse.

Figure 8 is a schematic diagram showing the association between an HLA molecule and β -2-microglobulin highlighting the homologous positions of the three base-pair changes that have been found in the predicted HH gene protein product.

Figure 9 shows the oligonucleotide sequences used for amplification (SEQ ID NOS:24 and 25) and OLA determination (SEQ ID NO:26, 27 and 28) of the 24d1 gene mutation of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

As used herein, the term "random chromosomes" refers to chromosomes from randomly chosen individuals who are not known to be affected with HH. Similarly, the term "unaffected individuals" refers to individuals who are not known to be affected with HH. The term "affected chromosomes" as used herein refers to chromosomes from individuals who have been diagnosed as having HH as determined by hepatic iron index and liver biopsy. Similarly, the term "affected individuals" refers to individuals who have been diagnosed as having HH.

As used herein, "marker" refers to a DNA sequence polymorphism flanked by unique regions. These regions flanking the "marker" can be utilized for the design and construction of oligonucleotides for amplifying the relevant DNA portions and detecting the polymorphisms therein.

The term "HH disease" refers to hereditary hemochromatosis disease. The criteria utilized herein to assess whether a patient is affected with the HH disease (i.e., whether the patient is an "affected individual" having "affected chromosomes") has been established by the diagnostic criteria set out in Crawford et al. Am J Hum Genet 57:362-

5 367 (1995) where at least two of the following four criteria were met: (i) liver biopsy showing HIC greater than 4660 micrograms/gram of liver, (ii) HII greater than or equal to 2.0, (iii) Perl stain of 3 or greater, or (iv) greater than 4 grams of iron removed by phlebotomy (greater than 16 therapeutic phlebotomies).

"HH gene" as used herein refers to a gene whose mutated forms are
10 associated with HH disease. This definition includes various sequence polymorphisms, mutations, and/or sequence variants wherein nucleotide substitutions in the gene sequence do not affect the function of the gene product. Generally, the HH gene is found on Chromosome 6 and includes the DNA sequences shown in Figures 3 and 4 and all functional equivalents. The term "HH gene" includes not only coding sequences but also
15 regulatory regions such as promoter, enhancer, and terminator regions. The term further includes all introns and other DNA sequences spliced from the final HH gene RNA transcript. Further, the term includes the coding sequences as well as the non-functional sequences found in non-human species. All DNA sequences provided herein are understood to include complementary strands unless otherwise noted. It is understood
20 that an oligonucleotide may be selected from either strand of the HH genomic or cDNA sequences. Furthermore, RNA equivalents can be prepared by substituting uracil for thymine, and are included in the scope of this definition, along with RNA copies of the DNA sequences of the invention isolated from cells. The oligonucleotide of the invention can be modified by the addition of peptides, labels, and other chemical moieties and are
25 understood to be included in the scope of this definition.

The terms "HH protein" and "HH gene product" refer to MHC Class I-like molecules encoded by the HH gene. The term includes protein as isolated from human and animal sources, produced by enzymatic or chemical means, or through recombinant expression in an organism. The term further includes "normal" and "wild-type" forms of
30 the protein and mutant forms of the protein that are responsible or involved in HH disease. Encompassed within this definition are forms of the protein including polymorphic forms of the protein in which the amino acid changes do not affect the

essential functioning of the protein in its role as either "normal" or "wild-type" or mutant forms of the protein.

"Ancestral DNA" as used herein refers to DNA that is inherited in unchanged form through multiple generations. Such DNA is sometimes referred to herein as DNA that is "identical by descent."

The term "ancestral mutation" as used herein refers to the disease causing mutation inherited through multiple generations.

II. Introduction to HH Gene Discovery

Through the analysis of affected chromosomes as compared to random chromosomes, in accordance with the present invention, we have identified, isolated, and sequenced the cDNA corresponding to the normal and mutant HH gene (Feder, J.N. et al., Nature Genetics 13:399-408(1996). In addition, we have sequenced the cDNA corresponding to the gene's mRNA and have predicted the gene's protein product.

The HH disease gene is a novel gene on Chromosome 6 having significant sequence homology with HLA Class I genes. Interestingly, however, the gene is located at significant distance telomeric (approximately 4 Mbp) from the HLA Class I gene cluster on Chromosome 6. A single mutation in the gene appears responsible for the majority of HH disease. The mutation comprises a single nucleotide substitution of Guanine (G) to Adenine (A), where Guanine (G) is present in the unaffected DNA sequence and Adenine (A) is present in the affected DNA sequence. This mutation, referred to herein as 24d1, is illustrated in two partial sequences from the genomic DNA of the HH gene below and represented by SEQ ID NO:29 (unaffected) and SEQ ID NO:30 (affected):

24d1 Unaffected Sequence:

5'-GGAAGAGCAGAGATATACGTGCCAGGTGGAGCACCCAGG-3' (SEQ ID NO:29)

24d1 Affected Sequence:

5'-GGAAGAGCAGAGATATACGTACCAGGTGGAGCACCCAGG-3' (SEQ ID NO:30)

The G to A mutation at 24d1 is present in approximately 86% of all affected chromosomes and in only 4% of unaffected chromosomes, exemplifying its enrichment in the affected chromosomes.

As will be discussed in greater detail below, several factors provide a compelling conclusion that the above-mentioned gene of the present invention is in fact the HH gene, and that the 24d1 mutation is responsible for the majority of cases of HH disease. First, the location of the gene on Chromosome 6, in relative proximity to the HLA region, is the predicted location based on linkage disequilibrium mapping studies and haplotype analysis. Second, recent evidence demonstrated that β -2-microglobulin knock-out mice developed symptoms of iron overload disease. The predicted amino acid sequence of the gene product of the present invention possesses significant homology to HLA Class I molecules which are known to interact with β -2-microglobulin. Third, the principal mutation (24d1) causes a marked amino acid change (cys --> tyr) at a critical disulfide bridge held in common with HLA Class I proteins that is important to the secondary structure of such protein products. Changes affecting the disulfide bridge in HLA Class I molecules have been shown to prevent or minimize presentation of the protein on cell surfaces. Further, such amino acid changes would appear to substantially modify the manner in which the protein could associate or interact with β -2-microglobulin. Fourth, the 24d1 mutation is present in over 87% of HH patients while only present in 4% of random individuals, consistent with estimates of the frequency of the ancestral HH mutation in patients and the carrier frequency in random individuals.

A. Discovery of the HH Gene

1. Strategy

In order to identify the HH gene, we set out to determine allelic association patterns between known markers and the HH locus in the HLA region of Chromosome 6. Based upon this data, we generated physical clone coverage extending from D6S265, which is a marker that is centromeric of HLA-A, in a telomeric direction through D6S276, a marker at which the allelic association was no longer observed.

2. Allelic Association

As mentioned above, it is believed that there was a common ancestor who possessed a distinct DNA sequence within whose genome the common or ancestral HH mutation occurred. It appears that approximately 87% of the patients today are descendants of this disease founding individual and thus share the common mutation. As

will be appreciated, through the generations, chromosomes undergo genetic recombination during meiosis. Both genetic linkage mapping and disequilibrium mapping take advantage of this natural process to narrow and define the location of the disease causing gene. The smaller the distance between a disease locus and a genetic marker, the less likely that a recombination event will occur between them. Thus, as genetic markers are tested in a population of HH patients the markers closest to the disease locus will tend more often to have the allele that was present on the ancestral chromosome, while others, farther away, will tend to have different alleles brought in by genetic recombination. Our strategy for identifying the HH gene, and the mutation(s) responsible for the HH disease, exploited this phenomenon by first reconstructing the haplotype of the founding or ancestral chromosome spanning an 8Mb region. Secondly, we determined the minimal HH region that is "identical by descent" or shared in the chromosomes in our sample of HH patients.

The approach is shown in Figure 2 where areas of ancestral sequence that is "identical by descent" are indicated in shade and areas of non-identity are unmarked.

Particular markers are shown at the top of the Figure.

Towards the goal of identifying the HH gene, we undertook this type of strategy. Owing to the published allelic association of the HH gene with the HLA region, we directed our initial efforts to this region of Chromosome 6. Existing genetic markers were tested for association with the HH gene. Because of the founder or ancestral effect, described above, we expected that markers closer to the HH gene would display a greater degree of allelic association. Based upon this initial data we designed a strategy to develop markers over a 8Mb region extending telomeric from HLA-A.

The markers were generally developed by cloning random pieces of genomic DNA, known to represent this region of the chromosome as described in the next section and as shown in Figure 1. The clones containing CA repeat elements were identified by hybridization and their sequences determined. The sequence information was used to design primers within the unique DNA flanking the CA repeat, for use in PCR. If the CA repeat proved to be polymorphic in a random sample of chromosomes, then the markers were assayed in HH patients. In this effort 46 CA microsatellite markers covering approximately 8Mb, were identified and scored in our patients. We detected the pattern of overlapping ancestral DNA present on patient chromosomes as depicted in Figure 2. As will be appreciated, the minimal area of DNA that is "identical by descent"

on all the ancestral HH chromosomes is between, but not including, markers 241-29 and 63-3, surrounding marker 241-5. This is the region within which the HH gene must lie and where we conducted our search for the gene as described below.

3. Physical Mapping

Primary clone coverage of the genomic region telomeric of the MHC locus on Chromosome 6p was obtained by assembling an overlapping set of YAC clones that span the region between D6S265 and D6S276. Initial YAC contigs were seeded by screening the CEPH MegaYAC library for the sequence tag sites (STSs) D6S258,

D6S306, D6S105, D6S464 and D6S276. Additional YACs containing these STSs were identified in the CEPH and the MIT/Whitehead databases. The three initial YAC contigs were expanded and eventually merged into a single contig by bidirectional walking using STSs developed from the ends of YAC inserts. An STS-content map comprising 64 STSs and 44 YACs across the HH region was constructed. In order to determine precise physical distances, a set of 14 YACs were selected for RARE-cleavage mapping (Gnirke et al. Genomics 24:199-210 (1994)) and the construction of the distance-calibrated YAC-contig and STS content maps which are shown in Figure 1.

Bacterial clones were identified by PCR-based and hybridization-based screening of comprehensive human cosmid, p1, BAC, and PAC libraries. Figure 1 also shows the bacterial clone contig across approximately 1 Mbp of genomic DNA that includes the region represented by YAC 241. The STS-content map indicating the STS and clone order is depicted in Figure 1. YACs, BACs, PACs and P1 clones are denoted by the suffices y, b, pc and p, respectively.

In Figure 1, the markers are characterized as follows: D6S248 (Orphanos, V. et al. Hum Mol Genet 2:2196 (1993)); D6S258, D6S265, D6S276, D6S306, D6S464 (Gyapay, G. et al. Nature Genetics 7:246-339 (1994)); 258-2, G4, HHp61, HHp89, HLA-A, H241-4, H241-6, H4073-3, RFP (Unpublished STS's to genomic DNA developed by the Assignee of the present application.); D6S1281, P6116 (Murray, J.C. et al. Science 265:2049-2054 (1994)); HLA-F (Fullan, A. and Thomas, W. Hum Molec Genet. 3:2266 (1994)); MOG (Roth, M-P. et al. Genomics 28:241-250 (1995)); 1A2, 1E.4, 2B8, 18B4, 19D9, 24E.2, 63-1, 63-3, 3321-1, 4073-1, HB63-2, HB65-1, HB65-2, HB68-1, HB373-8, H241-5, H241-29, H731-1, H950-1, H950-2, H950-3, H950-4, H950-

6, H950-8, H3216-1, H4072-2, H4440-1, H4440-2, H5091-1 (CA repeats described in co-pending U.S. Patent Application Serial No.08/599,252, filed February 9, 1996, which is a continuation-in-part of U.S. Patent Application Serial No. 08/559,302, filed November 15, 1995, which is a continuation-in-part of U.S. Patent Application Serial No. 5 08/436,074, filed May 8, 1995, the disclosures of which are hereby incorporated by reference in their entirety.); D6S1001 (Stone, C. et al. Hum Molec Genet 3:2043-2046 (1994)); D6S105 (Weber, J.L. et al. Nucl. Acids Res. 19:968 (1991)).

The markers indicated at the top of Figure 2 are those that are labeled with asterisks in Figure 1. Other than marker 24d1, all of the markers indicated (i.e., 241-4, 10 96-1, 65-2, 65-1, 241-6, 241-29, 241-5, 63-3, 63-1, 63-2, 373-8, and 373-29) are CA repeat markers. The numbers indicated in the chart with respect to the CA repeat markers refers to the size of the allele upon PCR amplification and sizing of the resulting product on acrylamide gels. The 24d1 marker, as discussed above, is a single base-pair mutation as represented by the G to A base substitution that is present in affected 15 chromosomes as illustrated in SEQ ID NO:29 and SEQ ID NO:30. The results of genotyping for each of the two chromosomes from the patients are indicated. DNA that is identical by descent is indicated by shading.

As will be appreciated, eight patient haplotypes displayed evidence of recombination events delineating the minimal HH region. The tract of DNA that is 20 "identical by descent" on all of the ancestral HH chromosomes is between, but not including, markers 241-29 and 63-3. Genomic sequencing has determined this region to be approximately 250 Kb in size. This region includes markers 241-5 and 24d1. For definition of telomeric and centromeric boundaries, see Figure 2, Patient HC75 and Patients HC2, HC22, HC50, HC87, HC91, HC125, and HC143.

25 4. Identification of cDNA 24

Based upon allelic association data, we delineated a region encompassed by YAC 241 as the region most likely to contain the HH gene. As one of our approaches to identify genes within the HH region, direct selection experiments were performed on 30 YAC 241. Morgan, J.G. et al. Nucl Acids Res 20:5173-5179 (1992).

Briefly, YAC DNA was isolated by pulse-field gel electrophoresis, digested with Mbo I and linkers ligated to the resulting fragments. The DNA was then amplified

by PCR using primers containing biotin on their 5' end. Similarly, cDNA was prepared from poly A+ RNA from fetal brain, small intestine and liver, digested with Mbo I, linkers ligated and amplified by PCR. The cDNA was 'blocked' with DNA clones representing human ribosomal RNA, histone genes as well as with repetitive DNA (Cot-1, Gibco).

Two rounds of solution hybridization were carried out to the prescribed value of Cot 100. The DNA fragments were cloned into pSP72 and sequenced. Four hundred and sixty-five clones were sequenced and arranged into 162 overlapping contigs, referred to herein as DS clones.

Representative DS clone sequences from each contig were searched against the public databases (NCBI) and interesting homologies were noted. One in particular, known as DS34 showed convincing homology to MHC Class I protein encoding genes. Small STSs were designed from each of the 162 contigs and the contigs were mapped in relation to the existing STS content map of the region.

Clones that mapped to the delineated minimal HH region of YAC 241 were given priority for further analysis. In conjunction with its homology to MHC Class I genes, DS34 mapped within our minimal region, and thus was considered a candidate for the HH gene. The STSs were subsequently used to determine which cDNA library was appropriate for obtaining full length cDNA clones.

Three directionally cloned plasmid-based cDNA libraries were employed (Gibco); brain, liver and testis. It was discovered that DS34 was present in all three libraries. Subsequently, DS34 was random primer labeled and used to screen colony lifts of cDNA libraries using standard procedures. Three clones were obtained from the testis library. The largest of these, 2.7 Kb, was designated cDNA24 and was sequenced completely on both strands.

5. Mutation Analysis of cDNA24

The candidate gene encompassed in cDNA24 was analyzed to detect mutations in the HH affected chromosomes as compared to unaffected chromosomes.

In connection with this work, patient DNA and RNA was obtained as follows. Lymphoblastoid cell lines from random and HH affected individuals were established by transformation of peripheral blood mononuclear cells with Epstein-Barr

Virus. Chromosomal DNA was purified from these cells by standard methods (Maniatis et al. Molecular Cloning - A Laboratory Manual (2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989))). PolyA+ RNA was purified using Fast Track (Invitrogen).

Mutation analysis was accomplished as follows. Initial searching for the

- 5 HH mutation in cDNA24 was accomplished through RT-PCR (reverse transcription-polymerase chain reaction, Dracopoli, N. et al. eds. Current Protocols in Human Genetics (J. Wiley & Sons, New York (1994)) method. First, from the genotype analysis, homozygous HH patients with the ancestral haplotype were identified (see previous sections). First strand cDNAs were synthesized through use of Superscript
10 reverse transcriptase (Life Technologies) using polyA+ RNA from transformed lymphoblastoid cell lines from two homozygous ancestral patients (HC9 and HC14) and those from two unaffected individuals (NY8 and CEPH 11840) as templates.

From these first strand cDNAs, coding regions corresponding to the cDNA24 sequence were amplified into three overlapping PCR products (designated herein
15 as A, B, and C) to facilitate efficient amplification and sequencing. A nested set of primers were used to increase specificity in generating the three products. The primers utilized are shown in Table 1:

TABLE 1

PCR Product	Name	Primer Set for 1st Nested PCR	Name	Primer Set for 2nd Nested PCR
"A"	P17	5'-CAA AAG AAG CGG AGA TTT AAC G-3'	P19	5'-AGA TTT AAC GGG GAC GTG C-3'
	P18	5'-AGA GGT CAC ATG ATG TGT CAC C-3'	P20	5'-AGG AGG CAC TTG TTG GTC C-3'
"B"	P5	5'-CTG AAA GGG TGG GAT CAC AT-3'	P7	5'-AAA ATC ACA ACC ACA GCA AAG-3'
	P6	5'-CAA GGA GTT CGT CAG GCA AT-3'	P8	5'-TTC CCA CAG TGA GTC TGC AG-3'
"C"	P9	5'-CAA TGG GGA TGG GAC CTA C-3'	P11	5'-ATA TAC GTG CCA GGT GGA GC-3'
	P10	5'-CCT CTT CAC AAC CCC TTT CA-3'	P12	5'-CAT AGC TGT GCA ACT CAC ATC A-3'

30 P17 (SEQ ID NO:31); P19 (SEQ ID NO:32); P18 (SEQ ID NO:33); P20 (SEQ ID NO:34); P5 (SEQ ID NO:18); P7 (SEQ ID NO:35); P6 (SEQ ID NO:19); P8 (SEQ ID NO:36); P9 (SEQ ID NO:37); P11 (SEQ ID NO:38); P10 (SEQ ID NO:39); and P12 (SEQ ID NO:40).

Amplified DNA products (PCR-products) were purified using gelase (Epicentre), and DNA sequences of these PCR-fragments were determined by the dideoxy
35 chain termination method using fluorescently labeled dideoxy nucleotides on an ABI 377 DNA sequencer.

Comparison of DNA sequences derived from these PCR-fragments identified a single nucleotide change in the cDNA24 coding region as represented by SEQ ID NO:29 and SEQ ID NO:30 at nucleotide 845. (Note, the first nucleotide of the open reading frame was counted as nucleotide 1. *See* Figure 4). The nucleotide at this position in two unaffected individuals was a G, while two HH affected individuals had an A at this position.

This mutation was designated as 24d1. The allele containing a G at this position was named as 24d1(G) and the allele containing an A in this position was named 24d1(A). The mutation causes an amino acid change from a cysteine (Cys282) to a tyrosine. This cysteine residue is conserved in all the known Class I MHC molecules and contributes a sulfur to the formation of a disulfide bridge that is present in the immunoglobulin constant region like domain (Ig domain, Gussow et al. Immunogenetics 25:313-322 (1987); Bjorkman and Parham Ann Rev Biochem 59:253 (1990)). In the case of Class I MHC molecules, it has been shown that a similar change in the reciprocal cysteine involved in the disulfide bridge abolishes the function of the protein by causing a defect in cell surface expression (Miyazaki et al. Proc. Natl. Acad. Sci. U.S.A. 83:757-761 (1986)). Thus, due to the high degree of conservation seen in the structure, it is likely that the 24d1 mutation would interfere with the function of cDNA 24 protein products.

The genomic sequence surrounding the 24d1 mutation is provided in SEQ ID NO:29 (unaffected 24d1(G) allele) and SEQ ID NO:30 (affected 24d1(A) allele).

The frequency of the mutant 24d1(A) allele and the normal 24d1(G) allele was determined in random chromosomes and affected chromosomes through use of an oligonucleotide ligation assay (OLA assay). *See* Nickerson et al. Proc. Natl. Acad. Sci. U.S.A. 87:8923-8927 (1990). Chromosomal DNA from these individuals was prepared from either a lymphoblastoid cell line or peripheral blood cells. First, DNA corresponding to exon 4 was amplified by PCR using primers designed against intron DNA sequences flanking exon 4. *See* Figure 6 which provides the precise location of the sequences used for primer design. The presence of the 24d1(A) allele or the 24d1(G) allele was determined by OLA using the oligonucleotides outlined in Figure 5. Figure 5 shows the sequences of preferred primers used for amplification and analysis of the above base mutation. The amplification primers for 24d1 are labeled 24d1.P1 (SEQ ID NO:13)

and 24d1.P2 (SEQ ID NO:14). The oligonucleotides used in the sequence determination by OLA for 24d1 are designated 24d1.A (SEQ ID NO:15), 24d1.B (SEQ ID NO:16), and 24d1.X (SEQ ID NO:17). As indicated in the sequences shown, "bio" indicates biotin coupling, "p" indicates 5'-phosphate, and "dig" indicates coupled digoxigenin.

The result from this OLA assay with 164 HH affected individuals and 134 unaffected random individuals is shown in Table 2.

TABLE 2

Frequencies of Alleles as % of Chromosomes Tested		
	Affected Chromosomes (N=328)	Random Chromosomes (N=268)
24d1 "A"	86%	4%
24d1 "G"	14%	96%

The 24d1(A) mutation occurs in 86% of the chromosomes from HH affected individuals (affected chromosomes) as compared to 4% in the chromosomes from random individuals (random chromosomes). This approximates the estimated frequency of the ancestral HH mutation in the general population. Among these 164 affected individuals, 137 were homozygous for the 24d1(A) allele and 9 were heterozygous for the 24d1(A) and the 24d1(G) alleles, while the remaining 18 were homozygous for the 24d1(G) allele. The distribution of homozygotes and heterozygotes for the 24d1 alleles significantly deviates from that expected by Hardy-Weinberg equilibrium, suggesting the possibility of either mutant alleles that complement one another or genetic heterogeneity. Regardless of this fact, 24d1 homozygosity provides identification of 84% of HH patients in our sample.

In addition to the 24d1 mutation, other sequence variants were also detected within certain subpopulations of patients. In this regard, sequence analysis of the cDNA24 gene was extended to the remaining individuals who are either 24d1(G) homozygotes or 24d1(A)/24d1(G) heterozygotes. Eighteen 24d1(G) homozygous HH patient and nine 24d1 heterozygotes patients were analyzed. All the exons that contain the cDNA24 open reading frame were amplified from these individuals through the use of PCR primers directed against introns and exons. DNA sequences of these PCR products

were determined by dideoxy chain termination methods. This analysis identified two additional sequence variants (24d2 and 24d7) in the coding region of cDNA24.

The first additional variant, 24d2, occurs at nucleotide 187. (Note, the first nucleotide of the open reading frame was counted as nucleotide 1. *See Figure 4*).

5 The two alleles of this variant are 24d2(C) (C at this position) and 24d2(G) (G at this position). CDNA24 as well as NY8 and CEPH 11840 were homozygous for the 24d2(C) allele, while DNAs from some patients (HC74, HC82 and others) were 24d2(C)/24d2(G) heterozygous. The 24d2(C) allele encodes a histidine (His63) while 24d2(G) encodes an aspartic acid, thus creating an amino acid change in the presumed peptide binding domain
10 of the protein product. As with 24d1, changes to certain amino acids in the peptide binding domains of MHC Class I proteins can also disrupt intracellular transport and assembly (Salter, *Immunogenetics* 39:266-271 (1994)).

The genomic sequence surrounding the variant for 24d2(C) and 24d2(G) is provided below:

15 **24d2(C):**

AGCTGTTTCGTGTTCTATGAT**C**ATGAGAGTCGCCGTGTGGA (SEQ ID NO:41)

24d2(G):

AGCTGTTTCGTGTTCTATGAT**G**ATGAGAGTCGCCGTGTGGA (SEQ ID NO:42)

20 The frequency of the 24d2 mutant allele versus the normal allele was determined through OLA as described above. The results from the OLA assays are shown in Table 3.

TABLE 3

Frequencies of Alleles as % of Chromosomes Tested		
	Affected Chromosomes (N=328)	Random Chromosomes (N=158)
25 24d2 "C"	95%	82%
24d2 "G"	5%	18%

As shown in Table 3, the 24d2(G) allele occurs in 5% of the chromosomes from HH affected individuals (affected chromosomes) and in 18% of the chromosomes
30 from random individuals (random chromosomes). The frequency of the 24d2(G) allele in

the patients was lower than that of random chromosomes because this allele was associated with some of the nonancestral chromosomes and the majority of the HH patient chromosomes were ancestral. The remainder of the chromosomes had the 24d2(C) allele. When one looks at the distribution of the 24d2(G) allele containing chromosomes within the patient population, one notices an enrichment of the 24d2(G) allele in 24d1 heterozygotes. Eighty-nine percent or 8 out of 9 heterozygotes for 24d1 have the 24d2(G) allele as compared to the expected 18%. Thus, the 24d2(G) allele is enriched in 24d1 heterozygous patients indicating that the 24d2 mutation has a role in HH disease.

A third nucleotide change was identified at nucleotide 193 in one patient (HC43) and was named 24d7. (Note, the first nucleotide of the open reading frame was counted as nucleotide 1. *See Figure 4*). All other patients analyzed, as well as random controls, including NY8 and CEPH 11840 had an allele 24d7(A) (A at this position), while HC43 was a 24d7(A)/24d7(T) heterozygote. The 24d7(A) allele encodes a serine (Ser65) while the 24d7(T) allele changes this to a cysteine codon, also within the presumed peptide binding domain of the cDNA 24 protein product.

The genomic sequence surrounding the polymorphism for 24d7(A) and 24d7(T) is provided below:

24d7(A):

TGTTCTATGATCATGAGAGTCGCCGTGTGGAG (SEQ ID NO:43)

24d7(T):

TGTTCTATGATCATGAGTGTGCCGTGTGGAG (SEQ ID NO:44)

The frequency of the 24d7 mutant allele versus normal allele was determined through OLA as described above. The results from the OLA assays are shown in Table 4.

TABLE 4

Frequencies of Alleles as % of Chromosomes Tested		
	Affected Chromosomes (N=266)	Random Chromosomes (N=156)
24d7 "A"	99.6%	97%
24d7 "T"	0.4%	3%

In Table 4, The 24d7(T) allele was observed in only one chromosome present in the patient sample (HC43) (0.4%) and present in four chromosomes from the unaffected individuals (3%). The presence of the 24d7(T) allele shows no increase in risk of acquiring HH and thus may only be a polymorphic variant within the population.

B. Characterization of the HH Gene

1. Sequence

The complete sequence of cDNA24 (of which the coding region is shown in Figure 4) was used to search public databases (NCBI) for homology to known gene sequences using the BlastX search algorithm. Substantial homology to MHC Class I molecules from a variety of species was obtained.

Next, the sequence was analyzed for the existence of open-reading frames (ORF's). The largest ORF, as shown in Figure 4, encodes a polypeptide of 348 amino acids with a predicted molecular mass of approximately 38 KD. As will be appreciated, the molecular weight/mass can vary due to possible substitutions or deletions of certain amino acid residues. In addition, the molecular weight/mass of the polypeptide can vary due to the addition of carbohydrate moieties and in connection with certain phosphorylation events and other post-translational modifications. The remainder of the cDNA, 1.4 Kb appears to be non-coding; one poly A addition site (AATAAA) is present 20 bp upstream of the poly A tail (not shown in Figure 4).

A search of translated public database (NCBI) using a six way translation of cDNA24 showed significant homology between cDNA 24 and previously cloned MHC proteins. The search revealed 39% identity and 58% similarity of the amino acid residues. Besides MHC Class I proteins, the HH gene product shows similarity to other proteins known to contain motifs related to the immunoglobulin constant region, such as β -2-microglobulin and zinc- α -2-glycoprotein. See Bjorkman, P. and Parham, P. Ann Rev Biochem 59:253 (1990). A multiple sequence alignment was carried out between several MHC Class I proteins (Fig. 7). The results indicate that the homology between cDNA 24 and MHC extends throughout the cDNA 24 protein, including the peptide-binding region, immunoglobulin-like region, transmembrane region and cytoplasmic region. Of particular

interest is the conservation of the position of several cysteine residues which function in protein folding via disulfide bonds.

cDNA 24 tissue expression was determined by probing polyA+ RNA Northern blots (Clontech). One major transcript of approximately 4.4 Kb was observed in all of the 16 tissues tested including small intestine and liver.

The genomic region corresponding to cDNA 24 was cloned and sequenced. CDNA 24 is comprised of apparently seven exons, covering approximately 11 Kb of sequence. The putative seventh exon is completely non-coding and contains one poly (A)+ addition signal. In the region of the predicted start site of transcription, there are no consensus CAAT or TATA boxes, nor are there any start like β GAP-like sequences recently suggested by Rothenberg and Volland, *supra* (1996). One CpG island was found to overlap the first exon and extend into the first intron. Within this island are the consensus cis-acting binding sites for the transcription factors Sp1 (2 sites) and AP1 (1 site) (McVector software, Oxford Molecular). The lack of any recognizable TATA boxes and the presence of Sp1 and AP2 binding sites is consistent with the low level of transcription associated with the gene.

2. Structure/Function of the HH Gene Product

The predicted translation product of cDNA 24, herein referred to as the HH gene and HH gene product or HH protein, was aligned to other MHC proteins for which there was a high degree of homology at the amino acid level (Figure 7). MHC Class I proteins are comprised of several distinct domains: peptide binding domains (α 1 and α 2), immunoglobulin like domain (α 3), a transmembrane region, and a small cytoplasmic portion. The HH gene product shows homology throughout all four of these domains. Further confirmation of the structural relationship between the HH gene product and MHC Class I molecules was obtained through analysis of the primary sequence using McVector software (Oxford Molecular).

The HH gene product is similar to MHC Class 1 molecules when comparing hydrophilicity, surface probability, and secondary structure. A conserved structural feature of Class 1 molecules is the presence of several intradomain disulfide bonds between positions Cys-101 and Cys-164 in the α 2 helix and between Cys-203 and Cys-259 in the α 3 helix. This domain structure is conserved between all Class 1

molecules. The disulfide bond in the $\alpha 3$ helix forms the interface through which the molecule interacts with the β -2-microglobulin protein, a protein which associates with MHC Class I molecules in the endoplasmic reticulum and functions as a molecular chaperone.

5 The HH protein possesses all four cysteine residues in conserved positions common to MHC Class I molecules. This data indicates a structural relationship with MHC Class I Molecules and a potential interaction with β -2-microglobulin (or a related protein) as well.

10 It has been demonstrated that when the cysteine at position 203 is mutated, thus disrupting the disulfide bridge that is formed between Cys-203 and Cys-259, intracellular transport of the mutated protein is blocked. *See Miyazaki et al. supra* (1986). As will be appreciated, the mutation (24d1) of the present invention corresponds to the reciprocal cysteine (Cys-259; Cys-282 in the HH protein) in the disulfide bridge that was demonstrated by Miyazaki et al. to abolish intracellular transport. Thus, it is
15 predicted that the 24d1 mutation ablates expression of the HH protein on cell surfaces.

 Sequence studies of MHC Class I molecules have shown that these molecules are among the most polymorphic proteins known to date. The majority of this variation is located in the $\alpha 1$ and $\alpha 2$ domains of the molecule. In contrast, the HH gene product displays little polymorphism in this region. In this respect, the HH protein is
20 more similar to the non-classical MHC class of proteins which show little or no allelic variation. The functions of the non-classical MHC Class I proteins, such as HLA-E, F, and G proteins, are unknown, although HLA-G may play a role in maternal/fetal immune interactions. Campbell, R.D. and Trousdale, J. Immunology Today 14:349 (1993).

 Therefore, the HH protein appears to differ from MHC Class I molecules
25 in one important respect. Although it has maintained all of the structural hallmarks of MHC Class I molecules, it does not appear to be polymorphic and has presumably evolved a different function. This function appears to be participation in the control of body iron levels, for example, through the direct binding of free iron, binding of other iron-bound proteins, or signaling involved in regulation of iron levels. Iron-bound
30 proteins or other proteins involved in signaling could associate with the HH protein in a manner similar to β -2-microglobulin or could be bound in the peptide-binding region of the protein.

In addition, the protein could exert its effects by indirectly regulating iron adsorption through intercellular signaling, i.e., T-cell activation and subsequent specific cell proliferation via cytokine release. Alternatively, the expression of the HH protein could be regulated by iron or cytokines. As such, its interaction with other signaling molecules or receptors, such as Tfr, would be modulated. Directly related to our discovery of the gene responsible for HH is the data of de Sousa et al. (*Immun Lett* 39:105-111 (1994)). Analysis of previously constructed, β -2-microglobulin knockout mice indicated that mice homozygous for the defect progressively accumulated iron in a manner indistinguishable from human hemochromatosis. These mice also mimic an additional phenotype observed in HH patients, an abnormally low number of CD8+ T cells. Therefore, β -2-microglobulin knock-out mice possess two characteristics of human HH, iron loading of the internal organs and a defective T cell repertoire. Clearly, human β -2-microglobulin which maps to Chromosome 15 is not responsible for HH. However, β -2-microglobulin knock-out mice could phenocopy HH by preventing the associated murine HH homolog of cDNA 24 from assuming its functional structure and presentation on the surface of cells.

An important link between the HH protein and iron metabolism has been demonstrated. One of the major mechanisms by which cells and tissues uptake iron is via receptor-mediated endocytosis of iron-loaded transferrin. Transferrin itself binds to cell surface receptors (transferrin receptors, Tfr) which are responsible for iron uptake. Transferrin receptors are regulated by a variety of physiologic stimuli including cytokines and iron. It has now been demonstrated that the HH protein interacts directly with the Tfr in the plasma membrane. Labeling of cell-surface proteins by biotinylation followed by immunoprecipitation with HH protein specific antibodies demonstrates that Tfr physically interacts with the HH protein. Co-immunoprecipitation experiments by first immunoprecipitating with HH protein antibodies followed by Western blotting with Tfr antibodies corroborates these results. In contrast, the HH protein containing the 24d1 mutation fails to interact with the Tfr. The normal HH protein/Tfr interaction could regulate the activity of the Tfr to transport iron-bound transferrin either by change in receptor affinity, receptor number (including expression), or by a change in the rate of receptor internalization and recycling. The HH protein containing the 24d1 mutation

would then lead to unregulated iron metabolism and HH disease by failing to interact with the Tfr and modulating its activity.

Thus, the HH gene encodes a protein with striking similarity to MHC Class I proteins. The gene product has maintained a structural feature essential for proper and functional recognition of a chaperone protein (β -2-microglobulin) whose disruption in mice causes a phenocopy of HH disease. The HH protein interacts with β 2-microglobulin and the Tfr and is expressed on the cell-surface. When mutated as in 24d1, the interactions with β 2-microglobulin and Tfr are lost and the protein no longer is located on the cell-surface.

3. Protein Purification

The HH protein can be purified by one of several methods which have been selected based upon the molecular properties revealed by its sequence and its homology to MHC Class I molecules. Since the molecule possesses properties of an integral membrane protein, i.e. contains a transmembrane domain, the protein must first be isolated from the membrane fraction of cells using detergent solubilization. A variety of detergents useful for this purpose are well known in the art.

Once solubilized, the HH protein can be further purified by conventional affinity chromatography techniques. The conventional approaches of ion exchange, hydrophobic interaction, and/or organomercurial chromatographies can be utilized. These methodologies take advantage of natural features of the primary structure, such as: charged amino acid residues, hydrophobic transmembrane domains, and sulfhydryl-containing cysteine residues, respectively. In the affinity chromatography approach use is made of immunoaffinity ligands or of the proposed interaction of the HH protein with β -2-microglobulin, calnexin or similar molecules. In the former, the affinity matrix consists of antibodies (polyclonal or monoclonal) specific to the HH protein coupled to an inert matrix. The production of antibodies specific to the HH protein are described in Section (III)(A)(3), entitled "Antibodies". In the latter method, various ligands which are proposed to specifically interact with the HH protein based on its homology with MHC Class I molecules could be immobilized on an inert matrix. For example, β -2-microglobulin, β -2-microglobulin-like molecules, or other specific proteins such as calnexin or calnexin-like molecules, and the like, or portions and/or fragments

thereof, can be utilized. General methods for preparation and use of affinity matrices are well known in the art.

Criteria for the determination of the purity of the HH protein include those standard to the field of protein chemistry. These include N-terminal amino acid determination, one and two-dimensional polyacrylamide gel electrophoresis, and silver staining. The purified protein is useful for use in studies related to the determination of secondary and tertiary structure, as aid in drug design, and for *in vitro* study of the biological function of the molecule.

10 III. Applications

A. HH Screening

With knowledge of the primary mutation of the HH gene as disclosed herein, screening for presymptomatic homozygotes, including prenatal diagnosis, and screening for heterozygotes can be readily carried out.

15 1. General

There are at least four levels at which the diagnostic information from the HH gene can be used. The first is to assist in the medical diagnosis of a symptomatic patient. In this application, a patient with a high index of suspicion for being affected with HH could be tested with the gene-based diagnostic. A positive result would show that the individual was homozygous for the common HH mutation. This would provide a rapid and non-invasive confirmation that the individual corresponded to the fraction of the population homozygous for this mutation. Such a result would help rule out other causes of iron overload in that individual. In the case of a heterozygote or compound heterozygote for 24d1 and 24d2, this individual may also be affected with HH.

The second level of application would be in first degree relatives of newly diagnosed probands. Currently recommended medical practice is to screen all such first degree relatives, as they are at a higher risk for disease and, if identified, could benefit from therapeutic intervention.

30 The third level of screening would be in individuals afflicted with diseases that are known to be sequelae of HH disease. Such diseases include cirrhosis of the liver, diabetes, arthritis, reproductive dysfunction, and heart disease. It has been estimated, for

example, that as many as 1% of individuals with diabetes may be so afflicted because of HH disease. In addition, other conditions such as sporadic porphyria cutanea tarda can be screened for using an HH gene mutation diagnosis. When secondary to HH disease, some of the pathology of these diseases can be reversed upon phlebotomy therapy.

5 Furthermore, it has been disclosed that the potential for hemochromatosis interferes with the effectiveness of interferon treatment of hepatitis C (Bacon, B. Abstracts of the Fifth Conference of the International Association for the Study of Disorders of Iron Metabolism 15-16 1995)). Therefore, it will be beneficial to perform screening with gene-based diagnostics in these disease populations.

10 The fourth level of screening is to screen the general population for homozygotes and, potentially, heterozygotes. Several cost-benefit analyses have suggested that there is value in such screenings for the identification of presymptomatic individuals. Once identified, such individuals could be targeted for preventative phlebotomy or treatment with the therapeutic compositions of the invention.

15

2. Nucleic Acid Based Screening

Individuals carrying mutations in the HH gene may be detected at either the DNA, the RNA, or the protein level using a variety of techniques that are well known in the art. The genomic DNA used for the diagnosis may be obtained from body cells, such as those present in peripheral blood, urine, saliva, bucca, surgical specimen, and autopsy specimens. The DNA may be used directly or may be amplified enzymatically *in vitro* through use of PCR (Saiki et al. Science 239:487-491 (1988)) or other *in vitro* amplification methods such as the ligase chain reaction (LCR) (Wu and Wallace Genomics 4:560-569 (1989)), strand displacement amplification (SDA) (Walker et al. Proc. Natl. Acad. Sci. U.S.A. 89:392-396 (1992)), self-sustained sequence replication (3SR) (Fahy et al. PCR Methods Appl. 1:25-33 (1992)), prior to mutation analysis. The methodology for preparing nucleic acids in a form that is suitable for mutation detection is well known in the art.

25 The detection of mutations in specific DNA sequences, such as the HH gene, can be accomplished by a variety of methods including, but not limited to, restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage (Kan and Dozy Lancet ii:910-912 (1978)), hybridization with

30

allele-specific oligonucleotide probes (Wallace et al. Nucl Acids Res 6:3543-3557 (1978)), including immobilized oligonucleotides (Saiki et al. Proc. Natl. Acad. Sci. U.S.A. 86:6230-6234 (1989)) or oligonucleotide arrays (Maskos and Southern Nucl Acids Res 21:2269-2270 (1993)), allele-specific PCR (Newton et al. Nucl Acids Res 17:2503-2516 (1989)), mismatch-repair detection (MRD) (Faham and Cox Genome Res 5:474-482 (1995)), binding of MutS protein (Wagner et al. Nucl Acids Res 23:3944-3948 (1995)), denaturing-gradient gel electrophoresis (DGGE) (Fisher and Lerman et al. Proc. Natl. Acad. Sci. U.S.A. 80:1579-1583 (1983)), single-strand-conformation-polymorphism detection (Orita et al. Genomics 5:874-879 (1983)), RNAase cleavage at mismatched base-pairs (Myers et al. Science 230:1242 (1985)), chemical (Cotton et al. Proc. Natl. Acad. Sci. U.S.A. 85:4397-4401 (1988)) or enzymatic (Youil et al. Proc. Natl. Acad. Sci. U.S.A. 92:87-91 (1995)) cleavage of heteroduplex DNA, methods based on allele specific primer extension (Syvänen et al. Genomics 8:684-692 (1990)), genetic bit analysis (GBA) (Nikiforov et al. Nucl Acids Res 22:4167-4175 (1994)), the oligonucleotide-ligation assay (OLA) (Landegren et al. Science 241:1077 (1988)), the allele-specific ligation chain reaction (LCR) (Barrany Proc. Natl. Acad. Sci. U.S.A. 88:189-193 (1991)), gap-LCR (Abravaya et al. Nucl Acids Res 23:675-682 (1995)), and radioactive and/or fluorescent DNA sequencing using standard procedures well known in the art.

In addition to the genotype described above, as described in co-pending PCT application WO 96/35802 published November 14, 1996, genotypes characterized by the presence of the alleles 19D9:205; 18B4:235; 1A2:239; 1E4:271; 24E2:245; 2B8:206; 3321-1:98 (denoted 3321-1:197 therein); 4073-1:182; 4440-1:180; 4440-2:139; 731-1:177; 5091-1:148; 3216-1:221; 4072-2:170 (denoted 4072-2:148 therein); 950-1:142; 950-2:164; 950-3:165; 950-4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, alleles D6S258:199, D6S265:122, D6S105:124, D6S306:238, D6S464:206; and D6S1001:180, and/or alleles associates with the HHP-1, the HHP-19 or HHP-29 single base-pair polymorphisms can also be used to assist in the identification of an individual whose genome contains the common HH mutation. For example, the assessing step can be performed by a process which comprises subjecting the DNA or RNA to amplification using oligonucleotide primers flanking the base-pair polymorphism 24d1 and/or 24d2 and

oligonucleotide primers flanking at least one of the base-pair polymorphisms HHP-1, HHP-19, and HHP-29, oligonucleotide primers flanking at least one of the microsatellite repeat alleles, or oligonucleotide primers for any combination of polymorphisms or microsatellite repeat alleles thereof.

5 Oligonucleotides useful in diagnostic assays are typically at least 8 consecutive nucleotides in length, and may range upwards of 18 nucleotides in length. Such oligonucleotides can be derived from either the HH genomic or cDNA sequences. Preferred oligonucleotides of at least 8 nucleotides in length include 1-46, 48-123; 120-369; 365-394; 390-540; 538-646; 643-1004; 1001-1080; 1083-1109; 1106-1304; 1301-10 1366; 1363-1386; 1389-1514; 1516-1778; 1773-1917; 1921-2010; 2051-2146; 2154-2209; 2234-2368; 2367-2422; 2420-2464; 2465-2491; 2488-2568; 2872-2901; 2902-2934; 2936-2954; 2449-3001; 3000-3042; 3420-3435; 3451-3708; 3703-3754; 3750-3770; 3774-3840; 3840-3962; 3964-3978; 3974-3992; 3990-4157; 4153-4251; 4257-4282; 4284-4321; 4316-4333; 4337-4391; 4386-4400; 4398-4436; 4444-4547; 4572-4714; 4709-4777; 5165-5397; 15 5394-6582; 5578-5696; 5691-5709; 5708-5773; 5773-5816; 5818-5849; 5889-6045; 6042-6075; 6073-6108; 6113-6133; 6150-6296; 6292-6354; 6356-6555; 6555-6575; 6575-6616; 6620-6792; 6788-6917; 6913-7027; 7023-7061; 7056-7124; 7319-7507; 7882-8000; 7998-8072; 8073-8098; 9000-9037; 9486-9502; 9743-9811; 9808-9831; 9829-9866; 9862-9986; 9983-10075; 10072-10091; 10091-10195; 10247-10263; 10262-10300; 10299-10448; 20 10448-10539; 10547-10564; 10580-10612; 10608-10708; 10703-10721; 10716-10750; 10749-10774; 10774-10800; and 10796-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 9 nucleotides in length include 1-47; 47-124; 119-370; 364-395; 389-541; 537-647; 642-1005; 1000-1081; 1082-1110; 1105-1305; 1300-1367; 1362-1387; 1388-1515; 1515-1918; 1920-2011; 2050-2147; 2153-2210; 25 2233-2369; 2366-2423; 2419-2465; 2464-2492; 2487-2569; 2871-2935; 2935-3002; 2999-3043; 3419-3436; 3450-3755; 3749-3771; 3773-3841; 3839-3963; 3963-3979; 3973-3993; 3989-4158; 4152-4252; 4256-4283; 4283-4334; 4336-4401; 4397-4437; 4443-4548; 4571-4778; 5164-5398; 5393-5583; 5577-5710; 5707-5774; 5772-5817; 5817-5850; 5888-6046; 6041-6076; 6072-6109; 6112-6134; 6149-6355; 6355-6556; 6554-6576; 6574-6793; 6787-30 7125; 7318-7508; 7881-8001; 7997-8073; 8072-8099; 8999-9038; 9485-9503; 9742-9812; 9807-9832; 9828-9867; 9861-9987; 9982-10076; 10071-10092; 10090-10196; 10246-

10264; 10261-10301; 10298-10449; 10447-10540; 10546-10565; 10579-10751; 10748-10775; 10773-10801; and 10795-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 10 nucleotides in length include 1-48;
46-125; 118-1006; 999-1082; 1081-1111; 1104-1306; 1299-1368; 1361-1388; 1387-1516;
5 1514-1919; 1919-2012; 2049-2148; 2152-2211; 2232-2370 2365-2424; 2418-2466; 2463-
2493; 2486-2570; 2870-2936; 2934-3003; 2998-3044; 3418-3437; 3449-3772; 3772-3842;
3838-3964; 3962-3994; 3988-4284; 4282-4335; 4335-4402; 4396-4438; 4442-4549; 4570-
4779; 5163-5711; 5706-5775; 5771-5818; 5816-5851; 5867-6047; 6040-6077; 6071-6110;
6111-6135; 6148-6356; 6354-6577; 6573-7126; 7317-7509; 7880-8074; 8071-8100; 8998-
10 9039; 9484-9504; 9741-9813; 9806-9833; 9827-9988; 9981-10093; 10089-10197; 10245-
10265; 10260-10302; 10297-10450; 10446-10541; 10545-10566; 10578-10752; 10747-
10776; and 10772-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 11 nucleotides in length include 1-49;
45-1389; 1386-1517, 1513-1920; 1918-2013; 2048-2149; 2151-2212; 2231-2371; 2364-
15 2425; 2417-2467; 2462-2571; 2869-2937; 2933-3004; 2997-3045; 3417-3438; 3448-3773;
3771-3843; 3837-3965; 3961-3995; 3987-4285; 4281-4336; 4334-4403; 4395-4439; 4441-
4550; 4569-4780; 5162-5712; 5705-5776; 5770-5819; 5815-5852; 5886-6111; 6100-6136;
6147-6357; 6353-6578; 6572-7127; 7316-7510; 7879-8075; 8070-8101; 8997-9040; 9483-
9505; 9740-10198; 10244-10266; 10257-10303; 10296-10451; 10445-10542; 10544-
20 10567; 10577-10753; 10746-10777; and 10771-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 12 nucleotides in length include 1-50,
44-1390; 1385-1518; 1512-1921; 1917-2014; 2047-2150; 2150-2213; 2230-2372; 2363-
2468; 2461-2572; 2868-2938; 2932-3005; 2996-3046; 3416-3439; 3447-3774; 3770-3844;
3836-3966; 3960-4286; 4280-4337; 4333-4440; 4440-4551; 4568-4781; 5161-5713; 5704-
25 5777; 5669-5820; 5814-5853; 5885-6112; 6109-6137; 6146-6358; 6352-6579; 6571-7128;
7315-7511; 7878-8076; 8069-8102; 8996-9041; 9482-9506; 9739-10199; 10243-10267;
10256-10304; 10295-10452; 10444-10543; 10543-10566; 10576-10754; 10745-10778; and
10770-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 13 nucleotides in length include 1-51;
30 43-1391; 1384-1519; 1511-1922; 1916-2015; 2046-2151; 2149-2214; 2229-2469; 2460-
2573; 2867-2939; 2931-3047; 3415-3440; 3446-3775; 3769-3845; 3835-3967; 3959-4287;
4279-4338; 4332-4441; 4439-4552; 4567-4782; 5160-5778; 5668-5821; 5813-5854; 5884-

6113; 6108-6138; 6145-6359; 6351-6580; 6570-7129; 7314-7512; 7877-8077; 8068-8103; 8995-9042; 9481-9507; 9738-10200; 10242-10453; 10443-10544; 10542-10567; 10575-10779; and 10769-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 14 nucleotides in length include 1-52;
 5 42-1392; 1383-1520; 1510-1923; 1915-2016; 2045-2152; 2148-2215; 2228-2574; 2866-2940; 2930-3048; 3414-3441; 3445-3776; 3768-3968; 3959-4288; 4278-4339; 4331-4442; 4438-4553; 4566-4783; 5159-5822; 5812-5855; 5883-6114; 6107-6139; 6144-6360; 6350-6581; 6569-7130; 7313-7513; 7876-8078; 8067-8104; 8994-9043; 9480-9508; 9737-10201; 10241-10454; 10442-10545; 10541-10568; and 10574-10825 of SEQ ID NO:1, 3,
 10 5, or 7. Preferred oligonucleotides of at least 15 nucleotides in length include 1-53; 41-1393; 1382-1521; 1509-1924; 1914-2017; 2044-2153; 2147-2216; 2227-2575; 2865-2942; 2929-3049; 3413-3442; 3444-3777; 3767-3969; 3958-4289; 4277-4340; 4330-4443; 4437-4554; 4565-4784; 5158-5823; 5811-5856; 5882-6115; 6106-6140; 6143-6361; 6349-7131; 7312-7514; 7875-8105; 8993-9044; 9479-9509; 9736-10202; 10240-10546; 10540-10569; and 10573-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 16 nucleotides in length include 1-1394; 1381-1925; 1913-2018; 2043-2154; 2146-2217; 2226-2576; 2864-3050; 3412-3443; 3443-3778; 3766-4341; 4329-4444; 4436-4555; 4564-4785; 5157-5857; 5881-6116; 6105-6141; 6142-7132; 7311-7515; 7874-8106; 8992-9045; 9478-9510; 9735-10203; 10239-
 20 10547; 10539-10570; and 10572-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 17 nucleotides in length include 1-1926; 1912-2019; 2042-2155; 2145-2218; 2225-2577; 2863-3051; 3411-3779; 3765-4342; 4329-4445; 4435-4556; 4563-4786; 5156-5858; 5880-6117; 6104-6142; 6141-7133; 7310-7516; 7873-8107; 8991-9046; 9477-9511; 9734-10204; 10238-10548; 10538-10571; and
 25 10571-10825 of SEQ ID NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 18 nucleotides in length include 1-2020; 2041-2156; 2144-2219; 2224-2578; 2862-3052; 3410-3780; 3764-4446; 4434-4557; 4562-4787; 5155-5859; 5879-6118; 6103-6143; 6140-7134; 7309-7517; 7872-8108; 8990-9047; 9476-9512; 9733-10205; 10237-10549; 10537-10572; and 10570-10825 of SEQ ID
 30 NO:1, 3, 5, or 7.

Preferred oligonucleotides of at least 8 nucleotides in length include 1-55; 55-251; 250-306; 310-376; 380-498; 500-528; 516-543; 541-578; 573-592; 590-609; 611-

648; 642-660; 664-717; 712-727; 725-763; 772-828; 813-874; 872-928; 913-942; 940-998; 997-1046; 1054-1071; 1076-1116; 1115-1182; 1186-1207; 1440-1483; 1482-1620; 2003-2055; 2057-2107; 2116-2200; and 2453-2469 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 9 nucleotides in length include 1-56;
 5 54-252; 249-307; 309-377; 379-499; 499-529; 515-544; 540-579; 572-593; 589-610; 610-649; 641-661; 663-718; 711-728; 724-764; 771-829; 812-875; 871-929; 912-943; 939-999; 996-1047; 1053-1072; 1075-1117; 1114-1183; 1185-1208; 1439-1484; 1481-1629; 2002-2056; 2056-2108; 2115-2201; and 2452-2470 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 10 nucleotides in length include 1-57;
 10 53-253; 248-308; 308-378; 378-500; 498-530; 514-545; 539-580; 571-594; 588-611; 609-662; 662-729; 723-765; 770-876; 870-944; 938-1000; 995-1048; 1052-1073; 1074-1118; 1113-1184; 1184-1209; 1438-1485; 1480-1630; 2001-2057; 2055-2109; 2114-2202; and 2451-2471 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 11 nucleotides in length include 1-58;
 15 52-254; 247-309; 307-379; 377-501; 497-531; 513-546; 538-595; 587-612; 608-663; 661-730; 722-766; 769-877; 869-1049; 1051-1074; 1073-1119; 1112-1185; 1183-1210; 1437-1486; 1479-1631; 2000-2058; 2054-2110; 2113-2203; and 2450-2472 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 12 nucleotides in length include 1-
 20 255; 246-310; 306-380; 376-502; 496-596; 586-613; 607-664; 660-767; 768-1050; 1050-1075; 072-1120; 1111-1186; 1182-1211; 1436-1487; 1478-1632; 1999-2059; 2053-2121; 2112-2204; and 2449-2473 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 13 nucleotides in length include 1-
 25 311; 305-381; 375-503; 495-614; 606-665; 659-768; 767-1051; 1049-1076; 1071-1121; 1110-1187; 1181-1212; 1435-1633; 1998-2060; 2052-2205 and 2448-2474 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 14 nucleotides in length include 1-
 30 312; 304-382; 374-504; 494-615; 605-666; 658-769; 766-1052; 1048-1077; 1070-1188; 1180-1213; 1434-1634; 1997-2061; 2051-2206; and 2447-2475 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 15 nucleotides in length include 1-
 313; 303-383; 373-505; 493-616; 604-667; 657-770; 765-1053; 1047-1078; 1069-1189;

1179-1214; 1433-1635; 1996-2062; 2050-2207; and 2446-2476 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 16 nucleotides in length include 1-314; 302-384; 372-668; 656-771; 764-1054; 1046-1079; 1068-1190; 1178-1215; 1432-
5 1636; 1995-2208; and 2445-2477 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 17 nucleotides in length include 1-315; 301-385; 371-669; 655-772; 763-1055; 1045-1080; 1067-1191; 1177-1216; 1431-1637; 1994-2209; and 2444-2478 of SEQ ID NO:9, 10, 11 or 12.

Preferred oligonucleotides of at least 18 nucleotides in length include 1-
10 773; 762-1056; 1044-1081; 1066-1192; 1176-1217; 1430-1638; 1993-2210; and 2443-2479 of SEQ ID NO:9, 10, 11 or 12.

Such preferred oligonucleotides can also be used as part of an oligonucleotide pair, wherein the second member of the pair is any oligonucleotide of at least 8 consecutive nucleotides selected from SEQ ID NOS:1, 3, 5, 7, 9, 10, 11, or 12.

15 It will be appreciated that such preferred oligonucleotides can be a part of a kit for detecting polymorphisms in the HH gene, especially for the detection of polymorphisms in HH DNA or RNA in a patient sample.

As will be appreciated, the mutation analysis may also be performed on samples of RNA by reverse transcription into cDNA therefrom. Furthermore, mutations
20 may also be detected at the protein level using antibodies specific for the mutant and normal HH protein, respectively. It may also be possible to base an HH mutation assay on altered cellular or subcellular localization of the mutant form of the HH protein.

3. Antibodies

25 As mentioned above, antibodies can also be used for the screening of the presence of the HH gene, the mutant HH gene, and the protein products therefrom. In addition, antibodies are useful in a variety of other contexts in accordance with the present invention. As will be appreciated, antibodies can be raised against various epitopes of the HH protein. Such antibodies can be utilized for the diagnosis of HH and,
30 in certain applications, targeting of affected tissues.

Thus, in accordance with another aspect of the present invention a kit is provided that is suitable for use in screening and assaying for the presence of the HH

gene by an immunoassay through use of an antibody which specifically binds to a gene product of the HH gene in combination with a reagent for detecting the binding of the antibody to the gene product.

Antibodies raised in accordance with the invention can also be utilized to
5 provide extensive information on the characteristics of the protein and of the disease process and other valuable information which includes but is not limited to:

1. Antibodies can be used for the immunostaining of cells and tissues to determine the precise localization of the protein. Immunofluorescence and immuno-electron microscopy techniques which are well known in the art can be
10 used for this purpose. Defects in the HH gene or in other genes which cause an altered localization of the HH protein are expected to be localizable by this method.

2. Antibodies to distinct isoforms of the HH protein (i.e., wild-type or mutant-specific antibodies) can be raised and used to detect the presence or
15 absence of the wild-type or mutant gene products by immunoblotting (Western blotting) or other immunostaining methods. Such antibodies can also be utilized for therapeutic applications where, for example, binding to a mutant form of the HH protein reduces the consequences of the mutation.

3. Antibodies can also be used as tools for affinity purification of HH
20 protein. Methods such as immunoprecipitation or column chromatography using immobilized antibodies are well known in the art and are further described in Section (II)(B)(3), entitled "Protein Purification" herein.

4. Immunoprecipitation with specific antibodies is useful in
25 characterizing the biochemical properties of the HH protein. Modifications of the HH protein (i.e., phosphorylation, glycosylation, ubiquitization, and the like) can be detected through use of this method. Immunoprecipitation and Western blotting are also useful for the identification of associating molecules that are involved in signal transduction processes which regulate iron transport or other metabolic functions important in the HH disease process.

5. Antibodies can also be utilized in connection with the isolation and
30 characterization of tissues and cells which express HH protein. For example, HH protein expressing cells can be isolated from peripheral blood, bone marrow, liver,

and other tissues, or from cultured cells by fluorescence activated cell sorting (FACS) ("Antibodies" Cold Spring Harbor Press). Cells can be mixed with antibodies (primary antibodies) with or without conjugated dyes. If non-conjugated antibodies are used, a second dye-conjugated antibody (secondary antibody) which binds to the primary antibody can be added. This process allows the specific staining of cells or tissues which express the HH protein.

Antibodies against the HH protein are prepared by several methods which include, but are not limited to:

1. The potentially immunogenic domains of the protein are predicted from hydropathy and surface probability profiles. Then oligopeptides which span the predicted immunogenic sites are chemically synthesized. These oligopeptides can also be designed to contain the specific mutant amino acids to allow the detection of and discrimination between the mutant versus wild-type gene products. Rabbits or other animals are immunized with the synthesized oligopeptides coupled to a carrier such as KLH to produce anti-HH protein polyclonal antibodies. Alternatively, monoclonal antibodies can be produced against the synthesized oligopeptides using conventional techniques that are well known in the art ("Antibodies" Cold Spring Harbor Press). Both *in vivo* and *in vitro* immunization techniques can be used. For therapeutic applications, "humanized" monoclonal antibodies having human constant and variable regions are often preferred so as to minimize the immune response of a patient against the antibody. Such antibodies can be generated by immunizing transgenic animals which contain human immunoglobulin genes. See Jakobovits et al. Ann NY Acad Sci 764:525-535 (1995).

2. Antibodies can also be raised against expressed HH protein products from cells. Such expression products can include the full length expression product or parts or fragments thereof. Expression can be accomplished using conventional expression systems, such as bacterial, baculovirus, yeast, mammalian, and other overexpression systems using conventional recombinant DNA techniques. The proteins can be expressed as fusion proteins with a histidine tag, glutathione-S-transferase, or other moieties, or as nonfused proteins. Expressed proteins can be purified using conventional protein purification methods

or affinity purification methods that are well known in the art. Purified proteins are used as immunogens to generate polyclonal or monoclonal antibodies using methods similar to those described above for the generation of anti-peptide antibodies.

In each of the techniques described above, once hybridoma cell lines are prepared, monoclonal antibodies can be made through conventional techniques of priming mice with pristane and intraperitoneally injecting such mice with the hybrid cells to enable harvesting of the monoclonal antibodies from ascites fluid.

In connection with synthetic and semi-synthetic antibodies, such terms are intended to cover antibody fragments, isotype switched antibodies, humanized antibodies (mouse-human, human-mouse, and the like), hybrids, antibodies having plural specificities, fully synthetic antibody-like molecules, and the like.

B. Molecular Biology

1. Expression Systems

"Expression systems" refer to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. In order to effect transformation, the expression system may be included on a vector; however, the relevant DNA may then also be integrated into the host chromosome.

As used herein "cell", "cell line", and "cell culture" are used interchangeably and all such designations include progeny. Thus, "transformants" or "transformed cells" includes the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny which have the same functionality as screened for in the originally transformed cell, are included. Where distinct designations are intended, it will be clear from the context.

In general terms, the production of a recombinant form of HH gene product typically involves the following:

First a DNA encoding the mature (used here to include all normal and mutant forms of the proteins) protein, the preprotein, or a fusion of the HH protein to an

additional sequence cleavable under controlled conditions such as treatment with peptidase to give an active protein, is obtained. If the sequence is uninterrupted by introns it is suitable for expression in any host. If there are introns, expression is obtainable in mammalian or other eukaryotic systems capable of processing them. This sequence
 5 should be in excisable and recoverable form. The excised or recovered coding sequence is then placed in operable linkage with suitable control sequences in an expression vector. The construct is used to transform a suitable host, and the transformed host is cultured under selective conditions to effect the production of the recombinant HH protein. Optionally the HH protein is isolated from the medium or from the cells and purified as
 10 described in Section (II)(B)(3), entitled "Protein Purification".

Each of the foregoing steps can be done in a variety of ways. For example, the desired coding sequences can be obtained by preparing suitable cDNA from cellular mRNA and manipulating the cDNA to obtain the complete sequence. Alternatively, genomic fragments may be obtained and used directly in appropriate hosts.
 15 The construction of expression vectors operable in a variety of hosts are made using appropriate replicons and control sequences, as set forth below. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to provide an excisable gene to insert into these vectors.

The control sequences, expression vectors, and transformation methods are
 20 dependent on the type of host cell used to express the gene. Generally, prokaryotic, yeast, insect, or mammalian cells are presently useful as hosts. Prokaryotic hosts are in general the most efficient and convenient for the production of recombinant proteins. However, eukaryotic cells, and, in particular, mammalian cells, are often preferable because of their processing capacity and post-translational processing of human proteins.

25 Prokaryotes most frequently are represented by various strains of *E. coli*. However, other microbial strains may also be used, such as *Bacillus subtilis* and various species of *Pseudomonas* or other bacterial strains. In such prokaryotic systems, plasmid or bacteriophage vectors which contain origins of replication and control sequences compatible with the host are used. A wide variety of vectors for many prokaryotes are
 30 known (Maniatis et al. Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982)); Sambrook et al. Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989));

Meth. Enzymology 68 (Academic Press, Orlando, Fla. (1979, 1983, 1987)); Pouwells et al. Cloning Vectors: A Laboratory Manual (Elsevier, Amsterdam (1987))). Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems, the tryptophan (trp) promoter system and the lambda derived PL promoter and N-gene ribosome binding site, which has become useful as a portable control cassette (U.S. Patent No. 4,711,845). However, any available promoter system compatible with prokaryotes can be used (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987)).

In addition to bacteria, eukaryotic microbes, such as yeast, may also be used as hosts. Laboratory strain *Saccharomyces cerevisiae* or Baker's yeast, is most often used although other strains are commonly available.

Vectors employing the 2 micron origin of replication and other plasmid vectors suitable for yeast expression are known (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987)). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes. Additional promoters known in the art include the promoters for 3-phosphoglycerate kinase, and those for other glycolytic enzymes, such as glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters, which have the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytichrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization. *See* Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987). It is also believed that terminator sequences at the 3' end of the coding sequences are desirable. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. Many of the useful vectors contain control sequences derived from the enolase gene containing plasmid peno46 or the

LEU2 gene obtained from Yepl3, however, any vector containing a yeast compatible promoter, origin of replication, and other control sequences is suitable (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987)).

5 It is also, of course, possible to express genes encoding polypeptides in eukaryotic host cell cultures derived from multicellular organisms (Cruz and Patterson *Tissue Culture* (Academic Press, Orlando (1973)); Meth. Enzymology *supra.* (1979); Freshney *Culture of Animal Cells: A Manual of Basic Techniques* (2d ed., Alan R. Liss, NY (1987))). Useful host cell lines include murine myelomas N51, VERO and HeT
10 cells, SF9 or other insect cell lines, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and later promoters from Simian Virus 40 (SV 40), or other viral promoters such as those from polyoma, adenovirus 2, bovine papilloma virus, or avian sarcoma viruses, herpes virus family (such
15 as cytomegalovirus, herpes simplex virus, or Epstein-Barr virus), or immunoglobulin promoters and heat shock promoters (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); Pouwells et al. *supra.* (1987)). In addition, regulated promoters, such as metallothionine (i.e., MT-1 and MT-2), glucocorticoid, or antibiotic gene "switches" can be used.

20 General aspects of mammalian cell host system transformations have been described by Axel (U.S. Patent No. 4,399,216). It now appears also that "enhancer" regions are important in optimizing transformation. Generally, "enhancer" regions are sequences found upstream of the promoter region. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a
25 common mechanism for DNA replication in eukaryotes. Plant cells are also now available as hosts, and control sequences compatible with plant cells such as the nopaline synthase promoter and polyadenylation signal sequences are available (Pouwells et al. *supra.* (1987); Meth Enzymology 118 (Academic Press, Orlando (1987)); Gelvin et al. Plant Molecular Biology Manual (Kluwer Academic Publishers, Dordrecht (1990))).

30 Depending on the host cell used, transformation is done using standard techniques appropriate to such cells (Maniatis et al. *supra.* (1982); Sambrook et al. *supra.* (1989); Meth. Enzymology *supra.* (1979, 1983, 1987); U.S. Patent No. 4,399,216; Meth

Enzymology *supra* (1986); Gelvin et al. *supra*. (1990)). Such techniques include, without limitation, calcium treatment employing calcium chloride for prokaryotes or other cells which contain substantial cell wall barriers; infection with *Agrobacterium tumefaciens* for certain plant cells; calcium phosphate precipitation, DEAE, lipid transfection systems (such as Lipofectin™ and Lipofectamine™), and electroporation methods for mammalian cells without cell walls, and, microprojectile bombardment for many cells including, plant cells. In addition, DNA may be delivered by viral delivery systems such as retroviruses or the herpes family, adenoviruses, baculoviruses, or semliki forest virus, as appropriate for the species of cell line chosen.

C. Function Experiments

Expression systems for the HH gene product, for example as described in the previous Section, allow for the study of the function of the HH gene product, in either normal or wild-type form and/or mutated form. Such analyses are useful in providing insight into the disease causing process that is derived from mutations in the gene.

Judging from the sequence similarity of the HH gene to MHC Class I molecules, the HH gene product is expected to be expressed on cell surfaces. As discussed earlier, the HH protein is known to be expressed on the surfaces of cells of tissues from normal individuals and on cells transfected with the non-mutated gene.

1. Analysis of Iron Metabolism

The HH gene (mutated, normal, or wild-type) can be utilized in an assay of iron metabolism. The gene is expressed, with or without any accompanying molecules, in cells lines or primary cells derived from HH patients, healthy individuals, or cells from other organisms (such as rodents, insects, bacteria, amphibians, etc.). Uptake of iron by these cells is measured, for example through the use of radioactive isotopes.

Methodology for assessing affinity, binding, and transport of I^{125} -transferrin binding to the Tfr have been described in detail (Mulford and Lodish, J. Biol. Chem. 263(11):5455-5461 (1988)). It can be predicted that the unmutated HH protein would modulate the activity of the Tfr whereas, the HH protein containing the 24d1 mutation would be unable to modulate the Tfr by virtue of its failure to interact with and modulate other molecules important to iron metabolism such as iron transport "channels". In such cases the 24d1

mutation could be expected to result in unregulated iron transport. Further, binding of iron to the HH gene product can also be measured. Such experiments assist in assessing the role of the HH gene and HH gene product in iron uptake, binding, and transport by and in cells.

5

2. Analysis of Lead and other Metal Metabolism

Increased accumulation of lead and certain other metals has been reported in HH homozygotes. See Barton et al. J Lab Clin Med 124:193-198 (1994). As discussed above in connection with iron, the metabolism of lead and other metals can be assessed.

10

3. Analysis of MHC Function

As discussed above, the HH gene products share significant structural similarity with Class I MHC molecules. Class I MHC molecules have several well known and measurable activities. Expression of the HH gene products through the use of appropriate expression systems allows for the analysis of whether the HH gene products possess similar activities.

15

a. Peptide Presentation Assay

Peptide presentation can be measured through use of a number of well known techniques. One method is to express the HH gene product on the surface of mammalian cells. Thereafter, the HH gene product can be purified from the cell surface analyzed for peptide binding, through, for example, high performance liquid chromatography (HPLC) after elution. Amino acid sequences of any bound peptides can be determined through conventional sequencing techniques (i.e., Edman degradation).

20

25

Another technique to analyze peptide presentation is to express the HH gene product on a cell that does not conventionally possess peptide presentation activity (i.e., *Drosophila melanogaster* derived Schneider cells. See Rammensee et al. Ann Rev Immunol 11:213-244 (1993). In such a system, MHC Class I molecules are expressed on the cell surface "empty" (i.e., without any bound peptide). Thereafter, through the addition of a particular peptide to the system, the binding of the particular peptide to the

30

empty Class I molecule can be measured. *See* Rammensee et al. *supra.* (1993). A similar assay can be utilized in connection with the HH gene products.

b. T-cell Activation and Activation of Other Cells

5 It has been observed that, in at least some HH patients, there is a decrease in the numbers of CD8+ T-cells. (Reimao et al. C.R. Acad Sci Paris 313:481 (1991)). This is a striking phenotype as a similar phenotype is associated with the β -2-microglobulin knock-out mice (Koller et al. Science 248:1127 (1990); Zijlstra et al. Nature 344:742 (1990)). The role of MHC Class I proteins in the development of the T-
10 cell repertoire is well documented. *See* Doherty Adv Immun 27:51 (1979). Animals lacking CD8+ T-cells would be expected to be more susceptible to a variety of infections and cancers. The β -2-microglobulin knock-out mice have been kept under pathogen-free conditions so that the long-term consequences of lacking CD8+ T-cells has not been ascertained. Humans, however, when deficient in CD8+ T-cells, have shown several
15 conditions that are consistent with a compromised immune system, most notably a 200 fold increase in the incidence of hepatocellular carcinomas. *See* Niederau et al. N Engl J Med 313:1256 (1985).

Further, it is known that Class I MHC molecules are involved in the activation and differentiation of T-cells through the interaction between MHC molecules
20 and α/β or γ/δ T-cell receptors. Methods to measure T-cell activation are well known in the art. *See* Schild et al. Cell 76:29-37 (1994) and others). Signaling events in other cell types can also be measured. *See* Leibson Immunity 3:5-8 (1995). Thus, expression of the HH gene product on cells that are co-cultured with various T-cells can be used as an assay to measure T-cell differentiation and activation induced by the HH gene product.
25 In particular, as mentioned above, differentiation and activation of CD8+ T-cells can be determined and measured and the role of the normal and mutant HH gene and gene products therein assessed.

c. Identification of Downstream Cells

30 The assays described above can be utilized to monitor and determine other cellular interactions between "downstream cells" and the HH gene protein product. Cells

that interact with the HH gene protein product can be analyzed for uptake of iron and iron binding as described above.

d. Determination of Cellular Markers

As discussed above, the HH protein is expressed on the surface of cells. As such, the HH gene product can be utilized as a cell-surface marker and detected through the use of FACS or other means utilizing antibodies to the HH protein. The failure of the HH protein with the 24d1 mutation to be presented on cell surfaces provides the opportunity for use as a non-DNA based diagnostic for HH disease.

D. Therapeutics

Identification of the HH gene and its gene product also has therapeutic implications. Indeed, one of the major aims of the present invention is the development of therapies to circumvent or overcome the defect leading to HH disease. Envisioned are pharmacological, protein replacement, antibody therapy, and gene therapy approaches. In addition, the development of animal models useful for developing therapies and for understanding the molecular mechanisms of HH disease are envisioned.

Peptide binding domains of MHC molecules have ligands, or are known to bind ligands, and we expect that the HH protein may directly bind iron or other metals or bind to a ligand (such as a peptide) that binds iron or other metals. Therefore, we expect that the HH protein represents a new approach to iron and other metal chelation, which may be useful, in addition to its role in iron overload in HH disease, in a variety of other diseases and conditions that are secondary to other disease interventions, including, without limitation, transfusions, thalassaemias, and hemolytic anemias. Delivery of the HH protein or parts thereof, or its ligand by either gene therapy or through protein replacement represents a new approach to metal chelation or iron modulatory agents.

Further, because molecules that bind to iron or other metals, we envision that the approach can be utilized for chelation or sequestration of metals, such as copper, lead, zinc, cadmium, or other toxic moieties. Further, since iron is a catalyst for oxidative processes that are known to be deleterious in multiple biological systems, including, without limitation, vascular disease, inflammation, atherosclerosis, lung injury,

ischemia, and the like, we envision that the HH protein and/or fragments thereof, including ligands and fragments thereof, can be utilized in anti-oxidative therapies.

An additional aspect of HH disease and iron overload disease is that hepatic iron concentration has been shown to correlate with non-response to α -interferon treatment for chronic hepatitis. See Van Tiel et al. J Hepatology 20:410-415 (1994) and Olynyk et al. Gastroenterology 108:1104-1109 (1995). Thus, the HH protein and/or fragments or ligands thereto can be utilized in the lowering of hepatic iron levels so as to facilitate increased response to α -interferon in the treatment of these diseases.

1. Pharmacological

In the pharmacological approach, drugs which circumvent or overcome the defective HH gene function are sought. In this approach modulation of HH gene function can be accomplished by agents or drugs which are designed to interact with different aspects of the HH protein structure or function or which mimic the HH protein interaction with other molecules such as the Tfr. For example, a drug, antibody or other modulating protein (i.e. β -2-microglobulin or calnexin or similarly acting molecules or parts thereof) could be designed to bind to the HH protein and correct a defective structure.

Alternatively, a drug might bind to a specific functional residue(s) thereby, increasing or decreasing the affinity for ligand, substrate or cofactor such as Tfr. The assay for such a compound would be to promote or inhibit an interaction between the HH protein and the Tfr or similar molecule or could be a measure of Tfr turnover or endocytosis.

Efficacy of a drug or agent can be identified in a screening program in which modulation is monitored in *in vitro* cell systems. Indeed, the present invention provides for host cell systems which express various mutant HH proteins (especially the 24d1 and 24d2 mutations noted in this application) and are suited for use as primary screening systems. Candidate drugs can be evaluated by incubation with these cells and measuring cellular functions dependent on the HH gene or by measuring proper HH protein folding or processing. Such assays might also entail measuring receptor-like activity, iron transport and metabolism, gene transcription or other upstream or downstream biological function as dictated by studies of HH gene function.

Alternatively, cell-free systems can also be utilized. Purified HH protein can be reconstituted into artificial membranes or vesicles and drugs screened in a cell-free system. Such systems are often more convenient and are inherently more amenable to high throughput types of screening and automation.

5 A variety of drugs and other therapeutic agents have been proposed as useful in the treatment of HH disease and other iron or other metal overload type diseases. *See, for example*, Great Britain Patent Application No. 2,293,269 A, assigned to Merck Sharp & Dohme Ltd., World Patent Application No. WO 95/16663, assigned to Ciba Geigy AG, German Patent Application No. 4,327,226 A1, assigned to Hoechst AG,
 10 World Patent Application No. WO 94/21243, assigned to the University of Nebraska, Canadian Patent Application No. 2,115,224 A, assigned to Bayer Corp., Miles Inc., and others, Canadian Patent Application No. 2,115,222 A, assigned to Bayer Corp., Miles Inc., and others, U.S. Patent No. 5,385,918 and Canadian Patent Application No. 2,115,221 A, assigned to Bayer Corp., Miles Inc., and others, World Patent Application
 15 No. WO 94/11367, assigned to Ciba Geigy AG and the University of Florida, World Patent Application No. WO 94/01463, assigned to the University of British Columbia, U.S. Patent No. 5,256,676, assigned to British Technology Group Ltd., U.S. Patent No. 5,420,008, assigned to Oriental Yeast Co. Ltd., World Patent Application No. WO 94/04186, U.S. Patent No. 5,075,469, assigned to Yissum Research and Development
 20 Co., European Patent Application No. 346,281, assigned to Ciba Geigy AG, European Patent Application No. 315,434, assigned to Yissum Research and Development Co., U.S. Patent Nos. 5,424,057, 5,328,992, and 5,185,368, assigned to Ciba Geigy AG, U.S. Patent Nos. 5,104,865, 4,912,118, 4,863,913, and 4,666,927, assigned to National Research and Development Corp., DD Patent Application No. 208,609, assigned to Akad
 25 Wissenschaft, and U.S. Patent No. 4,434,156, assigned to the Salk Institute for Biological Studies. The invention is useful for the screening of such proposed drugs or other therapeutic agents for specific activity in HH disease models, assays, and design of molecules based thereon.

In vivo testing of HH disease-modifying compounds is also required as a
 30 confirmation of activity observed in the *in vitro* assays. Animal models of HH disease are envisioned and discussed in the section entitled "Animal Models", below, in the present application.

Drugs can be designed to modulate HH gene and HH protein activity from knowledge of the structure and function correlations of HH protein and from knowledge of the specific defect in various HH mutant proteins. For this, rational drug design by use of X-ray crystallography, computer-aided molecular modeling (CAMP), quantitative or qualitative structure-activity relationship (QSAR), and similar technologies can further focus drug discovery efforts. Rational design allows prediction of protein or synthetic structures which can interact with and modify the HH protein activity. Such structures may be synthesized chemically or expressed in biological systems. This approach has been reviewed in Capsey et al., Genetically Engineered Human Therapeutic Drugs, Stockton Press, New York (1988). Further, combinatorial libraries can be designed, synthesized and used in screening programs.

The present invention application also envisions that the treatment of HH disease can take the form of modulation of another protein or step in the pathway in which the HH gene or its protein product participates in order to correct the physiological abnormality. Without being limited to any one theory, Tfr may be the appropriate target for therapeutic treatments for HH. Furthermore, as an MHC-like molecule one could envision that the HH protein acts as a receptor or modulator for iron-binding or iron-regulating molecules. As such intracellular signalling or transport functions could be affected by alterations in HH protein function. Such functions and their effector molecules would also be targets for HH disease-modifying therapies.

In order to administer therapeutic agents based on, or derived from, the present invention, it will be appreciated that suitable carriers, excipients, and other agents may be incorporated into the formulations to provide improved transfer, delivery, tolerance, and the like.

A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, (15th Edition, Mack Publishing Company, Easton, Pennsylvania (1975)), particularly Chapter 87, by Blaug, Seymour, therein. These formulations include for example, powders, pastes, ointments, jelly, waxes, oils, lipids, anhydrous absorption bases, oil-in-water or water-in-oil emulsions, emulsions carbowax (polyethylene glycols of a variety of molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax.

Any of the foregoing formulations may be appropriate in treatments and therapies in accordance with the present invention, provided that the active agent in the formulation is not inactivated by the formulation and the formulation is physiologically compatible.

5

2. Protein Replacement Therapy

The present invention also relates to the use of polypeptide or protein replacement therapy for those individuals determined to have a defective HH gene. Treatment of HH disease could be performed by replacing the defective HH protein with
10 normal protein or its functional equivalent in therapeutic amounts.

HH polypeptide can be prepared for therapy by any of several conventional procedures. First, HH protein can be produced by cloning the HH cDNA into an appropriate expression vector, expressing the HH gene product from this vector in an *in vitro* expression system (cell-free or cell-based) and isolating the HH protein from the
15 medium or cells of the expression system. General expression vectors and systems are well known in the art. In addition, the invention envisions the potential need to express a stable form of the HH protein in order to obtain high yields and obtain a form readily amenable to intravenous administration. Stable high yield expression of proteins have been achieved through systems utilizing lipid-linked forms of proteins as described in
20 Wettstein et al. J Exp Med 174:219-228 (1991) and Lin et al. Science 249:677-679 (1990).

HH protein or portions thereof can be prepared synthetically. Alternatively, the HH protein can be prepared from total protein samples by affinity chromatography. Sources would include tissues expressing normal HH protein, *in vitro*
25 systems (outlined above), or synthetic materials. The affinity matrix would consist of antibodies (polyclonal or monoclonal) coupled to an inert matrix. In addition, various ligands which specifically interact with the HH protein could be immobilized on an inert matrix. For example, β -2-microglobulin or portions thereof, β -2-microglobulin-like molecules, or other specific proteins such as calnexin and calnexin-like molecules or
30 portions thereof. General methods for preparation and use of affinity matrices are well known in the art.

Protein replacement therapy requires that HH protein be administered in an appropriate formulation. The HH protein can be formulated in conventional ways standard to the art for the administration of protein substances. Delivery may require packaging in lipid-containing vesicles (such as Lipofectin™ or other cationic or anionic lipid or certain surfactant proteins) that facilitate incorporation into the cell membrane. The HH protein formulations can be delivered to affected tissues by different methods depending on the affected tissue. For example, iron absorption is initiated in the GI tract. Therefore, delivery by catheter or other means to bypass the stomach would be desirable. In other tissues, IV delivery will be the most direct approach.

3. Gene Therapy

Gene therapy utilizing recombinant DNA technology to deliver the normal form of the HH gene into patient cells or vectors which will supply the patient with gene product *in vivo* is also contemplated within the scope of the present invention. In gene therapy of HH disease, a normal version of the HH gene is delivered to affected tissue(s) in a form and amount such that the correct gene is expressed and will prepare sufficient quantities of HH protein to reverse the effects of the mutated HH gene. Current approaches to gene therapy include viral vectors, cell-based delivery systems and delivery agents. Further, *ex vivo* gene therapy could also be useful. In *ex vivo* gene therapy, cells (either autologous or otherwise) are transfected with the normal HH gene or a portion thereof and implanted or otherwise delivered into the patient. Such cells thereafter express the normal HH gene product *in vivo* and would be expected to assist a patient with HH disease in avoiding iron overload normally associated with HH disease. *Ex vivo* gene therapy is described in U.S. Patent No. 5,399,346 to Anderson et al., the disclosure of which is hereby incorporated by reference in its entirety. Approaches to gene therapy are discussed below:

a. Viral Vectors

Retroviruses are often considered the preferred vector for somatic gene therapy. They provide high efficiency infection, stable integration and stable expression (Friedman, T. Progress Toward Human Gene Therapy. Science 244:1275 (1989)). The full length HH gene cDNA or portions thereof can be cloned into a retroviral vector

driven by its endogenous promoter or from the retroviral LTR. Delivery of the virus could be accomplished by direct implantation of virus directly into the affected tissue.

Other delivery systems which can be utilized include adenovirus, adeno-associated virus (AAV), vaccinia virus, bovine papilloma virus or members of the herpes virus group such as Epstein-Barr virus. Viruses with tropism to the gut and viruses engineered with tissue specific promoters are also envisioned. Viruses can be, and preferably are, replication deficient.

b. Cell-based Delivery

Much work has been performed in recent years regarding producing transgenic cells possessing therapeutic genes. Such cells could be directly implanted or implanted within a membrane-based matrix. For these purposes, many cells types would suffice but cells particularly derived from the target organs such as gut or liver are particularly useful. Examples include fetal liver or fetal gut epithelial cells.

c. Non-viral gene transfer

Other methods of inserting the HH gene into the appropriate tissues may also be productive. Many of these agents, however, are of lower efficiency than viral vectors and would potentially require infection *in vitro*, selection of transfectants, and reimplantation. This would include calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. A particularly attractive idea is the use of liposomes (i.e., LIPOFECTINTM), which might be possible to carry out *in vivo*. Synthetic cationic lipids and DNA conjugates also appear to show some promise and may increase the efficiency and ease of carrying out this approach.

4. Animal Models

The generation of a mouse or other animal model of HH disease is important for both an understanding the biology of the disease but also for testing of potential therapies. Currently only a single animal model of HH disease exists. As was demonstrated by de Sousa et al. (Immunol. Letts 39:105-111 (1994)) and Rothenberg and Voland (Proc. Natl. Acad. Sci. U.S.A. 93:1529-1534 (1996)) it is possible to develop a model of HH disease by interfering with the normal expression of $\beta 2$ -microglobulin. $\beta 2$ -

microglobulin is necessary for the proper folding and surface presentation of MHC class I molecules. Mice with a disrupted $\beta 2$ -microglobulin gene were created that do not express $\beta 2$ -microglobulin protein on the surface of most cells. Mice with this mutation possess almost no CD8+ cytotoxic T lymphocytes and develop progressive hepatic iron overload similar to HH disease. This model is somewhat limited in its representation of HH disease in humans as $\beta 2$ -microglobulin serves as a chaperone-like molecule for most, if not all, MHC I molecules thereby, affecting more biological systems than just those anticipated to be affected by disruption of the HH gene.

This invention envisions the creation of a more specific animal model of HH disease by inactivation of the homologous HH gene in a number of species including mice, rats, pigs, and primates. These models will be novel in that targeting the homologous HH gene alone will more specifically represent the diseases as described in humans.

Techniques for specifically inactivating genes by homologous recombination in embryonic stem cells (ES cells) have been described (Capecchi Science 244:1288 (1989)). More specifically, as isogenic SvJ-129 mouse genomic BAC library can be screened with a human HH gene cDNA probe. The resultant clones are then sequenced to ensure sequence identity to the house HH gene homologue cDNA. A targeting vector is then constructed from the mouse genomic DNA consisting of two approximately 3 Kb mouse HH gene genomic fragments as 5' and 3' arms. These arms would be chosen to flank a region critical to the function of the HH gene product, such as exon 4 (the immunoglobulin-like region which contains the proposed critical $\beta 2$ -microglobulin interactive domain and essential disulfide linkage). However, other regions such as the initiation codon in exon 1 or membrane-proximal regions could also be targeted. In place of the exon 4 region would be placed a neomycin resistance gene under the control of the phosphoglycerate kinase (pgk 1) promoter. The 5' arm of the vector is flanked externally by the pgk 1-herpes thymidine kinase gene for negative selection.

The targeting vector is then transfected into R1 ES cells and the transfectants subjected to positive and negative selection (G418 and ganciclovir, respectively). PCR is then used to screen surviving colonies for the desired homologous recombinations. These are confirmed by Southern blot analysis.

Subsequently, several mutant clones are picked and injected into C57BL/6 blastocysts to produce high-percentage chimeric animals. These are then mated to C57BL/6 females. Heterozygous offspring are then mated to produce homozygous mutants. These offspring can then be tested for the HH gene mutation by Southern blot analysis. In addition, these animals are tested by RT-PCR to assess whether the targeted homologous recombination results in ablation of HH gene mRNA. These results can be confirmed by Northern blot analysis and RNase protection assays.

Once established, the HH gene $-/-$ mice can be studied for development of HH-like disease and also be utilized to examine which tissues and cell types are involved in the disease process. These animals can also be used to introduce the mutant or normal human HH gene or for introduction of the homologous gene to that species and containing the 24d1 or other HH disease-causing mutations. Methods for these transgenic procedures are well known to those versed in the art and have been described by Murphy and Carter, Transgenesis Techniques, Humana Press, 1993. Alternatively, homologous recombination procedures similar to those described above can be utilized to introduce the 24d1 or 24d2 mutations directly into the endogenous mouse gene.

5. Down Regulation of the HH Gene or HH Gene Product

In certain therapeutic applications, it is desirable to down regulate the expression and/or function of the HH gene, the mutant HH gene, the HH protein, or the mutant HH protein. For example, down regulation of the normal HH gene or the normal HH protein is desirable in situations where iron is underaccumulated in the body, for example in certain anemias (i.e., thalassaemias, hemolytic anemias, transfusions). On the other hand, down regulation of the mutant HH gene or the HH protein is desirable in situations where iron is overaccumulated in the body.

As discussed above in the Section entitled "Antibodies," antibodies specific to the normal or the mutant HH protein can be prepared. Such antibodies can be used therapeutically in HH disease. For example, to block the action of the mutant or normal HH gene if the function associated with the mutant protein is an upregulation of the normal HH protein function and leads to an overaccumulation of iron in the body, as mentioned above. Similarly, antibodies can be used therapeutically to block action of an HH protein that is causing an underaccumulation of iron in the body.

In a similar manner, the HH gene, either in normal or in a mutant form, can be downregulated through the use of antisense oligonucleotides directed against the gene or its transcripts. A similar strategy can be utilized as discussed above in connection with antibodies. For a particularly valuable review of the design

- 5 considerations and use of antisense oligonucleotides, see Uhlmann et al. Chemical Reviews 90:543-584 (1990) the disclosure of which is hereby incorporated by reference. The antisense oligonucleotides of the present invention may be synthesized by any of the known chemical oligonucleotide synthesis methods. Such methods are generally described, for example, in Winnacker From Genes to Clones: Introduction to Gene
 10 Technology, VCH Verlagsgesellschaft mhH (H. Ibelgaufts trans. 1987). Antisense oligonucleotides are most advantageously prepared by utilizing any of the commercially available, automated nucleic acid synthesizers. One such device, the Applied Biosystems 380B DNA Synthesizer, utilizes β -cyanoethyl phosphoramidite chemistry.

- Since the complete nucleotide synthesis of DNA complementary to the HH
 15 gene and the mutant HH genes' mRNA transcript is known, antisense oligonucleotides hybridizable with any portion of such transcripts may be prepared by oligonucleotide synthesis methods known to those skilled in the art. While any length oligonucleotide may be utilized in the practice of the invention, sequences shorter than 12 bases may be less specific in hybridizing to the target mRNA, may be more easily destroyed by
 20 enzymatic digestion, and may be destabilized by enzymatic digestion. Hence, oligonucleotides having 12 or more nucleotides are preferred. Long sequences, particularly sequences longer than about 40 nucleotides, may be somewhat less effective in inhibiting translation because of decreased uptake by the target cell. Thus, oligomers of 12-40 nucleotides are preferred, more preferably 15-30 nucleotides, most preferably
 25 18-26 nucleotides. Sequences of 18-24 nucleotides are most particularly preferred.

ILLUSTRATIVE EXAMPLES

The following examples are provided to illustrate certain aspects of the present invention and not intended as limiting the subject matter thereof:

Example 1 HH Diagnostic: OLA Assay

As discussed above, the oligonucleotide ligation assay (OLA) (Nickerson, D.A. et al. Proc Natl Acad Sci USA 87:8923-8927 (1990)) is highly effective for detecting single nucleotide changes in DNA and RNA, such as the 24d1, 24d2, and 24d7 mutations or sequence variations. Thus, in accordance with the present invention, there is provided an assay kit to detect mutations in the HH gene through use of an OLA assay.

In the OLA assay, a sample of DNA or cDNA reverse transcribed from RNA is amplified, generally through use of polymerase chain reaction (PCR) amplification, followed by ligation with upstream and downstream oligonucleotides specific to either side of the mutation sought to be assayed. Either the upstream or the downstream oligonucleotide includes a base complementary to the mutated or normal allele and the upstream or downstream oligonucleotide is labeled to enable detection of hybridization to the variant base.

Oligonucleotides complementary to the upstream or downstream sequence of the DNA or RNA in the sample, plus the mutated or normal allele, are ordinarily utilized in parallel so that detection of heterozygosity and homozygosity is possible.

Generally, the kit includes reaction chambers in which to conduct amplification of DNA or reverse transcribed RNA from patient samples, ligation reactions, and detection of ligation products. One exemplary reaction chamber that can be utilized to conduct such steps is a microtiter plate. The kit can be provided with or without reagents and oligonucleotides for use in the assay. In general, however, in a preferred embodiment, the kit is provided with oligonucleotides for amplifying at least a portion of a patient's DNA or RNA across the mutation that is to be detected. As will be appreciated, oligonucleotide primers can be designed to virtually any portion of the DNA or transcription products flanking the nucleotide sought to be assayed, up to and including, and in some cases even exceeding 500 bases away from the mutation to be assayed. Further, ligation oligonucleotides can be designed in a variety of lengths.

Samples (either DNA or reverse transcribed RNA) are placed into the reaction vessel(s) with appropriate primers, nucleotides, buffers, and salts and subjected to PCR amplification. The PCR products are then assayed for single base mutations using OLA.

Suitable genomic DNA-containing samples from patients can be readily obtained and the DNA extracted therefrom using conventional techniques. For example, DNA can be isolated and prepared in accordance with the method described in Dracopoli, N. et al. eds. Current Protocols in Human Genetics (J. Wiley & Sons, New York (1994)), the disclosure of which is hereby incorporated by reference in its entirety. Most typically, a blood sample, a buccal swab, a hair follicle preparation, or a nasal aspirate is used as a source of cells to provide the DNA.

Alternatively, RNA from an individual (i.e., freshly transcribed or messenger RNA) can be easily utilized in accordance with the present invention for the detection of the selected base mutation. Total RNA from an individual can be isolated according to the procedure outlined in Sambrook, J. et al. Molecular Cloning - A Laboratory Manual (2nd Ed., Cold Spring Harbor Laboratory Press, New York (1989)) the disclosure of which is hereby incorporated by reference.

When using either DNA or RNA samples for the detection of base mutations in an OLA assay, the patient DNA or reverse transcribed RNA is first amplified, followed by assaying for ligation. In a preferred embodiment, the amplification primers for detecting the 24d1 mutation in DNA are shown in Figure 5 and labeled 24d1.P1 (SEQ ID NO:13) and 24d1.P2 (SEQ ID NO:14), designed as shown in Figure 6. Also on Figure 5, the oligonucleotides used in the sequence determination by OLA for 24d1 are designated 24d1.A (SEQ ID NO:15), 24d1.B (SEQ ID NO:16), and 24d1.X (SEQ ID NO:17). As indicated in the sequences shown, "bio" indicates biotin coupling, "p" indicates 5'-phosphate, and "dig" indicates coupled digoxigenin. It will be appreciated that the binding of biotin and digoxigenin can be reversed. In other words, digoxigenin can be bound to the 5' end of oligonucleotides 24d1.A and 24d1.B and biotin can be bound to the 3' end of the 24d1.X oligonucleotide.

The use of RNA, as opposed to DNA, follows essentially an identical approach: the RNA is isolated and after reverse transcription the characteristic base mutation can be detected as described above. In order to perform PCR amplification of the RNA prior to OLA assay, the following oligonucleotide primers are preferably utilized:

Forward Primer

24d1.P3 CTG AAA GGG TGG GAT CAC AT (SEQ ID NO:18)

Reverse Primer

24d1.P4 CAA GGA GTT CGT CAG GCA AT (SEQ ID NO:19)

5 In amplification, a solution containing the DNA sample (obtained either directly or through reverse transcription of RNA) is mixed with an aliquot of each of dATP, dCTP, dGTP and dTTP (i.e., Pharmacia LKB Biotechnology, NJ), an aliquot of each of the DNA specific PCR primers, an aliquot of *Taq* polymerase (i.e., Promega, WI), and an aliquot of PCR buffer, including $MgCl_2$ (i.e., Promega) to a final volume.

10 Followed by pre-denaturation (i.e., at 95°C for 7 minutes), PCR is carried out in a DNA thermal cycler (i.e., Perkin-Elmer Cetus, CT) with repetitive cycles of annealing, extension, and denaturation. As will be appreciated, such steps can be modified to optimize the PCR amplification for any particular reaction, however, exemplary conditions utilized include denaturation at 95°C for 1 minute, annealing at 55°C for 1

15 minute, and extension at 72°C for 4 minutes, respectively, for 30 cycles. Further details of the PCR technique can be found in Erlich, "PCR Technology," Stockton Press (1989) and U.S. Patent No. 4,683,202, the disclosure of which is incorporated herein by reference.

 Following PCR amplification, the PCR products are subjected to a ligation

20 assay. Generally, ligation of the oligonucleotides requires a 5'-phosphate and a 3'-OH held in proximity by annealing to a complementary DNA strand (i.e., the PCR product), ligation buffer, and DNA ligase. A phosphodiester bond is formed through the reaction. If, however, there is a sequence dissimilarity at the point of ligation, ligation will not be accomplished and no phosphodiester bond will be formed.

25 In a preferred assay, two ligation oligonucleotides are utilized (i.e., such as the ligation oligonucleotides mentioned above for the detection of the 24d1 mutation (SEQ ID NO:15 and SEQ ID NO:17 for detection of the G allele or SEQ ID NO:16 and SEQ ID NO:17 for detection of the A allele)). The PCR products and the ligation oligonucleotides are suspended in ligation buffer, including NAD, with a DNA ligase,

30 preferably amp-ligase (Epicentre) which is a thermal ligase. Ten cycles of ligation are performed at 94°C for 20 seconds and 58°C for 2 minutes in a thermal cycler. The reaction is stopped with EDTA and the product is transferred to streptavidin-coated plates

and incubated for 45 minutes. Thereafter the wells are alkaline washed to denature the oligonucleotides from the initial PCR products and then washed with TRIS buffer to remove any unbound materials (i.e., all products other than the biotinylated products which bind to the streptavidin on the plates).

5 Detection is accomplished, preferably, through use of an anti-digoxigenin antibody conjugated with alkaline phosphatase (Boehringer-Mannheim) which is added and incubated at 37°C for 30 minutes. The plates are washed with TRIS buffer to remove any unbound antibody. An ELISA detection kit (Life Technologies) is utilized where NADPH is used as a substrate where the alkaline phosphatase conjugated to the antibody
10 cleaves NADPH to NADH. The NADH produced by this reaction is used as a cofactor for diaphorase to turn INF-violet to Formazan which generates a red color. Presence of the red color provides a positive signal that ligation occurred and lack of the red color indicates that ligation did not occur, which indicates the presence or absence of the specific base being assayed.

15 As will be appreciated, the OLA assay allows the differentiation between individuals who are homozygous versus heterozygous for particular mutations (such as the 24d1 mutation, for which the ligation oligonucleotides mentioned above are designed, or the 24d2 mutation). This feature allows one to rapidly and easily determine whether an individual is at a significant risk of developing HH. Oligonucleotides useful for
20 amplifying and detecting the 24d2 mutant and normal alleles are provided in Figure 9.

In the OLA assay, when carried out in microtiter plates, for example, one well is used for the determination of the presence of the normal allele (i.e., the 24d1:G allele) and a second well is used for the determination of the presence of the mutated allele (i.e., the 24d1:A allele). Thus, the results for an individual who is heterozygous
25 for the 24d1 mutation will show a signal in each of the A and G wells and an individual who is homozygous for the 24d1:A allele will show a signal in only the A well. Those individuals who are homozygous for the A allele at 24d1 are, as discussed above, homozygous for the common ancestral HH-mutation and are at a significant risk of developing HH disease.

30 In particular, therefore, a kit for detecting the 24d1 mutation by OLA assay is provided. In the kit, amplification primers for DNA or RNA (or generally primers for amplifying a sequence of genomic DNA, reverse transcription products, complementary

products) including the 24d1 mutated and normal alleles are provided. Ligation assay oligonucleotides are also preferably provided. The kit further includes separate reaction wells and reagents for detecting the presence of homozygosity or heterozygosity for the 24d1 mutation.

5 Within the same kit, or in separate kits, oligonucleotides for amplification and detection of other differences (such as the 24d2 mutation and/or the 24d7 sequence variant) can also be provided. If in the same kit as that used for detection of the 24d1 mutation, separate wells and reagents are provided, and homozygosity and heterozygosity can similarly be determined.

10 Because of the enrichment of the 24d2 mutation in individuals who are heterozygous for the 24d1 mutation, kits are specifically envisioned in accordance with the invention which screen for the presence of the 24d2 mutation when 24d1 heterozygosity is detected.

15 **Example 2 HH Diagnostic: Other Nucleotide Based Assays**

 As will be appreciated, a variety of other nucleotide based detection techniques are available for the detection of mutations in samples of RNA or DNA from patients. *See, for example*, Section (III)(A)(2), above, entitled "Nucleic Acid Based Screening." Any one or any combination of such techniques can be used in accordance
20 with the invention for the design of a diagnostic device and method for the screening of samples of DNA or RNA for HH gene mutations in accordance with the invention, such as the mutations and sequence variants identified herein (24d1, 24d2, and 24d7). Further, other techniques, currently available, or developed in the future, which allow for the specific detection of mutations and sequence variants in the HH gene are contemplated in
25 accordance with the invention.

 Through use of any such techniques, it will be appreciated that devices and methods can be readily developed by those of ordinary skill in the art to rapidly and accurately screen for mutations and sequence variants in the HH gene in accordance with the invention.

30 Thus, in accordance with the invention, there is provided a nucleic acid based test for HH gene mutations and sequence variants which comprises providing a sample of a patient's DNA or RNA and assessing the DNA or RNA for the presence of

one or more HH gene mutations or sequence variants. Samples of patient DNA or RNA (or genomic, transcribed, reverse transcribed, and/or complementary sequences to the HH gene) can be readily obtained as described in Example 1. Through the identification and characterization of the HH gene as taught and disclosed in the present invention, one of
5 ordinary skill in the art can readily identify the genomic, transcribed, reverse transcribed, and/or complementary sequences to the HH gene sequence in a sample and readily detect differences therein. Such differences in accordance with the present invention can be the 24d1, 24d2, and/or 24d7 mutations or sequence variations identified and characterized in accordance herewith. Alternatively, other differences might similarly be detectable.

10 Kits for conducting and/or substantially automating the process of identification and detection of selected changes, as well as reagents utilized in connection therewith, are therefore envisioned in accordance with the invention of the present invention.

15 **Example 3 HH Diagnostic: Antibody Based Assay**

As discussed in Section (III)(A)(3), herein, entitled "Antibodies," antibodies specific to both the normal/wild-type or mutated gene products of the HH gene can be readily prepared. Thus, in accordance with the invention a kit for the detection of an HH gene product, and particularly, the mutated HH gene product is provided for use
20 in a diagnostic test for the presence of HH disease.

Antibody based tests are well known in the art. In general, a sample of tissue, cells, or bodily fluid is obtained, or provided, from a patient. If the sample contains cells or tissues, typically the sample is disrupted to free the HH gene product. Alternatively, if surface expression exists, whole cells can be utilized. Thereafter, the
25 sample is contacted with an antibody specific to the selected HH gene product and binding of the antibody, if any, is detected. Typically, the antibody is bound to, either directly, or through another moiety (i.e., biotin), a label to facilitate detection of hybridization. Such label can be radioactive, fluorescent, a dye, a stain, or the like.

Thus, antibodies for diagnostic applications, and diagnostic kits including
30 antibodies (and/or other reagents utilized in connection therewith) are provided in accordance with the invention.

Example 4 HH Therapy: *In Vivo* Gene Therapy

The discovery of the HH gene in accordance with the invention also provides a therapeutic for HH disease in the form of gene therapy. In the present example, gene therapy is accomplished *in vivo*. In *in vivo* gene therapy, a patient is
 5 treated with a gene product in a form that is designed to cause the patient to express the gene.

The coding region of the HH gene, or parts or portions thereof, can be incorporated into a suitable vector for use in the treatment of HH disease. Indeed, the coding region of the HH gene is of a manageable size for incorporation in a viral vector,
 10 such as a retroviral or adenoviral vectors. Generally, the vector will be construct to include suitable promoters, enhancers, and the like. Additional information related to the design of HH gene construct for use in gene therapy is provided in Section (III)(B)(1), entitled "Expression Systems."

Viral vector systems have been indicated as highly efficient in transferring
 15 genes to mammals containing deficient genes. See, for example, Crystal Am. J. Med. 92(6A):44S-52S (1992); Lemarchand et al. Proc. Nat'l Acad. Sci. USA 89(14):6482-6486 (1992) the disclosures of which are hereby incorporated by reference.

The viral vector can also be conveniently administered to a patient. For example, administration may be accomplished through, for example, liquid lavage, direct
 20 injection, or through *ex vivo* treatment of cells, followed by reinfusion of such cells into the patient. Particularly preferred tissues for delivery of vectors including the HH gene are the liver and the gut. It will be appreciated that liquid lavage or direct injection can be utilized for delivery of the vector to the gut, while direct injection will presumably be necessary for delivery to the liver.

Example 5 HH Therapy: Protein Replacement Therapy

As discussed above, also provided in accordance with the invention is a therapy for HH disease involving replacement of the HH protein product. Where a patient is diagnosed as having HH disease and is not producing, or is underproducing, the
 30 normal HH gene product, such patient can be treated by replacing the normal HH gene product to assist the patient's body in combating HH disease.

The HH gene product can be produced through the methods discussed above in connection with the Section entitled "Protein Purification" above.

Delivery of the HH gene product can be accomplished as discussed in connection with Section entitled "Therapeutics" above.

5

Example 6 HH Therapy: Drug Design and Screening

As discussed above in connection with the Section entitled "Pharmacological," the HH gene and parts and portions thereof can be utilized for drug screening. Cell-based and cell-free assays are envisioned in accordance with the invention. As discussed above, a variety of drugs and other therapeutics have been proposed to have activity in HH disease. Compounds such as those described can be assayed in cellular systems containing the HH gene or the mutations therein. Cellular functions such as HH protein folding, iron uptake, transport, metabolism, receptor-like activities, other upstream or downstream processes, such as gene transcription and other signaling events, and the like can be assayed. Each of these functions can be analyzed using conventional techniques that are well known in the art.

10

15

It is expected that through use of such assays, compounds can be rapidly screened for potential activity in HH disease and compounds showing high activity can be used for the construction of combinatorial libraries. Candidates from the combinatorial libraries can be re-assayed and those with better activity than the parent compound can be analyzed for clinical development.

20

Example 7 HH Study: Animal Models of HH Disease

As discussed above, through knowledge of the gene-associated mutations responsible for HH disease, it is now possible to prepare transgenic animals as models of the HH disease. Such animals are useful in both understanding the mechanisms of HH disease as well as use in drug discovery efforts. The animals can be used in combination with cell-based or cell-free assays for drug screening programs.

25

In preparation of transgenic animals in accordance with the invention, genes within embryonic stem cells (ES cells) can be inactivated by homologous recombination. See Capecci *supra*. (1989). Specifically, an isogenic mouse genomic library (i.e., an Sv-129 library) can be screened with a human HH gene cDNA probe.

30

The resultant clones from the library are then sequenced to ensure sequence identity to the mouse HH gene homologous cDNA. A targeting vector is then constructed from the mouse genomic DNA consisting of two approximately 3 Kb genomic fragments from the mouse HH gene as 5' and 3' homologous arms. These arms would be chosen to flank a region critical to the function of the HH gene product, such as exon 4 (the immunoglobulin-like region which contains the proposed critical β -2-microglobulin interactive domain and essential disulfide linkage). However, other regions could also be targeted.

In place of exon 4, negative and positive selectable markers can be placed, for example, to abolish the activity of the HH gene. As a positive selectable marker a neo gene under control of phosphoglycerate kinase (pgk-1) promoter may be used and as a negative selectable marker the 5' arm of the vector can be flanked by a pgk-1 promoted herpes simplex thymidine kinase (HSV-TK) gene can be used.

The vector is then transfected into R1 ES cells and the transfectants are subjected to positive and negative selection (i.e., G418 and gancyclovir, respectively, where neo and HSV-TK are used). PCR is then used to screen for surviving colonies for the desired homologous recombination events. These are confirmed by Southern blot analysis.

Subsequently, several mutant clones are picked and injected into C57BL/6 blastocytes to produce high-percentage chimeric animals. The animals are then mated to C57BL/6 females. Heterozygous offspring can then be tested for the HH gene mutation by Southern blot analysis. In addition, these animals are tested by RT-PCR to assess whether the targeted homologous recombination results in the ablation of the HH gene mRNA. These results are confirmed by Northern blot analysis and RNase protection assays.

Once established, the HH gene $-/-$ mice can be studied for the development of HH-like disease and can also be utilized to examine which cells and tissue-types are involved in the HH disease process. The animals can also be used to introduce the mutant or normal HH gene or for the introduction of the homologous gene to that species (i.e., mouse) and containing the 24d1, 24d2, or other disease causing mutations. Methods for the above-described transgenic procedures are well known to those versed in the art and are described in detail by Murphy and Carter *supra* (1993).

The techniques described above can also be used to introduce the 24d1 or 24d2 mutations, or other homologous mutations in the animal, into the homologous animal gene. As will be appreciated, similar techniques to those described above, can be utilized for the creation of many transgenic animal lines, i.e., pig, sheep, goat, ape, orangutan, primate, or the like, and mice are only demonstrative.

Example 8 HH Diagnostic: Allele-specific oligonucleotide-hybridization assay

As discussed above, an allele-specific oligonucleotide-hybridization assay (Wallace et al., Nucleic Acids Res. 6:3543-3556 (1978)) can be used to discriminate between normal and mutated alleles of the hemochromatosis gene.

A sample of DNA or cDNA reverse transcribed from RNA is subjected to PCR so as to amplify the DNA segment that contains the polymorphic site. The PCR product is immobilized on a solid support, denatured and hybridized with 2 separate oligonucleotide probes that anneal to the complementary strand of the immobilized PCR product in an allele-specific fashion. The oligonucleotides are identical in sequence except for the polymorphic site (which is typically near the center of the oligonucleotide sequence). The first oligonucleotide can form a perfect and therefore relatively stable double helix with the PCR product containing allele 1, whereas annealing of oligonucleotide 1 to allele-2-containing PCR product will result in a less stable hybrid due to the interruption of the double helix by the mismatched base-pair. Similarly, oligonucleotide 2 will form a stable hybrid with allele-2 containing PCR product but not with PCR product containing allele 1. Heterozygous DNA samples will give rise to a mixed PCR product that will hybridize to both allele-specific oligonucleotides. The allele-specific oligonucleotide probes are typically between 15 and 20 nucleotides in length with the polymorphic site near the center of the oligonucleotide sequence, as a mismatch near the center is expected to have the most destabilizing effect on a heteroduplex.

Prior to performing the allele-specific oligonucleotide-hybridization assay for the A and G alleles at the 24d1 locus, genomic DNA or cDNA reverse-transcribed from RNA is subjected to PCR using the following primers:

TGGCAAGGGTAAACAGATCC

(SEQ ID NO:13)

CTCAGGCACTCCTCTCAACC

(SEQ ID NO:14)

Prior to performing the allele-specific oligonucleotide-hybridization assay for the two 24d2 alleles, genomic DNA or cDNA reverse-transcribed from RNA is subjected to PCR using the following primers:

ACATGGTTAAGGCCTGTTGC (SEQ ID NO:24)

5 GCCACATCTGGCTTGAAATT (SEQ ID NO:25)

The PCR is performed in standard PCR-reaction buffer (e.g., 1X GeneAmp reaction buffer from Perkin Elmer with 1.5 mM Mg^{++}) for 35-30 cycles using an annealing temperature of 60°C.

After PCR, the reaction mixture is boiled for 3 minutes and then chilled on ice. One volume of 20X SSC buffer is added and approximately 2 μ l of the mixture spotted onto two duplicate nylon filters (one for each allele) that have been pre-wetted in 10X SSC buffer. Alternatively, a dot-blotting or slot-blotting apparatus may be used. The membranes are soaked in 0.5M NaOH/1.5M NaCl solution, neutralized in 0.5M Tris-HCl, pH 7.5, and subjected to UV crosslinking to form a covalent bond between the denatured PCR product and the filter.

Examples of oligonucleotide sequences specific for the 24d1 and 24d2 alleles are given in the following table. It is possible to design allele-specific oligonucleotides that differ from the ones shown in size and/or position of the polymorphic site. Oligonucleotides of complementary sequence may be used as well.

20

Allele Example of allele-specific oligonucleotides

24d1:G 5' ATATACGTGCCAGGTGG (SEQ ID NO:45)

24d1:A 5' ATATACGTACCAGGTGG (SEQ ID NO:46)

24d2:C 5' TCTATGATCATGAGAGT (SEQ ID NO:47)

25 24d2:G 5' TCTATGATGATGAGAGT (SEQ ID NO:48)

The oligonucleotides are radiolabeled at the 5' end using gamma ^{32}P ATP and T4 polynucleotide kinase using standard procedures (Sambrook, Fritsch, Maniatis, Molecular Cloning, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) 11.31). One membrane containing PCR amplified 24d1 locus is subjected to hybridization with the labeled oligonucleotide probe specific for the 24d1:G allele. The duplicate membrane is hybridized with the oligonucleotide specific for the 24d1:A allele. Similarly, duplicate membranes containing PCR amplified 24d2 locus are

subjected to separate hybridizations with the two allele-specific oligonucleotides for 24d2. The stringency of the hybridization conditions (hybridization temperature, salt concentration of the hybridization and post-hybridization wash solutions, temperature and duration of the post-hybridization washes) are empirically determined to optimize sensitivity and specificity of the assay. Guidelines for suitable ranges of hybridization conditions are available in most standard laboratory manuals (e.g., Sambrook, Fritsch, Maniatis, Molecular Cloning, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) 11.45-61).

After the last post-hybridization wash, radiolabeled probe that is bound to the spotted PCR product is detected by autoradiography. DNA samples from patient who are homozygous for the 24d1G allele give rise to a positive hybridization signal with the 24d1G-specific oligonucleotide but not with the 24d1A-specific oligonucleotide probe. DNA samples from 24d1:A homozygotes give rise to a positive signal with the 24d1:A-specific, but not with the 24d1:G-specific probe. Heterozygous samples are positive for both probes. 24d2 genotypes are called in an analogous fashion. In order to facilitate the interpretation of hybridization results, suitable control DNA samples of known genotype are processed along with unknown DNA samples.

Example 9 HH Diagnostic: Allele-specific PCR assay

As discussed above, an allele-specific PCR assay (Newton et al, Nucleic Acids Res. 17:2503-2516 (1989)) can be used to discriminate between normal and mutated alleles of the hemochromatosis gene.

The allele-specific PCR assay exploits differences in priming efficiency of a perfectly-matched PCR primer and a mismatched PCR primer. Typically, the two allele-specific primers are identical except for the allele-specific nucleotide at the 3' end. The primer specific for allele 1 can form a perfect duplex upon annealing to denatured target DNA containing allele 1, whereas its 3' nucleotide will not be base-paired after annealing to allele-2-containing target DNA. Conversely, the allele-2-specific primer can form a perfect double helix after annealing to allele-2-containing DNA but will have an unpaired 3' nucleotide when annealed to allele-1-containing DNA. Only the cognate primer can be efficiently extended by DNA polymerase. Each allele-specific primer is used in combination with a third, common PCR primer. Depending on the genotype of

the DNA sample, either one or the other or both primer-pairs will give rise to a PCR product.

Examples of PCR primer pairs for allele-specific amplification of the 24d1 and 24d2 loci are given in the following table. Suitable alternative allele-specific primers

may have more or less nucleotides at their 5' end. It is also possible to design allele-specific primers that can anneal to the other strand of the target DNA. The common PCR primer may be any non-repetitive sequence of 10 or more nucleotides on the complementary strand that is within "PCRable distance" of the allele-specific primer and has a suitable annealing temperature. Suitable primer pairs can be selected using published guidelines (e.g., Kramer, M.F and Coen, D.M. in Current Protocols in Molecular Biology, Ausubel, F.M. et al., eds., Wiley, Chapter 15.03) or by using primer-picking programs such as PRIMER (Lincoln, S.E., Daly, M.J., Lander, E.S. 1991. PRIMER: A Computer Program for Automatically Selecting PCR Primers. Version 0.5 Manual. MIT Center for Genome Research and Whitehead Institute for Biomedical Research. Nine Cambridge Center. Cambridge, Massachusetts 02142) or OSP (Hillier, L. and Green, P. (1991): OSP: A computer program for choosing PCR and DNA sequencing primers. PCR Methods and Applications, 1:124-128).

Allele	Allele-specific PCR primer	SEQ ID NO:	Common PCR primer	SEQ ID NO:	Size (bp)
24d1:G	5' TGGGTGCTCCACCTGGC	49	TGGCAAGGGTAAACAGATCC	13	296
24d1:A	5' TGGGTGCTCCACCTGGT	50	TGGCAAGGGTAAACAGATCC	13	296
24d2:C	5' CACACGGCGACTCTCATG	51	ACATGGTTAAGGCCTGTTGC	24	159
24d2:G	5' CACACGGCGACTCTCATC	52	ACATGGTTAAGGCCTGTTGC	24	159

The PCR is performed according to standard protocols procedures (e.g., Sambrook, Fritsch, Maniatis, Molecular Cloning, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) 14.18) and the reaction mixture analyzed by electrophoresis on a polyacrylamide or an agarose gel. The PCR product is visualized by EtBr staining. The stringency of the PCR reaction conditions is empirically determined (by changing parameters such as annealing temperature of $MgCl_2$ concentration) to optimize sensitivity and allele-specificity of the assay.

DNA samples from patient who are homozygous for the 24d1:G allele give rise to a positive PCR reaction with the primer pair containing the 24d1:G-specific primer but not with the 24d1:A-specific primer. DNA samples from 24d1:A homozygotes give rise to a positive signal with the 24d1:A-specific, but not the 24d1:G-specific PCR primer. Heterozygous samples are positive in both reactions. 24d2 genotypes are called in an analogous fashion. In order to facilitate the interpretation of PCR results, suitable control DNA samples of known genotype are processed along with unknown DNA samples.

10 **Example 10 HH Diagnostic: Template-directed incorporation assay**

As discussed above, the template-directed incorporation assay can be used to discriminate between normal and mutated alleles of the hemochromatosis gene. In this assay, an oligonucleotide primer is designed that anneals to the target DNA such that its 3' end is immediately adjacent to the polymorphic position. DNA polymerase and 4 different dideoxy nucleotides are added. Depending on the allele present, the primer is extended by one of two alternative dideoxy nucleotides.

In one embodiment of this assay (Chen & Kwok, Nucleic Acids Res. 25:347-353 (1997)), the primer carries a fluorescent moiety (fluorescein, the "donor") at its 5' end, and the two allele-specific dideoxynucleotides carry another fluorescent dye (ROX, the "acceptor" molecule). After extension of the 5' fluorescein-labeled primer molecule with the ROX-labeled ddNTP dyes, both donor and acceptor are attached to the same molecule and thus in close proximity. Upon excitation of a fluorescein molecule that is in close proximity to a ROX molecule, a physical phenomenon called fluorescence resonance energy transfer (FRET) can take place, i.e., part of the excitation energy is transferred from the fluorescein molecule to the ROX molecule, which in turn emits a photon. Since the emission spectrum of the acceptor is different than that of the donor, the FRET can be analyzed by measuring the ROX-emission upon excitation of fluorescein. Two separate extension reactions, one with the ROX-labeled ddNTP specific for allele 1 and one with the ROX-labeled ddNTP specific for allele 2, are performed, and each extension reaction is followed by measuring the FRET from fluorescein to ROX. The target region is typically preamplified by PCR.

Examples of oligonucleotide primers and dideoxynucleotide combinations suitable for the discrimination between the 2 respective 24d1 and 24d2 alleles are given in the following table. Two alternative sets are given, one for each strand.

locus	Primer	SEQ ID NO:	ROX-ddNTP (normal allele)	ROX-ddNTP (mutant allele)
5 24d1	(1) F-GGAAGAGCAGAGATATACGT	53	ROX-ddG	ROX-ddA
24d1	(2) F-GGCCTGGGTGCTCCACCTGG	54	ROX-ddC	ROX-ddU
24d2	(3) F-AGCTGTTCGTGTTCTATGAT	55	ROX-ddC	ROX-ddG
24d2	(4) F-CTCCACACGGCGACTCTCAT	56	ROX-ddG	ROX-ddC

10 After PCR amplification of the 24d1 or 24d2 locus using standard conditions (see above), the PCR product is purified by gel-electrophoresis. Two separate primer-extension reactions (each containing fluorescein-labeled primer, the allele-specific ROX-labeled ddNTP and three unlabeled ddNTPs) are set up and the reaction performed by thermocycling (35 cycles) between 93°C and 50°C. NaOH is added to the reaction

15 mixtures, and the incorporation of ROX-labeled ddNTP is measured by determining ROX emission (605 nm) upon excitation of fluorescein (488 nm) on a fluorescence spectrophotometer. The data are normalized, processed and plotted as described by Chen & Kwok, Nucleic Acids Res. 25:347-353 (1997)).

20 DNA samples that are homozygous for the normal 24d1 allele will give rise to a positive FRET signal after extension of primer (1) with ROX-ddG whereas the extension-reaction of primer (1) in the presence of ROX-ddA will be negative. In contrast, DNA samples that are homozygous for the mutant 24d1 allele will be positive only in the reaction with ROX-ddA. Heterozygous samples will be positive with both ROX-ddG and ROX-ddA, but the FRET signal will be lower than with homozygous

25 samples. Extension reactions containing Primer (2) and either ROX-ddC or ROX-ddU are analyzed in an analogous fashion, as are the 24d2 genotyping reactions based on allele-specific extension of either primer (3) or primer (4). In order to facilitate the interpretation of the results, DNA samples of known genotype are processed along with unknown DNA samples.

Example 11 HH Diagnostic: PNA-mediated PCR-clamping Assay

Many diagnostic methods involve the formation of a hybrid comprising the test DNA and an allele specific probe, usually an DNA oligonucleotide. It is possible to use a peptide nucleic acid oligonucleotide (PNA) probe instead. PNA differ from DNA in that the DNA ribose-phosphate backbone is replaced by a peptide backbone. Due to this chemical difference, PNA-DNA hybrids differ from DNA-DNA hybrids in several respects: PNA-DNA hybrids have a higher thermal stability (because of the lack of electrostatic repulsion between the two backbones); the difference in melting temperature between a perfectly matched and a mismatched hybrid is larger for PNA-DNA than for their DNA-DNA counterparts thus increasing the specificity of the interaction; PNA-DNA hybrids are no substrate for DNA polymerase, i.e., the PNA cannot serve as a PCR primer.

In the following example (based on Orum et al., Nucleic Acids Res. 21:5332-5336 (1993) and Thiede et al. Nucleic Acids Res. 24, 983-984 (1996)), an allele-specific PNA oligonucleotide competes with the 3' end of a generic DNA-oligonucleotide primer for annealing to the target DNA. If the PNA oligonucleotide matches the sequence of the target strand, it will out-compete the PCR primer resulting in a negative PCR reaction. If the target DNA differs from the PNA probe at one position, the PNA-DNA interaction is much weaker, the PCR primer can anneal and give rise to an amplification product.

The DNA sample to be tested is split into four aliquots. The first aliquot receives a PNA-oligonucleotide that matches the normal 24d1 sequence, the second receives an PNA-oligonucleotide that matches the mutant 24d1 allele, the third and fourth aliquots receive PNA oligos that match normal and mutated 24d2 alleles, respectively. The reactions are complemented with PCR primers to amplify the 24d1 and 24d2 loci, respectively. The various combinations of PNA oligonucleotides and PCR primers are specified below. In this reaction the cognate PNA probe will abolish a reaction. In order to discriminate between specific inhibition and other causes for negative PCR reaction (such as unspecific inhibitors or omission of essential ingredients) PCR primers specific for another, unrelated genomic locus can be included (which should be amplifiable regardless of the which PNA oligonucleotide is present and regardless of the genotype at 24d1 or 24d2 of the DNA sample).

Allele	PNA	SEQ ID NO:	PCR primer 1	SEQ ID NO:
24d1:G	GCTCCACCTGGCACG	57	CTCAGGCACTCCTCTCAACC	14
24d1:A	GCTCCACCTGGTACG	58	CTCAGGCACTCCTCTCAACC	14
24d2:C	GCGACTCTCATCATC	59	GCCACATCTGGCTTGAAATT	25
5 24d2:G	GCGACTCTCATGATC	60	GCCACATCTGGCTTGAAATT	25

Allele	PCR primer 2	SEQ ID NO:	Size (bp)
24d1:G	GGAAGAGCAGAGATATACGT	53	131
24d1:A	GGAAGAGCAGAGATATACGT	53	131
10 24d2:C	AGCTGTTCGTGTTCTATGAT	55	87
24d2:G	AGCTGTTCGTGTTCTATGAT	55	87

The PCR is performed according to standard protocols procedures (e.g., Sambrook, Fritsch, Maniatis, Molecular Cloning, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989) 14.18) and the reaction mixture analyzed by electrophoresis on a polyacrylamide or an agarose gel. The PCR product is visualized by EtBr staining. The stringency of the PCR reaction conditions is empirically determined (by changing parameters such as annealing temperature of $MgCl_2$ concentration) to optimize sensitivity and allele-specificity of the assay.

DNA samples from patients who are homozygous for the 24d1:G allele fail to amplify in presence of the 24d1:G-specific PNA but should give rise to a 131-bp PCR product in presence of the 24d1:A-specific PNA oligonucleotide. DNA samples from 24d1:A homozygotes will be negative in the reaction containing the 24d1:A-specific PNA but positive in the reaction with the 24d1:G-specific PNA molecule. Heterozygous samples will be positive in both reactions. 24d2 genotypes are called in an analogous fashion. In order to facilitate the interpretation of PCR results, suitable control DNA samples of known genotype are processed along with unknown DNA samples.

Example 12 HH Diagnostic: Ligase-Chain-Reaction Assay

The ligase chain reaction (LCR; Wu & Wallace, Genomics 4: 560-569 (1989)) is an amplification method which is based on the template-dependent ligation of two adjacent oligonucleotides. The DNA sample is denatured in the presence of two pairs of oligonucleotides. Upon lowering the reaction temperature, pair 1 will anneal side-by-side on one strand, pair 2 will anneal side-by-side at the identical position on the complementary strand. Two of the oligonucleotides carry a phosphate group at their 5' end thus allowing the enzyme DNA ligase to form a covalent bond between the two oligonucleotides annealed on the same strand. After ligation, the temperature is raised again, and another annealing and ligation cycle is performed. Since non-ligated oligonucleotide pairs can anneal to the ligation products formed in the previous cycle, the amount of ligated oligonucleotides will double with each reaction cycle leading to an exponential amplification of double-stranded DNA consisting of the two ligated complementary oligonucleotide-pairs. Because the ligation does not occur in the presence of a mismatch between the template and one of the two oligonucleotides at any of the positions flanking the ligation junction, an allele-specific LCR amplification assays can be developed (Barany, Proc. Natl. Acad. Sci. USA 88: 189-193 (1991)).

Traditionally, the LCR oligonucleotides are radiolabeled and the LCR-amplification product is detected as a radioactive electrophoresis band, which is larger than the input oligonucleotides. Modern high-throughput incarnations of this method use fluorescently-labeled oligonucleotides in combination with ABI-type sequencers or capillary-electrophoresis systems to resolve input from product oligonucleotides. In the following example, the LCR-product is detected by a solid-phase-capture/detection-tagging strategy similar to that described above for OLA (Nickerson et al., in Current Protocols in Human Genetics, Ausubel, F.M. et al., eds., Wiley, Chapter 2.6), i.e., one of the oligonucleotides is biotinylated and its ligation partner is digoxigenin labeled; hence only the ligated product will bind to a streptavidin-coated plate and give rise to a positive reaction with an anti-digoxigenin antibody.

To increase the number of target molecules prior to performing the allele-specific LCR assay for the A and G alleles the 24d1 and 24d2 loci may be preamplified from total genomic DNA or cDNA reverse-transcribed from RNA by PCR

using the following primer pairs. This preamplification step is optional. Alternatively one can start with total genomic DNA and perform more LCR cycles to amplify the two loci during the LCR itself.

24d1:

5 TGGCAAGGGTAAACAGATCC (SEQ ID NO:13)
CTCAGGCACTCCTCTCAACC (SEQ ID NO:14)

24d2:

ACATGGTTAAGGCCTGTTGC (SEQ ID NO:24)
GCCACATCTGGCTTGAAATT (SEQ ID NO:25)

10 The PCR is performed in standard PCR-reaction buffer (e.g., 1X GeneAmp reaction buffer from Perkin Elmer with 1.5 mM Mg⁺⁺) for 35-30 cycles using an annealing temperature of 60°C.

Two allele-specific LCR-reactions are set up for each locus containing thermostable ligase, and the following combination of oligonucleotides:

15	Allele	oligonucleotide-pair 1	SEQ ID NO:	oligonucleotide-pair 2	SEQ ID NO:
	24d1:G	bio-GCCTGGGTGCTCCACCTGGC	61	bio-GAAGAGCAGAGATATACGTG	63
		pACGTATATCTCTGCTCTTCC-dig	62	pCCAGGTGGAGCACCCAGGCC-dig	64
	24d1:A	bio-GCCTGGGTGCTCCACCTGGT	65	bio-GAAGAGCAGAGATATACGTA	67
		pACGTATATCTCTGCTCTTCC-dig	66	pCCAGGTGGAGCACCCAGGCC-dig	68
	24d2:C	bio-TCCACACGGCGACTCTCATG	69	bio-GCTGTTCGTGTTCTATGATC	71
		pATCATAGAACACGAACAGCT-dig	70	pATGAGAGTCGCCGTGTGGAG-dig	72
	24d2:G	bio-TCCACACGGCGACTCTCATC	73	bio-GCTGTTCGTGTTCTATGATG	75
		pATCATAGAACACGAACAGCT-dig	74	pATGAGAGTCGCCGTGTGGAG-dig	76

20

The reaction mixes are subjected to 5-10 thermocycles (for PCR amplified targets) or 25-30 thermocycles (for non-amplified samples), with each cycle consisting of a 30 sec denaturation step at 94°C and a 2 min. ligation step at 60°C.

25 After the last cycle, the reaction mixtures are transferred to streptavidin-coated microtiter plates to capture biotinylated oligonucleotides. Un-ligated 3'-digoxigenin-labeled oligonucleotides are removed by denaturation and extensive washing. Finally, captured and digoxigenin-containing (i.e., ligated) products are detected with an anti-digoxigenin Fab fragment that is conjugated to alkaline phosphatase,

whose presence in turn is assayed by a suitable colorimetric reaction, similar to the detection procedure described above for OLA assays.

Example 13 RFLP-Southern Analysis

Genomic DNA from individuals can be digested using restriction endonucleases and size fractionated in agarose gels by electrophoresis (Kan and Dozy, Lancet ii:910-912 (1978)). The DNA fragments are then transferred to nylon membranes (or nitrocellulose) and fixed by standard techniques such as chemical or UV crosslinking. A DNA probe such as the cDNA or genomic DNA surrounding the mutation can be labeled by either ³²P or other conventional methods and hybridized to the filters, washed and exposed to X-ray film. For detection of the 24d1 mutation, either Rsa I or Sna BI restriction endonucleases can be used. In both cases the 24d1 mutation creates an additional site. For detection of the 24d2 mutation, either Bcl I, Sau 3A, Mbo I, or Dpn II restriction endonucleases can be used. In all cases the 24d2 mutation destroys a site.

Example 14 RFLP-PCR Analysis

Genomic DNA from individuals can be amplified using the polymerase chain reaction using oligonucleotide primers that flank the 24d1 and 24d2 mutations. For example the following sets of primers can be used:

24d1 5' TGGCAAGGGTAAACAGATCC 3' (SEQ ID NO:13)

5' CTCAGGCACTCCTCTCAACC 3' (SEQ ID NO:14)

PCR product = 390 bp

24d2 5' ACATGGTTAAGGCCTGTTGC 3' (SEQ ID NO:24)

5' GCCACATCTGGCTTGAAATT 3' (SEQ ID NO:25)

PCR product = 208 bp

The resulting product sizes are given. These PCR products can be subjected to restriction endonuclease digestion using the same enzymes described in the RFLP - Southern Analysis example. For detection of the 24d1 mutation, either Rsa I or Sna BI restrictions endonucleases can be used. The wild type (unmutated) allele will have a 250 bp and a 140 bp band following Rsa I digestions and size fractionation on agarose gels with ethidium bromide staining. The mutant allele will produce 3 bands of 250 bp,

111 bp, and 29 bp under the same conditions. For detection of the 24d2 mutation, either Bcl I, Sau 3A, Mbo I, or Dpn II restriction endonucleases can be used. In all cases the 24d2 mutation destroys a site. In the example of using Bcl I the wild type allele will result in band sizes of 138 bp and 70 bp. The mutant allele destroys a site resulting in a
5 band size of 208 bp.

INCORPORATION BY REFERENCE

All references (including books, articles, papers, patents, and patent applications) cited herein are hereby expressly incorporated by reference in their entirety
10 for all purposes.

EQUIVALENTS

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and
15 this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as fall within the scope of the invention and the limits of the appended claims.

WHAT IS CLAIMED IS:

1 1. An isolated nucleic acid comprising a nucleic acid sequence selected
2 from the group consisting of:

3 a. nucleic acid sequences corresponding to the nucleic acid of
4 SEQ ID NO:1;

5 b. nucleic acid sequences corresponding to the nucleic acid
6 sequences selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID
7 NO:7;

8 c. nucleic acid sequences corresponding to the nucleic acid
9 sequence of SEQ ID NO:9; and

10 d. nucleic acid sequences corresponding to the nucleic acid
11 sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, and
12 SEQ ID NO:12.

1 2. The nucleic acid of claim 1, wherein the nucleic acid is genomic
2 DNA.

1 3. The nucleic acid of claim 2, wherein the DNA is cDNA.

1 4. The nucleic acid of claim 1, wherein the nucleic acid is a nucleic
2 acid sequence corresponding to the nucleic acid of SEQ ID NO:1.

1 5. The nucleic acid of claim 1, wherein the nucleic acid is a nucleic
2 acid sequence corresponding to the nucleic acid sequence of SEQ ID NO:9.

1 6. The nucleic acid of claim 1 wherein the nucleic acid is a nucleic
2 acid sequence corresponding to a nucleic acid sequence selected from the group consisting
3 of SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7.

1 7. The nucleic acid of claim 1, wherein the nucleic acid is a nucleic
2 acid sequence corresponding to a nucleic acid sequence selected from the group consisting
3 of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

1 8. A nucleic acid comprising an RNA equivalent of the nucleic acid of
2 claim 1.

1 9. A cloning vector comprising a coding sequence of a nucleic acid as
2 set forth in any one of claims 1 through 7 and a replicon operative in a host cell for the
3 vector.

1 10. An expression vector comprising a coding sequence of a nucleic
2 acid set forth in any one of claims 1 through 7 operably linked with a promoter sequence
3 capable of directing expression of the coding sequence in host cells for the vector.

1 11. Host cells transformed with a vector as set forth in any one of
2 claims 9 and 10.

1 12. A method of producing a mutant HH polypeptide comprising:
2 a. transforming host cells with a vector capable of expressing a
3 polypeptide from a nucleic acid sequence as set forth in any one of claims 6 and 7;
4 b. culturing the cells under conditions suitable for production of
5 the polypeptide; and
6 c. recovering the polypeptide.

1 13. A peptide product selected from the group consisting of:
2 a. a polypeptide having the amino acid sequence corresponding
3 to the sequence of SEQ ID NO:2;
4 b. a polypeptide having the amino acid sequence corresponding
5 to the sequence of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8;
6 c. a peptide comprising at least 6 amino acid residues
7 corresponding to the sequence of SEQ ID NO:2; and

8 d. a peptide comprising at least 6 amino acid residues
9 corresponding to the sequence of SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8.

1 14. The peptide product of claim 13, wherein the peptide is labelled.

1 15. The peptide product of claim 13, wherein the peptide is a fusion
2 protein.

1 16. Use of a peptide as set forth in any one of claims 13 through 15 as
2 an immunogen for the production of antibodies.

1 17. An antibody produced in accordance with claim 16.

1 18. The antibody of claim 17, wherein the antibody is labelled.

1 19. The antibody of claim 17, wherein the antibody is bound to a solid
2 support.

1 20. The antibody of claim 17, wherein the antibody is monoclonal.

1 21. A method to determine the presence or absence of the common
2 hereditary hemochromatosis (HH) gene mutation in an individual comprising:
3 providing DNA or RNA from the individual; and
4 assessing the DNA or RNA for the presence or absence of the HH-
5 associated allele A of a base-pair mutation designated herein 24d1,
6 wherein, as a result, the absence of the allele indicates the absence of the
7 HH gene mutation in the genome of the individual and the presence of the allele indicates
8 the presence of the HH gene mutation in the genome of the individual.

1 22. The method of claim 21, wherein the method further comprises
2 assessing the RNA or DNA for the presence of 24d2.

1 23. The method of claim 21, wherein the method further comprises
2 assessing the RNA or DNA for the presence of at least one of polymorphisms HHP-1,
3 HHP-19, or HHP-29, or microsatellite repeat alleles 19D9:205; 18B4:235; 1A2:239;
4 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-
5 1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-
6 4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-
7 1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122,
8 D6S105:124; D6S306:238; D6S464:206; and D6S1001:180,

1 24. The method of claim 22, wherein the method further comprises
2 assessing the RNA or DNA for the presence of at least one of polymorphisms HHP-1,
3 HHP-19, or HHP-29, or microsatellite repeat alleles 19D9:205; 18B4:235; 1A2:239;
4 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-
5 1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-
6 4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-
7 1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122,
8 D6S105:124; D6S306:238; D6S464:206; or D6S1001:18.

1 25. A method for diagnosing whether a patient is afflicted with
2 hereditary hemochromatosis (HH) disease, comprising:
3 a. contacting cells of the patient with antibodies directed against
4 an epitope on an HH protein product corresponding substantially to SEQ ID NO:2 and
5 b. observing whether the antibodies localize on the cells,
6 wherein, the observing step, if antibodies do not localize to the cell it is
7 likely that the patient is afflicted with HH.

1 26. The method of claim 25, wherein the method is conducted *in vitro*.

1 27. The method of claim 25, wherein the method is conducted *in vivo*.

1 28. A method for treating a patient diagnosed as having hereditary
2 hemochromatosis (HH) disease and homozygous for a 24d1(A) mutation, comprising

3 delivering a polypeptide corresponding to the amino acid sequence of SEQ ID NO:2 to
4 tissues of the patient.

1 29. The method of claim 28, wherein the polypeptide is delivered
2 directly to the tissues.

1 30. The method of claim 28, wherein the polypeptide is delivered
2 intravenously.

1 31. The method of claim 28, wherein the polypeptide is delivered to the
2 tissues through gene therapy.

1 32. An animal model for hereditary hemochromatosis (HH) disease,
2 comprising a mammal possessing a mutant or knocked-out HH gene.

1 33. Metal chelation agents derived from nucleic acid sequences in
2 accordance with claim 1 or from a peptide product in accordance with Claim 13 in a
3 physiologically acceptable carrier.

1 34. The chelation agent of claim 33, wherein the metal is selected from
2 the group consisting of iron, mercury, cadmium, lead, and zinc.

1 35. A method to screen mammals for susceptibility to metal toxicities,
2 comprising, screening such mammals for a mutation in the HH gene and wherein those
3 mammals identified as having a mutation are more susceptible to metal toxicities than
4 mammals not identified as having a mutation.

1 36. The method of claim 35, wherein the metal is selected from the
2 group consisting of iron, mercury, cadmium, lead, and zinc.

1 37. A method for selecting patients infected with hepatitis virus for α -
2 interferon treatment, comprising screening such patients for a mutation in the HH gene

3 and wherein those patients not identified as having a mutation are selected to proceed with
4 α -interferon treatment and those identified as having a mutation are selected to undergo
5 phlebotomy prior to α -interferon treatment.

1 38. A T-cell differentiation factor comprising a moiety selected from the
2 group consisting of molecules derived from nucleic acid sequences in accordance with
3 claim 1 and from a peptide product in accordance with claim 13.

1 39. A method for screening potential therapeutic agents for activity in
2 connection with HH disease, comprising:
3 providing a screening tool selected from the group consisting of a
4 cell line, a cell free extract, and a mammal containing or expressing a defective HH gene
5 or gene product;
6 contacting the screening tool with the potential therapeutic agent;
7 and
8 assaying the screening tool for an activity selected from the group
9 consisting of HH protein folding, iron uptake, iron transport, iron metabolism, receptor-
10 like activities, upstream processes, downstream processes, gene transcription, and
11 signaling events.

1 40. A therapeutic agent for the mitigation of injury due to oxidative
2 processes *in vivo*, comprising a moiety selected from the group consisting of molecules
3 derived from nucleic acid sequences in accordance with claim 1 and from a peptide
4 produce in accordance with claim 13.

1 41. A method for diagnosing a patient as having an increased risk of
2 developing HH disease, comprising:
3 providing DNA or RNA from the individual; and
4 assessing the DNA or RNA for the presence or absence of
5 the HH-associated allele A or a base mutation designated herein 24d1 in combination with
6 assessing the DNA or RNA for the HH-associated allele G of a base mutation designated
7 herein 24d2,

8 wherein, as a result, the absence of the alleles indicates the absence of the
9 HH gene mutation in the genome of the individual and the presence of the alleles
10 indicates the presence of the HH gene mutation in the genome of the individual and an
11 increase risk of developing HH disease.

1 42. The method of claim 41, wherein the method further comprises
2 assessing the RNA or DNA for the presence of at least one of polymorphisms HHP-1,
3 HHP-19, or HHP-29, or microsatellite repeat alleles 19D9:205; 18B4:235; 1A2:239;
4 1E4:271; 24E2:245; 2B8:206; 3321-1:98; 4073-1:182; 4440-1:180; 4440-2:139; 731-
5 1:177; 5091-1:148; 3216-1:221; 4072-2:170; 950-1:142; 950-2:164; 950-3:165; 950-
6 4:128; 950-6:151; 950-8:137; 63-1:151; 63-2:113; 63-3:169; 65-1:206; 65-2:159; 68-
7 1:167; 241-5:108; 241-29:113; 373-8:151; and 373-29:113, D6S258:199, D6S265:122,
8 D6S105:124; D6S306:238; D6S464:206; and D6S1001:180.

1 43. A therapeutic agent for the mitigation of iron overload, comprising
2 a moiety selected from the group consisting of molecules derived from nucleic acid
3 sequences in accordance with claim 1 and from a peptide product in accordance with
4 claim 13.

1 44. A method for treating hereditary hemochromatosis (HH) disease
2 comprising:
3 providing an antibody directed against an HH protein sequence or
4 peptide product; and
5 delivering the antibody to affected tissues or cells in a patient having
6 HH.

1 45. An antisense oligonucleotide directed against a transcriptional
2 product of a nucleic acid sequence selected from the group consisting of SEQ ID NO:1,
3 SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID
4 NO:11, and SEQ ID NO:12.

1 46. An oligonucleotide of at least 8 nucleotides in length selected from
2 nucleotides 1-46, 48-123; 120-369; 365-394; 390-540; 538-646; 643-1004; 1001-1080;
3 1083-1109; 1106-1304; 1301-1366; 1363-1386; 1389-1514; 1516-1778; 1773-1917; 1921-
4 2010; 2051-2146; 2154-2209; 2234-2368; 2367-2422; 2420-2464; 2465-2491; 2488-2568;
5 2872-2901; 2902-2934; 2936-2954; 2449-3001; 3000-3042; 3420-3435; 3451-3708; 3703-
6 3754; 3750-3770; 3774-3840; 3840-3962; 3964-3978; 3974-3992; 3990-4157; 4153-4251;
7 4257-4282; 4284-4321; 4316-4333; 4337-4391; 4386-4400; 4398-4436; 4444-4547; 4572-
8 4714; 4709-4777; 5165-5397; 5394-6582; 5578-5696; 5691-5709; 5708-5773; 5773-5816;
9 5818-5849; 5889-6045; 6042-6075; 6073-6108; 6113-6133; 6150-6296; 6292-6354; 6356-
10 6555; 6555-6575; 6575-6616; 6620-6792; 6788-6917; 6913-7027; 7023-7061; 7056-7124;
11 7319-7507; 7882-8000; 7998-8072; 8073-8098; 9000-9037; 9486-9502; 9743-9811; 9808-
12 9831; 9829-9866; 9862-9986; 9983-10075; 10072-10091; 10091-10195; 10247-10263;
13 10262-10300; 10299-10448; 10448-10539; 10547-10564; 10580-10612; 10608-10708;
14 10703-10721; 10716-10750; 10749-10774; 10774-10800; and 10796-10825 of SEQ ID
15 NO:1, 3, 5, or 7.

1 47. An oligonucleotide pair comprising an oligonucleotide of claim 46 and
2 an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,
3 or 7.

1 48. An oligonucleotide of at least 9 nucleotides in length selected from
2 nucleotides 1-47; 47-124; 119-370; 364-395; 389-541; 537-647; 642-1005; 1000-1081;
3 1082-1110; 1105-1305; 1300-1367; 1362-1387; 1388-1515; 1515-1918; 1920-2011; 2050-
4 2147; 2153-2210; 2233-2369; 2366-2423; 2419-2465; 2464-2492; 2487-2569; 2871-2935;
5 2935-3002; 2999-3043; 3419-3436; 3450-3755; 3749-3771; 3773-3841; 3839-3963; 3963-
6 3979; 3973-3993; 3989-4158; 4152-4252; 4256-4283; 4283-4334; 4336-4401; 4397-4437;
7 4443-4548; 4571-4778; 5164-5398; 5393-5583; 5577-5710; 5707-5774; 5772-5817; 5817-
8 5850; 5888-6046; 6041-6076; 6072-6109; 6112-6134; 6149-6355; 6355-6556; 6554-6576;
9 6574-6793; 6787-7125; 7318-7508; 7881-8001; 7997-8073; 8072-8099; 8999-9038; 9485-
10 9503; 9742-9812; 9807-9832; 9828-9867; 9861-9987; 9982-10076; 10071-10092; 10090-
11 10196; 10246-10264; 10261-10301; 10298-10449; 10447-10540; 10546-10565; 10579-
12 10751; 10748-10775; 10773-10801; and 10795-10825 of SEQ ID NO:1, 3, 5, or 7.

1 49. An oligonucleotide pair comprising an oligonucleotide of claim 48 and
2 an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,
3 or 7.

1 50. An oligonucleotide of at least 10 nucleotides in length selected from
2 nucleotides 1-48; 46-125; 118-1006; 999-1082; 1081-1111; 1104-1306; 1299-1368; 1361-
3 1388; 1387-1516; 1514-1919; 1919-2012; 2049-2148; 2152-2211; 2232-2370 2365-2424;
4 2418-2466; 2463-2493; 2486-2570; 2870-2936; 2934-3003; 2998-3044; 3418-3437; 3449-
5 3772; 3772-3842; 3838-3964; 3962-3994; 3988-4284; 4282-4335; 4335-4402; 4396-4438;
6 4442-4549; 4570-4779; 5163-5711; 5706-5775; 5771-5818; 5816-5851; 5867-6047; 6040-
7 6077; 6071-6110; 6111-6135; 6148-6356; 6354-6577; 6573-7126; 7317-7509; 7880-8074;
8 8071-8100; 8998-9039; 9484-9504; 9741-9813; 9806-9833; 9827-9988; 9981-10093;
9 10089-10197; 10245-10265; 10260-10302; 10297-10450; 10446-10541; 10545-10566;
10 10578-10752; 10747-10776; and 10772-10825 of SEQ ID NO:1, 3, 5, or 7.

1 51. An oligonucleotide pair comprising an oligonucleotide of claim 50 and
2 an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,
3 or 7.

1 52. An oligonucleotide of at least 11 nucleotides in length selected from
2 nucleotides 1-49; 45-1389; 1386-1517, 1513-1920; 1918-2013; 2048-2149; 2151-2212;
3 2231-2371; 2364-2425; 2417-2467; 2462-2571; 2869-2937; 2933-3004; 2997-3045; 3417-
4 3438; 3448-3773; 3771-3843; 3837-3965; 3961-3995; 3987-4285; 4281-4336; 4334-4403;
5 4395-4439; 4441-4550; 4569-4780; 5162-5712; 5705-5776; 5770-5819; 5815-5852; 5886-
6 6111; 6100-6136; 6147-6357; 6353-6578; 6572-7127; 7316-7510; 7879-8075; 8070-8101;
7 8997-9040; 9483-9505; 9740-10198; 10244-10266; 10257-10303; 10296-10451; 10445-
8 10542; 10544-10567; 10577-10753; 10746-10777; and 10771-10825 of SEQ ID NO:1, 3,
9 5, or 7.

1 53. An oligonucleotide pair comprising an oligonucleotide of claim 26 and
2 an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,
3 or 7.

1 54. An oligonucleotide of at least 12 nucleotides in length selected from
2 nucleotides 1-50, 44-1390; 1385-1518; 1512-1921; 1917-2014; 2047-2150; 2150-2213;
3 2230-2372; 2363-2468; 2461-2572; 2868-2938; 2932-3005; 2996-3046; 3416-3439; 3447-
4 3774; 3770-3844; 3836-3966; 3960-4286; 4280-4337; 4333-4440; 4440-4551; 4568-4781;
5 5161-5713; 5704-5777; 5669-5820; 5814-5853; 5885-6112; 6109-6137; 6146-6358; 6352-
6 6579; 6571-7128; 7315-7511; 7878-8076; 8069-8102; 8996-9041; 9482-9506; 9739-
7 10199; 10243-10267; 10256-10304; 10295-10452; 10444-10543; 10543-10566; 10576-
8 10754; 10745-10778; and 10770-10825 of SEQ ID NO:1, 3, 5, or 7.

1 55. An oligonucleotide pair comprising an oligonucleotide of claim 54 and
2 an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3, 5,
3 or 7.

1 56. An oligonucleotide of at least 13 nucleotides in length selected from
2 nucleotides 1-51; 43-1391; 1384-1519; 1511-1922; 1916-2015; 2046-2151; 2149-2214;
3 2229-2469; 2460-2573; 2867-2939; 2931-3047; 3415-3440; 3446-3775; 3769-3845; 3835-
4 3967; 3959-4287; 4279-4338; 4332-4441; 4439-4552; 4567-4782; 5160-5778; 5668-5821;
5 5813-5854; 5884-6113; 6108-6138; 6145-6359; 6351-6580; 6570-7129; 7314-7512; 7877-
6 8077; 8068-8103; 8995-9042; 9481-9507; 9738-10200; 10242-10453; 10443-10544;
7 10542-10567; 10575-10779; and 10769-10825 of SEQ ID NO:1, 3, 5, or 7.

1 57. An oligonucleotide pair comprising an oligonucleotide of claim 56
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,
3 5, or 7.

1 58. An oligonucleotide of at least 14 nucleotides in length selected from
2 nucleotides 1-52; 42-1392; 1383-1520; 1510-1923; 1915-2016; 2045-2152; 2148-2215;
3 2228-2574; 2866-2940; 2930-3048; 3414-3441; 3445-3776; 3768-3968; 3959-4288; 4278-

4 4339; 4331-4442; 4438-4553; 4566-4783; 5159-5822; 5812-5855; 5883-6114; 6107-6139;
5 6144-6360; 6350-6581; 6569-7130; 7313-7513; 7876-8078; 8067-8104; 8994-9043; 9480-
6 9508; 9737-10201; 10241-10454; 10442-10545; 10541-10568; and 10574-10825 of SEQ
7 ID NO:1, 3, 5, or 7.

1 59. An oligonucleotide pair comprising an oligonucleotide of claim 58
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,
3 5, or 7.

1 60. An oligonucleotide of at least 15 nucleotides in length selected from
2 nucleotides 1-53; 41-1393; 1382-1521; 1509-1924; 1914-2017; 2044-2153; 2147-2216;
3 2227-2575; 2865-2942; 2929-3049; 3413-3442; 3444-3777; 3767-3969; 3958-4289; 4277-
4 4340; 4330-4443; 4437-4554; 4565-4784; 5158-5823; 5811-5856; 5882-6115; 6106-6140;
5 6143-6361; 6349-7131; 7312-7514; 7875-8105; 8993-9044; 9479-9509; 9736-10202;
6 10240-10546; 10540-10569; and 10573-10825 of SEQ ID NO:1, 3, 5, or 7.

1 61. An oligonucleotide pair comprising an oligonucleotide of claim 60
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,
3 5, or 7.

1 62. An oligonucleotide of at least 16 nucleotides in length selected from
2 nucleotides 1-1394; 1381-1925; 1913-2018; 2043-2154; 2146-2217; 2226-2576; 2864-
3 3050; 3412-3443; 3443-3778; 3766-4341; 4329-4444; 4436-4555; 4564-4785; 5157-5857;
4 5881-6116; 6105-6141; 6142-7132; 7311-7515; 7874-8106; 8992-9045; 9478-9510; 9735-
5 10203; 10239-10547; 10539-10570; and 10572-10825 of SEQ ID NO:1, 3, 5, or 7.

1 63. An oligonucleotide pair comprising an oligonucleotide of claim 62
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,
3 5, or 7.

1 64. An oligonucleotide of at least 17 nucleotides in length selected from
2 nucleotides 1-1926; 1912-2019; 2042-2155; 2145-2218; 2225-2577; 2863-3051; 3411-

3 3779; 3765-4342; 4329-4445; 4435-4556; 4563-4786; 5156-5858; 5880-6117; 6104-6142;
4 6141-7133; 7310-7516; 7873-8107; 8991-9046; 9477-9511; 9734-10204; 10238-10548;
5 10538-10571; and 10571-10825 of SEQ ID NO:1, 3, 5, or 7.

1 65. An oligonucleotide pair comprising an oligonucleotide of claim 64
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,
3 5, or 7.

1 66. An oligonucleotide of at least 18 nucleotides in length selected from
2 nucleotides 1-2020; 2041-2156; 2144-2219; 2224-2578; 2862-3052; 3410-3780; 3764-
3 4446; 4434-4557; 4562-4787; 5155-5859; 5879-6118; 6103-6143; 6140-7134; 7309-7517;
4 7872-8108; 8990-9047; 9476-9512; 9733-10205; 10237-10549; 10537-10572; and 10570-
5 10825 of SEQ ID NO:1, 3, 5, or 7.

1 67. An oligonucleotide pair comprising an oligonucleotide of claim 66
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:1, 3,
3 5, or 7.

1 68. An oligonucleotide of at least 8 nucleotides in length selected from
2 nucleotides 1-55; 55-251; 250-306; 310-376; 380-498; 500-528; 516-543; 541-578; 573-
3 592; 590-609; 611-648; 642-660; 664-717; 712-727; 725-763; 772-828; 813-874; 872-
4 928; 913-942; 940-998; 997-1046; 1054-1071; 1076-1116; 1115-1182; 1186-1207; 1440-
5 1483; 1482-1620; 2003-2055; 2057-2107; 2116-2200; and 2453-2469 of SEQ ID NO:9,
6 10, 11 or 12.

1 69. An oligonucleotide pair comprising an oligonucleotide of claim 68
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 70. An oligonucleotide of at least 9 nucleotides in length selected from
2 nucleotides 1-56; 54-252; 249-307; 309-377; 379-499; 499-529; 515-544; 540-579; 572-
3 593; 589-610; 610-649; 641-661; 663-718; 711-728; 724-764; 771-829; 812-875; 871-

4 929; 912-943; 939-999; 996-1047; 1053-1072; 1075-1117; 1114-1183; 1185-1208; 1439-
5 1484; 1481-1629; 2002-2056; 2056-2108; 2115-2201; and 2452-2470 of SEQ ID NO:9,
6 10, 11 or 12.

1 71. An oligonucleotide pair comprising an oligonucleotide of claim 70
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 72. An oligonucleotide of at least 10 nucleotides in length selected from
2 nucleotides 1-57; 53-253; 248-308; 308-378; 378-500; 498-530; 514-545; 539-580; 571-
3 594; 588-611; 609-662; 662-729; 723-765; 770-876; 870-944; 938-1000; 995-1048; 1052-
4 1073; 1074-1118; 1113-1184; 1184-1209; 1438-1485; 1480-1630; 2001-2057; 2055-2109;
5 2114-2202; and 2451-2471 of SEQ ID NO:9, 10, 11 or 12.

1 73. An oligonucleotide pair comprising an oligonucleotide of claim 72
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 74. An oligonucleotide of at least 11 nucleotides in length selected from
2 nucleotides 1-58; 52-254; 247-309; 307-379; 377-501; 497-531; 513-546; 538-595; 587-
3 612; 608-663; 661-730; 722-766; 769-877; 869-1049; 1051-1074; 1073-1119; 1112-1185;
4 1183-1210; 1437-1486; 1479-1631; 2000-2058; 2054-2110; 2113-2203; and 2450-2472 of
5 SEQ ID NO:9, 10, 11 or 12.

1 75. An oligonucleotide pair comprising an oligonucleotide of claim 76
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 76. An oligonucleotide of at least 12 nucleotides in length selected from
2 nucleotides 1-255; 246-310; 306-380; 376-502; 496-596; 586-613; 607-664; 660-767;
3 768-1050; 1050-1075; 072-1120; 1111-1186; 1182-1211; 1436-1487; 1478-1632; 1999-
4 2059; 2053-2121; 2112-2204; and 2449-2473 of SEQ ID NO:9, 10, 11 or 12.

1 77. An oligonucleotide pair comprising an oligonucleotide of claim 76
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 78. An oligonucleotide of at least 13 nucleotides in length selected from
2 nucleotides 1-311; 305-381; 375-503; 495-614; 606-665; 659-768; 767-1051; 1049-1076;
3 1071-1121; 1110-1187; 1181-1212; 1435-1633; 1998-2060; 2052-2205 and 2448-2474 of
4 SEQ ID NO:9, 10, 11 or 12.

1 79. An oligonucleotide pair comprising an oligonucleotide of claim 78
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 80. An oligonucleotide of at least 14 nucleotides in length selected from
2 nucleotides 1-312; 304-382; 374-504; 494-615; 605-666; 658-769; 766-1052; 1048-1077;
3 1070-1188; 1180-1213; 1434-1634; 1997-2061; 2051-2206; and 2447-2475 of SEQ ID
4 NO:9, 10, 11 or 12.

1 81. An oligonucleotide pair comprising an oligonucleotide of claim 80
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 82. An oligonucleotide of at least 15 nucleotides in length selected from
2 nucleotides 1-313; 303-383; 373-505; 493-616; 604-667; 657-770; 765-1053; 1047-1078;
3 1069-1189; 1179-1214; 1433-1635; 1996-2062; 2050-2207; and 2446-2476 of SEQ ID
4 NO:9, 10, 11 or 12.

1 83. An oligonucleotide pair comprising an oligonucleotide of claim 82
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO 9, 10,
3 11, or 12.

1 84. An oligonucleotide of at least 16 nucleotides in length selected from
2 nucleotides 1-314; 302-384; 372-668; 656-771; 764-1054; 1046-1079; 1068-1190; 1178-
3 1215; 1432-1636; 1995-2208; and 2445-2477 of SEQ ID NO:9, 10, 11 or 12.

1 85. An oligonucleotide pair comprising an oligonucleotide of claim 84
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 86. An oligonucleotide of at least 17 nucleotides in length selected from
2 nucleotides 1-315; 301-385; 371-669; 655-772; 763-1055; 1045-1080; 1067-1191; 1177-
3 1216; 1431-1637; 1994-2209; and 2444-2478 of SEQ ID NO:9, 10, 11 or 12.

1 87. An oligonucleotide pair comprising an oligonucleotide of claim 86
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 88. An oligonucleotide of at least 18 nucleotides in length selected from
2 nucleotides 1-773; 762-1056; 1044-1081; 1066-1192; 1176-1217; 1430-1638; 1993-2210;
3 and 2443-2479 of SEQ ID NO:9, 10, 11 or 12.

1 89. An oligonucleotide pair comprising an oligonucleotide of claim 88
2 and an oligonucleotide of at least 8 nucleotides in length selected from SEQ ID NO:9, 10,
3 11, or 12.

1 90. A kit for detection of a polymorphism in the HH gene in a patient
2 sample, the kit comprising at least one oligonucleotide of at least 8 nucleotides in length
3 selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11, or 12, wherein
4 the oligonucleotide is used to amplify a region of HH DNA or RNA in a patient sample.

1 91. The kit of claim 90, further comprising at least a second
2 oligonucleotide selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 10, 11,
3 or 12, wherein the first and second oligonucleotides comprise a primer pair.

5


HEREDITARY HEMOCHROMATOSIS GENE**ABSTRACT OF THE DISCLOSURE**

The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.

H:\HOME\RAF\WORK\17957\520\520.APP

Figure 1

Genetic map of the HLA-A locus on chromosome 6p21.3





Patients	Markers										
	241-4	65-2	65-1	241-6	241-29	24d1	241-5	63-3	63-1	63-2	373-8
HC2	144	161	208	193	117	A	108	169	151	113	151
	144	159	206	205	113	A	108	169	151	113	151
HC22	144	159	206	205	113	A	108	169	151	113	151
	144	161	208	193	117	A	108	169	151	113	151
HC25	144	167	210	205	113	A	108	169	151	113	159
	144	159	206	205	113	A	108	169	151	113	151
HC29	144	159	206	205	113	A	108	169	135	133	155
	144	159	208	205	113	A	108	169	151	113	151
HC41	144	159	206	205	113	A	108	169	151	113	151
	144	159	206	205	113	A	108	169	151	113	151
HC50	144	161	210	193	119	A	108	169	151	113	151
	144	159	206	205	113	A	108	169	151	113	151
HC75	144	159	206	205	113	A	108	167	139	131	153
	144	159	206	205	113	A	108	169	151	113	149
HC87	144	161	208	193	117	A	108	169	151	113	147
	144	159	206	205	113	A	108	169	151	113	151
HC91	144		208	193	117	A	108	169	151	113	155
	144	159	206	205	113	A	108	169	151	113	149
HC125	146	161	210	205	115	A	108	169	151	113	153
	144	159	206	205	113	A	108	169	151	113	151
HC143	146	161	210	193	117	A	108	169	151	113	151
	146	159	206	205	113	A	108	169	151	113	151

[illegible]

-360 tctaaggttg agataaaatt tttaaagtga tgattgaatt ttgaaaatca
 -310 taaatattta aatatctaaa gttcagatca gaacattgag aagctacttt
 -260 ccccaatcaa caacaccctc tcaggattta aaaaccaagg gggacactgg
 -210 atcacctagt gtttcacaag caggtacctt ctgctgtagg agagagagaa
 -160 ctaaagttct gaaagacctg ttgcttttca ccaggaagtt ttactgggca

 -110 tctcctgagc ctaggcaata gctgtagggt gacttctgga gccatccccg
 -60 tttccccgcc ccccaaaaga agcggagatt taacggggac gtgcggccag
 -10 agctggggaa
 1 ATGGGCCCCG GAGCCAGGCC GCGGCTTCTC CTCCTGATGC TTTTGCAGAC
 51 CGCGTCTCTG CAGGGGCGCT TGCTGCgtga gtccgagggc tgcgggcgaa

 101 ctagggggcg ggcgggggtg gaaaaatcga aactagcttt ttctttgcgc
 151 ttgggagttt gctaactttg gaggacctgc tcaacctat ccgcaagccc
 201 ctctccctac tttctgcgtc cagacccctg gagggagtgc ctaccactga
 251 actgcagata ggggtccctc gcccaggac ctgccccctc ccccggtgt
 301 cccggtctct cggagtgaact tttggaaccg cccactccct tccccaaact

 351 agaatgcttt taaataaatc tcgtagtctc tcacttgagc tgagctaagc
 401 ctggggctcc ttgaacctgg aactcgggtt tatttccaat gtcagctgtg
 451 cagttttttc ccagtcctc tccaaacagg aagttcttcc ctgagtgtt
 501 gccgagaagg ctgagcaaac ccacagcagg atccgcacgg ggtttccacc
 551 tcagaacgaa tgcgttgggc ggtgggggag cgaaagagtg gcgttgggga

 601 tctgaattct tcaccattcc acccactttt ggtgagacct ggggtggagg
 651 tctctagggt gggaggtccc tgagagaggc ctacctcggg cctttcccca
 701 ctcttggcaa ttgttctttt gcctggaaaa ttaagtatat gttagtttg
 751 aacgtttgaa ctgaacaatt ctcttttcgg ctaggcttta ttgatttgca
 801 atgtgctgtg taattaagag gcctctctac aaagtactga taatgaacat

 851 gtaagcaatg cactcacttc taagtacat tcatatctga tcttatttga
 901 ttttctactag gcatagggag gtaggagcta ataatacgtt tattttacta
 951 gaagttaact ggaattcaga ttatataact cttttcaggt tacaagaac
 1001 ataaataatc tggttttctg atgttatttc aagtactaca gctgcttcta
 1051 atcttagttg acagtgattt tgccctgtag tgtagcacag tgttctgtgg

 1101 gtcacacgcc ggcctcagca cagcactttg agttttggta ctacgtgtat
 1151 ccacatttta cacatgacaa gaatgaggca tggcacggcc tgcttcctgg
 1201 caaatattat caatggtaca ctgggctttg gtggcagagc tcatgtctcc
 1251 acttcatagc tatgattctt aaacatcaca ctgcattaga ggttgaataa
 1301 taaaatttca tgttgagcag aaatattcat tgtttacaag tgtaaatgag

 1351 tcccagccat gtgttgact gttcaagccc caagggagag agcagggaaa
 1401 caagtcttta ccctttgata ttttgcatc tagtgggaga gatgacaata
 1451 agcaaatgag cagaaagata tacaacatca ggaaatcatg ggtgtgtga
 1501 gaagcagaga agtcagggca agtcactctg gggctgacac ttgagcagag
 1551 acatgaagga aataagaatg atattgactg ggagcagtat ttcccaggca

 1601 aactgagtgg gcctggcaag ttggattaaa aagcgggttt tctcagcact
 1651 actcatgtgt gtgtgtgtgg gggggggggg cggcgtgggg gtgggaaggg
 1701 ggactaccat ctgcatgtag gatgtctagc agtatcctgt cctccctact
 1751 cactaggtgc taggagcact ccccagctc tgacaaccaa aaatgtctct
 1801 aaactttgcc acatgtcacc tagtagacaa actcctgggtt aagaagctcg

 1851 ggttgaaaaa aataaacaag tagtgctggg gagtagaggc caagaagtag
 1901 gtaatgggct cagaagagga gccacaaaca aggttgtgca ggcgcctgta

Figure 3 (1 of 5)

1951 ggctgtggtg tgaattctag ccaaggagta acagtgatct gtcacaggct
 2001 tttaaaagat tgctctggct gctatgtgga aagcagaatg aaggagagcaa
 2051 cagtaaaagc agggagccca gccaggaagc tggtacacag tccaggcaag

 2101 aggtagtggg gtgggctggg tgggaacaga aaaggagtg acaaaccatt
 2151 gtctcctgaa tatattctga aggaagtgtc tgaaggattc tatgttgtgt
 2201 gagagaaaga gaagaattgg ctgggtgtag tagctcatgc caaggaggag
 2251 gccaaaggaga gcagattcct gagctcagga gttcaagacc agcctgggca
 2301 acacagcaaa accccttctc tacaaaaaat acaaaaatta gctgggtgtg

 2351 gtggcatgca cctgtgatcc tagctactcg ggaggctgag gtggagggta
 2401 ttgcttgagc ccaggaaagt gaggctgcag tgagccatga ctgtgccact
 2451 gtacttcagc ctaggtgaca gagcaagacc ctgtctcccc tgacccctcg
 2501 aaaaagagaa gagttaagt tgactttgtt ctttatttta attttattgg
 2551 cctgagcagt ggggtaattg gcaatgccat tcttgagatg gtgaaggcag

 2601 aggaaagagc agtttggggg aaatcaagga tctgcatttg ggacatgtta
 2651 agtttgagat tccagtcagg cttccaagtg gtgaggccac ataggcagtt
 2701 cagtgttaaga attcaggacc aaggctgggc acgggtggctc acttctgtaa
 2751 tcccagcact ttggtggctg aggcaggtag atcatttgag gtcaggagtt
 2801 tgagacaagc ttggccaaca tggtgaaacc ccatgtctac taaaaatata

 2851 aaaattagcc tgggtgtggtg gcgcacgcct atagtcccag gttttcagga
 2901 ggcttaggta ggagaatccc ttgaaccag gaggtgcagg ttgcagtgag
 2951 ctgagattgt gccactgcac tccagcctgg gtgatagagt gagactctgt
 3001 ctcaaaaaaa aaaaaaaaaa aaaaaaaaaa aactgaagga attattcctc
 3051 aggatttggg tctaatttgc cctgagcacc aactcctgag ttcaactacc

 3101 atggctagac acaccttaac attttctaga atccaccagc tttagtggag
 3151 tctgtctaata catgagtatt ggaataggat ctgggggcag tgaggggggtg
 3201 gcagccacgt gtggcagaga aaagcacaca aggaaagagc acccaggact
 3251 gtcatatgga agaaagacag gactgcaact cacccttcac aaaatgagga
 3301 ccagacacag ctgatggtat gagttgatgc aggtgtgttg agcctcaaca

 3351 tctgtctccc ctctactac acatggttaa ggctgttgct tctgtctcca
 3401 ggttcacact ctctcacta cctctcagc ggtgcctcag agcaggacct
 3451 tggctcttcc ttgttgaaag ctttgggcta cgtggatgac cagctgttgc

G T

 3501 tgttctatga tcagagagt cgcctgttg agccccaac tccatgggtt
 3551 tccagtagaa ttcaagcca gatgtggctg cagctgagtc agagctgaa

 3601 agggtgggat ccatgttca ctgtgactt ctggactatt atggaaaatc
 3651 acaaccacag caagggtatg tggagagggg gctcacctt cctgaggttg
 3701 tcagagcttt tcatcttttc atgcatcttg aaggaaacag ctggaagtct
 3751 gaggtcttgt gggagcaggg aagagggag gaatttgctt cctgagatca
 3801 tttggctcct ggggatggtg gaaataggga cctattcctt tggttgcagt

 3851 taacaaggct ggggattttt ccagagtcac acaccctgca ggtcatcctg
 3901 ggctgtgaaa tgcaagaaga caacagtacc gagggctact ggaagtacgg
 3951 gtatgatggg caggaccacc ttgaattctg cctgacaca ctggattgga
 4001 gagcagcaga acccagggcc tggcccacca agctggagtg ggaagccac
 4051 aagattcggg ccaggcagaa cagggcctac ctggagaggg actgccctgc

 4101 acagctgcag cagttgcttg agctggggag aggtgttttg gaccaacaag
 4151 gtatggtgga aacacacttc tgccctata ctctagtggc agagtggagg
 4201 aggttgacag gcacggaatc cctggttgga gtttcagagg tggctgaggc

Figure 3 (2 of 5)

4251 tgtgtgcctc tccaaattct gggaaggac tttctcaatc ctagagtctc
 4301 taccttataa ttgagatgta tgagacagcc acaagtcctg ggtttaattt

 4351 cttttctcca tgcataatgc tcaaaggaa gtgtctatgg cccttgcttt
 4401 ttatttaacc aataatcttt tgtatattta tacctgttaa aaattcagaa
 4451 atgtcaaggc cgggcacggt ggctcaccac tgtaatccca gcactttggg
 4501 aggccgaggc ggggtgtcac aaggtcagga gtttgagacc agcctgacca
 4551 acatggtgaa acccgctctc aaaaaaatac aaaaattagc tggtcacagt

 4601 catgcgacc tgtagtccca gctaattgga aggctgaggc aggagcatcg
 4651 cttgaacctg ggaagcggaa gttgcactga gccaaagatc cgccactgca
 4701 ctccagccta ggcagcagag tgagactcca tcttaaaaaa aaaaaaaaaa
 4751 aaaaaaagag aattcagaga tctcagctat catatgaata ccaggacaaa
 4801 atatcaagtg aggccactta tcagagtaga agaatccttt aggttaaaag

 4851 tttctttcat agaacatagc aataatcact gaagctacct atcttacaag
 4901 tccgttcttt ataacaatgc ctccataggt gaccaggtg aaactgacca
 4951 tctgtattca atcattttca atgcacataa agggcaattt tatctatcag
 5001 aacaaagAAC atgggtAACa gatatgtata ttacatgtg aggagaacaa
 5051 gctgatctga ctgctctcca agtgacactg tgtagagtc caatcttagg

 5101 acacaaatg gtgtctctcc ttagcttgt tttttctga aaagggtatt
 5151 tcttctctcc aacctataga aggaagtga agttccagtc ttcctggcaa
 5201 gggtaaACag atccccctc ctcctcttc ctcttctctg tcaagTGCCT
 5251 CCTTGGTGA AGGTGACACA TCATGTGACC TCTTCAGTGA CCACTCTACG
 5301 GTGTGGGGCC TTGAACACT ACCCCAGAA CATCACCATG AAGTGGCTGA

 5351 AGGATAAGCA GCCAATGGAT GCCAAGGAGT TCGAACCTAA AGACGTATTG
 5401 CCCAATGGGG ATGGGACCTA CCAGGGCTGG ATAACCTTGG CTGTACCCCC

 A
 5451 TGGGAAGAG CAGAGATATA CGTGCCAGGT GGAGCACCCA GGCCTGGATC
 5501 AGCCCTCAT TGTGATCTGG Ggtatgtgac tgatgagagc caggagctga
 5551 gaaaatctat tgggggttga gaggagtgcc tgaggaggtg attatggcag

 5601 tgagatgagg atctgctctt tgtagggggg tgggctgagg gtggcaatca
 5651 aaggctttaa cttgcttttt ctgttttagA GCCCTCACCG TCTGGCACCC
 5701 TATGATGG AGTCATCAGT GGAATTGCTG TTTTGTCTGT CATCTGTTC
 5751 ATTGGAATTT GTTCATAAT ATTAAGGAAG AGGCAGGGTT CAAGtgagta
 5801 ggaacaaggg ggaagtctct tagtacctct gcccagggc acagtgggaa

 5851 gaggggcaga ggggatctgg catccatggg aagcattttt ctcatattata
 5901 ttctttgggg acaccagcag ctccctggga gacagaaaat aatggttctc
 5951 cccagaatga aagtctctaa ttcaacaaac atcttcagag cacctactat
 6001 tttgcaagag ctgtttaagg tagtacaggg gctttgaggt tgagaagtca
 6051 ctgtggctat tctcagaacc caaatctggt agggaaatgaa attgatagca

 6101 agtaaatgta gttaaagaag accccatgag gtcctaaagc aggcaggaag
 6151 caaatgctta ggggtgcaaa ggaaagaatg atcacattca gctggggatc
 6201 aagatagcct tctggatctt gaaggagaag ctggattcca ttaggtgagg
 6251 ttgaagatga tgggaggtct acacagacgg agcaaccatg ccaagtagga
 6301 gagtataagg catactggga gattagaaat aattactgta ccttaaccct

 6351 gagtttgctg agctatcact caccaattat gcattttctac cccctgaaca
 6401 tctgtggtgt agggaaaaga gaatcagaaa gaagccagct catacagagt
 6451 ccaagggtct tttgggatat tgggttatga tcaactgggt gtcattgaag
 6501 gatcctaaga aaggaggacc acgatctccc ttatatggtg aatgtgttgt
 6551 taagaagtta gatgagaggt gaggagacca gttagaagc caataagcat

Figure 3 (3 of 5)

6601 ttccagatga gagataatgg ttcttgaaat ccaatagtgc ccaggtctaa
6651 attgagatgg gtgaatgagg aaaataagga agagagaaga ggcaagatgg
6701 tgcctaggtt tgtgatgcct ctttctctggg tctcttgtct ccacagGAGG
6751 AGCCATGGGG CACTACGTCT TAGCTGAACG TGAGTGAcac gcagcctgca
6801 gactcactgt ggggaaggaga caaaactaga gactcaaaga gggagtgcac

6851 ttatgagctc ttcattgttc aggagagagt tgaacctaaa catagaaatt
6901 gcctgacgaa ctcttctgatt ttagccttct ctgttcattt cctcaaaaag
6951 atttcccat ttaggtttct gagttcctgc atgccggtga tccctagctg
7001 tgacctctcc cctggaactg tctctcatga acctcaagct gcatctagag
7051 gcttctctca tttctcctg cacctcagag acatacacct atgtcatttc

7101 atttcttatt tttggaagag gactccttaa atttggggga cttacatgat
7151 tcattttaac atctgagaaa agctttgaac cctgggacgt ggctagtcac
7201 aaccttacca gatttttaca catgtatcta tgcattttct ggacccttc
7251 aacttttct tgaatcctc tctctgtgtt acccagtaac tcactctgca
7301 ccaagccttg gggattcttc catctgattg tgatgtgagt tgcacagcta

7351 tgaaggctgt acactgcacg aatggaagag gcacctgtcc cagaaaaagc
7401 atcatggcta tctgtgggta gtatgatggg tgttttttagc aggtaggagg
7451 caaatatctt gaaaggggtt gtgaagagggt gttttttcta attggcatga
7501 aggtgtcata cagatttgca aagtttaatg gtgccttcat ttgggatgct
7551 actctagtat tccagacctg aagaatcaca ataattttct acctggtctc

7601 tccttgttct gataatgaaa attatgataa ggatgataaa agcacttact
7651 tcgtgtccga ctcttctgag cacctactta catgcattac tgcattgcat
7701 tcttacaata attctatgag ataggtacta ttatcccat tctttttta
7751 aatgaagaaa gtgaagtagg cgggacacgg tggctcacgc ctgtaatccc
7801 agcactttgg gagggcaaaag cgggtggatc acgaggtcag gagatcgaga

7851 ccatcctggc taacatgggtg aaaccccatc tctaataaaa atacaaaaaa
7901 ttagctgggc gtgggtggcag acgcctgtag tcccagctac tcggaaggct
7951 gaggcaggag aatggcatga acccaggagg cagagcttgc agtgagccga
8001 gtttgcgcca ctgcaactcca gcctaggtga cagagtgaaga ctccatctca
8051 aaaaaataaa aataaaaaa aaaaaatgaa aaaaaaaga aagtgaagta

8101 tagagtatct catagtttgt cagtgataga aacaggtttc aaactcagtc
8151 aatctgaccg tttgatacat ctccagacac actacattca gtagtttaga
8201 tgcctagaat aaatagagaa ggaaggagat ggctcttctc ttgtctcatt
8251 tgtgttcttc tgagttagct tgaatcacat gaagggaac agcagaaac
8301 aaccaactga tctcagctg tcatgtttcc tttaaaagtc cctgaaggaa

8351 ggtcctggaa tgtgactccc ttgctcctct gttgctctct ttggcattca
8401 tttctttgga ccctacgcaa ggaactgtaat tgggtggggac agctagtggc
8451 cctgctgggc ttcacacacg gtgtcctccc taggccagtg cctctggagt
8501 cagaactctg gtggtatttc cctcaatgaa gtggagtaag ctctctcatt
8551 ttgagatggt ataattggaag ccaccaagtg gcttagagga tgcccaggtc

8601 cttccatgga gccactgggg ttccgggtgca cattaaaaaa aaatctaac
8651 caggacattc aggaattgct agattctggg aaatcagttc accatgttca
8701 aaagatctt tttttttttt ttgagactct attgcccagg ctggagtgca
8751 atggcatgat ctcggtcac tgtaacctct gcctcccagg ttcaagcgat
8801 tctcctgtct cagcctccca agtagctggg attacaggcg tgcaccacca

8851 tgcccggtca atttttgtat ttttagtaga gacagggttt caccatgttg
8901 gccaggctg tctcgaactc tctgacctc gtgatccgcc tgccctgggc
8951 tcccaaagtg ctgagattac aggtgtgagc caccctgcc agccgtcaaa

Figure 3 (4 of 5)

9001 agagtcttaa tatatatatc cagatggcat gtgtttactt tatgttacta
 9051 catgcacttg gctgcataaa tgtggtacaa gcattctgtc ttgaaggcca

 9101 ggtgcttcag gataccatat acagctcaga agtttcttct ttaggcatta
 9151 aatttttagca aagatatctc atctcttctt ttaaaccatt ttcttttttt
 9201 gtggttagaa aagttatgta gaaaaaagta aatgtgattt acgctcattg
 9251 tagaaaagct ataaaatgaa tacaattaaa gctgttattt aattagccag
 9301 tgaaaaacta ttaacaactt gtctattacc tgttagtatt attgttgcac

 9351 taaaaatgca tataactttaa taaatgtata ttgtattgta tactgcatga
 9401 ttttattgaa gttcttggtc atcttggtga tataacttaac cgctttgtca
 9451 ttttgagac atttattttg cttctaattt ctttacattt tgtcttacgg
 9501 aatattttca ttcaactgtg gtagccgaat taatcgtgtt tcttcaactc
 9551 agggacattg tcgtctaagt tgtaagacac tggttatttt accagcaaac

 9601 cattctgaaa gcataatgaca aattatttct ctcttaatat cttactatac
 9651 tgaaagcaga ctgctataag gcttcactta ctcttctacc tcataaggaa
 9701 tatgttacaa ttaatttatt aggttaagcat ttgttttata ttggttttat
 9751 ttcacctggg ctgagatttc aagaaacacc ccagtcttca cagtaacaca
 9801 tttcactaac acatttacta aacatcagca actgtggcct gttaattttt

 9851 ttaatagaaa ttttaagtcc tcattttctt tcggtgtttt ttaagcttaa
 9901 tttttctggc tttattcata aattcttaag gtcaactaca tttgaaaaat
 9951 caaagacctg catttttaaat tcttattcac ctctggcaaa accattcaca
 10001 aaccatggta gtaaagagaa gggtagacac tgggtggccat aggtaaatgt
 10051 accacgggtg tccggtgacc agagatgcag cgctgagggg tttcctgaag

 10101 gtaaaggaat aaagaatggg tggaggggag tgcactggaa atcacttgta
 10151 gagaaaagcc cctgaaaatt tgagaaaaca aacaagaaac tacttaccag
 10201 ctatttgaat tgctggaatc acaggccatt gctgagctgc ctgaactggg
 10251 aacacaacag aaggaaaaca aaccactctg ataatcattg agtcaagtac
 10301 agcaggtgat tgaggactgc tgagaggtac aggccaaaat tcttatgttg

 10351 tattataata atgtcatctt ataatactgt cagtatttta taaaacattc
 10401 ttcacaaact cacacacatt taaaaacaaa acactgtctc taaaatcccc
 10451 aaatttttca taaac

Figure 3 (5 of 5)

[illegible]

atgggcccgc cgagccagggc
M G P R A R

ca cgcagcctgc agactcactg tgggaaggag acaaaactag agactcaaaag
agggagtgc tttatgagct cttcatgttc caggagagag ttgaacctaa acatagaaat
tgcctgacga actccttgat tttagccttc tctgttcatt tcctcaaaaa gatttcccca

FIGURE 5

PCR Primers used for Amplification of 24d1 Alleles

24d1.P1 (forward primer)
5'-TGGCAAGGGTAAACAGATCC-3' (SEQ ID NO:13)

24d1.P2 (reverse primer)
5'-CTCAGGCACTCCTCTCAACC-3' (SEQ ID NO:14)

OLA Oligonucleotides for 24d1

Upstream Oligonucleotides (5'-biotinylated)

24d1.A (common allele)
5'-bio-GGAAGAGCAGAGATATACGTG-3' (SEQ ID NO:15)

24d1.B (hemochromatosis allele)
5'-bio-GGAAGAGCAGAGATATACGTA-3' (SEQ ID NO:16)

Downstream Oligonucleotides (5'-phosphorylated)

24d1.X 5'-p-CCAGGTGGAGCACCCAGG-dig-3' (SEQ ID NO:17)

FIGURE 6

Figure 6a

5'—TATTTCTTCCTCCAACCTATAGAAGGAAGTGAAAGTTCAGTCTTCCTGGCAAGGGTAAACAGATCCCC
TCTCCTCATCCTTCCTCTTTCCTGTCAAGTGCCTCCTTTGGTGAAGGTGACACATCATGTGACCTCTTCAG
TGACCACTCTACGGTGTCTGGGCCTTGAAGTACTACCCCCAGAACATCACCATGAAGTGGCTGAAGGATA
AGCAGCCAATGGATGCCAAGGAGTTCGAACCTAAAGACGTATTGCCCAATGGGGATGGGACCTACCAGG
GCTGGATAACCTTGGCTGTACCCCCTGGGGAAGAGCAGAGATATACGTGCCAGGTGGAGCACCCAGGC
CTGGATCAGCCCCTCATTGTGATCTGGGGTATGTGACTGATGAGAGCCAGGAGCTGAGAAAATCTATTGG
GGGTTGAGAGGAGTGCCTGAGGAGGTAATTATGGCAGTGAGATGAGGATCTGCTCTTTGTTAGGGGGTG
GGCTGAGGGTGGCAATCAAAGGCTTTAACTT-3'
(SEQ ID NO:20)

Figure 6b

5'—TATTTCTTCCTCCAACCTATAGAAGGAAGTGAAAGTTCAGTCTTCCTGGCAAGGGTAAACAGATCCCC
TCTCCTCATCCTTCCTCTTTCCTGTCAAGTGCCTCCTTTGGTGAAGGTGACACATCATGTGACCTCTTCAG
TGACCACTCTACGGTGTCTGGGCCTTGAAGTACTACCCCCAGAACATCACCATGAAGTGGCTGAAGGATA
AGCAGCCAATGGATGCCAAGGAGTTCGAACCTAAAGACGTATTGCCCAATGGGGATGGGACCTACCAGG
GCTGGATAACCTTGGCTGTACCCCCTGGGGAAGAGCAGAGATATACGTACCAGGTGGAGCACCCAGGC
CTGGATCAGCCCCTCATTGTGATCTGGGGTATGTGACTGATGAGAGCCAGGAGCTGAGAAAATCTATTGG
GGGTTGAGAGGAGTGCCTGAGGAGGTAATTATGGCAGTGAGATGAGGATCTGCTCTTTGTTAGGGGGTG
GGCTGAGGGTGGCAATCAAAGGCTTTAACTT-3'
(SEQ ID NO:21)

Figure 7

III protein	MGPRAR	PALLL	LM	LO	TA	VL	QGR	LR	SH	SL	HL	YL	EM	GA	SE	OD	LG	SL	FE	AL	GL	GY	VD	DD	QL	FE
RLA	-MG	SI	P	PR	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	
hMHIC	-MA	VMA	P	RR	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	LL	
III protein	YDHE	-SR	RV	EP	RT	PW	VSS	RI	SS	QM	WL	QL	SL	SK	GW	DM	FT	VD	FW	TI	ME	NH	HS	-K	ES	HT
RLA	EDSD	AA	SP	PR	ME	QRA	PW	MG	-Q	VE	PE	YWD	QQT	QIA	KD	TA	QTF	RV	NI	NT	AL	RY	YN	QS	AG	SH
hMHIC	EDSD	AA	SP	PR	ME	QRA	PW	IE	-Q	EG	PE	YWD	GET	TR	KV	KA	HS	QT	HR	VD	LG	TL	RG	Y	NQ	SA
III protein	IQV	IL	GC	EM	QED	N	-S	TE	GY	WK	YGY	DG	QD	HL	EC	PD	EL	DW	RA	AE	PR	AW	PT	KL	EM	ER
RLA	PQT	ME	GC	EV	WA	DG	RF	FG	YR	QY	AY	DG	AD	YI	AL	NE	DL	RS	WT	AA	AD	TA	AA	QNT	QK	WE
hMHIC	LOM	ME	GC	DV	GS	DW	RF	LR	GY	HO	YAY	DD	GK	DY	IA	LK	ED	LR	SV	TA	AD	MA	AA	QT	TK	HE
III protein	RQ	RA	YLER	D	C	PA	QL	LO	LE	LE	L	G	R	V	LD	QO	V	P	L	V	K	V	T	H	V	T
RLA	R	-H	RAY	LER	E	C	V	E	N	L	R	Y	L	E	M	G	K	E	T	L	Q	R	A	D	E	P
hMHIC	Q	-L	RAY	LER	E	C	V	E	N	L	R	Y	L	E	M	G	K	E	T	L	Q	R	A	D	E	P
III protein	TK	KW	LKD	-K	Q	P	MD	A	K	E	F	E	P	K	D	V	L	P	N	G	D	G	T	Y	Q	G
RLA	SL	TW	Q	R	D	G	E	D	Q	T	Q	D	T	E	L	V	E	T	R	-P	G	G	D	G	T	F
hMHIC	SL	TW	Q	R	D	G	E	D	Q	T	Q	D	T	E	L	V	E	T	R	-P	G	G	D	G	T	F
III protein	IV	I	WE	P	S	P	S	-G	T	V	I	G	V	I	S	G	I	A	V	E	V	I	L	P	I	G
RLA	TL	T	WE	P	PA	Q	P	T	AL	I	V	G	I	V	AG	-V	L	G	V	L	L	I	L	G	A	V
hMHIC	TL	T	WE	P	PA	Q	P	T	AL	I	P	V	G	I	AG	L	V	L	E	G	AV	IT	GA	V	V	AA
III protein	GSD	D	SL	MP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
RLA	GSD	D	SL	MP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
hMHIC	GSD	D	SL	MP	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

Figure 8




FIGURE 9

PCR Primers used for Amplification of 24d2 Alleles

- 24.P2.1 (forward primer)
5'-ACATGGTTAAGGCCTGTTGC-3' (SEQ ID NO:24)
- 24.P2.2 (reverse primer)
5'-GCCACATCTGGCTTGAAATT-3' (SEQ ID NO:25)

OLA Oligonucleotides for 24d2

Upstream Oligonucleotides (5'-biotinylated)

- 24d2.A (common allele)
5'-bio-AGCTGTTCGTGTTCTATGATC-3' (SEQ ID NO:26)
- 24d2.B (hemochromatosis allele)
5'-bio-AGCTGTTCGTGTTCTATGATG-3' (SEQ ID NO:27)

Downstream Oligonucleotides (5'-phosphorylated)

- 24d2.X 5'-p-ATGAGAGTCGCCGTGTGGA-dig-3' (SEQ ID NO:28)

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **HEREDITARY HEMOCHROMATOSIS GENE** the specification of which ___ is attached hereto or X was filed on April 4, 1997 as Application No. ___ and was amended on ___ (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign applications(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
			Yes _ No _
			Yes _ No _

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/630,912	04/04/96	_ Patented <u>X</u> Pending _ Abandoned
08/632,673	04/16/96	_ Patented <u>X</u> Pending _ Abandoned
08/652,265	05/23/96	_ Patented <u>X</u> Pending _ Abandoned

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.







Renee A. Fitts, Reg. No. 35,136
 William M. Smith, Reg. No. 30,223
 Joe Liebeschuetz, Reg. No. 37,505

Send Correspondence to: William M. Smith TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834	Direct Telephone Calls to: (Name, Reg. No., Telephone No.) Name: William M. Smith Reg. No.: 30,223 Telephone: (415) 326-2400
--	---

Full Name of Inventor 1	Last Name THOMAS	First Name WINSTON	Middle Name or Initial J.	
Residence & Citizenship	City SAN MATEO	State/Foreign Country CA	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 40 WHITE PLAINS CT.	City SAN MATEO	State/Country CA	Zip Code 94402
Full Name of Inventor 2	Last Name DRAYNA	First Name DENNIS	Middle Name or Initial T.	
Residence & Citizenship	City BETHESDA	State/Foreign Country MD	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 120 CENTER DRIVE #409	City BETHESDA	State/Country MD	Zip Code 20814
Full Name of Inventor 3	Last Name FEDER	First Name JOHN	Middle Name or Initial N.	
Residence & Citizenship	City MOUNTAIN VIEW	State/Foreign Country CA	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 411 B WEST DANA STREET	City MOUNTAIN VIEW	State/Country CA	Zip Code 94041
Full Name of Inventor 4	Last Name GNIRKE	First Name ANDREAS	Middle Name or Initial	
Residence & Citizenship	City SAN CARLOS	State/Foreign Country CA	Country of Citizenship GERMANY	
Post Office Address	Post Office Address 1220 HIGHLAND CT.	City SAN CARLOS	State/Country CA	Zip Code 94070
Full Name of Inventor 5	Last Name RUDDY	First Name DAVID	Middle Name or Initial	
Residence & Citizenship	City SAN FRANCISCO	State/Foreign Country CA	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 2336 B GOUGH STREET	City SAN FRANCISCO	State/Country CA	Zip Code 94109

Full Name of Inventor 6	Last Name TSUCHIHASHI	First Name ZENTA	Middle Name or Initial	
Residence & Citizenship	City MENLO PARK	State/Foreign Country CA	Country of Citizenship JAPAN	
Post Office Address	Post Office Address 9 LIGHT WAY	City MENLO PARK	State/Country CA	Zip Code 94025
Full Name of Inventor 7	Last Name WOLFF	First Name ROGER	Middle Name or Initial K.	
Residence & Citizenship	City MILL VALLEY	State/Foreign Country CA	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 41 EUGENE STREET	City MILL VALLEY	State/Country CA	Zip Code 94941

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  WINSTON J. THOMAS	Signature of Inventor 2 DENNIS T. DRAYNA	Signature of Inventor 3  JOHN N. FEDER
Date 4/16/97	Date	Date 4-16-97
Signature of Inventor 4  ANDREAS GNIRKE	Signature of Inventor 5  DAVID RUDDY	Signature of Inventor 6  ZENTA TSUCHIHASHI
Date 4-16-97	Date 4-16-97	Date 4-16-97
Signature of Inventor 7  ROGER K. WOLFF		
Date 4/16/97		

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **HEREDITARY HEMOCHROMATOSIS GENE** the specification of which ___ is attached hereto or X was filed on April 4, 1997 as Application No. ___ and was amended on ___ (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign applications(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119
			Yes _ No _
			Yes _ No _

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/630,912	04/04/96	_ Patented <u>X</u> Pending _ Abandoned
08/632,673	04/16/96	_ Patented <u>X</u> Pending _ Abandoned
08/652,265	05/23/96	_ Patented <u>X</u> Pending _ Abandoned

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.


Renee A. Fitts, Reg. No. 35,136
William M. Smith, Reg. No. 30,223
Joe Liebeschuetz, Reg. No. 37,505

Send Correspondence to: William M. Smith TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834	Direct Telephone Calls to: (Name, Reg. No., Telephone No.) Name: William M. Smith Reg. No.: 30,223 Telephone: (415) 326-2400
--	---

Full Name of Inventor 1	Last Name THOMAS	First Name WINSTON	Middle Name or Initial J.	
Residence & Citizenship	City SAN MATEO	State/Foreign Country CA	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 40 WHITE PLAINS CT.	City SAN MATEO	State/Country CA	Zip Code 94402
Full Name of Inventor 2	Last Name DRAYNA	First Name DENNIS	Middle Name or Initial T.	
Residence & Citizenship	City BETHESDA	State/Foreign Country MD	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 120 CENTER DRIVE #409	City BETHESDA	State/Country MD	Zip Code 20814
Full Name of Inventor 3	Last Name FEDER	First Name JOHN	Middle Name or Initial N.	
Residence & Citizenship	City MOUNTAIN VIEW	State/Foreign Country CA	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 411 B WEST DANA STREET	City MOUNTAIN VIEW	State/Country CA	Zip Code 94041
Full Name of Inventor 4	Last Name GNIRKE	First Name ANDREAS	Middle Name or Initial	
Residence & Citizenship	City SAN CARLOS	State/Foreign Country CA	Country of Citizenship GERMANY	
Post Office Address	Post Office Address 1220 HIGHLAND CT.	City SAN CARLOS	State/Country CA	Zip Code 94070
Full Name of Inventor 5	Last Name RUDDY	First Name DAVID	Middle Name or Initial	
Residence & Citizenship	City SAN FRANCISCO	State/Foreign Country CA	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 2336 B GOUGH STREET	City SAN FRANCISCO	State/Country CA	Zip Code 94109

Full Name of Inventor 6	Last Name TSUCHIHASHI	First Name ZENTA	Middle Name or Initial	
Residence & Citizenship	City MENLO PARK	State/Foreign Country CA	Country of Citizenship JAPAN	
Post Office Address	Post Office Address 9 LIGHT WAY	City MENLO PARK	State/Country CA	Zip Code 94025
Full Name of Inventor 7	Last Name WOLFF	First Name ROGER	Middle Name or Initial K.	
Residence & Citizenship	City MILL VALLEY	State/Foreign Country CA	Country of Citizenship U.S.A.	
Post Office Address	Post Office Address 41 EUGENE STREET	City MILL VALLEY	State/Country CA	Zip Code 94941

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1 WINSTON J. THOMAS	Signature of Inventor 2  DENNIS T. DRAYNA	Signature of Inventor 3 JOHN N. FEDER
Date	Date 4/24/97	Date
Signature of Inventor 4 ANDREAS GNIRKE	Signature of Inventor 5 DAVID RUDDY	Signature of Inventor 6 ZENTA TSUCHIHASHI
Date	Date	Date
Signature of Inventor 7 ROGER K. WOLFF		
Date		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Thomas *et al.*

Serial No.: 08/834,497

Group Art Unit: 1805

Filed: April 4, 1997

Examiner: W. Sandals

For: HEREDITARY
HEMOCHROMATOSIS GENE

Attorney Docket No.:
8907-0056-999

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)
AND REVOCATION AND POWER OF ATTORNEY

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified below. Attached hereto is a copy of the Notice of Recordation of Assignment Document for the above-identified application.

MERCATOR GENETICS, INC., a California corporation, having its principal place of business located at 4040 Campbell Avenue, Menlo Park, California, 94025, certifies that, subject to certain rights of the U.S. government, it is the assignee and owner of the entire right, title and interest in, to and under the invention described and claimed in the above-identified application, and hereby revokes all previous Powers of Attorney granted in this application and appoints the following attorneys:

S. Leslie Misrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Berj A. Terzian (Reg. No. 20060), Gerald J. Flintoft (Reg. No. 20823), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Isaac Jarkovsky (Reg. No. 22713), Joseph V. Colaianne (Reg. No. 20019), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No.

24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Palik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Jon R. Stark (Reg. No. 30111), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Ann L. Gisolfi (Reg. No. 31956), Mark A. Farley (Reg. No. 33170), and James G. Markey (Reg. No. 31636), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, its attorneys,

to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
0	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

MERCATOR GENETICS, INC

- 3 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Thomas, Winston J.
Drayna, Dennis T.
Feder, John N.
Gnirke, Andreas
Ruddy, David
Tsuchihashi, Zenta
Wolff, Roger K.
- (ii) TITLE OF INVENTION: Hereditary Hemochromatosis Gene
- (iii) NUMBER OF SEQUENCES: 44
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Townsend and Townsend and Crew LLP
 - (B) STREET: Two Embarcadero Center, Eighth Floor
 - (C) CITY: San Francisco
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 94111-3834
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/652,265
 - (B) FILING DATE: 23-MAY-1996
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Smith, William M.
 - (B) REGISTRATION NUMBER: 30,223
 - (C) REFERENCE/DOCKET NUMBER: 17957-000500
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (415) 576-0200
 - (B) TELEFAX: (415) 576-0300

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10825 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: join(361..436, 3762..4025, 4235..4510, 5606..5881, 6040..6153, 7107..7147)
 - (D) OTHER INFORMATION: /product= "Hereditary Hemochromatosis"

(HH) protein"
 /note= "Normal or wild-type (unaffected)
 Hereditary Hemochromatosis (HH) gene
 allele"

(ix) FEATURE:

(A) NAME/KEY: -
 (B) LOCATION: 140..7319
 (D) OTHER INFORMATION: /note= "start and stop positions for
 normal or wild-type (unaffected) allele
 cDNA (SEQ ID NO:9)"

(ix) FEATURE:

(A) NAME/KEY: -
 (B) LOCATION: 3852..3891
 (D) OTHER INFORMATION: /note= "start and stop positions for
 normal or wild-type (unaffected) genomic
 sequence surrounding variant for 24d2(C)
 allele (SEQ ID NO:41)"

(ix) FEATURE:

(A) NAME/KEY: -
 (B) LOCATION: 5507..6023
 (D) OTHER INFORMATION: /note= "start and stop positions for
 normal or wild-type (unaffected) genomic
 sequence surrounding variant for 24d1(G)
 allele (SEQ ID NO:20)"

(ix) FEATURE:

(A) NAME/KEY: allele
 (B) LOCATION: replace(3872, "c")
 (D) OTHER INFORMATION: /phenotype= "normal or wild-type
 (unaffected)"
 /label= 24d2

(ix) FEATURE:

(A) NAME/KEY: allele
 (B) LOCATION: replace(3878, "a")
 (D) OTHER INFORMATION: /phenotype= "normal or wild-type
 (unaffected)"
 /label= 24d7

(ix) FEATURE:

(A) NAME/KEY: allele
 (B) LOCATION: replace(5834, "g")
 (D) OTHER INFORMATION: /phenotype= "normal or wild-type
 (unaffected)"
 /label= 24d1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TCTAAGGTTG AGATAAAATT TTTAAATGTA TGATTGAATT TTGAAAATCA TAAATATTTA	60
AATATCTAAA GTTCAGATCA GAACATTGCG AAGCTACTTT CCCCAATCAA CAACACCCCT	120
TCAGGATTTA AAAACCAAGG GGGACACTGG ATCACCTAGT GTTTCACAAG CAGGTACCTT	180
CTGCTGTAGG AGAGAGAGAA CTAAAGTTCT GAAAGACCTG TTGCTTTTCA CCAGGAAGTT	240
TTACTGGGCA TCTCCTGAGC CTAGGCAATA GCTGTAGGGT GACTTCTGGA GCCATCCCCG	300

TTTCCCGGCC	CCCCAAAAGA	AGCGGAGATT	TAACGGGGAC	GTGCGGCCAG	AGCTGGGGAA	360
ATG GGC CCG CGA GCC AGG CCG GCG CTT CTC CTC CTG ATG CTT TTG CAG	408					
Met Gly Pro Arg Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln						
1 5 10 15						
ACC GCG GTC CTG CAG GGG CGC TTG CTG C GTGAGTCCGA GGGCTGCGGG	456					
Thr Ala Val Leu Gln Gly Arg Leu Leu						
20 25						
CGAACTAGGG GCGCGGCGGG GGTGGAAAAA TCGAACTAG CTTTTTCTTT GCGCTTGGGA	516					
GTTTGCTAAC TTTGGAGGAC CTGCTCAACC CTATCCGCAA GCCCCTCTCC CTACTTTCTG	576					
CGTCCAGACC CCGTGAGGGA GTGCCTACCA CTGAACTGCA GATAGGGGTC CCTCGCCCCA	636					
GGACCTGCCC CCTCCCCCGG CTGTCCCGGC TCTGCGGAGT GACTTTTGGA ACCGCCCCACT	696					
CCCTTCCCCC AACTAGAATG CTTTTAAATA AATCTCGTAG TTCCTCACTT GAGCTGAGCT	756					
AAGCCTGGGG CTCCTTGAAC CTGGAACCTCG GGTTTATTTT CAATGTCAGC TGTGCAGTTT	816					
TTTCCCAGT CATCTCCAAA CAGGAAGTTC TTCCCTGAGT GCTTGCCGAG AAGGCTGAGC	876					
AAACCCACAG CAGGATCCGC ACGGGGTTTC CACCTCAGAA CGAATGCGTT GGGCGGTGGG	936					
GGCGCGAAAG AGTGCGGTTG GGGATCTGAA TTCTTCACCA TTCCACCCAC TTTTGGTGAG	996					
ACCTGGGGTG GAGGTCTCTA GGGTGGGAGG CTCCTGAGAG AGGCCTACCT CGGGCCTTTC	1056					
CCCACCTCTTG GCAATTGTTT TTTTGCCTGG AAAATTAAGT ATATGTTAGT TTTGAACGTT	1116					
TGAACTGAAC AATTCTCTTT TCGGCTAGGC TTTATTGATT TGCAATGTGC TGTGTAATTA	1176					
AGAGGCCTCT CTACAAAGTA CTGATAATGA ACATGTAAGC AATGCACTCA CTTCTAAGTT	1236					
ACATTCATAT CTGATCTTAT TTGATTTTCA CTAGGCATAG GGAGGTAGGA GCTAATAATA	1296					
CGTTTATTTT ACTAGAAGTT AACTGGAATT CAGATTATAT AACTCTTTTC AGGTTACAAA	1356					
GAACATAAAT AATCTGGTTT TCTGATGTTA TTTCAAGTAC TACAGCTGCT TCTAATCTTA	1416					
GTTGACAGTG ATTTTGCCCT GTAGTGTAGC ACAGTGTTCT GTGGGTCA CA CGCCGGCCTC	1476					
AGCACAGCAC TTTGAGTTTT GGTACTACGT GTATCCACAT TTTACACATG ACAAGAATGA	1536					
GGCATGGCAC GGCCTGCTTC CTGGCAAATT TATTCAATGG TACACTGGGC TTTGGTGGCA	1596					
GAGCTCATGT CTCCACTTCA TAGCTATGAT TCTTAAACAT CACACTGCAT TAGAGGTTGA	1656					
ATAATAAAAT TTCATGTTGA GCAGAAATAT TCATTGTTTA CAAGTGTA AA TGAGTCCCAG	1716					
CCATGTGTTG CACTGTTCAA GCCCCAAGGG AGAGAGCAGG GAAACAAGTC TTTACCCTTT	1776					
GATATTTTGC ATTCTAGTGG GAGAGATGAC AATAAGCAAA TGAGCAGAAA GATATACAAC	1836					
ATCAGGAAAT CATGGGTGTT GTGAGAAGCA GAGAAGTCAG GGCAAGTCAC TCTGGGGCTG	1896					
ACACTTGAGC AGAGACATGA AGGAAATAAG AATGATATTG ACTGGGAGCA GTATTTCCCA	1956					
GGCAAACCTGA GTGGGCCTGG CAAGTTGGAT TAAAAAGCGG GTTTTCTCAG CACTACTCAT	2016					

GTGTGTGTGT GTGGGGGGGG GGGGCGGCGT GGGGGTGGGA AGGGGGGACTA CCATCTGCAT 2076
 GTAGGATGTC TAGCAGTATC CTGTCCTCCC TACTCACTAG GTGCTAGGAG CACTCCCCCA 2136
 GTCTTGACAA CCAAAAATGT CTCTAAACTT TGCCACATGT CACCTAGTAG ACAAACCTCT 2196
 GGTTAAGAAG CTCGGGTTGA AAAAAATAAA CAAGTAGTGC TGGGGAGTAG AGGCCAAGAA 2256
 GTAGGTAATG GGCTCAGAAG AGGAGCCACA AACAAGGTTG TGCAGGCGCC TGTAGGCTGT 2316
 GGTGTGAATT CTAGCCAAGG AGTAACAGTG ATCTGTCACA GGCTTTTAAA AGATTGCTCT 2376
 GGCTGCTATG TGGAAAGCAG AATGAAGGGA GCAACAGTAA AAGCAGGGAG CCCAGCCAGG 2436
 AAGCTGTTAC ACAGTCCAGG CAAGAGGTAG TGGAGTGGGC TGGGTGGGAA CAGAAAAGGG 2496
 AGTGACAAAC CATTGTCTCC TGAATATATT CTGAAGGAAG TTGCTGAAGG ATTCTATGTT 2556
 GTGTGAGAGA AAGAGAAGAA TTGGCTGGGT GTAGTAGCTC ATGCCAAGGA GGAGGCCAAG 2616
 GAGAGCAGAT TCCTGAGCTC AGGAGTTCAA GACCAGCCTG GGCAACACAG CAAAACCCCT 2676
 TCTCTACAAA AAATACAAAA ATTAGCTGGG TGTGGTGGCA TGCACCTGTG ATCCTAGCTA 2736
 CTCGGGAGGC TGAGGTGGAG GGTATTGCTT GAGCCCAGGA AGTTGAGGCT GCAGTGAGCC 2796
 ATGACTGTGC CACTGTACTT CAGCCTAGGT GACAGAGCAA GACCCTGTCT CCCCTGACCC 2856
 CCTGAAAAAG AGAAGAGTTA AAGTTGACTT TGTTCCTTAT TTTAATTTTA TTGGCCTGAG 2916
 CAGTGGGGTA ATTGGCAATG CCATTTCTGA GATGGTGAAG GCAGAGGAAA GAGCAGTTTG 2976
 GGGTAAATCA AGGATCTGCA TTTGGGACAT GTTAAGTTTG AGATTCCAGT CAGGCTTCCA 3036
 AGTGGTGAGG CCACATAGGC AGTTCAGTGT AAGAATTCAG GACCAAGGCT GGGCACGGTG 3096
 GCTCACTTCT GTAATCCAG CACTTTGGTG GCTGAGGCAG GTAGATCATT TGAGGTCAGG 3156
 AGTTTGAGAC AAGCTTGGCC AACATGGTGA AACCCCATGT CTACTAAAAA TACAAAAATT 3216
 AGCCTGGTGT GGTGGCGCAC GCCTATAGTC CCAGGTTTTT AGGAGGCTTA GGTAGGAGAA 3276
 TCCCTTGAAC CCAGGAGGTG CAGGTTGCAG TGAGCTGAGA TTGTGCCACT GCACTCCAGC 3336
 CTGGGTGATA GAGTGAGACT CTGTCTCAAA AAAAAAAAAA AAAAAAAAAA AAAAAACTGA 3396
 AGGAATTATT CCTCAGGATT TGGGTCTAAT TTGCCCTGAG CACCAACTCC TGAGTTCAAC 3456
 TACCATGGCT AGACACACCT TAACATTTTC TAGAATCCAC CAGCTTTAGT GGAGTCTGTC 3516
 TAATCATGAG TATTGGAATA GGATCTGGGG GCAGTGAGGG GGTGGCAGCC ACGTGTGGCA 3576
 GAGAAAAGCA CACAAGGAAA GAGCACCCAG GACTGTCATA TGGAAGAAAG ACAGGACTGC 3636
 AACTCACCTC TCACAAAATG AGGACCAGAC ACAGCTGATG GTATGAGTTG ATGCAGGTGT 3696
 GTGGAGCCTC AACATCCTGC TCCCCCTCCTA CTACACATGG TTAAGGCCTG TTGCTCTGTC 3756
 TCCAG GT TCA CAC TCT CTG CAC TAC CTC TTC ATG GGT GCC TCA GAG 3802
 Arg Ser His Ser Leu His Tyr Leu Phe Met Gly Ala Ser Glu

CAG GAC CTT GGT CTT TCC TTG TTT GAA GCT TTG GGC TAC GTG GAT GAC 3850
 Gln Asp Leu Gly Leu Ser Leu Phe Glu Ala Leu Gly Tyr Val Asp Asp
 40 45 50 55

CAG CTG TTC GTG TTC TAT GAT CAT GAG AGT CGC CGT GTG GAG CCC CGA 3898
 Gln Leu Phe Val Phe Tyr Asp His Glu Ser Arg Arg Val Glu Pro Arg
 60 65 70

ACT CCA TGG GTT TCC AGT AGA ATT TCA AGC CAG ATG TGG CTG CAG CTG 3946
 Thr Pro Trp Val Ser Ser Arg Ile Ser Ser Gln Met Trp Leu Gln Leu
 75 80 85

AGT CAG AGT CTG AAA GGG TGG GAT CAC ATG TTC ACT GTT GAC TTC TGG 3994
 Ser Gln Ser Leu Lys Gly Trp Asp His Met Phe Thr Val Asp Phe Trp
 90 95 100

ACT ATT ATG GAA AAT CAC AAC CAC AGC AAG G GTATGTGGAG AGGGGGCCTC 4045
 Thr Ile Met Glu Asn His Asn His Ser Lys
 105 110

ACCTTCCTGA GGTTGTCAGA GCTTTTCATC TTTTCATGCA TCTTGAAGGA AACAGCTGGA 4105

AGTCTGAGGT CTTGTGGGAG CAGGGAAGAG GGAAGGAATT TGCTTCCTGA GATCATTTGG 4165

TCCTTGGGGA TGGTGGAAAT AGGGACCTAT TCCTTTGGTT GCAGTTAACA AGGCTGGGGA 4225

TTTTTCAG AG TCC CAC ACC CTG CAG GTC ATC CTG GGC TGT GAA ATG 4272
 Glu Ser His Thr Leu Gln Val Ile Leu Gly Cys Glu Met
 115 120 125

CAA GAA GAC AAC AGT ACC GAG GGC TAC TGG AAG TAC GGG TAT GAT GGG 4320
 Gln Glu Asp Asn Ser Thr Glu Gly Tyr Trp Lys Tyr Gly Tyr Asp Gly
 130 135 140

CAG GAC CAC CTT GAA TTC TGC CCT GAC ACA CTG GAT TGG AGA GCA GCA 4368
 Gln Asp His Leu Glu Phe Cys Pro Asp Thr Leu Asp Trp Arg Ala Ala
 145 150 155

GAA CCC AGG GCC TGG CCC ACC AAG CTG GAG TGG GAA AGG CAC AAG ATT 4416
 Glu Pro Arg Ala Trp Pro Thr Lys Leu Glu Trp Glu Arg His Lys Ile
 160 165 170

CGG GCC AGG CAG AAC AGG GCC TAC CTG GAG AGG GAC TGC CCT GCA CAG 4464
 Arg Ala Arg Gln Asn Arg Ala Tyr Leu Glu Arg Asp Cys Pro Ala Gln
 175 180 185 190

CTG CAG CAG TTG CTG GAG CTG GGG AGA GGT GTT TTG GAC CAA CAA G 4510
 Leu Gln Gln Leu Leu Glu Leu Gly Arg Gly Val Leu Asp Gln Gln
 195 200 205

GTATGGTGGG AACACACTTC TGCCCCTATA CTCTAGTGGC AGAGTGGAGG AGGTTGCAGG 4570

GCACGGAATC CCTGGTTGGA GTTTCAGAGG TGGCTGAGGC TGTGTGCCTC TCCAAATTCT 4630

GGGAAGGGAC TTTCTCAATC CTAGAGTCTC TACCTTATAA TTGAGATGTA TGAGACAGCC 4690

ACAAGTCATG GGTTTAATTT CTTTTCTCCA TGCATATGGC TCAAAGGGAA GTGTCTATGG 4750

CCCTTGCTTT TTATTTAACC AATAATCTTT TGATATTTA TACCTGTAA AAATTCAGAA 4810

ATGTCAAGGC CGGGCACGGT GGCTCACCCC TGTAATCCCA GCACTTTGGG AGGCCGAGGC 4870

GGGTGGTCAC AAGGTCAGGA GTTTGAGACC AGCCTGACCA ACATGGTGAA ACCCGTCTCT	4930
AAAAAAATAC AAAAATTAGC TGGTCACAGT CATGCGCACC TGTAGTCCCA GCTAATTGGA	4990
AGGCTGAGGC AGGAGCATCG CTTGAACCTG GGAAGCGGAA GTTGCACTGA GCCAAGATCG	5050
CGCCACTGCA CTCCAGCCTA GGCAGCAGAG TGAGACTCCA TCTTAAAAAA AAAAAAAAAA	5110
AAAAAAGAG AATTTCAGAGA TCTCAGCTAT CATATGAATA CCAGGACAAA ATATCAAGTG	5170
AGGCCACTTA TCAGAGTAGA AGAATCCTTT AGGTTAAAAG TTTCTTTCAT AGAACATAGC	5230
AATAATCACT GAAGCTACCT ATCTTACAAG TCCGCTTCTT ATAACAATGC CTCCTAGGTT	5290
GACCCAGGTG AAACCTGACCA TCTGTATTCA ATCATTTTCA ATGCACATAA AGGGCAATTT	5350
TATCTATCAG AACAAAGAAC ATGGGTAACA GATATGTATA TTTACATGTG AGGAGAACAA	5410
GCTGATCTGA CTGCTCTCCA AGTGACACTG TGTTAGAGTC CAATCTTAGG ACACAAAATG	5470
GTGTCTCTCC TGTAGCTTGT TTTTTTCTGA AAAGGGTATT TCCTTCCTCC AACCTATAGA	5530
AGGAAGTGAA AGTTCCAGTC TTCCTGGCAA GGGTAAACAG ATCCCCCTCTC CTCATCCTTC	5590
CTCTTTCCTG TCAAG TG CCT CCT TTG GTG AAG GTG ACA CAT CAT GTG ACC	5640
Val Pro Pro Leu Val Lys Val Thr His His Val Thr	
210 215	
TCT TCA GTG ACC ACT CTA CGG TGT CGG GCC TTG AAC TAC TAC CCC CAG	5688
Ser Ser Val Thr Thr Leu Arg Cys Arg Ala Leu Asn Tyr Tyr Pro Gln	
220 225 230	
AAC ATC ACC ATG AAG TGG CTG AAG GAT AAG CAG CCA ATG GAT GCC AAG	5736
Asn Ile Thr Met Lys Trp Leu Lys Asp Lys Gln Pro Met Asp Ala Lys	
235 240 245	
GAG TTC GAA CCT AAA GAC GTA TTG CCC AAT GGG GAT GGG ACC TAC CAG	5784
Glu Phe Glu Pro Lys Asp Val Leu Pro Asn Gly Asp Gly Thr Tyr Gln	
250 255 260 265	
GGC TGG ATA ACC TTG GCT GTA CCC CCT GGG GAA GAG CAG AGA TAT ACG	5832
Gly Trp Ile Thr Leu Ala Val Pro Pro Gly Glu Glu Gln Arg Tyr Thr	
270 275 280	
TGC CAG GTG GAG CAC CCA GGC CTG GAT CAG CCC CTC ATT GTG ATC TGG G	5881
Cys Gln Val Glu His Pro Gly Leu Asp Gln Pro Leu Ile Val Ile Trp	
285 290 295	
GTATGTGACT GATGAGAGCC AGGAGCTGAG AAAATCTATT GGGGGTTGAG AGGAGTGCCT	5941
GAGGAGGTAA TTATGGCAGT GAGATGAGGA TCTGCTCTTT GTTAGGGGGT GGGCTGAGGG	6001
TGGCAATCAA AGGCTTTAAC TTGCTTTTTC TGTTTTAG AG CCC TCA CCG TCT	6053
Glu Pro Ser Pro Ser	
300	
GGC ACC CTA GTC ATT GGA GTC ATC AGT GGA ATT GCT GTT TTT GTC GTC	6101
Gly Thr Leu Val Ile Gly Val Ile Ser Gly Ile Ala Val Phe Val Val	
305 310 315	
ATC TTG TTC ATT GGA ATT TTG TTC ATA ATA TTA AGG AAG AGG CAG GGT	6149
Ile Leu Phe Ile Gly Ile Leu Phe Ile Ile Leu Arg Lys Arg Gln Gly	

320	325	330	
TCA A GTGAGTAGGA ACAAGGGGGA AGTCTCTTAG TACCTCTGCC CCAGGGCACA			6203
Ser			
335			
GTGGGAAGAG GGGCAGAGGG GATCTGGCAT CCATGGGAAG CATTCTCTC ATTTATATTC			6263
TTTGGGGACA CCAGCAGCTC CCTGGGAGAC AGAAAATAAT GGTTCTCCCC AGAATGAAAG			6323
TCTCTAATTC AACAAACATC TTCAGAGCAC CTACTATTTT GCAAGAGCTG TTTAAGGTAG			6383
TACAGGGGCT TTGAGGTTGA GAAGTCACTG TGGCTATTCT CAGAACCCAA ATCTGGTAGG			6443
GAATGAAATT GATAGCAAGT AAATGTAGTT AAAGAAGACC CCATGAGGTC CTAAAGCAGG			6503
CAGGAAGCAA ATGCTTAGGG TGTCAAAGGA AAGAATGATC ACATTGAGCT GGGGATCAAG			6563
ATAGCCTTCT GGATCTTGAA GGAGAAGCTG GATTCCATTA GGTGAGGTTG AAGATGATGG			6623
GAGGTCTACA CAGACGGAGC AACCATGCCA AGTAGGAGAG TATAAGGCAT ACTGGGAGAT			6683
TAGAAATAAT TACTGTACCT TAACCCTGAG TTTGCGTAGC TATCACTCAC CAATTATGCA			6743
TTTCTACCCC CTGAACATCT GTGGTGTAGG GAAAAGAGAA TCAGAAAGAA GCCAGCTCAT			6803
ACAGAGTCCA AGGGTCTTTT GGGATATTGG GTTATGATCA CTGGGGTGTC ATTGAAGGAT			6863
CCTAAGAAAG GAGGACCACG ATCTCCCTTA TATGGTGAAT GTGTTGTTAA GAAGTTAGAT			6923
GAGAGGTGAG GAGACCAGTT AGAAAGCCAA TAAGCATTTC CAGATGAGAG ATAATGGTTC			6983
TTGAAATCCA ATAGTGCCCA GGTCTAAATT GAGATGGGTG AATGAGGAAA ATAAGGAAGA			7043
GAGAAGAGGC AAGATGGTGC CTAGGTTTGT GATGCCTCTT TCCTGGGTCT CTTGTCTCCA			7103
CAG GA GGA GCC ATG GGG CAC TAC GTC TTA GCT GAA CGT GAG			7144
Arg Gly Ala Met Gly His Tyr Val Leu Ala Glu Arg Glu			
340	345		
TGACACGCAG CCTGCAGACT CACTGTGGGA AGGAGACAAA ACTAGAGACT CAAAGAGGGA			7204
GTGCATTTAT GAGCTCTTCA TGTTTCAGGA GAGAGTTGAA CCTAAACATA GAAATTGCCT			7264
GACGAACTCC TTGATTTTAG CCTTCTCTGT TCATTTCCTC AAAAAGATTT CCCCATTTAG			7324
GTTTCTGAGT TCCTGCATGC CGGTGATCCC TAGCTGTGAC CTCTCCCCTG GAACTGTCTC			7384
TCATGAACCT CAAGCTGCAT CTAGAGGCTT CCTTCATTTC CTCCGTCACC TCAGAGACAT			7444
ACACCTATGT CATTTCATTT CCTATTTTTG GAAGAGGACT CCTTAAATTT GGGGGACTTA			7504
CATGATTCAT TTAAACATCT GAGAAAAGCT TTGAACCCTG GGACGTGGCT AGTCATAACC			7564
TTACCAGATT TTTACACATG TATCTATGCA TTTTCTGGAC CCGTTCAACT TTTCTTTGA			7624
ATCCTCTCTC TGTGTTACCC AGTAACTCAT CTGTCACCAA GCCTTGGGGA TTCTTCCATC			7684
TGATTGTGAT GTGAGTTGCA CAGCTATGAA GGCTGTACAC TGCACGAATG GAAGAGGCAC			7744
CTGTCCCAGA AAAAGCATCA TGGCTATCTG TGGGTAGTAT GATGGGTGTT TTTAGCAGGT			7804

AGGAGGCAAA	TATCTTGAAA	GGGGTTGTGA	AGAGGTGTTT	TTTCTAATTG	GCATGAAGGT	7864
GTCATACAGA	TTTGCAAAGT	TTAATGGTGC	CTTCATTTGG	GATGCTACTC	TAGTATTCCA	7924
GACCTGAAGA	ATCACAATAA	TTTTCTACCT	GGTCTCTCCT	TGTTCTGATA	ATGAAAATTA	7984
TGATAAGGAT	GATAAAAGCA	CTTACTTTCGT	GTCCGACTCT	TCTGAGCACC	TACTTACATG	8044
CATTACTGCA	TGCACTTCTT	ACAATAATTC	TATGAGATAG	GTACTATTAT	CCCCATTTC	8104
TTTTTAAATG	AAGAAAGTGA	AGTAGGCCGG	GCACGGTGGC	TCACGCCTGT	AATCCCAGCA	8164
CTTTGGGAGG	CCAAAGCGGG	TGGATCACGA	GGTCAGGAGA	TCGAGACCAT	CCTGGCTAAC	8224
ATGGTGAAAC	CCCATCTCTA	ATAAAAATAC	AAAAAATTAG	CTGGGCGTGG	TGGCAGACGC	8284
CTGTAGTCCC	AGCTACTCGG	AAGGCTGAGG	CAGGAGAATG	GCATGAACCC	AGGAGGCAGA	8344
GCTTGCAGTG	AGCCGAGTTT	GCGCCACTGC	ACTCCAGCCT	AGGTGACAGA	GTGAGACTCC	8404
ATCTCAAAAA	AATAAAAATA	AAAATAAAAA	AATGAAAAAA	AAAAGAAAGT	GAAGTATAGA	8464
GTATCTCATA	GTTTGTCACT	GATAGAAACA	GGTTTCAAAC	TCAGTCAATC	TGACCGTTTG	8524
ATACATCTCA	GACACCACTA	CATTCACTAG	TTTAGATGCC	TAGAATAAAT	AGAGAAGGAA	8584
GGAGATGGCT	CTTCTCTTGT	CTCATTGTGT	TTCTTCTGAG	TGAGCTTGAA	TCACATGAAG	8644
GGGAACAGCA	GAAAACAACC	AACCTGATCCT	CAGCTGTCAT	GTTTCCTTTA	AAAGTCCCTG	8704
AAGGAAGGTC	CTGGAATGTG	ACTCCCTTGC	TCCTCTGTTG	CTCTCTTTGG	CATTCAATTC	8764
TTTGGACCCT	ACGCAAGGAC	TGTAATTGGT	GGGGACAGCT	AGTGGCCCTG	CTGGGCTTCA	8824
CACACGGTGT	CCTCCCTAGG	CCAGTGCCTC	TGGAGTCAGA	ACTCTGGTGG	TATTTCCCTC	8884
AATGAAGTGG	AGTAAGCTCT	CTCATTTTGA	GATGGTATAA	TGGAAGCCAC	CAAGTGGCTT	8944
AGAGGATGCC	CAGGTCCTTC	CATGGAGCCA	CTGGGGTTCC	GGTGACATT	AAAAAAAAAA	9004
TCTAACCAGG	ACATTCAGGA	ATTGCTAGAT	TCTGGGAAAT	CAGTTCACCA	TGTTCAAAG	9064
AGTCTTTTTT	TTTTTTTTGA	GACTCTATTG	CCCAGGCTGG	AGTGCAATGG	CATGATCTCG	9124
GCTCACTGTA	ACCTCTGCCT	CCCAGGTTCA	AGCGATTCTC	CTGTCTCAGC	CTCCCAAGTA	9184
GCTGGGATTA	CAGGCGTGCA	CCACCATGCC	CGGCTAATTT	TTGTATTTTT	AGTAGAGACA	9244
GGGTTTCACC	ATGTTGGCCA	GGCTGGTCTC	GAACCTCCT	GACCTCGTGA	TCCGCCTGCC	9304
TCGGCCTCCC	AAAGTGCTGA	GATTACAGGT	GTGAGCCACC	CTGCCCAGCC	GTCAAAAGAG	9364
TCTTAATATA	TATATCCAGA	TGGCATGTGT	TTACTTTATG	TTACTACATG	CACCTGGCTG	9424
CATAAATGTG	GTACAAGCAT	TCTGTCTTGA	AGGGCAGGTG	CTTCAGGATA	CCATATACAG	9484
CTCAGAAGTT	TCTTCTTTAG	GCATTAAATT	TTAGCAAAGA	TATCTCATCT	CTTCTTTTAA	9544
ACCATTTTCT	TTTTTTGTGG	TTAGAAAAGT	TATGTAGAAA	AAAGTAAATG	TGATTTACGC	9604
TCATTGTAGA	AAAGCTATAA	AATGAATACA	ATTAAAGCTG	TTATTTAATT	AGCCAGTGAA	9664

AAACTATTAA CAACTTGTCT ATTACCTGTT AGTATTATTG TTGCATTAAA AATGCATATA 9724
 CTTTAATAAA TGTATATTGT ATTGTATACT GCATGATTTT ATTGAAGTTC TTGTTTCATCT 9784
 TGTGTATATA CTTAATCGCT TTGTCATTTT GGAGACATTT ATTTTGCCTC TAATTTCTTT 9844
 ACATTTTGTC TTACGGAATA TTTTCATTCA ACTGTGGTAG CCGAATTAAT CGTGTTTCTT 9904
 CACTCTAGGG ACATTGTCGT CTAAGTTGTA AGACATTGGT TATTTTACCA GCAAACCATT 9964
 CTGAAAGCAT ATGACAAATT ATTTCTCTCT TAATATCTTA CTATACTGAA AGCAGACTGC 10024
 TATAAGGCTT CACTTACTCT TCTACCTCAT AAGGAATATG TTACAATTAA TTTATTAGGT 10084
 AAGCATTTGT TTTATATTGG TTTTATTTCA CCTGGGCTGA GATTTCAAGA AACACCCAG 10144
 TCTTCACAGT AACACATTTT ACTAACACAT TTTACTAAACA TCAGCAACTG TGGCCTGTTA 10204
 ATTTTTTTAA TAGAAATTTT AAGTCCTCAT TTTCTTTTCGG TGTTTTTTAA GCTTAATTTT 10264
 TCTGGCTTTA TTCATAAATT CTTAAGGTCA ACTACATTTG AAAAATCAAA GACCTGCATT 10324
 TTAAATTCTT ATTCACCTCT GGCAAAACCA TTCACAAACC ATGGTAGTAA AGAGAAGGGT 10384
 GACACCTGGT GGCCATAGGT AAATGTACCA CGGTGGTCCG GTGACCAGAG ATGCAGCGCT 10444
 GAGGGTTTTT CTGAAGGTAA AGGAATAAAG AATGGGTGGA GGGGCGTGCA CTGGAAATCA 10504
 CTTGTAGAGA AAAGCCCCTG AAAATTTGAG AAAACAAACA AGAACTACT TACCAGCTAT 10564
 TTGAATTGCT GGAATCACAG GCCATTGCTG AGCTGCCTGA ACTGGGAACA CAACAGAAGG 10624
 AAAACAAACC ACTCTGATAA TCATTGAGTC AAGTACAGCA GGTGATTGAG GACTGCTGAG 10684
 AGGTACAGGC CAAAATTCTT ATGTTGTATT ATAATAATGT CATCTTATAA TACTGTCAGT 10744
 ATTTTATAAA ACATTCTTCA CAACTCACA CACATTTAAA AACAAAACAC TGTCTCTAAA 10804
 ATCCCCAAAT TTTTCATAAA C 10825

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Gly Pro Arg Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln
 1 5 10 15
 Thr Ala Val Leu Gln Gly Arg Leu Leu Arg Ser His Ser Leu His Tyr
 20 25 30
 Leu Phe Met Gly Ala Ser Glu Gln Asp Leu Gly Leu Ser Leu Phe Glu
 35 40 45
 Ala Leu Gly Tyr Val Asp Asp Gln Leu Phe Val Phe Tyr Asp His Glu

50					55					60					
Ser	Arg	Arg	Val	Glu	Pro	Arg	Thr	Pro	Trp	Val	Ser	Ser	Arg	Ile	Ser
65					70					75					80
Ser	Gln	Met	Trp	Leu	Gln	Leu	Ser	Gln	Ser	Leu	Lys	Gly	Trp	Asp	His
				85					90					95	
Met	Phe	Thr	Val	Asp	Phe	Trp	Thr	Ile	Met	Glu	Asn	His	Asn	His	Ser
			100					105					110		
Lys	Glu	Ser	His	Thr	Leu	Gln	Val	Ile	Leu	Gly	Cys	Glu	Met	Gln	Glu
		115					120					125			
Asp	Asn	Ser	Thr	Glu	Gly	Tyr	Trp	Lys	Tyr	Gly	Tyr	Asp	Gly	Gln	Asp
	130					135					140				
His	Leu	Glu	Phe	Cys	Pro	Asp	Thr	Leu	Asp	Trp	Arg	Ala	Ala	Glu	Pro
145					150					155					160
Arg	Ala	Trp	Pro	Thr	Lys	Leu	Glu	Trp	Glu	Arg	His	Lys	Ile	Arg	Ala
				165					170					175	
Arg	Gln	Asn	Arg	Ala	Tyr	Leu	Glu	Arg	Asp	Cys	Pro	Ala	Gln	Leu	Gln
			180					185					190		
Gln	Leu	Leu	Glu	Leu	Gly	Arg	Gly	Val	Leu	Asp	Gln	Gln	Val	Pro	Pro
		195					200					205			
Leu	Val	Lys	Val	Thr	His	His	Val	Thr	Ser	Ser	Val	Thr	Thr	Leu	Arg
	210					215					220				
Cys	Arg	Ala	Leu	Asn	Tyr	Tyr	Pro	Gln	Asn	Ile	Thr	Met	Lys	Trp	Leu
225					230					235					240
Lys	Asp	Lys	Gln	Pro	Met	Asp	Ala	Lys	Glu	Phe	Glu	Pro	Lys	Asp	Val
				245					250					255	
Leu	Pro	Asn	Gly	Asp	Gly	Thr	Tyr	Gln	Gly	Trp	Ile	Thr	Leu	Ala	Val
			260					265					270		
Pro	Pro	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	Gln	Val	Glu	His	Pro	Gly
		275					280					285			
Leu	Asp	Gln	Pro	Leu	Ile	Val	Ile	Trp	Glu	Pro	Ser	Pro	Ser	Gly	Thr
	290					295					300				
Leu	Val	Ile	Gly	Val	Ile	Ser	Gly	Ile	Ala	Val	Phe	Val	Val	Ile	Leu
305					310					315					320
Phe	Ile	Gly	Ile	Leu	Phe	Ile	Ile	Leu	Arg	Lys	Arg	Gln	Gly	Ser	Arg
				325					330					335	
Gly	Ala	Met	Gly	His	Tyr	Val	Leu	Ala	Glu	Arg	Glu				
			340					345							

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10825 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: join(361..436, 3762..4025, 4235..4510, 5606..5881, 6040..6153, 7107..7147)
(D) OTHER INFORMATION: /product= "Hereditary Hemochromatosis (HH) protein containing the 24d1 mutation"
/note= "Hereditary Hemochromatosis (HH) gene 24d1 allele"

(ix) FEATURE:

(A) NAME/KEY: -
(B) LOCATION: 140..7319
(D) OTHER INFORMATION: /note= "start and stop positions for 24d1 allele cDNA (SEQ ID NO:10)"

(ix) FEATURE:

(A) NAME/KEY: -
(B) LOCATION: 3852..3891
(D) OTHER INFORMATION: /note= "start and stop positions for genomic sequence surrounding variant for 24d2(C) allele (SEQ ID NO:41)"

(ix) FEATURE:

(A) NAME/KEY: -
(B) LOCATION: 5507..6023
(D) OTHER INFORMATION: /note= "start and stop positions for genomic sequence surrounding variant for 24d1(A) allele (SEQ ID NO:21)"

(ix) FEATURE:

(A) NAME/KEY: allele
(B) LOCATION: replace(5834, "a")
(D) OTHER INFORMATION: /phenotype= "Hereditary Hemochromatosis (HH)"
/label= 24d1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TCTAAGGTTG AGATAAAATT TTTAAATGTA TGATTGAATT TTGAAAATCA TAAATATTTA	60
AATATCTAAA GTTCAGATCA GAACATTGCG AAGCTACTTT CCCCAATCAA CAACACCCCT	120
TCAGGATTTA AAAACCAAGG GGGACACTGG ATCACCTAGT GTTTCACAAG CAGGTACCTT	180
CTGCTGTAGG AGAGAGAGAA CTAAAGTTCT GAAAGACCTG TTGCTTTTCA CCAGGAAGTT	240
TTACTGGGCA TCTCCTGAGC CTAGGCAATA GCTGTAGGGT GACTTCTGGA GCCATCCCCG	300
TTTCCCCGCC CCCCAAAGA AGCGGAGATT TAACGGGGAC GTGCGGCCAG AGCTGGGGAA	360
ATG GGC CCG CGA GCC AGG CCG GCG CTT CTC CTC CTG ATG CTT TTG CAG	408
Met Gly Pro Arg Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln	
1 5 10 15	

ACC GCG GTC CTG CAG GGG CGC TTG CTG C GTGAGTCCGA GGGCTGCGGG	456
Thr Ala Val Leu Gln Gly Arg Leu Leu	
20 25	
CGAACTAGGG GCGCGGCGGG GGTGGAAAAA TCGAAACTAG CTTTTTCTTT GCGCTTGGA	516
GTTTGCTAAC TTTGGAGGAC CTGCTCAACC CTATCCGCAA GCCCCTCTCC CTACTTTCTG	576
CGTCCAGACC CCGTGAGGGA GTGCC'TACCA CTGAACTGCA GATAGGGGTC CCTCGCCCCA	636
GGACCTGCCC CCTCCCCCGG CTGTCCCGGC TCTGCGGAGT GACTTTTGGA ACCGCCCCACT	696
CCCTTCCCCC AACTAGAATG CTTTTAAATA AATCTCGTAG TTCCTCACTT GAGCTGAGCT	756
AAGCCTGGGG CTCCTTGAAC CTGGAAC'TCG GGT'TTAT'TTC CAATGTCAGC TGTGCAGTTT	816
TTTCCCCAGT CATCTCCAAA CAGGAAGTTC TTCCCTGAGT GCTTGCCGAG AAGGCTGAGC	876
AAACCCACAG CAGGATCCGC ACGGGGTTTC CACCTCAGAA CGAATGCGTT GGGCGGTGGG	936
GGCGCGAAAG AGTGGCGTTG GGGATCTGAA TTCTTCACCA TTCCACCCAC TTTTGGTGAG	996
ACCTGGGGTG GAGGTCTCTA GGGTGGGAGG CTCCTGAGAG AGGCCTACCT CGGGCCTTTC	1056
CCCACTCTTG GCAATTGTTT TTTTGCCTGG AAAATTAAGT ATATGTTAGT TTTGAACGTT	1116
TGAACTGAAC AATTCTCTTT TCGGCTAGGC TTTATTGATT TGCAATGTGC TGTGTAATTA	1176
AGAGGCCTCT CTACAAAGTA CTGATAATGA ACATGTAAGC AATGCACTCA CTTCTAAGTT	1236
ACATTCATAT CTGATCTTAT TTGATTTTCA CTAGGCATAG GGAGGTAGGA GCTAATAATA	1296
CGTTTATTTT ACTAGAAGTT AACTGGAATT CAGATTATAT AACTCTTTTC AGGTTACAAA	1356
GAACATAAAT AATCTGGTTT TCTGATGTTA TTTCAAGTAC TACAGCTGCT TCTAATCTTA	1416
GTTGACAGTG ATTTTGCCCT GTAGTGTAGC ACAGTGTTC GTGGGTCACA CGCCGGCCTC	1476
AGCACAGCAC TTTGAGTTTT GGTACTACGT GTATCCACAT TTTACACATG ACAAGAATGA	1536
GGCATGGCAC GGCCTGCTTC CTGGCAAATT TATTCAATGG TACACTGGGC TTTGGTGGCA	1596
GAGCTCATGT CTCCACTTCA TAGCTATGAT TCTTAAACAT CACACTGCAT TAGAGGTTGA	1656
ATAATAAAAT TTCATGTTGA GCAGAAATAT TCATTGTTTA CAAGTGTAAG TGAGTCCCAG	1716
CCATGTGTTG CACTGTTCAA GCCCCAAGGG AGAGAGCAGG GAAACAAGTC TTTACCCTTT	1776
GATATTTTGC ATTCTAGTGG GAGAGATGAC AATAAGCAAA TGAGCAGAAA GATATACAAC	1836
ATCAGGAAAT CATGGGTGTT GTGAGAAGCA GAGAAGTCAG GGCAAGTCAC TCTGGGGCTG	1896
ACACTTGAGC AGAGACATGA AGGAAATAAG AATGATATTG ACTGGGAGCA GTATTTCCCA	1956
GGCAA'ACTGA GTGGGCCTGG CAAGTTGGAT TAAAAAGCGG GTTTTCTCAG CACTACTCAT	2016
GTGTGTGTGT GTGGGGGGGG GGGGCGGCGT GGGGGTGGGA AGGGGGACTA CCATCTGCAT	2076
GTAGGATGTC TAGCAGTATC CTGTCCTCCC TACTCACTAG GTGCTAGGAG CACTCCCCCA	2136
GTCTTGACAA CCAAAAATGT CTCTAAACTT TGCCACATGT CACCTAGTAG ACAAACCTCT	2196

GGTTAAGAAG	CTCGGGTTGA	AAAAAATAAA	CAAGTAGTGC	TGGGGAGTAG	AGGCCAAGAA	2256
GTAGGTAATG	GGCTCAGAAG	AGGAGCCACA	AACAAGGTTG	TGCAGGCGCC	TGTAGGCTGT	2316
GGTGTGAATT	CTAGCCAAGG	AGTAACAGTG	ATCTGTCACA	GGCTTTTAAA	AGATTGCTCT	2376
GGCTGCTATG	TGGAAAGCAG	AATGAAGGGA	GCAACAGTAA	AAGCAGGGAG	CCCAGCCAGG	2436
AAGCTGTTAC	ACAGTCCAGG	CAAGAGGTAG	TGGAGTGGGC	TGGGTGGGAA	CAGAAAAGGG	2496
AGTGACAAAC	CATTGTCTCC	TGAATATATT	CTGAAGGAAG	TTGCTGAAGG	ATTCTATGTT	2556
GTGTGAGAGA	AAGAGAAGAA	TTGGCTGGGT	GTAGTAGCTC	ATGCCAAGGA	GGAGGCCAAG	2616
GAGAGCAGAT	TCCTGAGCTC	AGGAGTTCAA	GACCAGCCTG	GGCAACACAG	CAAAACCCCT	2676
TCTCTACAAA	AAATACAAAA	ATTAGCTGGG	TGTGGTGGCA	TGCACCTGTG	ATCCTAGCTA	2736
CTCGGGAGGC	TGAGGTGGAG	GGTATTGCTT	GAGCCCAGGA	AGTTGAGGCT	GCAGTGAGCC	2796
ATGACTGTGC	CACTGTACTT	CAGCCTAGGT	GACAGAGCAA	GACCCTGTCT	CCCCTGACCC	2856
CCTGAAAAAG	AGAAGAGTTA	AAGTTGACTT	TGTTCTTTAT	TTTAATTTTA	TTGGCCTGAG	2916
CAGTGGGGTA	ATTGGCAATG	CCATTTCTGA	GATGGTGAAG	GCAGAGGAAA	GAGCAGTTTG	2976
GGGTAAATCA	AGGATCTGCA	TTTGGGACAT	GTTAAGTTTG	AGATTCCAGT	CAGGCTTCCA	3036
AGTGGTGAGG	CCACATAGGC	AGTTCAGTGT	AAGAATTCAG	GACCAAGGCT	GGGCACGGTG	3096
GCTCACTTCT	GTAATCCCAG	CACTTTGGTG	GCTGAGGCAG	GTAGATCATT	TGAGGTCAGG	3156
AGTTTGAGAC	AAGCTTGGCC	AACATGGTGA	AACCCCATGT	CTACTAAAAA	TACAAAAATT	3216
AGCCTGGTGT	GGTGGCGCAC	GCCTATAGTC	CCAGGTTTTTC	AGGAGGCTTA	GGTAGGAGAA	3276
TCCCTTGAAC	CCAGGAGGTG	CAGGTTGCAG	TGAGCTGAGA	TTGTGCCACT	GCACTCCAGC	3336
CTGGGTGATA	GAGTGAGACT	CTGTCTCAAA	AAAAAAAAAA	AAAAAAAAAA	AAAAAACTGA	3396
AGGAATTATT	CCTCAGGATT	TGGGTCTAAT	TTGCCCTGAG	CACCAACTCC	TGAGTTCAAC	3456
TACCATGGCT	AGACACACCT	TAACATTTTC	TAGAATCCAC	CAGCTTTAGT	GGAGTCTGTC	3516
TAATCATGAG	TATTGGAATA	GGATCTGGGG	GCAGTGAGGG	GGTGGCAGCC	ACGTGTGGCA	3576
GAGAAAAGCA	CACAAGGAAA	GAGCACCCAG	GACTGTCTAT	TGGAAGAAAAG	ACAGGACTGC	3636
AACTCACCCCT	TCACAAAATG	AGGACCAGAC	ACAGCTGATG	GTATGAGTTG	ATGCAGGTGT	3696
GTGGAGCCTC	AACATCCTGC	TCCCCTCCTA	CTACACATGG	TTAAGGCCTG	TTGCTCTGTC	3756
TCCAG	GT TCA CAC TCT	CTG CAC TAC CTC	TTC ATG GGT GCC	TCA GAG		3802
	Arg Ser His Ser	Leu His Tyr Leu	Phe Met Gly Ala	Ser Glu		
	30		35			
CAG GAC CTT	GGT CTT TCC	TTG TTT GAA	GCT TTG GGC	TAC GTG GAT	GAC	3850
Gln Asp Leu	Gly Leu Ser	Leu Phe Glu	Ala Leu Gly	Tyr Val Asp	Asp	
40	45	50	55			
CAG CTG TTC	GTG TTC TAT	GAT CAT GAG	AGT CGC CGT	GTG GAG CCC	CGA	3898
Gln Leu Phe	Val Phe Tyr	Asp His Glu	Ser Arg Arg	Val Glu Pro	Arg	

60										65					70					
ACT	CCA	TGG	GTT	TCC	AGT	AGA	ATT	TCA	AGC	CAG	ATG	TGG	CTG	CAG	CTG	3946				
Thr	Pro	Trp	Val	Ser	Ser	Arg	Ile	Ser	Ser	Gln	Met	Trp	Leu	Gln	Leu					
75				80				85												
AGT	CAG	AGT	CTG	AAA	GGG	TGG	GAT	CAC	ATG	TTC	ACT	GTT	GAC	TTC	TGG	3994				
Ser	Gln	Ser	Leu	Lys	Gly	Trp	Asp	His	Met	Phe	Thr	Val	Asp	Phe	Trp					
90				95				100												
ACT	ATT	ATG	GAA	AAT	CAC	AAC	CAC	AGC	AAG	G	GTATGTGGAG	AGGGGGCCTC				4045				
Thr	Ile	Met	Glu	Asn	His	Asn	His	Ser	Lys											
105				110																
ACCTTCCTGA			GGTTGTCAGA			GCTTTTCATC			TTTTTCATGCA			TCTTGAAGGA			AACAGCTGGA		4105			
AGTCTGAGGT			CTTGTGGGAG			CAGGGAAGAG			GGAAGGAATT			TGCTTCCTGA			GATCATTTGG		4165			
TCCTTGGGGA			TGGTGGAAAT			AGGGACCTAT			TCCTTTGGTT			GCAGTTAACA			AGGCTGGGGA		4225			
TTTTTCCAG			AG TCC CAC ACC CTG CAG GTC ATC CTG GGC TGT GAA ATG														4272			
			Glu Ser His Thr Leu Gln Val Ile Leu Gly Cys Glu Met																	
			115			120						125								
CAA	GAA	GAC	AAC	AGT	ACC	GAG	GGC	TAC	TGG	AAG	TAC	GGG	TAT	GAT	GGG	4320				
Gln	Glu	Asp	Asn	Ser	Thr	Glu	Gly	Tyr	Trp	Lys	Tyr	Gly	Tyr	Asp	Gly					
130				135				140												
CAG	GAC	CAC	CTT	GAA	TTC	TGC	CCT	GAC	ACA	CTG	GAT	TGG	AGA	GCA	GCA	4368				
Gln	Asp	His	Leu	Glu	Phe	Cys	Pro	Asp	Thr	Leu	Asp	Trp	Arg	Ala	Ala					
145				150				155												
GAA	CCC	AGG	GCC	TGG	CCC	ACC	AAG	CTG	GAG	TGG	GAA	AGG	CAC	AAG	ATT	4416				
Glu	Pro	Arg	Ala	Trp	Pro	Thr	Lys	Leu	Glu	Trp	Glu	Arg	His	Lys	Ile					
160				165				170												
CGG	GCC	AGG	CAG	AAC	AGG	GCC	TAC	CTG	GAG	AGG	GAC	TGC	CCT	GCA	CAG	4464				
Arg	Ala	Arg	Gln	Asn	Arg	Ala	Tyr	Leu	Glu	Arg	Asp	Cys	Pro	Ala	Gln					
175				180				185				190								
CTG	CAG	CAG	TTG	CTG	GAG	CTG	GGG	AGA	GGT	GTT	TTG	GAC	CAA	CAA	G	4510				
Leu	Gln	Gln	Leu	Glu	Glu	Leu	Gly	Arg	Gly	Val	Leu	Asp	Gln	Gln						
195				200				205												
GTATGGTGGGA			AACACACTTC			TGCCCCCTATA			CTCTAGTGGC			AGAGTGGAGG			AGGTTGCAGG		4570			
GCACGGAATC			CCTGGTTGGA			GTTTCAGAGG			TGGCTGAGGC			TGTGTGCCTC			TCCAAATTCT		4630			
GGGAAGGGAC			TTTCTCAATC			CTAGAGTCTC			TACCTTATAA			TTGAGATGTA			TGAGACAGCC		4690			
ACAAGTCAATG			GGTTTAATTT			CTTTTCTCCA			TGCATATGGC			TCAAAGGGAA			GTGTCTATGG		4750			
CCCTTGCTTT			TTATTTAACC			AATAATCTTT			TGTATATTTA			TACCTGTTAA			AAATTTCAGAA		4810			
ATGTCAAGGC			CGGGCACGGT			GGCTCACCCC			TGTAATCCCA			GCACTTTGGG			AGGCCGAGGC		4870			
GGGTGGTCAC			AAGGTCAGGA			GTTTGAGACC			AGCCTGACCA			ACATGGTGAA			ACCCGTCTCT		4930			
AAAAAAATAC			AAAAATTAGC			TGGTCACAGT			CATGCGCACC			TGTAGTCCCA			GCTAATTGGA		4990			
AGGCTGAGGC			AGGAGCATCG			CTTGAACCTG			GGAAGCGGAA			GTTGCACTGA			GCCAAGATCG		5050			

CGCCACTGCA CTCCAGCCTA GGCAGCAGAG TGAGACTCCA TCTTAAAAAA AAAAAAAAAA 5110
 AAAAAAGAG AATTCAGAGA TCTCAGCTAT CATATGAATA CCAGGACAAA ATATCAAGTG 5170
 AGGCCACTTA TCAGAGTAGA AGAATCCTTT AGGTAAAAAG TTTCTTTCAT AGAACATAGC 5230
 AATAATCACT GAAGCTACCT ATCTTACAAG TCCGCTTCTT ATAACAATGC CTCCTAGGTT 5290
 GACCCAGGTG AAAGTGACCA TCTGTATTCA ATCATTTTCA ATGCACATAA AGGGCAATTT 5350
 TATCTATCAG AACAAAGAAC ATGGGTAACA GATATGTATA TTTACATGTG AGGAGAACAA 5410
 GCTGATCTGA CTGCTCTCCA AGTGACACTG TGTTAGAGTC CAATCTTAGG ACACAAAATG 5470
 GTGTCTCTCC TGTAGCTTGT TTTTCTCTGA AAAGGGTATT TCCTTCCTCC AACCTATAGA 5530
 AGGAAGTGAA AGTTCCAGTC TTCCTGGCAA GGGTAAACAG ATCCCCTCTC CTCATCCTTC 5590
 CTCTTTCCTG TCAAG TG CCT CCT TTG GTG AAG GTG ACA CAT CAT GTG ACC 5640
 Val Pro Pro Leu Val Lys Val Thr His His Val Thr
 210 215

TCT TCA GTG ACC ACT CTA CGG TGT CGG GCC TTG AAC TAC TAC CCC CAG 5688
 Ser Ser Val Thr Thr Leu Arg Cys Arg Ala Leu Asn Tyr Tyr Pro Gln
 220 225 230

AAC ATC ACC ATG AAG TGG CTG AAG GAT AAG CAG CCA ATG GAT GCC AAG 5736
 Asn Ile Thr Met Lys Trp Leu Lys Asp Lys Gln Pro Met Asp Ala Lys
 235 240 245

GAG TTC GAA CCT AAA GAC GTA TTG CCC AAT GGG GAT GGG ACC TAC CAG 5784
 Glu Phe Glu Pro Lys Asp Val Leu Pro Asn Gly Asp Gly Thr Tyr Gln
 250 255 260 265

GGC TGG ATA ACC TTG GCT GTA CCC CCT GGG GAA GAG CAG AGA TAT ACG 5832
 Gly Trp Ile Thr Leu Ala Val Pro Pro Gly Glu Glu Gln Arg Tyr Thr
 270 275 280

TAC CAG GTG GAG CAC CCA GGC CTG GAT CAG CCC CTC ATT GTG ATC TGG G 5881
 Tyr Gln Val Glu His Pro Gly Leu Asp Gln Pro Leu Ile Val Ile Trp
 285 290 295

GTATGTGACT GATGAGAGCC AGGAGCTGAG AAAATCTATT GGGGGTTGAG AGGAGTGCCT 5941
 GAGGAGGTAA TTATGGCAGT GAGATGAGGA TCTGCTCTTT GTTAGGGGGT GGGCTGAGGG 6001
 TGGCAATCAA AGGCTTTAAC TTGCTTTTTT TGTTTTAG AG CCC TCA CCG TCT 6053
 Glu Pro Ser Pro Ser
 300

GGC ACC CTA GTC ATT GGA GTC ATC AGT GGA ATT GCT GTT TTT GTC GTC 6101
 Gly Thr Leu Val Ile Gly Val Ile Ser Gly Ile Ala Val Phe Val Val
 305 310 315

ATC TTG TTC ATT GGA ATT TTG TTC ATA ATA TTA AGG AAG AGG CAG GGT 6149
 Ile Leu Phe Ile Gly Ile Leu Phe Ile Ile Leu Arg Lys Arg Gln Gly
 320 325 330

TCA A GTGAGTAGGA ACAAGGGGGA AGTCTCTTAG TACCTCTGCC CCAGGGCACA 6203
 Ser
 335

GTGGGAAGAG GGGCAGAGGG GATCTGGCAT CCATGGGAAG CATTTTCTC ATTTATATTC 6263
 TTTGGGGACA CCAGCAGCTC CCTGGGAGAC AGAAAATAAT GGTTCTCCCC AGAATGAAAG 6323
 TCTCTAATTC AACAAACATC TTCAGAGCAC CTACTATTTT GCAAGAGCTG TTTAAGGTAG 6383
 TACAGGGGCT TTGAGGTTGA GAAGTCACTG TGGCTATTCT CAGAACCCAA ATCTGGTAGG 6443
 GAATGAAATT GATAGCAAGT AAATGTAGTT AAAGAAGACC CCATGAGGTC CTAAAGCAGG 6503
 CAGGAAGCAA ATGCTTAGGG TGTCAAAGGA AAGAATGATC ACATTGAGCT GGGGATCAAG 6563
 ATAGCCTTCT GGATCTTGAA GGAGAAGCTG GATTCCATTA GGTGAGGTTG AAGATGATGG 6623
 GAGGTCTACA CAGACGGAGC AACCATGCCA AGTAGGAGAG TATAAGGCAT ACTGGGAGAT 6683
 TAGAAATAAT TACTGTACCT TAACCCTGAG TTTGCGTAGC TATCACTCAC CAATTATGCA 6743
 TTTCTACCCC CTGAACATCT GTGGTGTAGG GAAAAGAGAA TCAGAAAGAA GCCAGCTCAT 6803
 ACAGAGTCCA AGGGTCTTTT GGGATATTGG GTTATGATCA CTGGGGTGTC ATTGAAGGAT 6863
 CCTAAGAAAG GAGGACCACG ATCTCCCTTA TATGGTGAAT GTGTTGTTAA GAAGTTAGAT 6923
 GAGAGGTGAG GAGACCAGTT AGAAAGCCAA TAAGCATTTT CAGATGAGAG ATAATGGTTC 6983
 TTGAAATCCA ATAGTGCCCA GGTCTAAATT GAGATGGGTG AATGAGGAAA ATAAGGAAGA 7043
 GAGAAGAGGC AAGATGGTGC CTAGGTTTGT GATGCCTCTT TCCTGGGTCT CTTGTCTCCA 7103
 CAG GA GGA GCC ATG GGG CAC TAC GTC TTA GCT GAA CGT GAG 7144
 Arg Gly Ala Met Gly His Tyr Val Leu Ala Glu Arg Glu
 340 345
 TGACACGCAG CCTGCAGACT CACTGTGGGA AGGAGACAAA ACTAGAGACT CAAAGAGGGA 7204
 GTGCATTTAT GAGCTCTTCA TGTTTCAGGA GAGAGTTGAA CCTAAACATA GAAATTGCCT 7264
 GACGAACTCC TTGATTTTAG CCTTCTCTGT TCATTTCTCTC AAAAAGATTT CCCCATTTAG 7324
 GTTCTGAGT TCCTGCATGC CGGTGATCCC TAGCTGTGAC CTCTCCCCTG GAAGTGTCTC 7384
 TCATGAACCT CAAGCTGCAT CTAGAGGCTT CCTTCATTTT CTCCGTCACC TCAGAGACAT 7444
 ACACCTATGT CATTTTCATTT CCTATTTTTT GAAGAGGACT CCTTAAATTT GGGGGACTTA 7504
 CATGATTCAT TTTAACATCT GAGAAAAGCT TTGAACCCTG GGACGTGGCT AGTCATAACC 7564
 TTACCAGATT TTTACACATG TATCTATGCA TTTTCTGGAC CCGTTCAACT TTTCTTTTGA 7624
 ATCCTCTCTC TGTGTTACCC AGTAACTCAT CTGTCACCAA GCCTTGGGGA TTCTTCCATC 7684
 TGATTGTGAT GTGAGTTGCA CAGCTATGAA GGCTGTACAC TGCACGAATG GAAGAGGCAC 7744
 CTGTCCCAGA AAAAGCATCA TGGCTATCTG TGGGTAGTAT GATGGGTGTT TTTAGCAGGT 7804
 AGGAGGCAAAA TATCTTGAAA GGGGTTGTGA AGAGGTGTTT TTTCTAATTG GCATGAAGGT 7864
 GTCATACAGA TTTGCAAAGT TTAATGGTGC CTTCATTTGG GATGCTACTC TAGTATTCCA 7924
 GACCTGAAGA ATCACAATAA TTTTCTACCT GGTCTCTCCT TGTTCCTGATA ATGAAAATTA 7984

TGATAAGGAT	GATAAAAGCA	CTTACTTCGT	GTCCGACTCT	TCTGAGCACC	TACTTACATG	8044
CATTACTGCA	TGCACTTCTT	ACAATAATTC	TATGAGATAG	GTACTATTAT	CCCCATTTCT	8104
TTTTTAAATG	AAGAAAGTGA	AGTAGGCCGG	GCACGGTGGC	TCACGCCTGT	AATCCCAGCA	8164
CTTTGGGAGG	CCAAAGCGGG	TGGATCACGA	GGTCAGGAGA	TCGAGACCAT	CCTGGCTAAC	8224
ATGGTGAAAC	CCCATCTCTA	ATAAAAATAC	AAAAAATTAG	CTGGGCGTGG	TGGCAGACGC	8284
CTGTAGTCCC	AGCTACTCGG	AAGGCTGAGG	CAGGAGAATG	GCATGAACCC	AGGAGGCAGA	8344
GCTTGCACTG	AGCCGAGTTT	GCGCCACTGC	ACTCCAGCCT	AGGTGACAGA	GTGAGACTCC	8404
ATCTCAAAAA	AATAAAAATA	AAAATAAAAA	AATGAAAAAA	AAAAGAAAGT	GAAGTATAGA	8464
GTATCTCATA	GTTTGTCTAGT	GATAGAAACA	GGTTTCAAAC	TCAGTCAATC	TGACCGTTTG	8524
ATACATCTCA	GACACCACTA	CATTCACTAG	TTTAGATGCC	TAGAATAAAT	AGAGAAGGAA	8584
GGAGATGGCT	CTTCTCTTGT	CTCATTGTGT	TTCTTCTGAG	TGAGCTTGAA	TCACATGAAG	8644
GGGAACAGCA	GAAAACAACC	AACTGATCCT	CAGCTGTCAT	GTTTCCTTTA	AAAGTCCCTG	8704
AAGGAAGGTC	CTGGAATGTG	ACTCCCTTGC	TCCTCTGTTG	CTCTCTTTGG	CATTCAATTC	8764
TTTGGACCCCT	ACGCAAGGAC	TGTAATTGGT	GGGGACAGCT	AGTGGCCCTG	CTGGGCTTCA	8824
CACACGGTGT	CCTCCCTAGG	CCAGTGCCTC	TGGAGTCAGA	ACTCTGGTGG	TATTTCCCTC	8884
AATGAAGTGG	AGTAAGCTCT	CTCATTTTGA	GATGGTATAA	TGGAAGCCAC	CAAGTGGCTT	8944
AGAGGATGCC	CAGGTCCTTC	CATGGAGCCA	CTGGGGTTCC	GGTGCACATT	AAAAAAAAAA	9004
TCTAACCAGG	ACATTCAGGA	ATTGCTAGAT	TCTGGGAAAT	CAGTTCACCA	TGTTCAAAG	9064
AGTCTTTTTT	TTTTTTTTTGA	GACTCTATTG	CCCAGGCTGG	AGTGCAATGG	CATGATCTCG	9124
GCTCACTGTA	ACCTCTGCCT	CCCAGGTTCA	AGCGATTCTC	CTGTCTCAGC	CTCCCAAGTA	9184
GCTGGGATTA	CAGGCGTGCA	CCACCATGCC	CGGCTAATTT	TTGTATTTTT	AGTAGAGACA	9244
GGGTTTCACC	ATGTTGGCCA	GGCTGGTCTC	GAACTCTCCT	GACCTCGTGA	TCCGCCTGCC	9304
TCGGCCTCCC	AAAGTGCTGA	GATTACAGGT	GTGAGCCACC	CTGCCCAGCC	GTCAAAAGAG	9364
TCTTAATATA	TATATCCAGA	TGGCATGTGT	TTACTTTATG	TTACTACATG	CACTTGGCTG	9424
CATAAATGTG	GTACAAGCAT	TCTGTCTTGA	AGGGCAGGTG	CTTCAGGATA	CCATATACAG	9484
CTCAGAAGTT	TCTTCTTTAG	GCATTAAATT	TTAGCAAAGA	TATCTCATCT	CTTCTTTTAA	9544
ACCATTTTCT	TTTTTTGTGG	TTAGAAAAGT	TATGTAGAAA	AAAGTAAATG	TGATTTACGC	9604
TCATTGTAGA	AAAGCTATAA	AATGAATACA	ATTAAAGCTG	TTATTTAATT	AGCCAGTGAA	9664
AAACTATTAA	CAACTTGTCT	ATTACCTGTT	AGTATTATTG	TTGCATTAAA	AATGCATATA	9724
CTTTAATAAA	TGTATATTGT	ATTGTATACT	GCATGATTTT	ATTGAAGTTC	TTGTTCATCT	9784
TGTGTATATA	CTTAATCGCT	TTGTCATTTT	GGAGACATTT	ATTTTGCTTC	TAATTTCTTT	9844

ACATTTTGTC TTACGGAATA TTTTCATTCA ACTGTGGTAG CCGAATTAAT CGTGTTCCTT 9904
 CACTCTAGGG ACATTGTCGT CTAAGTTGTA AGACATTGGT TATTTTACCA GCAAACCATT 9964
 CTGAAAGCAT ATGACAAATT ATTTCTCTCT TAATATCTTA CTATACTGAA AGCAGACTGC 10024
 TATAAGGCTT CACTTACTCT TCTACCTCAT AAGGAATATG TTACAATTAA TTTATTAGGT 10084
 AAGCATTTGT TTTATATTGG TTTTATTTCA CCTGGGCTGA GATTTCAGA AACACCCCAG 10144
 TCTTCACAGT AACACATTTT ACTAACACAT TACTAAACA TCAGCAACTG TGGCCTGTTA 10204
 ATTTTTTTAA TAGAAATTTT AAGTCCTCAT TTTCTTTCGG TGTTTTTTAA GCTTAATTTT 10264
 TCTGGCTTTA TTCATAAATT CTTAAGGTCA ACTACATTTG AAAAATCAAA GACCTGCATT 10324
 TTAAATTCTT ATTCACCTCT GGCAAAACCA TTCACAAACC ATGGTAGTAA AGAGAAGGGT 10384
 GACACCTGGT GGCCATAGGT AAATGTACCA CGGTGGTCCG GTGACCAGAG ATGCAGCGCT 10444
 GAGGGTTTTT CTGAAGGTAA AGGAATAAAG AATGGGTGGA GGGGCGTGCA CTGGAAATCA 10504
 CTTGTAGAGA AAAGCCCCTG AAAATTTGAG AAAACAAACA AGAACTACT TACCAGCTAT 10564
 TTGAATTGCT GGAATCACAG GCCATTGCTG AGCTGCCTGA ACTGGGAACA CAACAGAAGG 10624
 AAAACAAACC ACTCTGATAA TCATTGAGTC AAGTACAGCA GGTGATTGAG GACTGCTGAG 10684
 AGGTACAGGC CAAAATTCTT ATGTTGTATT ATAATAATGT CATCTTATAA TACTGTCAGT 10744
 ATTTTATAAA ACATTCTTCA CAACTCACA CACATTTAAA AACAAAACAC TGTCTCTAAA 10804
 ATCCCCAAAT TTTTCATAAA C 10825

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Gly Pro Arg Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln
 1 5 10 15
 Thr Ala Val Leu Gln Gly Arg Leu Leu Arg Ser His Ser Leu His Tyr
 20 25 30
 Leu Phe Met Gly Ala Ser Glu Gln Asp Leu Gly Leu Ser Leu Phe Glu
 35 40 45
 Ala Leu Gly Tyr Val Asp Asp Gln Leu Phe Val Phe Tyr Asp His Glu
 50 55 60
 Ser Arg Arg Val Glu Pro Arg Thr Pro Trp Val Ser Ser Arg Ile Ser
 65 70 75 80
 Ser Gln Met Trp Leu Gln Leu Ser Gln Ser Leu Lys Gly Trp Asp His

85										90					95				
Met	Phe	Thr	Val	Asp	Phe	Trp	Thr	Ile	Met	Glu	Asn	His	Asn	His	Ser				
100										105					110				
Lys	Glu	Ser	His	Thr	Leu	Gln	Val	Ile	Leu	Gly	Cys	Glu	Met	Gln	Glu				
115										120					125				
Asp	Asn	Ser	Thr	Glu	Gly	Tyr	Trp	Lys	Tyr	Gly	Tyr	Asp	Gly	Gln	Asp				
130										135					140				
His	Leu	Glu	Phe	Cys	Pro	Asp	Thr	Leu	Asp	Trp	Arg	Ala	Ala	Glu	Pro				
145										150					155				
Arg	Ala	Trp	Pro	Thr	Lys	Leu	Glu	Trp	Glu	Arg	His	Lys	Ile	Arg	Ala				
165										170					175				
Arg	Gln	Asn	Arg	Ala	Tyr	Leu	Glu	Arg	Asp	Cys	Pro	Ala	Gln	Leu	Gln				
180										185					190				
Gln	Leu	Leu	Glu	Leu	Gly	Arg	Gly	Val	Leu	Asp	Gln	Gln	Val	Pro	Pro				
195										200					205				
Leu	Val	Lys	Val	Thr	His	His	Val	Thr	Ser	Ser	Val	Thr	Thr	Leu	Arg				
210										215					220				
Cys	Arg	Ala	Leu	Asn	Tyr	Tyr	Pro	Gln	Asn	Ile	Thr	Met	Lys	Trp	Leu				
225										230					235				
Lys	Asp	Lys	Gln	Pro	Met	Asp	Ala	Lys	Glu	Phe	Glu	Pro	Lys	Asp	Val				
245										250					255				
Leu	Pro	Asn	Gly	Asp	Gly	Thr	Tyr	Gln	Gly	Trp	Ile	Thr	Leu	Ala	Val				
260										265					270				
Pro	Pro	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Tyr	Gln	Val	Glu	His	Pro	Gly				
275										280					285				
Leu	Asp	Gln	Pro	Leu	Ile	Val	Ile	Trp	Glu	Pro	Ser	Pro	Ser	Gly	Thr				
290										295					300				
Leu	Val	Ile	Gly	Val	Ile	Ser	Gly	Ile	Ala	Val	Phe	Val	Val	Ile	Leu				
305										310					315				
Phe	Ile	Gly	Ile	Leu	Phe	Ile	Ile	Leu	Arg	Lys	Arg	Gln	Gly	Ser	Arg				
325										330					335				
Gly	Ala	Met	Gly	His	Tyr	Val	Leu	Ala	Glu	Arg	Glu								
340										345									

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 10825 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: join(361..436, 3762..4025, 4235..4510, 5606..5881, 6040..6153, 7107..7147)
- (D) OTHER INFORMATION: /product= "Hereditary Hemochromatosis (HH) protein containing the 24d2 mutation"
/note= "Hereditary Hemochromatosis (HH) gene 24d2 allele"

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 140..7319
- (D) OTHER INFORMATION: /note= "start and stop positions for 24d2 allele cDNA (SEQ ID NO:11)"

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 3852..3891
- (D) OTHER INFORMATION: /note= "start and stop positions for genomic sequence surrounding variant for 24d2(G) allele (SEQ ID NO:42)"

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 5507..6023
- (D) OTHER INFORMATION: /note= "start and stop positions for genomic sequence surrounding variant for 24d1(G) allele (SEQ ID NO:20)"

(ix) FEATURE:

- (A) NAME/KEY: allele
- (B) LOCATION: replace(3872, "g")
- (D) OTHER INFORMATION: /phenotype= "Hereditary Hemochromatosis (HH)"
/label= 24d2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

TCTAAGGTTG AGATAAAATT TTTAAATGTA TGATTGAATT TTGAAAATCA TAAATATTTA      60
AATATCTAAA GTTCAGATCA GAACATTGCG AAGCTACTTT CCCCATCAA CAACACCCCT      120
TCAGGATTTA AAAACCAAGG GGGACACTGG ATCACCTAGT GTTTCACAAG CAGGTACCTT      180
CTGCTGTAGG AGAGAGAGAA CTAAAGTTCT GAAAGACCTG TTGCTTTTCA CCAGGAAGTT      240
TTACTGGGCA TCTCCTGAGC CTAGGCAATA GCTGTAGGGT GACTTCTGGA GCCATCCCCG      300
TTTCCCCGCC CCCCAAAGA AGCGGAGATT TAACGGGGAC GTGCGGCCAG AGCTGGGGAA      360
ATG GGC CCG CGA GCC AGG CCG GCG CTT CTC CTC CTG ATG CTT TTG CAG      408
Met Gly Pro Arg Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln
  1             5             10             15

ACC GCG GTC CTG CAG GGG CGC TTG CTG C GTGAGTCCGA GGGCTGCGGG      456
Thr Ala Val Leu Gln Gly Arg Leu Leu
      20             25

CGAACTAGGG GCGCGGCGGG GGTGGAAAAA TCGAACTAG CTTTTTCTTT GCGCTTGGA      516

```

GTTCGCTAAC	TTTGGAGGAC	CTGCTCAACC	CTATCCGCAA	GCCCCCTCTCC	CTACTTTCTG	576
CGTCCAGACC	CCGTGAGGGA	GTGCCTACCA	CTGAACTGCA	GATAGGGGTC	CCTCGCCCCA	636
GGACCTGCCC	CCTCCCCCGG	CTGTCCCGGC	TCTGCGGAGT	GACTTTTGGA	ACCGCCCACT	696
CCCTTCCCCC	AACTAGAATG	CTTTTAAATA	AATCTCGTAG	TTCCTCACTT	GAGCTGAGCT	756
AAGCCTGGGG	CTCCTTGAAC	CTGGAACTCG	GGTTTATTTT	CAATGTCAGC	TGTGCAGTTT	816
TTTCCCCAGT	CATCTCCAAA	CAGGAAGTTC	TTCCCTGAGT	GCTTGCCGAG	AAGGCTGAGC	876
AAACCCACAG	CAGGATCCGC	ACGGGGTTTC	CACCTCAGAA	CGAATGCGTT	GGGCGGTGGG	936
GGCGCGAAAG	AGTGGCGTTG	GGGATCTGAA	TTCTTCACCA	TTCCACCCAC	TTTTGGTGAG	996
ACCTGGGGTG	GAGGTCTCTA	GGGTGGGAGG	CTCCTGAGAG	AGGCCTACCT	CGGGCCTTTC	1056
CCCACTCTTG	GCAATTGTTC	TTTTGCCTGG	AAAATTAAGT	ATATGTTAGT	TTTGAACGTT	1116
TGAACTGAAC	AATTCTCTTT	TCGGCTAGGC	TTTATTGATT	TGCAATGTGC	TGTGTAATTA	1176
AGAGGCCTCT	CTACAAAAGTA	CTGATAATGA	ACATGTAAGC	AATGCACTCA	CTTCTAAGTT	1236
ACATTCATAT	CTGATCTTAT	TTGATTTTCA	CTAGGCATAG	GGAGGTAGGA	GCTAATAATA	1296
CGTTTATTTT	ACTAGAAGTT	AACTGGAATT	CAGATTATAT	AACTCTTTTC	AGGTTACAAA	1356
GAACATAAAT	AATCTGGTTT	TCTGATGTTA	TTTCAAGTAC	TACAGCTGCT	TCTAATCTTA	1416
GTTGACAGTG	ATTTTGCCCT	GTAGTGTAGC	ACAGTGTTCT	GTGGGTCACA	CGCCGGCCTC	1476
AGCACAGCAC	TTTGAGTTTT	GGTACTACGT	GTATCCACAT	TTTACACATG	ACAAGAATGA	1536
GGCATGGCAC	GGCCTGCTTC	CTGGCAAATT	TATTCAATGG	TACACTGGGC	TTTGGTGGCA	1596
GAGCTCATGT	CTCCACTTCA	TAGCTATGAT	TCTTAAACAT	CACACTGCAT	TAGAGGTTGA	1656
ATAATAAAAT	TTCATGTTGA	GCAGAAATAT	TCATTGTTTA	CAAGTGTAAG	TGAGTCCCAG	1716
CCATGTGTTG	CACTGTTCAA	GCCCCAAGGG	AGAGAGCAGG	GAAACAAGTC	TTTACCCTTT	1776
GATATTTTGC	ATTCTAGTGG	GAGAGATGAC	AATAAGCAAA	TGAGCAGAAA	GATATACAAC	1836
ATCAGGAAAT	CATGGGTGTT	GTGAGAAGCA	GAGAAGTCAG	GGCAAGTCAC	TCTGGGGCTG	1896
ACACTTGAGC	AGAGACATGA	AGGAAATAAG	AATGATATTG	ACTGGGAGCA	GTATTTCCCA	1956
GGCAAACTGA	GTGGGCCTGG	CAAGTTGGAT	TAAAAAGCGG	GTTTTCTCAG	CACTACTCAT	2016
GTGTGTGTGT	GTGGGGGGGG	GGGGCGGCGT	GGGGGTGGGA	AGGGGGACTA	CCATCTGCAT	2076
GTAGGATGTC	TAGCAGTATC	CTGTCTCCC	TACTCACTAG	GTGCTAGGAG	CACTCCCCCA	2136
GTCTTGACAA	CCAAAAATGT	CTCTAAACTT	TGCCACATGT	CACCTAGTAG	ACAAACTCCT	2196
GGTTAAGAAG	CTCGGGTTGA	AAAAAATAAA	CAAGTAGTGC	TGGGGAGTAG	AGGCCAAGAA	2256
GTAGGTAATG	GGCTCAGAAG	AGGAGCCACA	AACAAGGTTG	TGCAGGCGCC	TGTAGGCTGT	2316
GGTGTGAATT	CTAGCCAAGG	AGTAACAGTG	ATCTGTCACA	GGCTTTTAAA	AGATTGCTCT	2376

GGCTGCTATG TGGAAAGCAG AATGAAGGGA GCAACAGTAA AAGCAGGGAG CCCAGCCAGG 2436
AAGCTGTTAC ACAGTCCAGG CAAGAGGTAG TGGAGTGGGC TGGGTGGGAA CAGAAAAGGG 2496
AGTGACAAAC CATTGTCTCC TGAATATATT CTGAAGGAAG TTGCTGAAGG ATTCTATGTT 2556
GTGTGAGAGA AAGAGAAGAA TTGGCTGGGT GTAGTAGCTC ATGCCAAGGA GGAGGCCAAG 2616
GAGAGCAGAT TCCTGAGCTC AGGAGTTCAA GACCAGCCTG GGCAACACAG CAAAACCCCT 2676
TCTCTACAAA AAATACAAA ATTAGCTGGG TGTGGTGGCA TGCACCTGTG ATCCTAGCTA 2736
CTCGGGAGGC TGAGGTGGAG GGTATTGCTT GAGCCAGGA AGTTGAGGCT GCAGTGAGCC 2796
ATGACTGTGC CACTGTACTT CAGCCTAGGT GACAGAGCAA GACCCTGTCT CCCCTGACCC 2856
CCTGAAAAAG AGAAGAGTTA AAGTTGACTT TGTCTTTTAT TTTAATTTTA TTGGCCTGAG 2916
CAGTGGGGTA ATTGGCAATG CCATTTCTGA GATGGTGAAG GCAGAGGAAA GAGCAGTTTG 2976
GGGTAAATCA AGGATCTGCA TTTGGGACAT GTTAAGTTTG AGATTCCAGT CAGGCTTCCA 3036
AGTGGTGAGG CCACATAGGC AGTTCAGTGT AAGAATTCAG GACCAAGGCT GGGCACGGTG 3096
GCTCACTTCT GTAATCCCAG CACTTTGGTG GCTGAGGCAG GTAGATCATT TGAGGTCAGG 3156
AGTTTGAGAC AAGCTTGGCC AACATGGTGA AACCCCATGT CTACTAAAAA TACAAAAATT 3216
AGCCTGGTGT GGTGGCGCAC GCCTATAGTC CCAGGTTTTT AGGAGGCTTA GGTAGGAGAA 3276
TCCCTTGAAC CCAGGAGGTG CAGGTTGCAG TGAGCTGAGA TTGTGCCACT GCACTCCAGC 3336
CTGGGTGATA GAGTGAGACT CTGTCTCAAA AAAAAAAAAA AAAAAAAAAA AAAAACTGA 3396
AGGAATTATT CCTCAGGATT TGGGTCTAAT TTGCCCTGAG CACCAACTCC TGAGTTCAAC 3456
TACCATGGCT AGACACACCT TAACATTTTC TAGAATCCAC CAGCTTTAGT GGAGTCTGTC 3516
TAATCATGAG TATTGGAATA GGATCTGGGG GCAGTGAGGG GGTGGCAGCC ACGTGTGGCA 3576
GAGAAAAGCA CACAAGGAAA GAGCACCCAG GACTGTCATA TGAAGAAAG ACAGGACTGC 3636
AACTCACCCCT TCACAAAATG AGGACCAGAC ACAGCTGATG GTATGAGTTG ATGCAGGTGT 3696
GTGGAGCCTC AACATCCTGC TCCCCTCCTA CTACACATGG TTAAGGCCTG TTGCTCTGTC 3756
TCCAG GT TCA CAC TCT CTG CAC TAC CTC TTC ATG GGT GCC TCA GAG 3802
Arg Ser His Ser Leu His Tyr Leu Phe Met Gly Ala Ser Glu
30 35
CAG GAC CTT GGT CTT TCC TTG TTT GAA GCT TTG GGC TAC GTG GAT GAC 3850
Gln Asp Leu Gly Leu Ser Leu Phe Glu Ala Leu Gly Tyr Val Asp Asp
40 45 50 55
CAG CTG TTC GTG TTC TAT GAT GAT GAG AGT CGC CGT GTG GAG CCC CGA 3898
Gln Leu Phe Val Phe Tyr Asp Asp Glu Ser Arg Arg Val Glu Pro Arg
60 65 70
ACT CCA TGG GTT TCC AGT AGA ATT TCA AGC CAG ATG TGG CTG CAG CTG 3946
Thr Pro Trp Val Ser Ser Arg Ile Ser Ser Gln Met Trp Leu Gln Leu
75 80 85

AGT CAG AGT CTG AAA GGG TGG GAT CAC ATG TTC ACT GTT GAC TTC TGG Ser Gln Ser Leu Lys Gly Trp Asp His Met Phe Thr Val Asp Phe Trp 90 95 100	3994
ACT ATT ATG GAA AAT CAC AAC CAC AGC AAG G GTATGTGGAG AGGGGGCCTC Thr Ile Met Glu Asn His Asn His Ser Lys 105 110	4045
ACCTTCCTGA GGTGTGTCAGA GCTTTTCATC TTTTCATGCA TCTTGAAGGA AACAGCTGGA	4105
AGTCTGAGGT CTTGTGGGAG CAGGGAAGAG GGAAGGAATT TGCTTCCTGA GATCATTTGG	4165
TCCTTGGGGA TGGTGGAAAT AGGGACCTAT TCCTTTGGTT GCAGTTAACA AGGCTGGGGA	4225
TTTTTCCAG AG TCC CAC ACC CTG CAG GTC ATC CTG GGC TGT GAA ATG Glu Ser His Thr Leu Gln Val Ile Leu Gly Cys Glu Met 115 120 125	4272
CAA GAA GAC AAC AGT ACC GAG GGC TAC TGG AAG TAC GGG TAT GAT GGG Gln Glu Asp Asn Ser Thr Glu Gly Tyr Trp Lys Tyr Gly Tyr Asp Gly 130 135 140	4320
CAG GAC CAC CTT GAA TTC TGC CCT GAC ACA CTG GAT TGG AGA GCA GCA Gln Asp His Leu Glu Phe Cys Pro Asp Thr Leu Asp Trp Arg Ala Ala 145 150 155	4368
GAA CCC AGG GCC TGG CCC ACC AAG CTG GAG TGG GAA AGG CAC AAG ATT Glu Pro Arg Ala Trp Pro Thr Lys Leu Glu Trp Glu Arg His Lys Ile 160 165 170	4416
CGG GCC AGG CAG AAC AGG GCC TAC CTG GAG AGG GAC TGC CCT GCA CAG Arg Ala Arg Gln Asn Arg Ala Tyr Leu Glu Arg Asp Cys Pro Ala Gln 175 180 185 190	4464
CTG CAG CAG TTG CTG GAG CTG GGG AGA GGT GTT TTG GAC CAA CAA G Leu Gln Gln Leu Leu Glu Leu Gly Arg Gly Val Leu Asp Gln Gln 195 200 205	4510
GTATGGTGGG AACACACTTC TGCCCCTATA CTCTAGTGGC AGAGTGGAGG AGGTTGCAGG	4570
GCACGGAATC CCTGGTTGGA GTTTCAGAGG TGGCTGAGGC TGTGTGCCTC TCCAAATTCT	4630
GGGAAGGGAC TTTCTCAATC CTAGAGTCTC TACCTTATAA TTGAGATGTA TGAGACAGCC	4690
ACAAGTCATG GGTTTAATTT CTTTCTCTCA TGCATATGGC TCAAAGGGAA GTGTCTATGG	4750
CCCTTGCTTT TTATTTAACC AATAATCTTT TGTATATTTA TACCTGTAA AAATTCAGAA	4810
ATGTCAAGGC CGGGCACGGT GGCTCACCCC TGTAATCCCA GCACTTTGGG AGGCCGAGGC	4870
GGGTGGTCAC AAGGTCAGGA GTTTGAGACC AGCCTGACCA ACATGGTGAA ACCCGTCTCT	4930
AAAAAAATAC AAAAATTAGC TGGTCACAGT CATGCGCACC TGTAAGTCCCA GCTAATTGGA	4990
AGGCTGAGGC AGGAGCATCG CTTGAACCTG GGAAGCGGAA GTTGCACTGA GCCAAGATCG	5050
CGCCACTGCA CTCCAGCCTA GGCAGCAGAG TGAGACTCCA TCTTAAAAAA AAAAAAAAAA	5110
AAAAAAGAG AATTCAGAGA TCTCAGCTAT CATATGAATA CCAGGACAAA ATATCAAGTG	5170
AGGCCACTTA TCAGAGTAGA AGAATCCTTT AGGTAAAAAG TTTCTTTCAT AGAACATAGC	5230

AATAATCACT GAAGCTACCT ATCTTACAAG TCCGCTTCTT ATAACAATGC CTCCTAGGTT 5290
GACCCAGGTG AAAC TGACCA TCTGTATTCA ATCATTTTCA ATGCACATAA AGGGCAATTT 5350
TATCTATCAG AACAAAGAAC ATGGGTAACA GATATGTATA TTTACATGTG AGGAGAACAA 5410
GCTGATCTGA CTGCTCTCCA AGTGACACTG TGTTAGAGTC CAATCTTAGG ACACAAAATG 5470
GTGTCTCTCC TG TAGCTTGT TTTTTTCTGA AAAGGGTATT TCCTTCCTCC AACCTATAGA 5530
AGGAAGTGAA AGTTCCAGTC TTCCTGGCAA GGGTAAACAG ATCCCCTCTC CTCATCCTTC 5590
CTCTTTCCTG TCAAG TG CCT CCT TTG GTG AAG GTG ACA CAT CAT GTG ACC 5640
Val Pro Pro Leu Val Lys Val Thr His His Val Thr
210 215
TCT TCA GTG ACC ACT CTA CGG TGT CGG GCC TTG AAC TAC TAC CCC CAG 5688
Ser Ser Val Thr Thr Leu Arg Cys Arg Ala Leu Asn Tyr Tyr Pro Gln
220 225 230
AAC ATC ACC ATG AAG TGG CTG AAG GAT AAG CAG CCA ATG GAT GCC AAG 5736
Asn Ile Thr Met Lys Trp Leu Lys Asp Lys Gln Pro Met Asp Ala Lys
235 240 245
GAG TTC GAA CCT AAA GAC GTA TTG CCC AAT GGG GAT GGG ACC TAC CAG 5784
Glu Phe Glu Pro Lys Asp Val Leu Pro Asn Gly Asp Gly Thr Tyr Gln
250 255 260 265
GGC TGG ATA ACC TTG GCT GTA CCC CCT GGG GAA GAG CAG AGA TAT ACG 5832
Gly Trp Ile Thr Leu Ala Val Pro Pro Gly Glu Glu Gln Arg Tyr Thr
270 275 280
TGC CAG GTG GAG CAC CCA GGC CTG GAT CAG CCC CTC ATT GTG ATC TGG G 5881
Cys Gln Val Glu His Pro Gly Leu Asp Gln Pro Leu Ile Val Ile Trp
285 290 295
GTATGTGACT GATGAGAGCC AGGAGCTGAG AAAATCTATT GGGGGTTGAG AGGAGTGCCT 5941
GAGGAGGTAA TTATGGCAGT GAGATGAGGA TCTGCTCTTT GTTAGGGGGT GGGCTGAGGG 6001
TGGCAATCAA AGGCTTTAAC TTGCTTTTTC TGTTTTAG AG CCC TCA CCG TCT 6053
Glu Pro Ser Pro Ser
300
GGC ACC CTA GTC ATT GGA GTC ATC AGT GGA ATT GCT GTT TTT GTC GTC 6101
Gly Thr Leu Val Ile Gly Val Ile Ser Gly Ile Ala Val Phe Val Val
305 310 315
ATC TTG TTC ATT GGA ATT TTG TTC ATA ATA TTA AGG AAG AGG CAG GGT 6149
Ile Leu Phe Ile Gly Ile Leu Phe Ile Ile Leu Arg Lys Arg Gln Gly
320 325 330
TCA A GTGAGTAGGA ACAAGGGGGA AGTCTCTTAG TACCTCTGCC CCAGGGCACA 6203
Ser
335
GTGGGAAGAG GGGCAGAGGG GATCTGGCAT CCATGGGAAG CATTTTTCTC ATTTATATTC 6263
TTTGGGGACA CCAGCAGCTC CCTGGGAGAC AGAAAATAAT GGTTCTCCCC AGAATGAAAG 6323
TCTCTAATTC AACAAACATC TTCAGAGCAC CTACTATTTT GCAAGAGCTG TTTAAGGTAG 6383

TACAGGGGCT	TTGAGGTTGA	GAAGTCACTG	TGGCTATTCT	CAGAACCCAA	ATCTGGTAGG	6443								
GAATGAAATT	GATAGCAAGT	AAATGTAGTT	AAAGAAGACC	CCATGAGGTC	CTAAAGCAGG	6503								
CAGGAAGCAA	ATGCTTAGGG	TGTCAAAGGA	AAGAATGATC	ACATTCAGCT	GGGGATCAAG	6563								
ATAGCCTTCT	GGATCTTGAA	GGAGAAGCTG	GATTCCATTA	GGTGAGGTTG	AAGATGATGG	6623								
GAGGTCTACA	CAGACGGAGC	AACCATGCCA	AGTAGGAGAG	TATAAGGCAT	ACTGGGAGAT	6683								
TAGAAATAAT	TACTGTACCT	TAACCCTGAG	TTTGCGTAGC	TATCACTCAC	CAATTATGCA	6743								
TTTCTACCCC	CTGAACATCT	GTGGTGTAGG	GAAAAGAGAA	TCAGAAAGAA	GCCAGCTCAT	6803								
ACAGAGTCCA	AGGGTCTTTT	GGGATATTGG	GTTATGATCA	CTGGGGTGTC	ATTGAAGGAT	6863								
CCTAAGAAAAG	GAGGACCACG	ATCTCCCTTA	TATGGTGAAT	GTGTTGTTAA	GAAGTTAGAT	6923								
GAGAGGTGAG	GAGACCAGTT	AGAAAGCCAA	TAAGCATTTC	CAGATGAGAG	ATAATGGTTC	6983								
TTGAAATCCA	ATAGTGCCCA	GGTCTAAATT	GAGATGGGTG	AATGAGGAAA	ATAAGGAAGA	7043								
GAGAAGAGGC	AAGATGGTGC	CTAGGTTTGT	GATGCCTCTT	TCCTGGGTCT	CTTGTCTCCA	7103								
CAG	GA	GGA	GCC	ATG	GGG	CAC	TAC	GTC	TTA	GCT	GAA	CGT	GAG	7144
	Arg	Gly	Ala	Met	Gly	His	Tyr	Val	Leu	Ala	Glu	Arg	Glu	
				340						345				
TGACACGCAG	CCTGCAGACT	CACTGTGGGA	AGGAGACAAA	ACTAGAGACT	CAAAGAGGGA	7204								
GTGCATTTAT	GAGCTCTTCA	TGTTTCAGGA	GAGAGTTGAA	CCTAAACATA	GAAATTGCCT	7264								
GACGAACTCC	TTGATTTTAG	CCTTCTCTGT	TCATTTCTCT	AAAAAGATTT	CCCCATTTAG	7324								
GTTTCTGAGT	TCCTGCATGC	CGGTGATCCC	TAGCTGTGAC	CTCTCCCCTG	GAAGTGTCTC	7384								
TCATGAACCT	CAAGCTGCAT	CTAGAGGCTT	CCTTCATTTC	CTCCGTCACC	TCAGAGACAT	7444								
ACACCTATGT	CATTTCATTT	CCTATTTTTG	GAAGAGGACT	CCTTAAATTT	GGGGGACTTA	7504								
CATGATTCAT	TTTAACATCT	GAGAAAAGCT	TTGAACCCTG	GGACGTGGCT	AGTCATAACC	7564								
TTACCAGATT	TTTACACATG	TATCTATGCA	TTTTCTGGAC	CCGTTCAACT	TTTCCTTTGA	7624								
ATCCTCTCTC	TGTGTTACCC	AGTAACTCAT	CTGTCACCAA	GCCTTGGGGA	TTCTTCCATC	7684								
TGATTGTGAT	GTGAGTTGCA	CAGCTATGAA	GGCTGTACAC	TGCACGAATG	GAAGAGGCAC	7744								
CTGTCCCAGA	AAAAGCATCA	TGGCTATCTG	TGGGTAGTAT	GATGGGTGTT	TTTAGCAGGT	7804								
AGGAGGCAAA	TATCTTGAAA	GGGGTTGTGA	AGAGGTGTTT	TTTCTAATTG	GCATGAAGGT	7864								
GTCATACAGA	TTTGCAAAGT	TTAATGGTGC	CTTCATTTGG	GATGCTACTC	TAGTATTCCA	7924								
GACCTGAAGA	ATCACAATAA	TTTTCTACCT	GGTCTCTCCT	TGTTCTGATA	ATGAAAATTA	7984								
TGATAAGGAT	GATAAAAGCA	CTTACTTCGT	GTCCGACTCT	TCTGAGCACC	TACTTACATG	8044								
CATTACTGCA	TGCACTTCTT	ACAATAATTC	TATGAGATAG	GTACTATTAT	CCCCATTTCT	8104								
TTTTTTAAATG	AAGAAAGTGA	AGTAGGCCGG	GCACGGTGGC	TCACGCCTGT	AATCCCAGCA	8164								

CTTTGGGAGG	CCAAAGCGGG	TGGATCACGA	GGTCAGGAGA	TCGAGACCAT	CCTGGCTAAC	8224
ATGGTGAAAC	CCCATCTCTA	ATAAAAATAC	AAAAAATTAG	CTGGGCGTGG	TGGCAGACGC	8284
CTGTAGTCCC	AGCTACTCGG	AAGGCTGAGG	CAGGAGAATG	GCATGAACCC	AGGAGGCAGA	8344
GCTTGCAGTG	AGCCGAGTTT	GCGCCACTGC	ACTCCAGCCT	AGGTGACAGA	GTGAGACTCC	8404
ATCTCAAAAA	AATAAAAATA	AAAATAAAAA	AATGAAAAAA	AAAAGAAAGT	GAAGTATAGA	8464
GTATCTCATA	GTTTGTCACT	GATAGAAACA	GGTTTCAAAC	TCAGTCAATC	TGACCGTTTG	8524
ATACATCTCA	GACACCACTA	CATTTCAGTAG	TTTAGATGCC	TAGAATAAAT	AGAGAAGGAA	8584
GGAGATGGCT	CTTCTCTTGT	CTCATTGTGT	TTCTTCTGAG	TGAGCTTGAA	TCACATGAAG	8644
GGGAACAGCA	GAAAAACAAC	AACTGATCCT	CAGCTGTCAT	GTTTCCTTTA	AAAGTCCCTG	8704
AAGGAAGGTC	CTGGAATGTG	ACTCCCTTGC	TCCTCTGTTG	CTCTCTTTGG	CATTCAATTC	8764
TTTGGACCCCT	ACGCAAGGAC	TGTAATTGGT	GGGGACAGCT	AGTGGCCCTG	CTGGGCTTCA	8824
CACACGGTGT	CCTCCCTAGG	CCAGTGCCTC	TGGAGTCAGA	ACTCTGGTGG	TATTTCCCTC	8884
AATGAAGTGG	AGTAAGCTCT	CTCATTTTGA	GATGGTATAA	TGGAAGCCAC	CAAGTGGCTT	8944
AGAGGATGCC	CAGGTCCTTC	CATGGAGCCA	CTGGGGTTCC	GGTGCACATT	AAAAAAAAAA	9004
TCTAACCAGG	ACATTTCAGGA	ATTGCTAGAT	TCTGGGAAAT	CAGTTCACCA	TGTTCAAAAG	9064
AGTCTTTTTT	TTTTTTTTTGA	GACTCTATTG	CCCAGGCTGG	AGTGCAATGG	CATGATCTCG	9124
GCTCACTGTA	ACCTCTGCCT	CCCAGGTTCA	AGCGATTCTC	CTGTCTCAGC	CTCCCAAGTA	9184
GCTGGGATTA	CAGGCGTGCA	CCACCATGCC	CGGCTAATTT	TTGTATTTTT	AGTAGAGACA	9244
GGGTTTCACC	ATGTTGGCCA	GGCTGGTCTC	GAACTCTCCT	GACCTCGTGA	TCCGCCTGCC	9304
TCGGCCTCCC	AAAGTGCTGA	GATTACAGGT	GTGAGCCACC	CTGCCCAGCC	GTCAAAAGAG	9364
TCTTAATATA	TATATCCAGA	TGGCATGTGT	TTACTTTATG	TTACTACATG	CACTTGGCTG	9424
CATAAATGTG	GTACAAGCAT	TCTGTCTTGA	AGGGCAGGTG	CTTCAGGATA	CCATATACAG	9484
CTCAGAAGTT	TCTTCTTTAG	GCATTAAATT	TTAGCAAAGA	TATCTCATCT	CTTCTTTTAA	9544
ACCATTTTCT	TTTTTTGTGG	TTAGAAAAGT	TATGTAGAAA	AAAGTAAATG	TGATTTACGC	9604
TCATTGTAGA	AAAGCTATAA	AATGAATACA	ATTAAAGCTG	TTATTTAATT	AGCCAGTGAA	9664
AAACTATTAA	CAACTTGTCT	ATTACCTGTT	AGTATTATTG	TTGCATTAAA	AATGCATATA	9724
CTTTAATAAA	TGTATATTGT	ATTGTATACT	GCATGATTTT	ATTGAAGTTC	TTGTTTCATCT	9784
TGTGTATATA	CTTAATCGCT	TTGTCATTTT	GGAGACATTT	ATTTTGCTTC	TAATTTCTTT	9844
ACATTTTGTC	TTACGGAATA	TTTTTCATTCA	ACTGTGGTAG	CCGAATTAAT	CGTGTTTCTT	9904
CACTCTAGGG	ACATTGTCGT	CTAAGTTGTA	AGACATTGGT	TATTTTACCA	GCAAACCATT	9964
CTGAAAGCAT	ATGACAAAAT	ATTTCTCTCT	TAATATCTTA	CTATACTGAA	AGCAGACTGC	10024

TATAAGGCTT CACTTACTCT TCTACCTCAT AAGGAATATG TTACAATTAA TTTATTAGGT 10084
AAGCATTGT TTTATATTGG TTTTATTTC CCTGGGCTGA GATTTCAGA AACACCCCAG 10144
TCTTCACAGT AACACATTTT ACTAACACAT TTAATAACA TCAGCAACTG TGGCCTGTTA 10204
ATTTTTTTAA TAGAAATTTT AAGTCCTCAT TTTCTTTCGG TGTTTTTTAA GCTTAATTTT 10264
TCTGGCTTTA TTCATAAATT CTTAAGGTCA ACTACATTTG AAAAATCAAA GACCTGCATT 10324
TTAAATTCTT ATTCACCTCT GGCAAAACCA TTCACAAACC ATGGTAGTAA AGAGAAGGGT 10384
GACACCTGGT GGCCATAGGT AAATGTACCA CGGTGGTCCG GTGACCAGAG ATGCAGCGCT 10444
GAGGGTTTTT CTGAAGGTAA AGGAATAAAG AATGGGTGGA GGGGCGTGCA CTGGAAATCA 10504
CTTGTAGAGA AAAGCCCCTG AAAATTTGAG AAAACAAACA AGAACTACT TACCAGCTAT 10564
TTGAATTGCT GGAATCACAG GCCATTGCTG AGCTGCCTGA ACTGGGAACA CAACAGAAGG 10624
AAAACAAACC ACTCTGATAA TCATTGAGTC AAGTACAGCA GGTGATTGAG GACTGCTGAG 10684
AGGTACAGGC CAAAATTCTT ATGTTGTATT ATAATAATGT CATCTTATAA TACTGTCTAGT 10744
ATTTTATAAA ACATTCTTCA CAACTCACA CACATTTAAA AACAAAACAC TGTCTCTAAA 10804
ATCCCCAAAT TTTTCATAAA C 10825

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Gly Pro Arg Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln
1 5 10 15
Thr Ala Val Leu Gln Gly Arg Leu Leu Arg Ser His Ser Leu His Tyr
20 25 30
Leu Phe Met Gly Ala Ser Glu Gln Asp Leu Gly Leu Ser Leu Phe Glu
35 40 45
Ala Leu Gly Tyr Val Asp Asp Gln Leu Phe Val Phe Tyr Asp Asp Glu
50 55 60
Ser Arg Arg Val Glu Pro Arg Thr Pro Trp Val Ser Ser Arg Ile Ser
65 70 75 80
Ser Gln Met Trp Leu Gln Leu Ser Gln Ser Leu Lys Gly Trp Asp His
85 90 95
Met Phe Thr Val Asp Phe Trp Thr Ile Met Glu Asn His Asn His Ser
100 105 110
Lys Glu Ser His Thr Leu Gln Val Ile Leu Gly Cys Glu Met Gln Glu

115					120					125					
Asp	Asn	Ser	Thr	Glu	Gly	Tyr	Trp	Lys	Tyr	Gly	Tyr	Asp	Gly	Gln	Asp
130						135					140				
His	Leu	Glu	Phe	Cys	Pro	Asp	Thr	Leu	Asp	Trp	Arg	Ala	Ala	Glu	Pro
145					150					155					160
Arg	Ala	Trp	Pro	Thr	Lys	Leu	Glu	Trp	Glu	Arg	His	Lys	Ile	Arg	Ala
				165					170					175	
Arg	Gln	Asn	Arg	Ala	Tyr	Leu	Glu	Arg	Asp	Cys	Pro	Ala	Gln	Leu	Gln
			180					185					190		
Gln	Leu	Leu	Glu	Leu	Gly	Arg	Gly	Val	Leu	Asp	Gln	Gln	Val	Pro	Pro
		195					200					205			
Leu	Val	Lys	Val	Thr	His	His	Val	Thr	Ser	Ser	Val	Thr	Thr	Leu	Arg
	210					215					220				
Cys	Arg	Ala	Leu	Asn	Tyr	Tyr	Pro	Gln	Asn	Ile	Thr	Met	Lys	Trp	Leu
225					230					235					240
Lys	Asp	Lys	Gln	Pro	Met	Asp	Ala	Lys	Glu	Phe	Glu	Pro	Lys	Asp	Val
				245					250					255	
Leu	Pro	Asn	Gly	Asp	Gly	Thr	Tyr	Gln	Gly	Trp	Ile	Thr	Leu	Ala	Val
			260					265					270		
Pro	Pro	Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	Gln	Val	Glu	His	Pro	Gly
		275					280					285			
Leu	Asp	Gln	Pro	Leu	Ile	Val	Ile	Trp	Glu	Pro	Ser	Pro	Ser	Gly	Thr
				290		295					300				
Leu	Val	Ile	Gly	Val	Ile	Ser	Gly	Ile	Ala	Val	Phe	Val	Val	Ile	Leu
305					310					315					320
Phe	Ile	Gly	Ile	Leu	Phe	Ile	Ile	Leu	Arg	Lys	Arg	Gln	Gly	Ser	Arg
				325					330					335	
Gly	Ala	Met	Gly	His	Tyr	Val	Leu	Ala	Glu	Arg	Glu				
			340					345							

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10825 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: join(361..436, 3762..4025, 4235..4510, 5606..5881, 6040..6153, 7107..7147)
- (D) OTHER INFORMATION: /product= "Hereditary Hemochromatosis (HH) protein containing both the 24d1

and 24d2 mutations"
 /note= "Hereditary Hemochromatosis (HH)
 gene containing a combination of both
 24d1 and 24d2 alleles"

(ix) FEATURE:

(A) NAME/KEY: -
 (B) LOCATION: 140..7319
 (D) OTHER INFORMATION: /note= "start and stop positions for
 cDNA containing a combination of both
 24d1 and 24d2 alleles
 (SEQ ID NO:12)"

(ix) FEATURE:

(A) NAME/KEY: -
 (B) LOCATION: 3852..3891
 (D) OTHER INFORMATION: /note= "start and stop positions for
 genomic sequence surrounding variant
 for 24d2(G) allele (SEQ ID NO:42)"

(ix) FEATURE:

(A) NAME/KEY: -
 (B) LOCATION: 5507..6023
 (D) OTHER INFORMATION: /note= "start and stop positions for
 genomic sequence surrounding variant
 for 24d1(A) allele (SEQ ID NO:21)"

(ix) FEATURE:

(A) NAME/KEY: allele
 (B) LOCATION: replace(3872, "g")
 (D) OTHER INFORMATION: /phenotype= "Hereditary Hemochromatosis
 (HH)"
 /label= 24d2

(ix) FEATURE:

(A) NAME/KEY: allele
 (B) LOCATION: replace(5834, "a")
 (D) OTHER INFORMATION: /phenotype= "Hereditary Hemochromatosis
 (HH)"
 /label= 24d1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TCTAAGGTTG AGATAAAATT TTAAATGTA TGATTGAATT TTGAAATCA TAAATATTTA	60
AATATCTAAA GTTCAGATCA GAACATTGCG AAGCTACTTT CCCCAATCAA CAACACCCCT	120
TCAGGATTTA AAAACCAAGG GGGACACTGG ATCACCTAGT GTTTCACAAG CAGGTACCTT	180
CTGCTGTAGG AGAGAGAGAA CTAAAGTTCT GAAAGACCTG TTGCTTTTCA CCAGGAAGTT	240
TTACTGGGCA TCTCCTGAGC CTAGGCAATA GCTGTAGGGT GACTTCTGGA GCCATCCCCG	300
TTTCCCCGCC CCCCAAAGA AGCGGAGATT TAACGGGGAC GTGCGGCCAG AGCTGGGGAA	360
ATG GGC CCG CGA GCC AGG CCG GCG CTT CTC CTC CTG ATG CTT TTG CAG	408
Met Gly Pro Arg Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln	
1 5 10 15	
ACC GCG GTC CTG CAG GGG CGC TTG CTG C GTGAGTCCGA GGGCTGCGGG	456
Thr Ala Val Leu Gln Gly Arg Leu Leu	

20

25

CGAACTAGGG	GCGCGGCGGG	GGTGGAAAAA	TCGAACTAG	CTTTTTCTTT	GCGCTTGGA	516
GTTTGCTAAC	TTTGAGGAC	CTGCTCAACC	CTATCCGAA	GCCCCTCTCC	CTACTTTCTG	576
CGTCCAGACC	CCGTGAGGGA	GTGCCTACCA	CTGAACTGCA	GATAGGGGTC	CCTCGCCCCA	636
GGACCTGCCC	CCTCCCCCGG	CTGTCCCGGC	TCTGCGGAGT	GACTTTTGGA	ACCGCCCCT	696
CCCTTCCCCC	AACTAGAATG	CTTTTAAATA	AATCTCGTAG	TTCCTCACTT	GAGCTGAGCT	756
AAGCCTGGGG	CTCCTTGAAC	CTGGAACCTG	GGTTTATTTT	CAATGTCAGC	TGTGCAGTTT	816
TTTCCCCAGT	CATCTCCAAA	CAGGAAGTTC	TTCCCTGAGT	GCTTGCCGAG	AAGGCTGAGC	876
AAACCCACAG	CAGGATCCGC	ACGGGGTTTC	CACCTCAGAA	CGAATGCGTT	GGGCGGTGGG	936
GGCGCGAAAG	AGTGGCGTTG	GGGATCTGAA	TTCTTCACCA	TTCCACCCAC	TTTTGGTGAG	996
ACCTGGGGTG	GAGGTCTCTA	GGGTGGGAGG	CTCCTGAGAG	AGGCCTACCT	CGGGCCTTTC	1056
CCCACTCTTG	GCAATTGTTT	TTTTGCCTGG	AAAATTAAGT	ATATGTTAGT	TTTGAACGTT	1116
TGAACTGAAC	AATTCTCTTT	TCGGCTAGGC	TTTATTGATT	TGCAATGTGC	TGTGTAATTA	1176
AGAGGCCTCT	CTACAAAGTA	CTGATAATGA	ACATGTAAGC	AATGCACTCA	CTTCTAAGTT	1236
ACATTCATAT	CTGATCTTAT	TTGATTTTCA	CTAGGCATAG	GGAGGTAGGA	GCTAATAATA	1296
CGTTTATTTT	ACTAGAAGTT	AACCTGGAAT	CAGATTATAT	AACTCTTTTC	AGGTTACAAA	1356
GAACATAAAT	AATCTGGTTT	TCTGATGTTA	TTTCAAGTAC	TACAGCTGCT	TCTAATCTTA	1416
GTTGACAGTG	ATTTTGCCCT	GTAGTGTAGC	ACAGTGTTCT	GTGGGTCACA	CGCCGGCCTC	1476
AGCACAGCAC	TTTGAGTTTT	GGTACTACGT	GTATCCACAT	TTTACACATG	ACAAGAATGA	1536
GGCATGGCAC	GGCCTGCTTC	CTGGCAAATT	TATTCAATGG	TACACTGGGC	TTTGGTGGCA	1596
GAGCTCATGT	CTCCACTTCA	TAGCTATGAT	TCTTAAACAT	CACACTGCAT	TAGAGGTGTA	1656
ATAATAAAAT	TTCATGTTGA	GCAGAAATAT	TCATTGTTTA	CAAGTGTAAT	TGAGTCCCAG	1716
CCATGTGTTG	CACTGTTCAA	GCCCCAAGGG	AGAGAGCAGG	GAAACAAGTC	TTTACCCTTT	1776
GATATTTTGC	ATTCTAGTGG	GAGAGATGAC	AATAAGCAAA	TGAGCAGAAA	GATATACAAC	1836
ATCAGGAAAT	CATGGGTGTT	GTGAGAAGCA	GAGAAGTCAG	GGCAAGTCAC	TCTGGGGCTG	1896
ACACTTGAGC	AGAGACATGA	AGGAAATAAG	AATGATATTG	ACTGGGAGCA	GTATTTCCCA	1956
GGCAAACTGA	GTGGGCCTGG	CAAGTTGGAT	TAAAAAGCGG	GTTTTCTCAG	CACTACTCAT	2016
GTGTGTGTGT	GTGGGGGGGG	GGGGCGGCGT	GGGGGTGGGA	AGGGGGACTA	CCATCTGCAT	2076
GTAGGATGTC	TAGCAGTATC	CTGTCTCTCC	TACTCACTAG	GTGCTAGGAG	CACTCCCCCA	2136
GTCTTGACAA	CCAAAAATGT	CTCTAAACTT	TGCCACATGT	CACCTAGTAG	ACAAACTCCT	2196
GGTTAAGAAG	CTCGGGTTGA	AAAAAATAAA	CAAGTAGTGC	TGGGGAGTAG	AGGCCAAGAA	2256

GTAGGTAATG GGCTCAGAAG AGGAGCCACA AACAAGGTTG TGCAGGCGCC TGTAGGCTGT 2316
 GGTGTGAATT CTAGCCAAGG AGTAACAGTG ATCTGTCACA GGCTTTTAAA AGATTGCTCT 2376
 GGCTGCTATG TGGAAAGCAG AATGAAGGGA GCAACAGTAA AAGCAGGGAG CCCAGCCAGG 2436
 AAGCTGTTAC ACAGTCCAGG CAAGAGGTAG TGGAGTGGGC TGGGTGGGAA CAGAAAAGGG 2496
 AGTGACAAAC CATTGTCTCC TGAATATATT CTGAAGGAAG TTGCTGAAGG ATTCTATGTT 2556
 GTGTGAGAGA AAGAGAAGAA TTGGCTGGGT GTAGTAGCTC ATGCCAAGGA GGAGGCCAAG 2616
 GAGAGCAGAT TCCTGAGCTC AGGAGTTCAA GACCAGCCTG GGCAACACAG CAAAACCCCT 2676
 TCTCTACAAA AAATACAAAA ATTAGCTGGG TGTGGTGGCA TGCACCTGTG ATCCTAGCTA 2736
 CTCGGGAGGC TGAGGTGGAG GGTATTGCTT GAGCCCAGGA AGTTGAGGCT GCAGTGAGCC 2796
 ATGACTGTGC CACTGTACTT CAGCCTAGGT GACAGAGCAA GACCCTGTCT CCCCTGACCC 2856
 CCTGAAAAAG AGAAGAGTTA AAGTTGACTT TGTTCTTTAT TTTAATTTTA TTGGCCTGAG 2916
 CAGTGGGGTA ATTGGCAATG CCATTTCTGA GATGGTGAAG GCAGAGGAAA GAGCAGTTTG 2976
 GGGTAAATCA AGGATCTGCA TTTGGGACAT GTTAAGTTTG AGATTCCAGT CAGGCTTCCA 3036
 AGTGGTGAGG CCACATAGGC AGTTCAGTGT AAGAATTCAG GACCAAGGCT GGGCACGGTG 3096
 GCTCACTTCT GTAATCCAG CACTTTGGTG GCTGAGGCAG GTAGATCATT TGAGGTCAGG 3156
 AGTTTGAGAC AAGCTTGGCC AACATGGTGA AACCCCATGT CTAATAAAAA TACAAAAATT 3216
 AGCCTGGTGT GGTGGCGCAC GCCTATAGTC CCAGGTTTTT AGGAGGCTTA GGTAGGAGAA 3276
 TCCCTTGAAC CCAGGAGGTG CAGGTTGCAG TGAGCTGAGA TTGTGCCACT GCACTCCAGC 3336
 CTGGGTGATA GAGTGAGACT CTGTCTCAAA AAAAAAAAAA AAAAAAAAAA AAAAACTGA 3396
 AGGAATTATT CCTCAGGATT TGGGTCTAAT TTGCCCTGAG CACCAACTCC TGAGTTCAAC 3456
 TACCATGGCT AGACACACCT TAACATTTTC TAGAATCCAC CAGCTTTAGT GGAGTCTGTC 3516
 TAATCATGAG TATTGGAATA GGATCTGGGG GCAGTGAGGG GGTGGCAGCC ACGTGTGGCA 3576
 GAGAAAAGCA CACAAGGAAA GAGCACCCAG GACTGTCATA TGGAAGAAAAG ACAGGACTGC 3636
 AACTCACCTC TCACAAAATG AGGACCAGAC ACAGCTGATG GTATGAGTTG ATGCAGGTGT 3696
 GTGGAGCCTC AACATCCTGC TCCCCTCCTA CTACACATGG TTAAGGCCTG TTGCTCTGTC 3756
 TCCAG GT TCA CAC TCT CTG CAC TAC CTC TTC ATG GGT GCC TCA GAG 3802
 Arg Ser His Ser Leu His Tyr Leu Phe Met Gly Ala Ser Glu
 30 35
 CAG GAC CTT GGT CTT TCC TTG TTT GAA GCT TTG GGC TAC GTG GAT GAC 3850
 Gln Asp Leu Gly Leu Ser Leu Phe Glu Ala Leu Gly Tyr Val Asp Asp 55
 40 45 50
 CAG CTG TTC GTG TTC TAT GAT GAT GAG AGT CGC CGT GTG GAG CCC CGA 3898
 Gln Leu Phe Val Phe Tyr Asp Asp Glu Ser Arg Arg Val Glu Pro Arg 70
 60 65 70

ACT CCA TGG GTT TCC AGT AGA ATT TCA AGC CAG ATG TGG CTG CAG CTG 3946
 Thr Pro Trp Val Ser Ser Arg Ile Ser Ser Gln Met Trp Leu Gln Leu
 75 80 85

AGT CAG AGT CTG AAA GGG TGG GAT CAC ATG TTC ACT GTT GAC TTC TGG 3994
 Ser Gln Ser Leu Lys Gly Trp Asp His Met Phe Thr Val Asp Phe Trp
 90 95 100

ACT ATT ATG GAA AAT CAC AAC CAC AGC AAG G GTATGTGGAG AGGGGGCCTC 4045
 Thr Ile Met Glu Asn His Asn His Ser Lys
 105 110

ACCTTCCTGA GGTGTGTCAGA GCTTTTCATC TTTTCATGCA TCTTGAAGGA AACAGCTGGA 4105

AGTCTGAGGT CTTGTGGGAG CAGGGAAGAG GGAAGGAATT TGCTTCCTGA GATCATTTGG 4165

TCCTTGGGGA TGGTGGAAAT AGGGACCTAT TCCTTTGGTT GCAGTTAACA AGGCTGGGGA 4225

TTTTTCAG AG TCC CAC ACC CTG CAG GTC ATC CTG GGC TGT GAA ATG 4272
 Glu Ser His Thr Leu Gln Val Ile Leu Gly Cys Glu Met
 115 120 125

CAA GAA GAC AAC AGT ACC GAG GGC TAC TGG AAG TAC GGG TAT GAT GGG 4320
 Gln Glu Asp Asn Ser Thr Glu Gly Tyr Trp Lys Tyr Gly Tyr Asp Gly
 130 135 140

CAG GAC CAC CTT GAA TTC TGC CCT GAC ACA CTG GAT TGG AGA GCA GCA 4368
 Gln Asp His Leu Glu Phe Cys Pro Asp Thr Leu Asp Trp Arg Ala Ala
 145 150 155

GAA CCC AGG GCC TGG CCC ACC AAG CTG GAG TGG GAA AGG CAC AAG ATT 4416
 Glu Pro Arg Ala Trp Pro Thr Lys Leu Glu Trp Glu Arg His Lys Ile
 160 165 170

CGG GCC AGG CAG AAC AGG GCC TAC CTG GAG AGG GAC TGC CCT GCA CAG 4464
 Arg Ala Arg Gln Asn Arg Ala Tyr Leu Glu Arg Asp Cys Pro Ala Gln
 175 180 185 190

CTG CAG CAG TTG CTG GAG CTG GGG AGA GGT GTT TTG GAC CAA CAA G 4510
 Leu Gln Gln Leu Glu Leu Gly Arg Gly Val Leu Asp Gln Gln
 195 200 205

GTATGGTGGG AACACACTTC TGCCCCATA CTCTAGTGGC AGAGTGGAGG AGGTTGCAGG 4570

GCACGGAATC CCTGGTTGGA GTTTCAGAGG TGGCTGAGGC TGTGTGCCTC TCCAAATTCT 4630

GGGAAAGGGAC TTTCTCAATC CTAGAGTCTC TACCTTATAA TTGAGATGTA TGAGACAGCC 4690

ACAAGTCATG GGTTTAATTT CTTTTCTCCA TGCATATGGC TCAAAGGGAA GTGTCTATGG 4750

CCCTTGCTTT TTATTTAACC AATAATCTTT TGTATATTTA TACCTGTTAA AAATTCAGAA 4810

ATGTCAAGGC CGGGCACGGT GGCTCACCCC TGTAATCCCA GCACTTTGGG AGGCCGAGGC 4870

GGGTGGTCAC AAGGTCAGGA GTTTGAGACC AGCCTGACCA ACATGGTGAA ACCCGTCTCT 4930

AAAAAAATAC AAAAATTAGC TGGTCACAGT CATGCGCACC TGTAAGTCCCA GCTAATTGGA 4990

AGGCTGAGGC AGGAGCATCG CTTGAACCTG GGAAGCGGAA GTTGCACTGA GCCAAGATCG 5050

CGCCACTGCA CTCCAGCCTA GGCAGCAGAG TGAGACTCCA TCTTAAAAAA AAAAAAAAAA 5110

AAAAAAGAG	AATTCAGAGA	TCTCAGCTAT	CATATGAATA	CCAGGACAAA	ATATCAAGTG	5170
AGGCCACTTA	TCAGAGTAGA	AGAATCCTTT	AGGTTAAAG	TTTCTTTCAT	AGAACATAGC	5230
AATAATCACT	GAAGCTACCT	ATCTTACAAG	TCCGCTTCTT	ATAACAATGC	CTCCTAGGTT	5290
GACCCAGGTG	AAACTGACCA	TCTGTATTCA	ATCATTTTCA	ATGCACATAA	AGGGCAATTT	5350
TATCTATCAG	AACAAAGAAC	ATGGGTAAAC	GATATGTATA	TTTACATGTG	AGGAGAACAA	5410
GCTGATCTGA	CTGCTCTCCA	AGTGACACTG	TGTTAGAGTC	CAATCTTAGG	ACACAAAATG	5470
GTGTCTCTCC	TGTAGCTTGT	TTTTTTCTGA	AAAGGGTATT	TCCTTCCTCC	AACCTATAGA	5530
AGGAAGTGAA	AGTTCCAGTC	TTCTGGCAA	GGGTAAACAG	ATCCCTCTC	CTCATCCTTC	5590
CTCTTTCCTG	TCAAG	TG CCT CCT TTG	GTG AAG GTG ACA	CAT CAT GTG ACC		5640
		Val Pro Pro Leu	Val Lys Val Thr	His His Val Thr		
			210	215		
TCT TCA GTG ACC ACT CTA CGG TGT CGG GCC TTG AAC TAC TAC CCC CAG						5688
Ser Ser Val Thr Thr Leu Arg Cys Arg Ala Leu Asn Tyr Tyr Pro Gln						
	220		225		230	
AAC ATC ACC ATG AAG TGG CTG AAG GAT AAG CAG CCA ATG GAT GCC AAG						5736
Asn Ile Thr Met Lys Trp Leu Lys Asp Lys Gln Pro Met Asp Ala Lys						
	235		240		245	
GAG TTC GAA CCT AAA GAC GTA TTG CCC AAT GGG GAT GGG ACC TAC CAG						5784
Glu Phe Glu Pro Lys Asp Val Leu Pro Asn Gly Asp Gly Thr Tyr Gln						
	250		255		260	265
GGC TGG ATA ACC TTG GCT GTA CCC CCT GGG GAA GAG CAG AGA TAT ACG						5832
Gly Trp Ile Thr Leu Ala Val Pro Pro Gly Glu Glu Gln Arg Tyr Thr						
		270			275	280
TAC CAG GTG GAG CAC CCA GGC CTG GAT CAG CCC CTC ATT GTG ATC TGG G						5881
Tyr Gln Val Glu His Pro Gly Leu Asp Gln Pro Leu Ile Val Ile Trp						
		285			290	295
GTATGTGACT GATGAGAGCC AGGAGCTGAG AAAATCTATT GGGGGTTGAG AGGAGTGCCT						5941
GAGGAGGTAA TTATGGCAGT GAGATGAGGA TCTGCTCTTT GTTAGGGGGT GGGCTGAGGG						6001
TGGCAATCAA AGGCTTTAAC TTGCTTTTTC TGTTTTAG AG CCC TCA CCG TCT						6053
					Glu Pro Ser Pro Ser	
					300	
GGC ACC CTA GTC ATT GGA GTC ATC AGT GGA ATT GCT GTT TTT GTC GTC						6101
Gly Thr Leu Val Ile Gly Val Ile Ser Gly Ile Ala Val Phe Val Val						
	305				310	315
ATC TTG TTC ATT GGA ATT TTG TTC ATA ATA TTA AGG AAG AGG CAG GGT						6149
Ile Leu Phe Ile Gly Ile Leu Phe Ile Ile Leu Arg Lys Arg Gln Gly						
	320				325	330
TCA A GTGAGTAGGA ACAAGGGGGA AGTCTCTTAG TACCTCTGCC CCAGGGCACA						6203
Ser						
335						
GTGGGAAGAG GGGCAGAGGG GATCTGGCAT CCATGGGAAG CATTTTTCTC ATTTATATTC						6263

TTTGGGGACA CCAGCAGCTC CCTGGGAGAC AGAAAATAAT GGTTCCTCCC AGAATGAAAG 6323
 TCTCTAATTC AACAAACATC TTCAGAGCAC CTACTATTTT GCAAGAGCTG TTTAAGGTAG 6383
 TACAGGGGGCT TTGAGGTTGA GAAGTCACTG TGGCTATTCT CAGAACCCAA ATCTGGTAGG 6443
 GAATGAAATT GATAGCAAGT AAATGTAGTT AAAGAAGACC CCATGAGGTC CTAAAGCAGG 6503
 CAGGAAGCAA ATGCTTAGGG TGTCAAAGGA AAGAATGATC ACATTCAGCT GGGGATCAAG 6563
 ATAGCCTTCT GGATCTTGAA GGAGAAGCTG GATTCCATTA GGTGAGGTTG AAGATGATGG 6623
 GAGGTCTACA CAGACGGAGC AACCATGCCA AGTAGGAGAG TATAAGGCAT ACTGGGAGAT 6683
 TAGAAATAAT TACTGTACCT TAACCCTGAG TTTGCGTAGC TATCACTCAC CAATTATGCA 6743
 TTTCTACCCC CTGAACATCT GTGGTGTAGG GAAAAGAGAA TCAGAAAGAA GCCAGCTCAT 6803
 ACAGAGTCCA AGGGTCTTTT GGGATATTGG GTTATGATCA CTGGGGTGTC ATTGAAGGAT 6863
 CCTAAGAAAG GAGGACCACG ATCTCCCTTA TATGGTGAAT GTGTTGTAA GAAGTTAGAT 6923
 GAGAGGTGAG GAGACCAGTT AGAAAGCCAA TAAGCATTTT CAGATGAGAG ATAATGGTTC 6983
 TTGAAATCCA ATAGTGCCCA GGTCTAAATT GAGATGGGTG AATGAGGAAA ATAAGGAAGA 7043
 GAGAAGAGGC AAGATGGTGC CTAGGTTTGT GATGCCTCTT TCCTGGGTCT CTTGTCTCCA 7103
 CAG GA GGA GCC ATG GGG CAC TAC GTC TTA GCT GAA CGT GAG 7144
 Arg Gly Ala Met Gly His Tyr Val Leu Ala Glu Arg Glu
 340 345
 TGACACGCAG CCTGCAGACT CACTGTGGGA AGGAGACAAA ACTAGAGACT CAAAGAGGGA 7204
 GTGCATTTAT GAGCTCTTCA TGTTTCAGGA GAGAGTTGAA CCTAAACATA GAAATTGCCT 7264
 GACGAACTCC TTGATTTTAG CCTTCTCTGT TCATTTCTCTC AAAAAGATTT CCCCATTAG 7324
 GTTTCTGAGT TCCTGCATGC CGGTGATCCC TAGCTGTGAC CTCTCCCCTG GAACTGTCTC 7384
 TCATGAACCT CAAGCTGCAT CTAGAGGCTT CCTTCATTTT CTCCGTCACC TCAGAGACAT 7444
 ACACCTATGT CATTTTATTT CCTATTTTTG GAAGAGGACT CCTTAAATTT GGGGGACTTA 7504
 CATGATTCAT TTTAACATCT GAGAAAAGCT TTGAACCCTG GGACGTGGCT AGTCATAACC 7564
 TTACCAGATT TTTACACATG TATCTATGCA TTTTCTGGAC CCGTTCAACT TTTCTTTTGA 7624
 ATCCTCTCTC TGTGTTACCC AGTAACTCAT CTGTCACCAA GCCTTGGGGA TTCTTCCATC 7684
 TGATTGTGAT GTGAGTTGCA CAGCTATGAA GGCTGTACAC TGCACGAATG GAAGAGGCAC 7744
 CTGTCCCAGA AAAAGCATCA TGGCTATCTG TGGGTAGTAT GATGGGTGTT TTTAGCAGGT 7804
 AGGAGGCAAA TATCTTGAAA GGGGTTGTGA AGAGGTGTTT TTTCTAATTG GCATGAAGGT 7864
 GTCATACAGA TTTGCAAAGT TTAATGGTGC CTTCATTTGG GATGCTACTC TAGTATTCCA 7924
 GACCTGAAGA ATCACAATAA TTTTCTACCT GGTCTCTCCT TGTTCGATA ATGAAAATTA 7984
 TGATAAGGAT GATAAAAGCA CTTACTTCGT GTCCGACTCT TCTGAGCACC TACTTACATG 8044

CATTACTGCA	TGCACTTCTT	ACAATAATTC	TATGAGATAG	GTACTATTAT	CCCCATTTCT	8104
TTTTTTAAATG	AAGAAAGTGA	AGTAGGCCGG	GCACGGTGGC	TCACGCCTGT	AATCCCAGCA	8164
CTTTGGGAGG	CCAAAGCGGG	TGGATCACGA	GGTCAGGAGA	TCGAGACCAT	CCTGGCTAAC	8224
ATGGTGAAAC	CCCATCTCTA	ATAAAAATAC	AAAAAATTAG	CTGGGCGTGG	TGGCAGACGC	8284
CTGTAGTCCC	AGCTACTCGG	AAGGCTGAGG	CAGGAGAATG	GCATGAACCC	AGGAGGCAGA	8344
GCTTGCAGTG	AGCCGAGTTT	GCGCCACTGC	ACTCCAGCCT	AGGTGACAGA	GTGAGACTCC	8404
ATCTCAAAAA	AATAAAAATA	AAAATAAAAA	AATGAAAAAA	AAAAGAAAGT	GAAGTATAGA	8464
GTATCTCATA	GTTTGTCACT	GATAGAAACA	GGTTTCAAAC	TCAGTCAATC	TGACCGTTTG	8524
ATACATCTCA	GACACCACTA	CATTCACTAG	TTTAGATGCC	TAGAATAAAT	AGAGAAGGAA	8584
GGAGATGGCT	CTTCTCTTGT	CTCATTGTGT	TTCTTCTGAG	TGAGCTTGAA	TCACATGAAG	8644
GGGAACAGCA	GAAAACAACC	AACTGATCCT	CAGCTGTCAT	GTTTCCTTTA	AAAGTCCCTG	8704
AAGGAAGGTC	CTGGAATGTG	ACTCCCTTGC	TCCTCTGTTG	CTCTCTTTGG	CATTCAATTC	8764
TTTGGAACCT	ACGCAAGGAC	TGTAATTGGT	GGGGACAGCT	AGTGGCCCTG	CTGGGCTTCA	8824
CACACGGTGT	CCTCCCTAGG	CCAGTGCCTC	TGGAGTCAGA	ACTCTGGTGG	TATTTCCCTC	8884
AATGAAGTGG	AGTAAGCTCT	CTCATTTTGA	GATGGTATAA	TGGAAGCCAC	CAAGTGGCTT	8944
AGAGGATGCC	CAGGTCCTTC	CATGGAGCCA	CTGGGGTTCC	GGTGACATT	AAAAAAAAAA	9004
TCTAACCAGG	ACATTCAGGA	ATTGCTAGAT	TCTGGGAAAT	CAGTTCACCA	TGTTCAAAAG	9064
AGTCTTTTTT	TTTTTTTTGA	GACTCTATTG	CCCAGGCTGG	AGTGCAATGG	CATGATCTCG	9124
GCTCACTGTA	ACCTCTGCCT	CCCAGGTTCA	AGCGATTCTC	CTGTCTCAGC	CTCCCAAGTA	9184
GCTGGGATTA	CAGGCGTGCA	CCACCATGCC	CGGCTAATTT	TTGTATTTT	AGTAGAGACA	9244
GGGTTTCACC	ATGTTGGCCA	GGCTGGTCTC	GAACCTCTCCT	GACCTCGTGA	TCCGCCTGCC	9304
TCGGCCTCCC	AAAGTGCTGA	GATTACAGGT	GTGAGCCACC	CTGCCCAGCC	GTCAAAAGAG	9364
TCTTAATATA	TATATCCAGA	TGGCATGTGT	TTACTTTATG	TTACTACATG	CACTTGGCTG	9424
CATAAATGTG	GTACAAGCAT	TCTGTCTTGA	AGGGCAGGTG	CTTCAGGATA	CCATATACAG	9484
CTCAGAAGTT	TCTTCTTTAG	GCATTAAATT	TTAGCAAAGA	TATCTCATCT	CTTCTTTTAA	9544
ACCATTTTCT	TTTTTTGTGG	TTAGAAAAGT	TATGTAGAAA	AAAGTAAATG	TGATTTACGC	9604
TCATTGTAGA	AAAGCTATAA	AATGAATACA	ATTAAAGCTG	TTATTTAATT	AGCCAGTGAA	9664
AAACTATTAA	CAACTTGTCT	ATTACCTGTT	AGTATTATTG	TTGCATTAAA	AATGCATATA	9724
CTTTAATAAA	TGTATATTGT	ATTGTATACT	GCATGATTTT	ATTGAAGTTC	TTGTTTCATCT	9784
TGTGTATATA	CTTAATCGCT	TTGTCATTTT	GGAGACATTT	ATTTTGCTTC	TAATTTCTTT	9844
ACATTTTGTC	TTACGGAATA	TTTTCATTCA	ACTGTGGTAG	CCGAATTAAT	CGTGTTTCTT	9904

CACTCTAGGG ACATTGTCGT CTAAGTTGTA AGACATTGGT TATTTTACCA GCAAACCATT 9964
 CTGAAAGCAT ATGACAAATT ATTTCTCTCT TAATATCTTA CTATACTGAA AGCAGACTGC 10024
 TATAAGGCTT CACTTACTCT TCTACCTCAT AAGGAATATG TTACAATTAA TTTATTAGGT 10084
 AAGCATTTGT TTTATATTGG TTTTATTTCA CCTGGGCTGA GATTTCAAGA AACACCCCAG 10144
 TCTTCACAGT AACACATTTT ACTAACACAT TTAATAACA TCAGCAACTG TGGCCTGTTA 10204
 ATTTTTTTTAA TAGAAATTTT AAGTCCTCAT TTTCTTTTCG TGTTTTTTAA GCTTAATTTT 10264
 TCTGGCTTTA TTCATAAATT CTTAAGGTCA ACTACATTTG AAAAATCAAA GACCTGCATT 10324
 TTAAATTCTT ATTCACCTCT GGCAAAACCA TTCACAAACC ATGGTAGTAA AGAGAAGGGT 10384
 GACACCTGGT GGCCATAGGT AAATGTACCA CGGTGGTCCG GTGACCAGAG ATGCAGCGCT 10444
 GAGGGTTTTT CTGAAGGTAA AGGAATAAAG AATGGGTGGA GGGGCGTGCA CTGGAAATCA 10504
 CTTGTAGAGA AAAGCCCCTG AAAATTTGAG AAAACAAACA AGAACTACT TACCAGCTAT 10564
 TTGAATTGCT GGAATCACAG GCCATTGCTG AGCTGCCTGA ACTGGGAACA CAACAGAAGG 10624
 AAAACAAACC ACTCTGATAA TCATTGAGTC AAGTACAGCA GGTGATTGAG GACTGCTGAG 10684
 AGGTACAGGC CAAAATTCTT ATGTTGTATT ATAATAATGT CATCTTATAA TACTGTCTAGT 10744
 ATTTTATAAA ACATTCTTCA CAACTCACA CACATTTAAA AACAAAACAC TGTCTCTAAA 10804
 ATCCCCAAAT TTTTCATAAA C 10825

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 348 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Gly Pro Arg Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln
 1 5 10 15
 Thr Ala Val Leu Gln Gly Arg Leu Leu Arg Ser His Ser Leu His Tyr
 20 25 30
 Leu Phe Met Gly Ala Ser Glu Gln Asp Leu Gly Leu Ser Leu Phe Glu
 35 40 45
 Ala Leu Gly Tyr Val Asp Asp Gln Leu Phe Val Phe Tyr Asp Asp Glu
 50 55 60
 Ser Arg Arg Val Glu Pro Arg Thr Pro Trp Val Ser Ser Arg Ile Ser
 65 70 75 80
 Ser Gln Met Trp Leu Gln Leu Ser Gln Ser Leu Lys Gly Trp Asp His
 85 90 95

Met Phe Thr Val Asp Phe Trp Thr Ile Met Glu Asn His Asn His Ser
 100 105 110
 Lys Glu Ser His Thr Leu Gln Val Ile Leu Gly Cys Glu Met Gln Glu
 115 120 125
 Asp Asn Ser Thr Glu Gly Tyr Trp Lys Tyr Gly Tyr Asp Gly Gln Asp
 130 135 140
 His Leu Glu Phe Cys Pro Asp Thr Leu Asp Trp Arg Ala Ala Glu Pro
 145 150 155 160
 Arg Ala Trp Pro Thr Lys Leu Glu Trp Glu Arg His Lys Ile Arg Ala
 165 170 175
 Arg Gln Asn Arg Ala Tyr Leu Glu Arg Asp Cys Pro Ala Gln Leu Gln
 180 185 190
 Gln Leu Leu Glu Leu Gly Arg Gly Val Leu Asp Gln Gln Val Pro Pro
 195 200 205
 Leu Val Lys Val Thr His His Val Thr Ser Ser Val Thr Thr Leu Arg
 210 215 220
 Cys Arg Ala Leu Asn Tyr Tyr Pro Gln Asn Ile Thr Met Lys Trp Leu
 225 230 235 240
 Lys Asp Lys Gln Pro Met Asp Ala Lys Glu Phe Glu Pro Lys Asp Val
 245 250 255
 Leu Pro Asn Gly Asp Gly Thr Tyr Gln Gly Trp Ile Thr Leu Ala Val
 260 265 270
 Pro Pro Gly Glu Glu Gln Arg Tyr Thr Tyr Gln Val Glu His Pro Gly
 275 280 285
 Leu Asp Gln Pro Leu Ile Val Ile Trp Glu Pro Ser Pro Ser Gly Thr
 290 295 300
 Leu Val Ile Gly Val Ile Ser Gly Ile Ala Val Phe Val Val Ile Leu
 305 310 315 320
 Phe Ile Gly Ile Leu Phe Ile Ile Leu Arg Lys Arg Gln Gly Ser Arg
 325 330 335
 Gly Ala Met Gly His Tyr Val Leu Ala Glu Arg Glu
 340 345

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1440 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS

(B) LOCATION: 222..1268

(ix) FEATURE:

(A) NAME/KEY: allele
(B) LOCATION: replace(408, "c")
(D) OTHER INFORMATION: /phenotype= "normal or wild-type
(unaffected)"
/label= 24d2

(ix) FEATURE:

(A) NAME/KEY: allele
(B) LOCATION: replace(414, "a")
(D) OTHER INFORMATION: /phenotype= "normal or wild-type
(unaffected)"
/label= 24d7

(ix) FEATURE:

(A) NAME/KEY: allele
(B) LOCATION: replace(1066, "g")
(D) OTHER INFORMATION: /phenotype= "normal or wild-type
(unaffected)"
/label= 24d1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GGGGACACTG GATCACCTAG TGTTTCACAA GCAGGTACCT TCTGCTGTAG GAGAGAGAGA	60
ACTAAAGTTC TGAAAGACCT GTTGCTTTTC ACCAGGAAGT TTTACTGGGC ATCTCCTGAG	120
CCTAGGCAAT AGCTGTAGGG TGACTTCTGG AGCCATCCCC GTTTCCTCCG CCCCCAAAAG	180
AAGCGGAGAT TTAACGGGGA CGTGCGGCCA GAGCTGGGGA A ATG GGC CCG CGA	233
Met Gly Pro Arg	
1	
GCC AGG CCG GCG CTT CTC CTC CTG ATG CTT TTG CAG ACC GCG GTC CTG	281
Ala Arg Pro Ala Leu Leu Leu Met Leu Leu Gln Thr Ala Val Leu	
5 10 15 20	
CAG GGG CGC TTG CTG CGT TCA CAC TCT CTG CAC TAC CTC TTC ATG GGT	329
Gln Gly Arg Leu Leu Arg Ser His Ser Leu His Tyr Leu Phe Met Gly	
25 30 35	
GCC TCA GAG CAG GAC CTT GGT CTT TCC TTG TTT GAA GCT TTG GGC TAC	377
Ala Ser Glu Gln Asp Leu Gly Leu Ser Leu Phe Glu Ala Leu Gly Tyr	
40 45 50	
GTG GAT GAC CAG CTG TTC GTG TTC TAT GAT CAT GAG AGT CGC CGT GTG	425
Val Asp Asp Gln Leu Phe Val Phe Tyr Asp His Glu Ser Arg Arg Val	
55 60 65	
GAG CCC CGA ACT CCA TGG GTT TCC AGT AGA ATT TCA AGC CAG ATG TGG	473
Glu Pro Arg Thr Pro Trp Val Ser Ser Arg Ile Ser Ser Gln Met Trp	
70 75 80	
CTG CAG CTG AGT CAG AGT CTG AAA GGG TGG GAT CAC ATG TTC ACT GTT	521
Leu Gln Leu Ser Gln Ser Leu Lys Gly Trp Asp His Met Phe Thr Val	
85 90 95 100	
GAC TTC TGG ACT ATT ATG GAA AAT CAC AAC CAC AGC AAG GAG TCC CAC	569

Asp	Phe	Trp	Thr	Ile	Met	Glu	Asn	His	Asn	His	Ser	Lys	Glu	Ser	His	
				105					110					115		
ACC	CTG	CAG	GTC	ATC	CTG	GGC	TGT	GAA	ATG	CAA	GAA	GAC	AAC	AGT	ACC	617
Thr	Leu	Gln	Val	Ile	Leu	Gly	Cys	Glu	Met	Gln	Glu	Asp	Asn	Ser	Thr	
			120					125					130			
GAG	GGC	TAC	TGG	AAG	TAC	GGG	TAT	GAT	GGG	CAG	GAC	CAC	CTT	GAA	TTC	665
Glu	Gly	Tyr	Trp	Lys	Tyr	Gly	Tyr	Asp	Gly	Gln	Asp	His	Leu	Glu	Phe	
			135				140					145				
TGC	CCT	GAC	ACA	CTG	GAT	TGG	AGA	GCA	GCA	GAA	CCC	AGG	GCC	TGG	CCC	713
Cys	Pro	Asp	Thr	Leu	Asp	Trp	Arg	Ala	Ala	Glu	Pro	Arg	Ala	Trp	Pro	
	150					155					160					
ACC	AAG	CTG	GAG	TGG	GAA	AGG	CAC	AAG	ATT	CGG	GCC	AGG	CAG	AAC	AGG	761
Thr	Lys	Leu	Glu	Trp	Glu	Arg	His	Lys	Ile	Arg	Ala	Arg	Gln	Asn	Arg	
165					170				175						180	
GCC	TAC	CTG	GAG	AGG	GAC	TGC	CCT	GCA	CAG	CTG	CAG	CAG	TTG	CTG	GAG	809
Ala	Tyr	Leu	Glu	Arg	Asp	Cys	Pro	Ala	Gln	Leu	Gln	Gln	Leu	Leu	Glu	
				185					190					195		
CTG	GGG	AGA	GGT	GTT	TTG	GAC	CAA	CAA	GTG	CCT	CCT	TTG	GTG	AAG	GTG	857
Leu	Gly	Arg	Gly	Val	Leu	Asp	Gln	Gln	Val	Pro	Pro	Leu	Val	Lys	Val	
			200					205					210			
ACA	CAT	CAT	GTG	ACC	TCT	TCA	GTG	ACC	ACT	CTA	CGG	TGT	CGG	GCC	TTG	905
Thr	His	His	Val	Thr	Ser	Ser	Val	Thr	Thr	Leu	Arg	Cys	Arg	Ala	Leu	
			215				220					225				
AAC	TAC	TAC	CCC	CAG	AAC	ATC	ACC	ATG	AAG	TGG	CTG	AAG	GAT	AAG	CAG	953
Asn	Tyr	Tyr	Pro	Gln	Asn	Ile	Thr	Met	Lys	Trp	Leu	Lys	Asp	Lys	Gln	
	230					235					240					
CCA	ATG	GAT	GCC	AAG	GAG	TTC	GAA	CCT	AAA	GAC	GTA	TTG	CCC	AAT	GGG	1001
Pro	Met	Asp	Ala	Lys	Glu	Phe	Glu	Pro	Lys	Asp	Val	Leu	Pro	Asn	Gly	
245					250					255					260	
GAT	GGG	ACC	TAC	CAG	GGC	TGG	ATA	ACC	TTG	GCT	GTA	CCC	CCT	GGG	GAA	1049
Asp	Gly	Thr	Tyr	Gln	Gly	Trp	Ile	Thr	Leu	Ala	Val	Pro	Pro	Gly	Glu	
				265					270					275		
GAG	CAG	AGA	TAT	ACG	TGC	CAG	GTG	GAG	CAC	CCA	GGC	CTG	GAT	CAG	CCC	1097
Glu	Gln	Arg	Tyr	Thr	Cys	Gln	Val	Glu	His	Pro	Gly	Leu	Asp	Gln	Pro	
			280				285						290			
CTC	ATT	GTG	ATC	TGG	GAG	CCC	TCA	CCG	TCT	GGC	ACC	CTA	GTC	ATT	GGA	1145
Leu	Ile	Val	Ile	Trp	Glu	Pro	Ser	Pro	Ser	Gly	Thr	Leu	Val	Ile	Gly	
			295				300						305			
GTC	ATC	AGT	GGA	ATT	GCT	GTT	TTT	GTC	GTC	ATC	TTG	TTC	ATT	GGA	ATT	1193
Val	Ile	Ser	Gly	Ile	Ala	Val	Phe	Val	Val	Ile	Leu	Phe	Ile	Gly	Ile	
			310				315					320				
TTG	TTC	ATA	ATA	TTA	AGG	AAG	AGG	CAG	GGT	TCA	AGA	GGA	GCC	ATG	GGG	1241
Leu	Phe	Ile	Ile	Leu	Arg	Lys	Arg	Gln	Gly	Ser	Arg	Gly	Ala	Met	Gly	
					330					335					340	
CAC	TAC	GTC	TTA	GCT	GAA	CGT	GAG	TGACACGCAG	CCTGCAGACT	CACTGTGGGA						1295
His	Tyr	Val	Leu	Ala	Glu	Arg	Glu									
				345												

(2) INFORMATION FOR SEQ ID NO:10:

(A) LENGTH: 1440 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ix) FEATURE:

(ix) FEATURE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GGGGACACTG	GATCACCTAG	TGTTTTCACAA	GCAGGTACCT	TCTGCTGTAG	GAGAGAGAGA	60
ACTAAAGTTC	TGAAAGACCT	GTTGCTTTTC	ACCAGGAAGT	TTTACTGGGC	ATCTCCTGAG	120
CCTAGGCAAT	AGCTGTAGGG	TGACTTCTGG	AGCCATCCCC	GTTTCCCCGC	CCCCCAAAG	180
AAGCGGAGAT	TTAACGGGGA	CGTGCGGCCA	GAGCTGGGGA	A ATG GGC CCG CGA		233
				Met Gly Pro Arg		
				1		
GCC AGG CCG GCG CTT CTC CTC CTG ATG CTT TTG CAG ACC GCG GTC CTG						281
Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln Thr Ala Val Leu						
5				10		15 20
CAG GGG CGC TTG CTG CGT TCA CAC TCT CTG CAC TAC CTC TTC ATG GGT						329
Gln Gly Arg Leu Leu Arg Ser His Ser Leu His Tyr Leu Phe Met Gly						
			25			30 35
GCC TCA GAG CAG GAC CTT GGT CTT TCC TTG TTT GAA GCT TTG GGC TAC						377
Ala Ser Glu Gln Asp Leu Gly Leu Ser Leu Phe Glu Ala Leu Gly Tyr						
			40			45 50
GTG GAT GAC CAG CTG TTC GTG TTC TAT GAT CAT GAG AGT CGC CGT GTG						425
Val Asp Asp Gln Leu Phe Val Phe Tyr Asp His Glu Ser Arg Arg Val						
			55			60 65
GAG CCC CGA ACT CCA TGG GTT TCC AGT AGA ATT TCA AGC CAG ATG TGG						473
Glu Pro Arg Thr Pro Trp Val Ser Ser Arg Ile TCA Ser Gln Met Trp						
70				75		80

CTG Leu 85	CAG Gln	CTG Leu	AGT Ser	CAG Gln	AGT Ser 90	CTG Leu	AAA Lys	GGG Gly	TGG Trp	GAT Asp 95	CAC His	ATG Met	TTC Phe	ACT Thr	GTT Val 100	521
GAC Asp	TTC Phe	TGG Trp	ACT Thr	ATT Ile 105	ATG Met	GAA Glu	AAT Asn	CAC His	AAC Asn 110	CAC His	AGC Ser	AAG Lys	GAG Glu	TCC Ser 115	CAC His	569
ACC Thr	CTG Leu	CAG Gln	GTC Val 120	ATC Ile	CTG Leu	GGC Gly	TGT Cys	GAA Glu 125	ATG Met	CAA Gln	GAA Glu	GAC Asp	AAC Asn 130	AGT Ser	ACC Thr	617
GAG Glu	GGC Gly	TAC Tyr 135	TGG Trp	AAG Lys	TAC Tyr	GGG Gly	TAT Tyr 140	GAT Asp	GGG Gly	CAG Gln	GAC Asp 145	CAC His	CTT Leu	GAA Glu	TTC Phe	665
TGC Cys 150	CCT Pro	GAC Asp	ACA Thr	CTG Leu	GAT Asp	TGG Trp 155	AGA Arg	GCA Ala	GCA Ala	GAA Glu	CCC Pro 160	AGG Arg	GCC Ala	TGG Trp	CCC Pro	713
ACC Thr 165	AAG Lys	CTG Leu	GAG Glu	TGG Trp	GAA Glu 170	AGG Arg	CAC His	AAG Lys	ATT Ile	CGG Arg 175	GCC Ala	AGG Arg	CAG Gln	AAC Asn	AGG Arg 180	761
GCC Ala	TAC Tyr	CTG Leu	GAG Glu	AGG Arg 185	GAC Asp	TGC Cys	CCT Pro	GCA Ala	CAG Gln 190	CTG Leu	CAG Gln	CAG Gln	TTG Leu	CTG Leu 195	GAG Glu	809
CTG Leu	GGG Gly	AGA Arg	GGT Gly 200	GTT Val	TTG Leu	GAC Asp	CAA Gln 205	CAA Gln	GTG Val	CCT Pro	CCT Pro	TTG Leu	GTG Val 210	AAG Lys	GTG Val	857
ACA Thr	CAT His 215	CAT His	GTG Val	ACC Thr	TCT Ser	TCA Ser	GTG Val 220	ACC Thr	ACT Thr	CTA Leu	CGG Arg 225	TGT Cys	CGG Arg	GCC Ala	TTG Leu	905
AAC Asn 230	TAC Tyr	TAC Tyr	CCC Pro	CAG Gln	AAC Asn	ATC Ile 235	ACC Thr	ATG Met	AAG Lys	TGG Trp 240	CTG Leu	AAG Lys	GAT Asp	AAG Lys	CAG Gln	953
CCA Pro 245	ATG Met	GAT Asp	GCC Ala	AAG Lys	GAG Glu 250	TTC Phe	GAA Glu	CCT Pro	AAA Lys	GAC Asp 255	GTA Val	TTG Leu	CCC Pro	AAT Asn	GGG Gly 260	1001
GAT Asp	GGG Gly	ACC Thr	TAC Tyr	CAG Gln 265	GGC Gly	TGG Trp	ATA Ile	ACC Thr	TTG Leu 270	GCT Ala	GTA Val	CCC Pro	CCT Pro	GGG Gly 275	GAA Glu	1049
GAG Glu	CAG Gln	AGA Arg	TAT Tyr 280	ACG Thr	TAC Tyr	CAG Gln	GTG Val	GAG Glu 285	CAC His	CCA Pro	GGC Gly	CTG Leu	GAT Asp 290	CAG Gln	CCC Pro	1097
CTC Leu	ATT Ile 295	GTG Val	ATC Ile	TGG Trp	GAG Glu	CCC Pro	TCA Ser 300	CCG Pro	TCT Ser	GGC Gly	ACC Thr	CTA Leu 305	GTC Val	ATT Ile	GGA Gly	1145
GTC Val 310	ATC Ile	AGT Ser	GGA Gly	ATT Ile	GCT Ala	GTT Val 315	TTT Phe	GTC Val	GTC Val	ATC Ile	TTG Leu 320	TTC Phe	ATT Ile	GGA Gly	ATT Ile	1193
TTG Leu	TTC Phe	ATA Ile	ATA Ile	TTA Leu	AGG Arg	AAG Lys	AGG Arg	CAG Gln	GGT Gly	TCA Ser	AGA Arg	GGA Gly	GCC Ala	ATG Met	GGG Gly	1241

325	330	335	340	
CAC TAC GTC TTA GCT GAA CGT GAG TGACACGCAG CCTGCAGACT CACTGTGGGA				1295
His Tyr Val Leu Ala Glu Arg Glu				
345				
AGGAGACAAA ACTAGAGACT CAAAGAGGGA GTGCATTTAT GAGCTCTTCA TGTTCAGGA				1355
GAGAGTTGAA CCTAACATA GAAATTGCCT GACGAACTCC TTGATTTTAG CCTTCTCTGT				1415
TCATTTCTCTC AAAAAGATTT CCCCA				1440

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1440 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 222..1268

(ix) FEATURE:

- (A) NAME/KEY: allele
- (B) LOCATION: replace(408, "g")
- (D) OTHER INFORMATION: /phenotype= "Hereditary Hemochromatosis (HH)"
/label= 24d2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGGGACACTG GATCACCTAG TGTTTCACAA GCAGGTACCT TCTGCTGTAG GAGAGAGAGA	60
ACTAAAGTTC TGAAAGACCT GTTGCTTTTC ACCAGGAAGT TTTACTGGGC ATCTCCTGAG	120
CCTAGGCAAT AGCTGTAGGG TGACTTCTGG AGCCATCCCC GTTTCCCCGC CCCCCAAAAG	180
AAGCGGAGAT TTAACGGGGA CGTGCGGCCA GAGCTGGGGA A ATG GGC CCG CGA	233
Met Gly Pro Arg	
1	
GCC AGG CCG GCG CTT CTC CTC CTG ATG CTT TTG CAG ACC GCG GTC CTG	281
Ala Arg Pro Ala Leu Leu Leu Leu Met Leu Leu Gln Thr Ala Val Leu	
5 10 15 20	
CAG GGG CGC TTG CTG CGT TCA CAC TCT CTG CAC TAC CTC TTC ATG GGT	329
Gln Gly Arg Leu Leu Arg Ser His Ser Leu His Tyr Leu Phe Met Gly	
25 30 35	
GCC TCA GAG CAG GAC CTT GGT CTT TCC TTG TTT GAA GCT TTG GGC TAC	377
Ala Ser Glu Gln Asp Leu Gly Leu Ser Leu Phe Glu Ala Leu Gly Tyr	
40 45 50	
GTG GAT GAC CAG CTG TTC GTG TTC TAT GAT GAT GAG AGT CGC CGT GTG	425

Val	Asp	Asp	Gln	Leu	Phe	Val	Phe	Tyr	Asp	Asp	Glu	Ser	Arg	Arg	Val	
		55					60					65				
GAG	CCC	CGA	ACT	CCA	TGG	GTT	TCC	AGT	AGA	ATT	TCA	AGC	CAG	ATG	TGG	473
Glu	Pro	Arg	Thr	Pro	Trp	Val	Ser	Ser	Arg	Ile	Ser	Ser	Gln	Met	Trp	
	70					75					80					
CTG	CAG	CTG	AGT	CAG	AGT	CTG	AAA	GGG	TGG	GAT	CAC	ATG	TTC	ACT	GTT	521
Leu	Gln	Leu	Ser	Gln	Ser	Leu	Lys	Gly	Trp	Asp	His	Met	Phe	Thr	Val	
	85				90					95					100	
GAC	TTC	TGG	ACT	ATT	ATG	GAA	AAT	CAC	AAC	CAC	AGC	AAG	GAG	TCC	CAC	569
Asp	Phe	Trp	Thr	Ile	Met	Glu	Asn	His	Asn	His	Ser	Lys	Glu	Ser	His	
				105					110					115		
ACC	CTG	CAG	GTC	ATC	CTG	GGC	TGT	GAA	ATG	CAA	GAA	GAC	AAC	AGT	ACC	617
Thr	Leu	Gln	Val	Ile	Leu	Gly	Cys	Glu	Met	Gln	Glu	Asp	Asn	Ser	Thr	
			120					125					130			
GAG	GGC	TAC	TGG	AAG	TAC	GGG	TAT	GAT	GGG	CAG	GAC	CAC	CTT	GAA	TTC	665
Glu	Gly	Tyr	Trp	Lys	Tyr	Gly	Tyr	Asp	Gly	Gln	Asp	His	Leu	Glu	Phe	
	135					140						145				
TGC	CCT	GAC	ACA	CTG	GAT	TGG	AGA	GCA	GCA	GAA	CCC	AGG	GCC	TGG	CCC	713
Cys	Pro	Asp	Thr	Leu	Asp	Trp	Arg	Ala	Ala	Glu	Pro	Arg	Ala	Trp	Pro	
	150					155					160					
ACC	AAG	CTG	GAG	TGG	GAA	AGG	CAC	AAG	ATT	CGG	GCC	AGG	CAG	AAC	AGG	761
Thr	Lys	Leu	Glu	Trp	Glu	Arg	His	Lys	Ile	Arg	Ala	Arg	Gln	Asn	Arg	
	165				170					175					180	
GCC	TAC	CTG	GAG	AGG	GAC	TGC	CCT	GCA	CAG	CTG	CAG	CAG	TTG	CTG	GAG	809
Ala	Tyr	Leu	Glu	Arg	Asp	Cys	Pro	Ala	Gln	Leu	Gln	Gln	Leu	Leu	Glu	
				185					190					195		
CTG	GGG	AGA	GGT	GTT	TTG	GAC	CAA	CAA	GTG	CCT	CCT	TTG	GTG	AAG	GTG	857
Leu	Gly	Arg	Gly	Val	Leu	Asp	Gln	Gln	Val	Pro	Pro	Leu	Val	Lys	Val	
			200				205						210			
ACA	CAT	CAT	GTG	ACC	TCT	TCA	GTG	ACC	ACT	CTA	CGG	TGT	CGG	GCC	TTG	905
Thr	His	His	Val	Thr	Ser	Ser	Val	Thr	Thr	Leu	Arg	Cys	Arg	Ala	Leu	
			215				220					225				
AAC	TAC	TAC	CCC	CAG	AAC	ATC	ACC	ATG	AAG	TGG	CTG	AAG	GAT	AAG	CAG	953
Asn	Tyr	Tyr	Pro	Gln	Asn	Ile	Thr	Met	Lys	Trp	Leu	Lys	Asp	Lys	Gln	
	230					235					240					
CCA	ATG	GAT	GCC	AAG	GAG	TTC	GAA	CCT	AAA	GAC	GTA	TTG	CCC	AAT	GGG	1001
Pro	Met	Asp	Ala	Lys	Glu	Phe	Glu	Pro	Lys	Asp	Val	Leu	Pro	Asn	Gly	
	245				250					255					260	
GAT	GGG	ACC	TAC	CAG	GGC	TGG	ATA	ACC	TTG	GCT	GTA	CCC	CCT	GGG	GAA	1049
Asp	Gly	Thr	Tyr	Gln	Gly	Trp	Ile	Thr	Leu	Ala	Val	Pro	Pro	Gly	Glu	
				265					270					275		
GAG	CAG	AGA	TAT	ACG	TGC	CAG	GTG	GAG	CAC	CCA	GGC	CTG	GAT	CAG	CCC	1097
Glu	Gln	Arg	Tyr	Thr	Cys	Gln	Val	Glu	His	Pro	Gly	Leu	Asp	Gln	Pro	
			280					285					290			
CTC	ATT	GTG	ATC	TGG	GAG	CCC	TCA	CCG	TCT	GGC	ACC	CTA	GTC	ATT	GGA	1145
Leu	Ile	Val	Ile	Trp	Glu	Pro	Ser	Pro	Ser	Gly	Thr	Leu	Val	Ile	Gly	
		295					300						305			

GTC ATC AGT GGA ATT GCT GTT TTT GTC GTC ATC TTG TTC ATT GGA ATT	1193
Val Ile Ser Gly Ile Ala Val Phe Val Val Ile Leu Phe Ile Gly Ile	
310 315 320	
TTG TTC ATA ATA TTA AGG AAG AGG CAG GGT TCA AGA GGA GCC ATG GGG	1241
Leu Phe Ile Ile Leu Arg Lys Arg Gln Gly Ser Arg Gly Ala Met Gly	
325 330 335 340	
CAC TAC GTC TTA GCT GAA CGT GAG TGACACGCAG CCTGCAGACT CACTGTGGGA	1295
His Tyr Val Leu Ala Glu Arg Glu	
345	
AGGAGACAAA ACTAGAGACT CAAAGAGGGA GTGCATTTAT GAGCTCTTCA TGTTTCAGGA	1355
GAGAGTTGAA CCTAAACATA GAAATTGCCT GACGAACTCC TTGATTTTAG CCTTCTCTGT	1415
TCATTTCTCTC AAAAAGATTT CCCCA	1440

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1440 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 222..1268

(ix) FEATURE:

- (A) NAME/KEY: allele
- (B) LOCATION: replace(408, "g")
- (D) OTHER INFORMATION: /phenotype= "Hereditary Hemochromatosis (HH)"
/label= 24d2

(ix) FEATURE:

- (A) NAME/KEY: allele
- (B) LOCATION: replace(1066, "a")
- (D) OTHER INFORMATION: /phenotype= "Hereditary Hemochromatosis (HH)"
/label= 24d1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GGGGACACTG GATCACCTAG TGTTTCACAA GCAGGTACCT TCTGCTGTAG GAGAGAGAGA	60
ACTAAAGTTC TGAAAGACCT GTTGCTTTTC ACCAGGAAGT TTTACTGGGC ATCTCCTGAG	120
CCTAGGCAAT AGCTGTAGGG TGA CTCTGG AGCCATCCCC GTTTCCCCGC CCCCCAAAAG	180
AAGCGGAGAT TTAACGGGGA CGTGCGGCCA GAGCTGGGGA A ATG GGC CCG CGA	233
Met Gly Pro Arg	

GCC	AGG	CCG	GCG	CTT	CTC	CTC	CTG	ATG	CTT	TTG	CAG	ACC	GCG	GTC	CTG	281
Ala	Arg	Pro	Ala	Leu	Leu	Leu	Leu	Met	Leu	Leu	Gln	Thr	Ala	Val	Leu	
5					10					15					20	
CAG	GGG	CGC	TTG	CTG	CGT	TCA	CAC	TCT	CTG	CAC	TAC	CTC	TTC	ATG	GGT	329
Gln	Gly	Arg	Leu	Leu	Arg	Ser	His	Ser	Leu	His	Tyr	Leu	Phe	Met	Gly	
				25					30					35		
GCC	TCA	GAG	CAG	GAC	CTT	GGT	CTT	TCC	TTG	TTT	GAA	GCT	TTG	GGC	TAC	377
Ala	Ser	Glu	Gln	Asp	Leu	Gly	Leu	Ser	Leu	Phe	Glu	Ala	Leu	Gly	Tyr	
			40					45					50			
GTG	GAT	GAC	CAG	CTG	TTC	GTG	TTC	TAT	GAT	GAT	GAG	AGT	CGC	CGT	GTG	425
Val	Asp	Asp	Gln	Leu	Phe	Val	Phe	Tyr	Asp	Asp	Glu	Ser	Arg	Arg	Val	
			55				60					65				
GAG	CCC	CGA	ACT	CCA	TGG	GTT	TCC	AGT	AGA	ATT	TCA	AGC	CAG	ATG	TGG	473
Glu	Pro	Arg	Thr	Pro	Trp	Val	Ser	Ser	Arg	Ile	Ser	Ser	Gln	Met	Trp	
	70					75					80					
CTG	CAG	CTG	AGT	CAG	AGT	CTG	AAA	GGG	TGG	GAT	CAC	ATG	TTC	ACT	GTT	521
Leu	Gln	Leu	Ser	Gln	Ser	Leu	Lys	Gly	Trp	Asp	His	Met	Phe	Thr	Val	
85					90					95					100	
GAC	TTC	TGG	ACT	ATT	ATG	GAA	AAT	CAC	AAC	CAC	AGC	AAG	GAG	TCC	CAC	569
Asp	Phe	Trp	Thr	Ile	Met	Glu	Asn	His	Asn	His	Ser	Lys	Glu	Ser	His	
				105					110					115		
ACC	CTG	CAG	GTC	ATC	CTG	GGC	TGT	GAA	ATG	CAA	GAA	GAC	AAC	AGT	ACC	617
Thr	Leu	Gln	Val	Ile	Leu	Gly	Cys	Glu	Met	Gln	Glu	Asp	Asn	Ser	Thr	
			120					125					130			
GAG	GGC	TAC	TGG	AAG	TAC	GGG	TAT	GAT	GGG	CAG	GAC	CAC	CTT	GAA	TTC	665
Glu	Gly	Tyr	Trp	Lys	Tyr	Gly	Tyr	Asp	Gly	Gln	Asp	His	Leu	Glu	Phe	
			135				140					145				
TGC	CCT	GAC	ACA	CTG	GAT	TGG	AGA	GCA	GCA	GAA	CCC	AGG	GCC	TGG	CCC	713
Cys	Pro	Asp	Thr	Leu	Asp	Trp	Arg	Ala	Ala	Glu	Pro	Arg	Ala	Trp	Pro	
	150					155					160					
ACC	AAG	CTG	GAG	TGG	GAA	AGG	CAC	AAG	ATT	CGG	GCC	AGG	CAG	AAC	AGG	761
Thr	Lys	Leu	Glu	Trp	Glu	Arg	His	Lys	Ile	Arg	Ala	Arg	Gln	Asn	Arg	
165					170					175					180	
GCC	TAC	CTG	GAG	AGG	GAC	TGC	CCT	GCA	CAG	CTG	CAG	CAG	TTG	CTG	GAG	809
Ala	Tyr	Leu	Glu	Arg	Asp	Cys	Pro	Ala	Gln	Leu	Gln	Gln	Leu	Leu	Glu	
				185					190					195		
CTG	GGG	AGA	GGT	GTT	TTG	GAC	CAA	CAA	GTG	CCT	CCT	TTG	GTG	AAG	GTG	857
Leu	Gly	Arg	Gly	Val	Leu	Asp	Gln	Gln	Val	Pro	Pro	Leu	Val	Lys	Val	
			200					205					210			
ACA	CAT	CAT	GTG	ACC	TCT	TCA	GTG	ACC	ACT	CTA	CGG	TGT	CGG	GCC	TTG	905
Thr	His	His	Val	Thr	Ser	Ser	Val	Thr	Thr	Leu	Arg	Cys	Arg	Ala	Leu	
			215				220					225				
AAC	TAC	TAC	CCC	CAG	AAC	ATC	ACC	ATG	AAG	TGG	CTG	AAG	GAT	AAG	CAG	953
Asn	Tyr	Tyr	Pro	Gln	Asn	Ile	Thr	Met	Lys	Trp	Leu	Lys	Asp	Lys	Gln	
	230					235					240					
CCA	ATG	GAT	GCC	AAG	GAG	TTC	GAA	CCT	AAA	GAC	GTA	TTG	CCC	AAT	GGG	1001
Pro	Met	Asp	Ala	Lys	Glu	Phe	Glu	Pro	Lys	Asp	Val	Leu	Pro	Asn	Gly	

245	250	255	260	
GAT GGG ACC TAC CAG GGC TGG ATA ACC TTG GCT GTA CCC CCT GGG GAA				1049
Asp Gly Thr Tyr Gln Gly Trp Ile Thr Leu Ala Val Pro Pro Gly Glu	265	270	275	
GAG CAG AGA TAT ACG TAC CAG GTG GAG CAC CCA GGC CTG GAT CAG CCC				1097
Glu Gln Arg Tyr Thr Tyr Gln Val Glu His Pro Gly Leu Asp Gln Pro	280	285	290	
CTC ATT GTG ATC TGG GAG CCC TCA CCG TCT GGC ACC CTA GTC ATT GGA				1145
Leu Ile Val Ile Trp Glu Pro Ser Pro Ser Gly Thr Leu Val Ile Gly	295	300	305	
GTC ATC AGT GGA ATT GCT GTT TTT GTC GTC ATC TTG TTC ATT GGA ATT				1193
Val Ile Ser Gly Ile Ala Val Phe Val Val Ile Leu Phe Ile Gly Ile	310	315	320	
TTG TTC ATA ATA TTA AGG AAG AGG CAG GGT TCA AGA GGA GCC ATG GGG				1241
Leu Phe Ile Ile Leu Arg Lys Arg Gln Gly Ser Arg Gly Ala Met Gly	325	330	335	340
CAC TAC GTC TTA GCT GAA CGT GAG TGACACGCAG CCTGCAGACT CACTGTGGGA				1295
His Tyr Val Leu Ala Glu Arg Glu	345			
AGGAGACAAA ACTAGAGACT CAAAGAGGGA GTGCATTTAT GAGCTCTTCA TGTTTCAGGA				1355
GAGAGTTGAA CCTAAACATA GAAATTGCCT GACGAACTCC TTGATTTTAG CCTTCTCTGT				1415
TCATTTCTCTC AAAAAGATTT CCCCCA				1440

(2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TGGCAAGGGT AAACAGATCC

20

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CTCAGGCACT CCTCTCAACC

20

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /mod_base= OTHER
/note= "N = 5'-biotinylated guanine
(bio-G) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

NGAAGAGCAG AGATATACGT G

21

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /mod_base= OTHER
/note= "N = 5'-biotinylated guanine
(bio-G) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

NGAAGAGCAG AGATATACGT A

21

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 1
- (D) OTHER INFORMATION: /mod_base= OTHER
/note= "N = 5'-phosphorylated cytosine
(p-C) "

(ix) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 18
- (D) OTHER INFORMATION: /mod_base= OTHER
/note= "N = 3'-digoxigenin-conjugated
guanine (G-dig) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

NCAGGTGGAG CACCCAGN

18

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CTGAAAGGGT GGGATCACAT

20

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CAAGGAGTTC GTCAGGCAAT

20

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 517 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..517
- (D) OTHER INFORMATION: /note= "normal or wild-type (unaffected) genomic sequence surrounding variant for 24d1(G) allele corresponding to positions 5507-6023 of genomic sequence containing the HH gene (SEQ ID NO:1)"

(ix) FEATURE:

- (A) NAME/KEY: allele
- (B) LOCATION: replace(328, "g")
- (D) OTHER INFORMATION: /phenotype= "normal or wild-type (unaffected)"
/label= 24d1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

```

TATTTCTTCTC CTCCAACCTA TAGAAGGAAG TGAAAGTTCC AGTCTTCCTG GCAAGGGTAA      60
ACAGATCCCC TCTCCTCATC CTTCTCTTTT CCTGTCAAGT GCCTCCTTTG GTGAAGGTGA      120
CACATCATGT GACCTCTTCA GTGACCACTC TACGGTGTCTG GGCCTTGAAC TACTACCCCC      180
AGAACATCAC CATGAAGTGG CTGAAGGATA AGCAGCCAAT GGATGCCAAG GAGTTCGAAC      240
CTAAAGACGT ATTGCCCAAT GGGGATGGGA CCTACCAGGG CTGGATAACC TTGGCTGTAC      300
CCCCTGGGGA AGAGCAGAGA TATACGTGCC AGGTGGAGCA CCCAGGCCTG GATCAGCCCC      360
TCATTGTGAT CTGGGGTATG TGAATGATGA GAGCCAGGAG CTGAGAAAAT CTATTGGGGG      420
TTGAGAGGAG TGCCTGAGGA GGTAATTATG GCAGTGAGAT GAGGATCTGC TCTTTGTTAG      480
GGGGTGGGCT GAGGGTGGCA ATCAAAGGCT TTAACCTT                               517

```

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 517 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: -
- (B) LOCATION: 1..517
- (D) OTHER INFORMATION: /note= "genomic sequence surrounding variant for 24d1(A) allele corresponding to positions 5507-6023 of genomic sequence containing the HH gene (SEQ ID NO:3)"

(ix) FEATURE:

- (A) NAME/KEY: allele
- (B) LOCATION: replace(328, "a")
- (D) OTHER INFORMATION: /phenotype= "Hereditary Hemochromatosis"

(HH) "
/label= 24d1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

```

TATTTCTTC CTCCAACCTA TAGAAGGAAG TGAAAGTTCC AGTCTTCCTG GCAAGGGTAA      60
ACAGATCCCC TCTCCTCATC CTTCTCTTTT CCTGTCAAGT GCCTCCTTTG GTGAAGGTGA      120
CACATCATGT GACCTCTTCA GTGACCACTC TACGGTGTCTG GGCCTTGAAC TACTACCCCC      180
AGAACATCAC CATGAAGTGG CTGAAGGATA AGCAGCCAAT GGATGCCAAG GAGTTCGAAC      240
CTAAAGACGT ATTGCCCAAT GGGGATGGGA CCTACCAGGG CTGGATAACC TTGGCTGTAC      300
CCCCTGGGGA AGAGCAGAGA TATACGTACC AGGTGGAGCA CCCAGGCCTG GATCAGCCCC      360
TCATTGTGAT CTGGGGTATG TGAAGTATGA GAGCCAGGAG CTGAGAAAAT CTATTGGGGG      420
TTGAGAGGAG TGCCTGAGGA GGTAATTATG GCAGTGAGAT GAGGATCTGC TCTTTGTTAG      480
GGGGTGGGCT GAGGGTGGCA ATCAAAGGCT TTAAGTCTT                                517

```

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 361 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

- (A) NAME/KEY: Protein
- (B) LOCATION: 1..361
- (D) OTHER INFORMATION: /note= "Rabbit leukocyte antigen (RLA)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```

Met Gly Ser Ile Pro Pro Arg Thr Leu Leu Leu Leu Leu Ala Gly Ala
1           5           10           15
Leu Thr Leu Lys Asp Thr Gln Ala Gly Ser His Ser Met Arg Tyr Phe
20          25          30
Tyr Thr Ser Val Ser Arg Pro Gly Leu Gly Glu Pro Arg Phe Ile Ile
35          40          45
Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala
50          55          60
Ala Ser Pro Arg Met Glu Gln Arg Ala Pro Trp Met Gly Gln Val Glu
65          70          75          80
Pro Glu Tyr Trp Asp Gln Gln Thr Gln Ile Ala Lys Asp Thr Ala Gln
85          90          95

```

Thr Phe Arg Val Asn Leu Asn Thr Ala Leu Arg Tyr Tyr Asn Gln Ser
 100 105 110
 Ala Ala Gly Ser His Thr Phe Gln Thr Met Phe Gly Cys Glu Val Trp
 115 120 125
 Ala Asp Gly Arg Phe Phe His Gly Tyr Arg Gln Tyr Ala Tyr Asp Gly
 130 135 140
 Ala Asp Tyr Ile Ala Leu Asn Glu Asp Leu Arg Ser Trp Thr Ala Ala
 145 150 155 160
 Asp Thr Ala Ala Gln Asn Thr Gln Arg Lys Trp Glu Ala Ala Gly Glu
 165 170 175
 Ala Glu Arg His Arg Ala Tyr Leu Glu Arg Glu Cys Val Glu Trp Leu
 180 185 190
 Arg Arg Tyr Leu Glu Met Gly Lys Glu Thr Leu Gln Arg Ala Asp Pro
 195 200 205
 Pro Lys Ala His Val Thr His His Pro Ala Ser Asp Arg Glu Ala Thr
 210 215 220
 Leu Arg Cys Trp Ala Leu Gly Phe Tyr Pro Ala Glu Ile Ser Leu Thr
 225 230 235 240
 Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu
 245 250 255
 Thr Arg Pro Gly Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val
 260 265 270
 Val Pro Ser Gly Glu Glu Gln Arg Tyr Thr Cys Arg Val Gln His Glu
 275 280 285
 Gly Leu Pro Glu Pro Leu Thr Leu Thr Trp Glu Pro Pro Ala Gln Pro
 290 295 300
 Thr Ala Leu Ile Val Gly Ile Val Ala Gly Val Leu Gly Val Leu Leu
 305 310 315 320
 Ile Leu Gly Ala Val Val Ala Val Val Arg Arg Lys Lys His Ser Ser
 325 330 335
 Asp Gly Lys Gly Gly Arg Tyr Thr Pro Ala Ala Gly Gly His Arg Asp
 340 345 350
 Gln Gly Ser Asp Asp Ser Leu Met Pro
 355 360

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 365 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(ix) FEATURE:

(A) NAME/KEY: Protein

(B) LOCATION: 1..365

(D) OTHER INFORMATION: /note= "Human Major Histocompatibility Class I (MHC) protein"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```

Met Ala Val Met Ala Pro Arg Thr Leu Val Leu Leu Leu Ser Gly Ala
1          5          10          15
Leu Ala Leu Thr Gln Thr Trp Ala Gly Ser His Ser Met Arg Tyr Phe
          20          25          30
Phe Thr Ser Val Ser Arg Pro Gly Arg Gly Glu Pro Arg Phe Ile Ala
          35          40          45
Val Gly Tyr Val Asp Asp Thr Gln Phe Val Arg Phe Asp Ser Asp Ala
          50          55          60
Ala Ser Gln Arg Met Glu Pro Arg Ala Pro Trp Ile Glu Gln Glu Gly
65          70          75          80
Pro Glu Tyr Trp Asp Gly Glu Thr Arg Lys Val Lys Ala His Ser Gln
          85          90          95
Thr His Arg Val Asp Leu Gly Thr Leu Arg Gly Tyr Tyr Asn Gln Ser
          100          105          110
Glu Ala Gly Ser His Thr Leu Gln Met Met Phe Gly Cys Asp Val Gly
          115          120          125
Ser Asp Trp Arg Phe Leu Arg Gly Tyr His Gln Tyr Ala Tyr Asp Gly
          130          135          140
Lys Asp Tyr Ile Ala Leu Lys Glu Asp Leu Arg Ser Trp Thr Ala Ala
145          150          155          160
Asp Met Ala Ala Gln Thr Thr Lys His Lys Trp Glu Ala Ala His Val
          165          170          175
Ala Glu Gln Leu Arg Ala Tyr Leu Glu Gly Thr Cys Val Glu Trp Leu
          180          185          190
Arg Arg Tyr Leu Glu Asn Gly Lys Glu Thr Leu Gln Arg Thr Asp Ala
          195          200          205
Pro Lys Thr His Met Thr His His Ala Val Ser Asp His Glu Ala Thr
          210          215          220
Leu Arg Cys Trp Ala Leu Ser Phe Tyr Pro Ala Glu Ile Thr Leu Thr
225          230          235          240
Trp Gln Arg Asp Gly Glu Asp Gln Thr Gln Asp Thr Glu Leu Val Glu
          245          250          255
Thr Arg Pro Ala Gly Asp Gly Thr Phe Gln Lys Trp Ala Ala Val Val
          260          265          270
Val Pro Ser Gly Gln Glu Gln Arg Tyr Thr Cys His Val Gln His Glu
          275          280          285

```

Gly	Leu	Pro	Lys	Pro	Leu	Thr	Leu	Arg	Trp	Glu	Pro	Ser	Ser	Gln	Pro
290						295					300				
Thr	Ile	Pro	Ile	Val	Gly	Ile	Ile	Ala	Gly	Leu	Val	Leu	Phe	Gly	Ala
305					310					315					320
Val	Ile	Thr	Gly	Ala	Val	Val	Ala	Ala	Val	Met	Trp	Arg	Arg	Lys	Ser
				325					330					335	
Ser	Asp	Arg	Lys	Gly	Gly	Ser	Tyr	Ser	Gln	Ala	Ala	Ser	Ser	Asp	Ser
			340					345					350		
Ala	Gln	Gly	Ser	Asp	Val	Ser	Leu	Thr	Ala	Cys	Lys	Val			
		355					360					365			

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

ACATGGTTAA GGCCTGTTGC

20

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GCCACATCTG GCTTGAAATT

20

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: modified_base
- (B) LOCATION: 1

(D) OTHER INFORMATION: /mod_base= OTHER
 /note= "N = 5'-biotinylated adenine
 (bio-A) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

NGCTGTTCGT GTTCTATGAT C

21

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: modified_base
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /mod_base= OTHER
 /note= "N = 5'-biotinylated adenine
 (bio-A) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

NGCTGTTCGT GTTCTATGAT G

21

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: modified_base
 (B) LOCATION: 1
 (D) OTHER INFORMATION: /mod_base= OTHER
 /note= "N = 5'-phosphorylated adenine
 (p-A) "

(ix) FEATURE:

(A) NAME/KEY: modified_base
 (B) LOCATION: 19
 (D) OTHER INFORMATION: /mod_base= OTHER
 /note= "N = 3'-digoxigenin-conjugated
 adenine (A-dig) "

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

NTGAGAGTCG CCGTGTGGN

19

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGAAGAGCAG AGATATACGT GCCAGGTGGA GCACCCAGG

39

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 39 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GGAAGAGCAG AGATATACGT ACCAGGTGGA GCACCCAGG

39

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

CAAAAGAAGC GGAGATTTAA CG

22

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

AGATTTAACG GGGACGTGC

19

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

AGAGGTCACA TGATGTGTCA CC

22

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

AGGAGGCACT TGTGTGGTCC

19

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

AAAATCACAA CCACAGCAAA G

21

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

TTCCCACAGT GAGTCTGCAG

20

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CAATGGGGAT GGGACCTAC

19

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

ATATACGTGC CAGGTGGAGC

20

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CCTCTTCACA ACCCCTTTCA

20

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

CATAGCTGTG CAACTCACAT CA

22

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

AGCTGTTCGT GTTCTATGAT CATGAGAGTC GCCGTGTGGA

40

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

AGCTGTTCGT GTTCTATGAT GATGAGAGTC GCCGTGTGGA

40

(2) INFORMATION FOR SEQ ID NO:43:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

TGTTCTATGA TCATGAGAGT CGCCGTGTGG AG

32

(2) INFORMATION FOR SEQ ID NO:44:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

32